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Abstract
Protozoan parasites of the genus Plasmodium are the causative agent of malaria. The
four human pathogenic species infect more than 500 million people each year, causing
the death of at least 1 million people. The most severe form of human malaria is caused
by P. falciparum, which is responsible for 90% of the malaria deaths. A major problem
in the treatment of this disease is resistance of the parasites against most of the existing
chemotherapies. Therefore, there is an urgent need to identify, validate and assess po-
tential new drug targets. The prerequisite of a potential drug target is that it should not
be of significance for the human host or it should be sufficiently different from the hu-
man counterpart, so that parasite-specific inhibition is feasible. Lipoic acid metabolism
in Plasmodium differs from that of mammals in some ways and therefore it might be a
promising target for the development of new antimalarials. This study investigated the
importance of lipoic acid ligation in P. falciparum using reverse genetic approaches, to
assess whether this pathway has potential for drug design. In addition, a spectrophoto-
metric assay system was developed that allowed the biochemical characterisation of lipoic
acid ligases and can be adapted to high-throughput screening approaches of inhibitors for
these enzymes.
Lipoic acid, also known as 6,8-thioctic acid, is an essential cofactor of α-keto acid de-
hydrogenase complexes (KADH) and the glycine cleavage system (GCV). The KADH
include the pyruvate dehydrogenase (PDH), branched chain α-keto acid dehydrogenase
(BCDH) and α-ketoglutarate dehydrogenase (KGDH), which are an integral part for any
cell’s metabolism. In Plasmodium spp. the lipoic acid dependent enzyme complexes
are found in the apicoplast, a plastid related organelle, and in the mitochondrion and
thus two organelle specific lipoylation pathways are present in these parasites. Biosyn-
thesis of the cofactor occurs in the apicoplast. Octanoyl-[acyl carrier protein]: protein
N-octanoyltransferase (LipB) catalyses the attachment of octanoyl-acyl carrier protein
(octanoyl-ACP) to the PDH and lipoic acid synthase (LipA) then catalyses the insertion
of two sulfurs into the octanoyl-chain to form lipoamide. In the mitochondrion, scav-
enged lipoic acid is ligated to the enzyme complexes by the action of lipoic acid protein
ligase A (LplA1), in an ATP-dependent reaction. However, a second lipoate protein ligase
A (LplA2) was identified in the genome of P. falciparum, but its subcellular localisation
could not be predicted using the available prediction programs. To further analyse its
localisation, parasites were generated expressing full length LplA2 in frame with green
fluorescent protein (GFP). In addition, immunofluorescence analyses on wild-type para-
sites using LplA2 specific antibodies were performed. These studies showed that LplA2
is dually targeted to the apicoplast as well as to the mitochondrion, raising the question
about potential redundancy between the ligases present in the parasites. To further anal-
yse this possibility, knock-out studies of lplA1 and lplA2 were performed in the human
and rodent malaria parasites P. falciparum and P. berghei, respectively. Knock-out studies
showed that LplA1 and LplA2 are non-redundant and strongly suggested that LplA1 is
crucial for intraerythrocytic development, whereas LplA2 is essential for sexual develop-
ment in the mosquito. According to these results it appears that (1) a key regulator of
lipoic acid metabolism in Plasmodium spp. is stage specific expression of the relevant
proteins and (2) both ligases are potential drug targets as knock-out of lplA1 appeared
impossible in the blood stages and knock-out of lplA2 resulted in the interruption of para-
site sexual development in the mosquito, and thus transmission of the parasites would be
blocked if LplA2 was inhibited.
To further analyse the biochemical properties of P. falciparum LplA1 and LplA2, a spec-
trophotometric assay system was developed, which is also suitable for the development
of a high-throughput assay system. The spectrophotometric assay monitors the first part
of the LplA reaction - the activation of lipoic acid by ATP. The released pyrophosphate
is converted to phosphate which is detected by acidic ammonium molybdate. Using the
Escherichia coli LplA protein as a positive control, kinetic parameters for the bacterial
protein were determined that are in reasonable agreement with the published data. The
results validate the assay and suggest that it might be suitable for inhibitor screening in
the future.
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11. Introduction
1.1. Malaria
Malaria is one of the most important infectious diseases in the world. About 40% of the
world’s population lives in malaria endemic areas and is therefore at risk of the disease
(Greenwood and Mutabingwa, 2002). Each year, more than 500 million people become
infected, resulting in the death of more than 1 million people. Many of them are young
children and pregnant woman. Most of the malaria cases occur in tropical Africa, but
Asia and South America are also affected (Figure 1.1) (WHO, 2007).
Figure 1.1.: Distribution of malaria in 2005
This figure displays the regions were malaria transmission occurred in 2005. White are the re-
gions without malaria, pale blue are regions with limited risk and dark blue are the areas where
malaria transmission occurs. This image was taken from the World Health Organisation (WHO)
(http://www.who.int/en/).
Malaria is caused by protozoan parasites of the genus Plasmodium. These parasites be-
long to the phylum of Apicomplexa that are defined by the presence of apical organelles
required for invasion of their host cell. Many different Plasmodium species are known
which can infect different vertebrate hosts including primates, rodents, birds and reptiles.
The four following species P. falciparum, P. vivax, P. ovale and P. malariae can cause the
disease in humans. Each of these four species is responsible for unique malaria outcomes.
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P. malariae, for example, undergoes a three day intraerythrocytic development cycle re-
sulting in recurring fever attacks every 72 hours, whereas the other three species undergo
a two day intraerythrocytic development cycle (Cook, 1996). P. vivax and P. ovale are
able to form dormant stages in the hepatocytes. These stages are known as hypnozoites
and they can survive for up to 20 years (Cogswell, 1992). On the contrary, P. falciparum
and P. malariae are not able to form dormant stages. P. falciparum infection results in the
most severe clinical symptoms of malaria and causes 90% of the malaria deaths. The most
widespread parasite is P. vivax, responsible for ∼80% of the worldwide malaria cases.
All Plasmodium parasites are transmitted by female mosquitoes of the genus Anopheles.
Of the ∼380 Anopheles species only 60 can transmit malaria (Cook, 1996). The female
mosquitoes themselves become infected during a blood-meal from an infected person and
transmit the parasites to the next person with the next blood-meal. The parasite’s life cy-
cle including the host switch between human and mosquito is explained in more detail in
the following section.
1.2. Life cycle of malaria parasites
Plasmodium parasites possess a complex life cycle, which switches between sexual and
asexual development (Figure 1.2). The sexual development (gamogony) as well as sporo-
gony takes place in the Anopheles mosquito whereas the parasites proceed through asex-
ual development (schizogony) in the human host. The asexual development in the par-
asite’s life cycle begins with the injection of infective sporozoites into the human by a
female Anopheles mosquito during a blood meal. The sporozoites migrate via the blood
and lymph systems to the liver where they invade hepatocytes. Here, the first asexual
reproduction (exoerythocytic schizogony) takes place. The sporozoites differentiate to
schizonts, which can produce up to 30,000 merozoites (Prudêncio et al., 2006). Upon
rupture of the hepatocyte, the merozoites are released into the blood stream where they
immediately invade erythrocytes, in which the second asexual reproduction (intraerythro-
cytic schizogony) occurs. Invasion is coordinated by the apical organelles of the mero-
zoite and results in the invagination of the erythrocyte plasma membrane to form the
parasitophorous vacuole, which surrounds the parasite and separates it from the erythro-
cyte cytosol (Gaur et al., 2004, Cowman and Crabb, 2006). Within the parasitophorous
vacuole, the parasite matures through the three different developmental stages. During
early intraerythrocytic development (1-18 hours after invasion) the parasites are in the
ring stage. In this stage the parasites show only low metabolic activity, although the par-
asite begins to modify its host cell and it starts to endocytose and digest the host cell
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cytoplasm. The parasite matures into the trophozoite stage (18-28 hours after invasion),
in which the host cell cytoplasm is ingested to obtain nutrients from the host cell. Partic-
ulary important is the haemoglobin, which is used as an amino acid source by the parasite
(Banerjee et al., 2002). Degradation of haemoglobin takes place in the parasite’s food vac-
uole and the remaining haem is converted into haemozoin, also known as malaria pigment
(Egan et al., 2002). Additionally, during the trophozoite stage RNA and protein synthe-
sis occurs at a high level and DNA synthesis is initiated (Arnot and Gull, 1998). During
the schizont stage (28-48 hours after invasion) Plasmodium parasites go through multiple
rounds of DNA replication and nuclear divisions to form a syncytial cell with 8-32 nuclei
(Arnot and Gull, 1998). Finally, the schizont undergos cytokinesis and mononucleated
merozoites are formed which are released upon rupture of the erythrocyte (Doerig et al.,
2000). Back in the blood stream, the merozoites infect more erythrocytes in which they
can continue the intraerythrocytic development cycle. This phase of the parasites devel-
opment is responsible for the symptoms of malaria. Rupture of infected erythrocytes and
the subsequent release of merozoites into the blood stream causes for example the symp-
tomatic cycling of fever observed in malaria patients (Miller et al., 2002).
Some merozoites will not proceed through the intraerythrocytic development cycle, but
will instead undergo gametocytogenesis during which they differentiate into either female
macrogametocytes or male microgametocytes (Talman et al., 2004). These are taken up
by a female Anopheles mosquito during a blood-meal and the sexual development within
the mosquito starts. The macrogametocytes form spherical macrogametes and each mi-
crogametocyte divides into 4-8 exflagellated microgametes (Sinden et al., 1978). Fu-
sion of macro- and microgametes in the mosquito’s midgut leads to the formation of the
diploid zygote which develops to the motile ookinete. The ookinete migrates through
the midgut epithelium and matures at the basal lamina into the immobile oocyst (Ma-
tuschewski, 2006). The oocyst goes through several rounds of asexual replication to form
sporozoites. These are released and travel to the salivary gland of the mosquito where they
invade the gland cells (Matuschewski, 2006). With the next blood meal of the mosquito
these highly infective sporozoites are injected into the human body, allowing the cycle of
infection between the human and mosquito host to continue.
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Figure 1.2.: Life cycle of malaria parasites
Plasmodium parasites possess a complex life cycle that switches between asexual development
in the human host, and sexual development in the mosquito host. A female anopheline mosquito
injects sporozoites into the blood stream of the human host during a blood meal. The sporo-
zoites migrate to the liver and invade hepatocytes. They reproduce asexually until thousands of
merozoites are formed and released through rupture of the hepatocyte. In the blood stream, the
merozoites invade erythrocytes in which they undergo the intraerythrocytic development cycle,
resulting in the release of merozoites. These invade more erythrocytes in which they either con-
tinue the intraerythrocytic development cycle or undergo gametocytogenesis, during which they
form either female or male gametocytes. These are taken up by a mosquito during a blood meal
and the sexual development in the mosquito’s midgut starts. The female gametocytes develop into
spherical macrogametes and the male gametocytes into 4-8 exflagellated microgametes. A macro-
and a microgamete fuse to form the zygote, which develops into the motile ookinete. The ookinete
traverses the midgut epithelium where it develops into an oocyst in which sporozoites are formed.
These are released and enter the mosquito’s salivary glands ready to infect the human host with
the next blood meal of the mosquito. The image was taken from Ménard (2005) with permission
from Nature Publishing Group.
1.3. Plasmodium falciparum
P. falciparum infections are responsible for the most severe form of malaria and can result
in cerebral malaria or pregnancy-related malaria. These disease outcomes are specific to
P. falciparum infections and are attributable to two phenomena of the infected erythro-
cytes called sequestration and rosetting (Miller et al., 2002). During the intraerythrocytic
developmental cycle, P. falciparum remodels the erythrocyte surface in a way that allows
the infected erythrocyte to adhere to the vascular endothelium (Kyes et al., 2001). Cy-
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toadherence is mediated by the antigenically variant P. falciparum erythrocyte membrane
protein 1 (PfEMP-1) on the surface of the infected erythrocytes (Kyes et al., 2001). It
is probably anchored in the plasma membrane by a putative transmembrane domain and
is associated on the cytoplasmic site with other parasite encoded proteins. These consist
predominantly of the knob-associated histidine rich protein (KAHRP), and together they
form protrusions on the erythrocyte surface known as "knobs" (Kilejian, 1979, Crabb
et al., 1997). PfEMP-1 interacts with several molecules expressed by endothelial cells
including CD36, intercellular adhesion molecule 1 (ICAM-1) and chondroitin sulfate A
(CSA), to promote adhesion to these cells. Data suggest that PfEMP-1 mediated adhe-
sion to ICAM-1 plays an important role in cerebral malaria (Turner et al., 1994) and that
adhesion to CSA contributes to pregnancy-related malaria (Fried and Duffy, 1996). Se-
questration to the endothelium also occurs in a number of other organs including the heart,
liver and kidneys, resulting in the blockage of the microvascular blood flow in the affected
organs (Miller et al., 2002). In addition, sequestration also prevents the infected erythro-
cytes being recognised and cleared by the spleen, and thus helps the parasite to evade the
host immune system (Miller et al., 2002). Rosetting is the second phenomenon of P. falci-
parum infected erythrocytes and consists of the attachment of infected cells to uninfected
erythrocytes. Again, this effect is mediated by the variant antigen family PfEMP-1, and
it was suggested that complement receptor 1 (CR1) on the surface of uninfected erythro-
cytes plays a key role in the rosetting phenotype (Rowe et al., 1997).
P. falciparum is the most studied parasite of the human infective Plasmodium species,
possibly because P. falciparum causes the most lethal form of malaria. Moreover, the
ability to culture these parasites in vitro has contributed largely to the study of this para-
site in more detail (Trager and Jensen, 1976). In 2002, the P. falciparum genome project
was completed (Gardner et al., 2002) and it has been widely used as a valuable tool to
further analyse these parasites. The completed genome is especially helpful in the quest
for new antimalarial drug targets and potential vaccine candidates. The nuclear genome
of P. falciparum is 22.9 megabase (Mb) in size comprising 14 chromosomes varying in
size between 0.643 and 3.29 Mb. With 80.6% of the genome consisting of (A+T), it is
the genome containing the highest (A+T) levels sequenced to date. In introns and in-
tergenic regions it even reaches (A+T) levels up to 90%. About 5300 protein encoding
genes were predicted, of which only 40% displayed sufficient similarities with genes in
other organisms to predict their potential protein function (Gardner et al., 2002).
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1.4. Chemotherapies
Currently, the main way to combat malaria is by chemotherapy using different antimalar-
ial drugs. However, widespread resistance against many of these drugs is a serious
problem, and therefore the identification of potential new antimalarial drug targets and
the development of new drugs is urgently required (Hyde, 2007). Vector control and
insecticide-treated mosquito nets are other possibilities to prevent infection with Plas-
modium parasites and "control" the disease, however, this is difficult to implement and
maintain in countries which are affected (Greenwood et al., 2005, Hill et al., 2006). Ad-
ditionally, great efforts are being taken to find and develop a vaccine against Plasmodium
parasites and although some progress has been made, this is still elusive (Targett, 2005,
Matuschewski and Mueller, 2007).
1.4.1. Quinoline antimalarials
Quinoline-based antimalarial drugs have been widely used in the treatment of malaria, but
resistance against these compounds is a major problem. Chloroquine, a 4-aminoquinoline,
was the antimalarial drug of choice for several decades due to it being highly effective and
cheap to produce (Cook, 1996). However, resistance has spread leaving only a few areas
in the world where malaria treatment with chloroquine is still successful (Winstanley and
Ward, 2006). Chloroquine is believed to target the polymerisation of toxic haem. It
enters the food vacuole and binds to haem, thus preventing its polymerisation to haemo-
zoin (Egan et al., 1997, Leed et al., 2002). As a result, the concentration of toxic haem
increases causing enhanced oxidative stress, membrane damage and eventually parasite
death (Loria et al., 1999). Chloroquine resistant parasites accumulate less chloroquine in
their food vacuole, which is associated with mutations in the multidrug resistance trans-
porter and chloroquine resistance transporter (Mu et al., 2003). Another phenomenon ob-
served in resistant parasites is that they contain higher levels of glutathione. It is thought
that glutathione detoxifies free haem and therefore protects the parasites from the in-
creased haem levels (Ginsburg and Golenser, 2003).
Primaquine, a 8-aminoquinoline, is used in combination therapy with other antimalarials
(mainly with chloroquine) in the treatment of P. vivax and P. ovale malaria (Galappaththy
et al., 2007). Primaquine is active against the dormant stages of these parasites and thus
is used to kill hypnozoites in the liver to prevent relapse of the disease (Winstanley and
Ward, 2006). The precise mode of action of primaquine is not known, but it is believed to
act on the mitochondria of the parasites (Foley and Tilley, 1998, Schlitzer, 2007).
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Other compounds used for malaria treatment are the methanolquinolines mefloquine
(known as Lariamr) and quinine, and halofantrine, a phenanthrene methanol (Bray et al.,
2005, Hyde, 2007). Quinine is a naturally occurring compound, which is extracted from
chinona bark. It is used as a prophylactic and in combination with antimalarial antibiotics
for the treatment of malaria. Mefloquine, quinine and halofantrine also enter the para-
site’s food vacuole but their exact mode of action is not known, although it is believed to
be different from chloroquine’s mode of action (Foley and Tilley, 1998, Schlitzer, 2007).
1.4.2. Artemisinin
Artemisinin is another naturally occurring compound found in the shrub Artemesia an-
nua. It has been used in China in the treatment of different diseases including malaria for
centuries. Its precise mode of action is not known. Several ways how artemisinin affect
parasites have been suggested. One possible mode of action is the inhibition of the pro-
duction of haemozoin by alkylation of haem (Meshnick, 1998). It has also been shown
that artemisinin and its derivates are redox active, producing reactive oxygen species and
thus increase oxidative stress for the parasites (Dong and Vennerstrom, 2003). In addition,
artemisinin was also shown to inhibit the serco/endoplasmatic reticulum Ca2+ ATPase
(Eckstein-Ludwig et al., 2003). Artemisinin based combination therapies (ACT) are now
recommended by the WHO for treatment of malaria due to widespread resistance against
other antimalarials such as chloroquine or antifolates.
1.4.3. Antifolates
Antifolates have been successfully used as antimalarials, but resistance against these
compounds has widely spread. Antifolates used in malaria therapy affect de novo fo-
late biosynthesis by inhibiting either the dihydrofolate reductase-thymilidate synthase
(DHFR-TS) or the hydroxymethylpterin pyrophosphokinase-dihydropteroate synthase
(HPPK-DHPS) (Hyde, 2007). Drugs like pyrimethamine or proguanil (which is
metabolised to the active form cycloguanil) inhibit DHFR activity whereas sulfonamides
and sulfone act on DHPS activity (Hyde, 2007). These compounds were initially used
in monotherapy, but resistant parasites developed quickly (Gregson and Plowe, 2005).
Combination of DHFR inhibitors with DHPS inhibitors showed synergistic effects in the
treatment of malaria and thus a combination of pyrimethamine and sulfadoxine (known
as Fansidarr) is used for the treatment of falciparum malaria (Gregson and Plowe, 2005,
Hyde, 2007). However, resistance against these compounds has widely spread, which are
caused by several point mutations in the respective genes resulting in different grades of
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resistance against these compounds. It was shown that pyrimethamine resistance is caused
by four point mutations within the DHFR gene (Wu et al., 1996), and resistance against
sulfadoxine is due to point mutations within the DHPS gene (Triglia et al., 1998). A com-
bination of these mutations in parasite populations is responsible for the pyrimethamine-
sulfadoxine treatment failure. Since 2003 a combination of chlorproguanil and dap-
sone (known as LapDapr) has been used as an antimalarial, but some resistance against
this drug has already been reported and thus it is currently tested in combination with
artemisinins (Schlitzer, 2007).
1.4.4. Atovaquone
Atovaquone is another compound used in chemotherapy of malaria. It is a structural
analog of ubiquinone and thus targets and inhibits cytochrome bc1 in the mitochon-
drial inner membrane, resulting in the collapse of the membrane potential (Sherman,
2005). In monotherapy, parasites with point mutations in the cytochrome b gene emerged
quickly conferring resistance against atovaquone (Kessl et al., 2005). In combination
with proguanil (known as Malaroner), it is more effective against parasites and also in-
duces less resistance (Hyde, 2007). The precise synergistic mechanism of atovaquone
and proguanil is not yet fully understood, but it appears that it is not associated with
proguanil’s function as an antifolate precursor; rather, it appears to sensitise the mito-
chondrion for atovaquone action (Sherman, 2005). However, the production of this drug
is problematic, as it is very expensive, and therefore not available for people living in
malaria endemic areas.
1.4.5. Antibiotics
Several antibiotics exhibit antimalarial activities and doxycycline, tetracycline and clin-
damycine are currently used in combination therapies (CDC, 2007). Generally it is be-
lieved that antibiotics affect pathways present in the apicoplast, the plastid-related or-
ganelle, and/or in the mitochondrion due to their bacterial origin (Goodman et al., 2007).
It was suggested that clindamycine inhibits protein translation in the apicoplast, as it
does in the related parasite Toxoplasma gondii (Camps et al., 2002). Doxycycline and
tetracycline also inhibit protein translation and it is believed that they affect the mito-
chondrion (Prapunwattana et al., 1988). Recent data, however, also suggest an effect on
the apicoplast (Dahl et al., 2006, Goodman et al., 2007). Other antibiotics affect parasite
viability in vitro and in vivo and they will be discussed in more detail below.
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1.5. Structure of Plasmodium falciparum
The asexual stages of P. falciparum mature in a 48 hour development cycle within an
erythrocyte. They contain a number of distinct organelles which play crucial roles dur-
ing their life cycle (Sherman, 2005). Figure 1.3 displays a 3D reconstruction image of a
merozoite, the invasive form of the parasite, taken from Bannister et al. (2000).
Figure 1.3.: Organisation of a P. falciparum merozoite
This image displays a reconstituted 3D image of a P. falciparum merozoite based on serial electron
microscope slides. The image is taken from Bannister et al. (2000) with permission from Elsevier.
The rhoptries, micronemes, dense granules and polar rings at the apical end are also
known as the apical organelles. They are formed during schizogony and are the key
players in invasion of the host cell. Other unique Plasmodium compartments include the
parasitophorous vacuole, which is generated during the invasion process and surrounds
the parasites in the erythrocyte cytoplasm. Also unique for Plasmodium parasites are the
cytostome and the food vacuole which are involved in endocytosis of host cell cytoplasm
and hemoglobin digestion. Membranous structures called Maurer’s clefts are generated
within the infected erythrocyte which are believed to play a role in protein trafficking to
the erythrocyte membrane. It is suggested that the Maurer’s clefts are generated by vesi-
cles that bud from the parasitophorous vacuole membrane (Spycher et al., 2006). Another
organelle unique to most apicomplexan parasites is the apicoplast, a plastid-related or-
ganelle. It is closely associated with the mitochondrion throughout the intraerythrocytic
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development cycle of the parasites. Because the apicoplast and the mitochondrion have
been thoroughly investigated in this thesis, both organelles are described in more detail
below.
1.5.1. The apicoplast
The apicoplast is a plastid-related organelle present in almost all apicomplexan parasites.
Apicomplexa like Cryptosporidium once possessed a plastid but lost it over time (Huang
et al., 2004). The apicoplast was acquired by secondary endosymbiosis of an already
plastid-bearing organism. Therefore, this organelle is surrounded by four membranes
(McFadden and Roos, 1999). The precise origin of the apicoplast is still controversial, but
it probably is derived from a red algae rather than a green algae (Sherman, 2005). During
the intraerythrocytic developmental stages, the apicoplast is closely associated with the
mitochondrion and, like this organelle, it elongates and branches out during schizogony.
Late in schizogony, the branched apicoplast divides so that each newly formed merozoite
contains a new apicoplast (van Dooren et al., 2005).
The apicoplast has retained its own 35 kb circular genome, and most of the 30 proteins
encoded by it play a role in their own synthesis (Wilson et al., 1991). This suggests that
after the endosymbiosis event the majority of the genes encoded in the genome of the
engulfed algae were transferred into the parasite nucleus. Genome analysis of P. falci-
parum revealed that∼10% of the nucleus encoded proteins are likely to be targeted to the
apicoplast (Gardner et al., 2002), and the mechanisms governing protein targeting to the
apicoplast will be explained in Chapter 1.6.4.
Inhibition of apicoplast DNA replication, transcription and translation by various an-
tibiotics leads to death of the parasites, suggesting a crucial role of this organelle for
parasite viability (Waters and Janse, 2004, Goodman et al., 2007). Indeed, some antibi-
otics are currently used in combination therapies for the treatment of malaria (see 1.4.5).
Interestingly, antibiotics can cause two distinct drug kinetic responses. Antibiotics like
ciprofloxacin, rifampicin and thiostrepton cause an immediate effect whereas clindamycin
and tetracycline result in the delayed death of the parasites (Goodman et al., 2007). The
"delayed death phenotype" is also observed in T. gondii. He et al. (2001) engineered T.
gondii mutants that are not able to segregate the apicoplast during endodygeny and thus
they produced parasites, which lack the apicoplast. These apicoplast lacking parasites
grew normally and were able to invade another host cell, however, then growth stopped
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and the parasites died (He et al., 2001). These experiments suggest that the "delayed
death phenotype" relates to apicoplast function and in that respect it was proposed that
the apicoplast might be essential for the establishment of the parasitophorous vacuole (He
et al., 2001). The "delayed death phenotype" occurs in both apicomplexan parasites but
interestingly, ciprofloxacin, an apicoplast replication inhibitor, causes immediate death
in P. falciparum but delayed death in T. gondii, suggesting that the apicoplast pathways
might fulfil different roles in Plasmodium and Toxoplasma parasites (Fichera et al., 1995,
Goodman et al., 2007).
The apicoplast is a non-photosynthetic plastid which contains a number of different bio-
chemical pathways. Fatty acid biosynthesis, for instance, occurs in the apicoplast. Like
in bacteria and plants, fatty acids in Plasmodium parasites are synthesised via the type II
pathway, which consists of single enzymes acting in concert to catalyse the condensation,
dehydration and reduction reactions (Ralph et al., 2004, White et al., 2005). Acetyl-CoA
is required in the first step of the pathway, and is provided by the pyruvate dehydrogenase
complex (PDH), which is also present in the apicoplast (Foth et al., 2005, McMillan et al.,
2005). Acetyl-CoA becomes carboxylated by acetyl-CoA carboxylase to form manoyl-
CoA, which is the committing step in fatty acid biosynthesis. Not all apicomplexan par-
asites possess a type II fatty acid synthesis pathway. Parasites like Cryptosporidium syn-
thesise fatty acids via the type I pathway in the cytosol, which is also present in mammals
and yeast (Zhu et al., 2000). The type I pathway consists of one protein (fatty acid syn-
thase), which contains all enzymatic reaction sites required for fatty acid synthesis (Smith
et al., 2003). Interestingly, the apicomplexan parasites T. gondii and Eimera tenella seem
to possess both fatty acid biosynthesis pathways, type II in the apicoplast and type I
potentially in the mitochondrion (Zhu, 2004, Mazumdar et al., 2006), suggesting that
differences exist in fatty acid metabolism between various Apicomplexa. Inhibition of
Plasmodium fatty acid synthesis by thiolactomycin, an inhibitor of the condensing en-
zymes FabB (β -ketoacyl-ACP synthase I), FabF (β -ketoacyl-ACP synthase II) and FabH
(β -ketoacyl-ACP synthase III) killed parasites in vitro (Waller et al., 1998). Triclosan also
killed parasites in vitro and was even able to clear mice infected with the rodent malaria
parasite P. berghei (Surolia and Surolia, 2001). It was shown that Triclosan inhibits FabI
(enoyl-ACP reductase) activity (Surolia and Surolia, 2001), making fatty acid biosynthe-
sis a potential antimalarial drug target.
Another important biosynthetic pathway present in the apicoplast is the non-mevalonate
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dependent isoprenoid biosynthesis. Like in bacteria and plants, the pathway in Plasmod-
ium parasites is 1-deoxy-D-xylulose-5-phosphate (DOXP) dependent. It was shown that
the antibiotic fosmidomycin inhibits DOXP reductoisomerase (catalysing the second step
in the pathway), killing P. falciparum in vitro and in vivo (Jomaa et al., 1999). Currently
fosmidomycin is used in clinical trials and it shows particularly promising results in com-
bination with clindamycin (Wiesner et al., 2002, Na-Bangchang et al., 2007).
Haem is an essential prosthetic group of, for example, cytochromes and is involved
in oxygen- and electron-transport. Although Plasmodium parasites generate free haem
through uptake and digestion of host cell haemoglobin, they rely on haem biosynthesis
(Surolia and Padmanaban, 1992). The pathway is divided between different compart-
ments including the apicoplast, mitochondrion and also possibly the cytosol (Ralph et al.,
2004). The first step of the reaction, the synthesis of δ -aminolevulinate from glycine
and succinyl-CoA, is catalysed by the δ -aminolevulinate synthase, which is located in
the mitochondrion (Varadharajan et al., 2002, Sato et al., 2004). The enzymes catalysing
the subsequent reactions in haem biosynthesis are present in the apicoplast (Sato et al.,
2004, van Dooren et al., 2006). However, the localisation of the last three enzymes in
the biosynthesis process, namely HemF (coproporphyrinogen oxidase), HemG (protopor-
phyrinogen oxidase) and HemH (ferrochelatase) is not clear, although HemH possibly
contains a N-terminal mitochondrial targeting peptide suggesting mitochondrial localisa-
tion (Ralph et al., 2004). On the contrary, HemG does not possess an obvious N-terminal
targeting peptide and thus could be a cytosolic protein. However, the mammalian HemG
is targeted to the mitochondrion by unknown internal targeting signals, a mechanism that
could also apply for the Plasmodium enzyme (Morgan et al., 2004, Dailey et al., 2005).
Prediction of HemF localisation is difficult because it contains several introns at the N-
terminus (Ralph et al., 2004). Further analyses are required to determine the exact locali-
sation of the last enzymes of the haem biosynthesis pathway.
Plasmodium possess different pathways for iron-sulphur ([Fe-S]) cluster biosynthesis.
The parasites are able to synthesise [Fe-S] cluster in the apicoplast as well as in the mi-
tochondrion (Seeber, 2002). The pathway in the apicoplast is likely to be responsible for
providing [Fe-S] cluster for enzymes like lipoic acid synthase (LipA), ferredoxin, tRNA
methylthiotransferase or IspG and IspH, both of which are involved in isoprenoid biosyn-
thesis.
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1.5.2. The mitochondrion
The mitochondrion in Plasmodium parasites was derived through primary endosymbiosis
of an α-proteobacterium resulting in an organelle surrounded by two membranes (van
Dooren et al., 2006). The appearance of mitochondria in Plasmodium parasites varies
between different species and life cycle stages. P. falciparum intraerythrocytic stages
contain a single mitochondrion without cristae, whereas P. falciparum gametocytes con-
tain multiple cristate mitochondria (Rudzinska, 1969, van Dooren et al., 2006). During
the intraerythrocytic development, the mitochondrion changes its morphology along with
the apicoplast. The mitochondrion elongates and branches during schizogony before it
divides. Multiple organelles are formed, which are segregated to the single merozoites
(van Dooren et al., 2005).
The mitochondrion in Plasmodium has retained a small 6 kb genome, which only encodes
three proteins, the cytochrome b, cytochrome c oxidase I and cytochrome c oxidase III, in
addition to 20 fragmented rRNAs (Sherman, 2005). Most of the genes of the mitochon-
drial genome were transferred to the parasites nuclear genome (Adams and Palmer, 2003).
Consequently, mitochondrial proteins encoded in the nucleus have to be transported to the
mitochondrion, and the precise mechanisms of mitochondrial protein targeting will be de-
scribed in Chapter 1.6.5.
One of the most important functions of the mitochondrion in mammals is the genera-
tion of ATP by oxidative phosphorylation, the main energy source for the cell. Therefore,
it was somewhat surprising when it was shown that the primary source of energy for P.
falciparum intraerythrocytic stages is provided by glycolysis (Bryant et al., 1964). Most
of the pyruvate generated during glycolysis is metabolised into lactate rather then into
acetyl-CoA like in mammals (Sherman, 2005). In mammals, this step is catalysed by
PDH, which links glycolysis with the TCA cycle. Because of these findings in Plasmod-
ium, it was initially thought that the parasites do not possess a TCA cycle. However,
the genome project revealed the presence of genes encoding all necessary proteins in the
genome (Gardner et al., 2002). Further analyses on the protein level, however, revealed
some differences to the mammalian counterpart, giving reason to speculate about the pre-
cise function of the Plasmodium TCA cycle. Citrate synthase, the first enzyme in the
cycle, is present in Plasmodium blood stages and it was confirmed to localise to the mito-
chondrion (Tonkin et al., 2004). Aconitase, catalysing the second step, the isomerisation
of citrate to isocitrate, is also present in the blood stages. It was shown that the enzyme
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possesses aconitase activity in vitro and localises to multiple destinations including the
mitochondrion, cytosol and food vacuole (Hodges et al., 2005). The third enzyme in the
TCA cycle is the isocitrate dehydrogenase. A potential mitochondrial enzyme was iden-
tified in the P. falciparum genome, and biochemical analyses revealed that the reaction
of the P. falciparum enzyme is NADP+ dependent in contrast to the mammalian enzyme,
which requires NAD+ (Wrenger and Müller, 2003). Because NADPH is produced during
the reaction, which can not be fed into the electron transport chain, it was suggested that
the isocitrate dehydrogenase might be involved in mitochondrial redox control. The sub-
sequent conversion of α-ketoglutarate to succinyl-CoA is catalysed by the multienzyme
complex α-ketoglutarate dehydrogenase, which is present in the mitochondrion (Gün-
ther et al., 2005, McMillan et al., 2005). The generated succinyl-CoA is either used for
haem biosynthesis or it is converted to succinate by the succinyl-CoA synthase. The pro-
tein consists of α and β subunits and homologues were identified in the P. falciparum
genome (van Dooren et al., 2006). The next enzyme in the TCA cycle is the succinate
dehydrogenase, which catalyses the conversion of succinate to fumarate. Additionally,
succinate dehydrogenase is also involved in oxidative phosphorylation (complex II), and
a functional homologue of the enzyme was identified in P. falciparum (Suraveratum et al.,
2000, Takeo et al., 2000). Fumarate is then converted into malate by a fumarate hydratase.
The homologue identified in P. falciparum showed, however, more similarity to the bac-
terial iron-sulphur cluster containing class I protein than to the class II protein found in
yeast and mammals (Flint et al., 1992, Gardner et al., 2002). In the final step of the TCA
cycle, malate is converted to oxaloacetate, catalysed by malate dehydrogenase. P. falci-
parum possess a homologue of this enzyme, however, it does not appear to localise to
the mitochondrion (Lang-Unnasch, 1995). Instead, a malate-quinone oxidoreductase was
identified with potential mitochondrial localisation. In Helicobacter pylori, this enzyme
replaces malate dehydrogenase in the TCA cycle, which has also been suggested for P.
falciparum (Kather et al., 2000, Gardner et al., 2002). Malate-quinone oxidoreductase is
a membrane bound flavoprotein which uses ubiquinone as electron acceptor and thus pro-
vides electrons for the electron transport chain (Uyemura et al., 2004). Although potential
homologues of all TCA cycle enzymes were identified, more studies are required to inves-
tigate their precise functions and confirm their predicted subcellular localisation. At the
moment it can only be speculated whether the Plasmodium TCA cycle in the intraerythro-
cytic stages provides reducing equivalents for the electron transport chain located at the
inner mitochondrial membrane. Since Plasmodium intraerythrocytic stages seem to rely
on glycolysis as their main energy source, it could be that the TCA cycle fulfills a biosyn-
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thetic role by providing molecules for other biochemical pathways such as succinyl-CoA
for haem biosynthesis. Other life cycle stages, however, might rely on the TCA cycle as
the prime energy source.
Plasmodium parasites maintain a membrane potential across their inner mitochondrial
membrane (Srivastava et al., 1997). This is achieved by electron transport across the
membrane into the intermembrane space, which is the basis of oxidative phosphorylation
in mammals. The electrons, which are transported in Plasmodium, are provided by sev-
eral dehydrogenases located in the inner membrane, which use ubiquinone as the electron
acceptor. These dehydrogenases include a single-subunit NADH dehydrogenase, dihy-
droorotate dehydrogenase, glycerol-3-phosphate dehydrogenase and malate-quinone ox-
idoreductase (van Dooren et al., 2006). In mammals, electrons are provided by the TCA
cycle and are transferred to the electron transport chain by complex I, a multi-subunit
NADH dehydrogenase. This enzyme is absent in Plasmodium parasites (Gardner et al.,
2002) but, as already mentioned above, the parasites possess several other dehydroge-
nases, which can provide electrons. P. falciparum also has homologues of complex II,
complex III and complex IV, which are responsible for the re-oxidisation of ubiquinone
and generation of the membrane potential by pumping protons into the intermembrane
space. Generally, ATP synthesis is driven by this membrane potential and is catalysed by
ATP synthase. However, homologous for only some ATP synthase subunits were iden-
tified in the P. falciparum genome (Gardner et al., 2002), suggesting that Plasmodium
mitochondria are not able to synthesise ATP via this route.
If the electron transport chain does not result in the production of ATP what other func-
tion might it have? Painter and colleagues recently suggested, that the main function
of the electron transport chain is to regenerate ubiquinone, and thus to provide oxidised
ubiquinone for dihydroorotate dehydrogenase (Painter et al., 2007). Dihydroorotate dehy-
drogenase is part of the pyrimidine biosynthesis pathway, which is essential for parasite
survival. P. falciparum are unable to scavenge pyrimidines and therefore rely on the de
novo synthesis. Dihydroorotate dehydrogenase is therefore a potential antimalarial drug
target, and by using high-throughput screening some potential Plasmodium specific in-
hibitors have already been identified (Baldwin et al., 2005).
Parts of the folate metabolism are also present in the mitochondrion, which is very im-
portant for parasite viability, as it is a target of several antimalarial drugs. Despite the
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importance of this pathway, its precise function is not very well understood (Hyde, 2005).
It is thought to be the main source of one-carbon (C1) units for other metabolic pathways,
including pyrimidine biosynthesis, which is required for DNA synthesis, and methionine
biosynthesis.
As mentioned above, [Fe-S] cluster biosynthesis occurs in the mitochondrion as well as in
the apicoplast. Mitochondrial proteins which require [Fe-S] cluster include for example
members of the electron transport chain, the aconitase and potentially the fumarate hy-
dratase. [Fe-S] cluster dependent enzymes are also found in the cytosol, and it is debated
whether the [Fe-S] cluster for these enzymes are provided by the mitochondrial pathway,
as it is the case in other organisms, or whether the apicoplast [Fe-S] cluster biosynthesis
pathway provides [Fe-S] cluster for the cytosolic proteins (van Dooren et al., 2006).
1.6. Protein targeting
Protein targeting in Plasmodium parasites is a very complex process, and multiple desti-
nations to target proteins exist. The following sections describe briefly what is known so
far about protein targeting to various destinations in Plasmodium parasites.
1.6.1. Protein targeting to the host cell
During the intraerythrocytic development cycle, the parasite remodels the erythrocyte,
a process which requires protein trafficking. It was shown that proteins targeted to the
host cell contain the Plasmodium export element/vacuolar targeting signal (PEXEL/VTS)
for translocation across the parasitophorous vacuole membrane (Hiller et al., 2004, Marti
et al., 2004). However, how the proteins get across this membrane is not known. Two
routes for transport to the erythrocyte membrane have been described. Proteins targeted
to the host cell like KAHRP or PfEMP-3 contain a typical signal peptide at their N-
terminus that allows co-translational import into the secretory pathway (Wickham et al.,
2001, Lopez-Estraño et al., 2003). The proteins are transported to the parasitophorous
vacuole and the PEXEL/VTS signal allows transport across the parasitophorous vacuole
membrane. In the erythrocyte cytosol, the proteins interact with the Maurer’s clefts, but
how they are transported to the cytoplasmatic side of the erythrocyte membrane is unclear.
Transport of PfEMP-1 to the erythrocyte membrane requires a different mechanism, since
PfEMP-1 does not contain a classical signal peptide and thus its entry into the secretory
system is not clear. Data suggest that PfEMP-1 enters the ER via its putative transmem-
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brane domain and is then transported to the parasitophorous vacuole membrane (Knuepfer
et al., 2005). It has been suggested that PfEMP-1 is packaged into the Maurer’s clefts
while they are forming by budding off the parasitophorous vacuolar membrane (Spycher
et al., 2006), and recently it was shown that P. falciparum skeleton binding protein 1
(PfSBP-1) is involved in this process (Maier et al., 2007). It seems that PfSBP-1 is also
required for PfEMP-1 trafficking to the erythrocyte surface (Maier et al., 2007). Further-
more, exported proteins were identified without an obvious PEXEL/VTS motif (Blisnick
et al., 2000, Spycher et al., 2003, Spielmann et al., 2006), suggesting yet another potential
trafficking route for these proteins. Potentially, these proteins are also exported while the
Maurer’s cleft are formed, but further analyses are required to support this hypothesis.
1.6.2. Protein targeting to the food vacuole
Host cell haemoglobin is endocytosed by the cytostome and is subsequently transported to
the food vacuole. Here, haemoglobin is digested by several proteases, which are targeted
to the food vacuole via the secretory system, requiring ER and Golgi transport (Tonkin
et al., 2006a). However, a food vacuole targeting peptide has not yet been described,
although recently it was shown that the first 120 amino acids of the cysteine protease
falcipain-2 are sufficient to target GFP to the food vacuole (Dasaradhi et al., 2007). These
data suggest that trafficking to the food vacuole might be mediated by a potential N-
terminal targeting peptide, but further analyses are required to support this finding. After
entry into the secretory system, two pathways for trafficking to the food vacuole were
described. The first was observed for the aspartic protease plasmepsin II, which is in-
volved in the first steps of haemoglobin degradation (Klemba et al., 2004a). The protein
contains a transmembrane domain and is transported through the ER as a membrane pro-
tein. It is trafficked to the cytostome and from there it is delivered to the food vacuole,
possibly through vesicular transport. In the food vacuole, the transmembrane domain is
cleaved releasing plasmepsin II into the food vacuole (Klemba et al., 2004a). A similar
trafficking mechanism was proposed for falcipain-2, which also contains a transmem-
brane domain (Dasaradhi et al., 2007). Interestingly, no classical signal peptide is found
at the N-terminus of this protein. But as already suggested for PfEMP-1 import into the
secretory system, the hydrophobic transmembrane domain might facilitate the import into
the ER. Another route of trafficking was described for dipeptide aminopeptidase I, which
contains no transmembrane domain (Klemba et al., 2004b). It was shown that the protease
enters the endomembrane system and targets to the food vacuole via the parasitophorous
vacuole, where it is taken up again during endocytosis and transported to the food vacuole.
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1.6.3. Protein targeting to the apical organelles
Protein trafficking to the apical organelles is not very well understood in P. falciparum. It
is known that targeting to the rhoptries in P. falciparum and T. gondii is via the ER and
Golgi (Howard and Schmidt, 1995), thus the proteins possess a classical N-terminal signal
peptide. Within the secretory system a second targeting step is required and for T. gondii it
has been shown that this is accomplished by either a tyrosin-based motif at the C-terminus
of the proteins, or by the interaction with other proteins. Indeed, targeting of membrane
proteins to the micronemes also requires a tyrosin-based and acidic amino acid-based mo-
tif in T. gondii (Cristina et al., 2000, Hoppe et al., 2000). These features are also found
in some Plasmodium proteins, however, for the P. falciparum rhoptry-associated protein
1 (RAP-1) and for the micronemal erythrocyte binding antigen 175 (EBA-175), it was
shown that the C-terminal tyrosin-based motifs are not required for correct targeting to
the organelles (Baldi et al., 2000, Gilberger et al., 2003). It was suggested that the proteins
potentially are transported in concert with other proteins, which escort them to the correct
organelle. Recently, Treeck and colleagues demonstrated that a luminal cysteine rich re-
gion at the C-terminus of EBA-175 together with correct timing of expression is crucial
for micronemal targeting of this protein (Treeck et al., 2006). Although this cysteine rich
region is highly conserved in the EBL-superfamily, it is not found in other micronemal
proteins like apical membrane antigen 1 (AMA-1) or subtilisin like protease (SUB2), sug-
gesting that multiple mechanisms facilitate micronemal protein targeting (Treeck et al.,
2006). Not very much is known about protein targeting to the dense granules. The only
requirement shown so far for correct targeting in P. falciparum was correct timing of ex-
pression. A GFP fusion protein of the ring infected erythrocyte antigen (RESA) was only
targeted to the dense granules when under control of its endogenous promoter (Rug et al.,
2004).
1.6.4. Protein targeting to the apicoplast
Since most of the proteins originally encoded by the plastid genome were transferred into
the nuclear genome, a machinery to import apicoplast proteins encoded by the nucleus had
to be developed. In plants, which contain a primary plastid, proteins designated for the
plastid contain a N-terminal transit peptide for translocation into the plastid (Vothknecht
and Soll, 2000, Jackson-Constan and Keegstra, 2001). The transit peptide is rich in basic
amino acids and thus contains a positive net-charge, and additionally contains a chaperone
binding site. The transit peptide interacts with protein complexes within the plastid mem-
branes, which facilitate the post-translational protein import. These protein complexes are
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known as Toc and Tic (Translocon at the outer/inner membrane of chloroplasts) (Soll and
Schleiff, 2004). During protein import, the transit peptide is cleaved once it has passed
the inner membrane, catalysed by a stromal processing peptidase producing the mature
protein (Richter and Lamppa, 1998). The situation in apicomplexan parasites is somewhat
more complicated than in plants, because the apicoplast is a secondary plastid surrounded
by four membranes rather than two. Thus, proteins targeted to the apicoplast possess, in
addition to the transit peptide, a signal peptide that allows import into the secretory path-
way (van Dooren et al., 2001). Nuclear encoded proteins that are directed to the apicoplast
possess a bipartite leader sequence that firstly imports the protein co-translationally into
the secretory system and secondly directs it to the apicoplast (Waller et al., 2000). It was
also suggested that apicoplast targeting through the secretory pathway is Golgi indepen-
dent and diverts straight from the ER to the apicoplast (DeRocher et al., 2005, Tonkin
et al., 2006b). Toc and Tic homologues were identified in the P. falciparum genome, and
it is speculated that they span the four apicoplast membranes to promote protein import
into the apicoplast (Mullin et al., 2006).
The likelihood of an apicoplast localisation of a protein can be estimated on the basis of
the bipartite leader sequence using several prediction programs including SignalP and the
Plasmodium specific PATS (prediction of apicoplast targeted sequences) (Nielsen et al.,
1997, Zuegge et al., 2001).
1.6.5. Protein targeting to the mitochondrion
Most of the mitochondrial proteins are encoded in the nucleus and thus need to be im-
ported into the mitochondrion. Mitochondrial protein import occurs post-translationally,
and targeting is facilitated via different pathways. The most widespread method for mi-
tochondrial protein import is via a N-terminal transit peptide, but internal signals and
transmembrane domains are also able to facilitate mitochondrial protein import (Pfanner
and Geissler, 2001). Mitochondrial protein import in P. falciparum has so far been shown
to be accomplished by N-terminal transit peptides, which if fused to green fluorescent
protein (GFP) direct GFP into the mitochondrion (Sato et al., 2003). Import of the pro-
tein across the two mitochondrial membranes is achieved by the protein complexes Tom
and Tim (Translocase of the outer/inner membrane) (Pfanner and Geissler, 2001). Ho-
mologues of the Tom and Tim complexes were identified in the P. falciparum genome,
suggesting that mitochondrial protein import in Plasmodium is similar to mitochondrial
protein import in other organisms (van Dooren et al., 2006).
As for apicoplast proteins, the potential mitochondrial localisation can be predicted by the
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nature of the transit peptide using programs like MitoProt, Predotar or the P. falciparum
specific PlasMit (Claros and Vincens, 1996, Bender et al., 2003, Small et al., 2004).
1.6.6. Dual protein targeting
In plants it has been shown that some proteins have multiple destinations and that these
proteins are dually targeted to different organelles (Silva-Filho, 2003). Different mecha-
nisms can be involved in the regulation of this process. Alternative splicing is one possi-
bility or the duplication of the gene with the acquisition of different 5’ ends can determine
the location of the protein. Alternative translation initiation or translation initiation from
non-AUG start codons are other ways of regulation. Post-translational modifications as
well as ambiguous targeting sequences can also play important roles in determining the
final localisation of a protein (Silva-Filho, 2003).
Multiple targeting has also been observed in P. falciparum. The zinc metalloprotease fal-
cilysin was shown to be targeted to the food vacuole, to the apicoplast and also likely to
the mitochondrion (Ponpuak et al., 2007). In the food vacuole, falcilysin participates in
the degradation of haemoglobin, whereas in the apicoplast and mitochondrion it was sug-
gested that it may be involved in transit peptide degradation. Different mechanisms that
might be involved in the multiple targeting of falcilysin were discussed by Ralph (2007)
and include potential post-translational modifications, alternative splicing and/or alterna-
tive translation initiation. Recently, dual targeting was also demonstrated in T. gondii.
Pino and colleagues showed dual targeting of proteins to the apicoplast and mitochon-
drion (Pino et al., 2007). The functions of the dually targeted proteins in T. gondii are
required by both organelles and the authors suggest that the main mechanism involved is
bimodal targeting. Generally, with the bimodal mechanism, dual localisation of a protein
is achieved by the different "organelle import machineries" recognising different parts of
the protein. In apicomplexan parasites one crucial step for dual targeting to the apicoplast
and the mitochondrion is the import into the secretory pathway. Bimodal targeting sug-
gests that the signal peptide of these dual targeted proteins is weak and is not recognised
by the signal recognition particle (SRP) at all times, resulting in some proteins trafficking
to the apicoplast via the secretory system and some proteins being post-translationally
imported into the mitochondrion. However, Pino and colleagues have also shown that
different translation initiation and differential splicing can affect the protein localisation,
and are likely to play a role in dual protein targeting (Pino et al., 2007).
Dual protein targeting in Plasmodium and Toxoplasma might allow the parasites to adapt
quickly to changes in their environment, but the precise mechanisms controlling dual tar-
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geting remain elusive and require further analyses.
1.7. Lipoic acid
Lipoic acid (6,8-thioctic acid or 1,2-dithiolane-3-pentanoic acid) and its reduced form,
dihydrolipoic acid, are naturally occurring thiol compounds, which were first isolated
1951 by Reed and colleagues (Reed et al., 1951) (Figure 1.4). Most of the lipoic acid
present in the cell is found in the protein-bound form, as it is an essential cofactor of the
α-keto acid dehydrogenase complexes (KADH) and the glycine cleavage system (GCV).
However, apart from being a cofactor of these enzyme complexes, lipoic acid and its
reduced form are potent antioxidants with a low redox potential of −0.32 V (Jocelyn,
1967).
A Lipoic acid
S S
OH
O
B Dihydrolipoic acid
SH SH
OH
O
Figure 1.4.: Chemical structure of (A) lipoic acid and its reduced form (B) dihydrolipoic
acid
1.7.1. Lipoic acid functions as an antioxidant
Due to the low redox potential, lipoic acid is not only able to scavenge reactive oxygen
species (ROS), but also has the power to reduce other disulfides such as glutathione disul-
fide (GSSG) or vitamin C non enzymatically (Jones et al., 2002). In this respect, lipoic
acid has been suggested as the "antioxidant of antioxidants" (Bilska and Wlodek, 2005).
Lipoic acid and dihydrolipoic acid are also able to chelate redox active metal ions such
as iron, thus preventing the production of highly reactive hydroxyl radicals through the
Fenton reaction (Packer et al., 1995, Suh et al., 2004b). The antioxidant characteristics of
lipoic acid could also play a role in Plasmodium, which is continuously exposed to oxida-
tive stress produced by host immune response but also by its own metabolism, particulary
during haemoglobin degradation (Müller, 2004). But not only free lipoic acid might act
as an antioxidant. In Mycobacterium tuberculosis it has been shown that protein-bound
lipoic acid reduces a thioredoxin-like protein and thus contributes to the pathogen’s an-
tioxidant defense (Bryk et al., 2002). P. falciparum and T. gondii thioredoxin can also be
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reduced by free lipoic acid in vitro, suggesting a potential function of lipoic acid in the
defense of oxidative stress in these parasites (Akerman and Müller, 2005). More research
is required to elucidate the potential role of lipoic acid as an antioxidant in apicomplexan
parasites.
Generally, the interest in lipoic acid has increased due to its antioxidant activities and its
pharmacologic properties are extensively investigated. It was, for example, shown that
lipoic acid has beneficial effects in the therapy of diabetes type 1 and type 2, which are
both associated with increased oxidative stress (Packer et al., 2001). Type 1 diabetes
is caused by autoimmune destruction of the insulin generating β -cells in the pancreas,
whereas in type 2 diabetes insulin resistance is one of the major problems (Packer et al.,
1995). The elevated glucose level in diabetes patients leads to an increase of ROS causing
increased oxidative stress, which can be reduced by lipoic acid (Packer et al., 1995, 2001,
Bilska and Wlodek, 2005). In type 2 diabetes, administration of lipoic acid additionally
increased glucose uptake into the cells by activating the insulin signalling cascade (Packer
et al., 2001, Konrad, 2005). Lipoic acid has also been shown to exhibit beneficial effects
in the treatment of other diseases associated with oxidative stress, such as neurodegener-
ative diseases like Alzheimer’s disease (Holmquist et al., 2007).
Additionally, lipoic acid can affect gene transcription regulation by influencing redox sen-
sitive transcription factors present in the cytosol, by either promoting or inhibiting their
translocation to the nucleus (Zhang and Frei, 2001, Suh et al., 2004a). One redox sensi-
tive transcription factor is nuclear factor-κB (NF-κB), and its translocation to the nucleus
is prevented by lipoic acid (Zhang and Frei, 2001, Bilska and Wlodek, 2005). This is
particularly interesting in the treatment of diseases like cancer or acquired deficiency syn-
drome (AIDS), because active NF-κB plays an important role in the progress of these
diseases (Patrick, 2000, Bilska and Wlodek, 2005). Another redox sensitive transcription
factor influenced by lipoic acid is nuclear factor erythroid2-related factor 2 (Nrf2). In
contrast to NF-κB, nuclear translocation of Nrf2 is increased and causes, for example, an
increased production of γ-glutamylcysteine synthetase (GCS), which catalyses the first
step in glutathione synthesis (Suh et al., 2004a). This suggests that lipoic acid is not only
able to reduce GSSG in the cell, but also increases its production.
Due to the antioxidant properties of lipoic acid, the cosmetic industry has also shown
extensive interest in lipoic acid, particularly because it was shown to reduce the signs of
skin ageing (Beitner, 2003).
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Lipoic acid research covers many different areas, since this compound seems to have a
variety of different effects. Beside its antioxidant properties, it is an essential cofactor
of several multienzyme complexes involved in energy and folate metabolism, and amino
acid degradation. Its role as a cofactor is of particular interest in this thesis, and lipoic
acid functions in these complexes and its production and attachment will be explained in
the following sections.
1.7.2. Lipoic acid functions as a cofactor of multienzyme complexes
1.7.2.1. α-Keto acid dehydrogenase complexes
Lipoic acid is a covalently attached cofactor of KADHs and is essential for their cat-
alytic activity. KADHs consist of multimers of three independent proteins, namely a
substrate specific α-keto acid decarboxylase (E1), an acyltransferase (E2) and a dihy-
drolipoamide dehydrogenase (E3). These multienzyme complexes can be up to 10 MDa
in size. In eukaryotes three KADHs are present, the pyruvate dehydrogenase (PDH), the
branched chain α-keto acid dehydrogenase (BCDH) and the α-ketoglutarate dehydroge-
nase (KGDH) (Perham, 2000).
Generally, KADHs convert an α-keto acid, NAD+ and coenzyme A (CoA) to CO2,
NADH and acyl-CoA and the reaction mechanism is shown in Figure 1.5. The substrate
specific E1 subunit contains thiamine pyrophosphate (TPP) as a cofactor, and catalyses
the decarboxylation of a α-keto acid, generating CO2 and acyl-TPP bound to the pro-
tein. Subsequently, the acyl-group is transferred to the lipoamide-group of the E2 subunit,
which is covalently attached to a specific lysine residue of the acyltransferase subunit. The
lipoamide transfers the acyl-group from the E1 subunit to coenzyme A to form acyl-CoA.
The last step in the reaction is the re-oxidation of dihydrolipoamide by the FAD contain-
ing E3 subunit producing NADH (Reed and Hackert, 1990, Perham, 2000).
The E2 subunits form homo-trimers, which assemble to either 24mers in a cubic organ-
isation or 60mers in a pentagonal dodecahedron organisation (Reed and Hackert, 1990).
This high molecular mass oligomer can be considered as the core of the multienzyme
complexes, and E1 and E3 subunits bind to this core. The E2 protein consists of three dis-
tinct domains. The N-terminal part of the protein is the lipoyl-domain, which contains the
signature lysine residue that is post-translationally modified by attachment of lipoic acid.
This domain is followed by a subunit binding domain, which confers binding of the E1
and E3 subunits to the E2 core structure. Subsequent to this is a catalytic domain found
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Figure 1.5.: General reaction mechanism of KADHs
The thiamine pyrophosphate dependent decarboxylase subunit (E1; blue) catalyses the decarboxy-
lation of an α-keto acid and the subsequent reductive acylation of the lipoyl-group bound to the
acyltransferase (E2; red). The E2 subunit catalyses the transfer of the acyl-group to CoA. The third
subunit, the dihydrolipoamide dehydrogenase (E3; green), re-oxidises the reduced lipoyl-group of
the E2-subunit with NAD+ as the final electron acceptor.
Abbreviations: RCOCOOH, α-keto acid; TPP, thiamine pyrophosphate; RCOH-TPP,
hydroxyacyl-thiamine pyrophosphate; RCO-S-LipSH, acyl-lipoamide; LipS2, lipoamide;
Lip(SH)2, dihydrolipoamide; CoASH, Co-enzyme A; RCO-CoA, acyl-CoA
at the C-terminus, which catalyses the transfer of the acyl-rest to coenzyme A producing
acyl-CoA and dihydrolipoamide. The domains are separated by flexible linker regions,
which are ∼20-30 amino acids long, and rich in the amino acids proline and alanine, giv-
ing them flexibility (Perham, 1991). Thus, these flexible linkers allow the lipoyl-domain
to function as a "swinging-arm", transporting reaction intermediates from the E1 to the E2
and E3 subunits (Aevarsson et al., 1999, Mooney et al., 2002). E2 subunits possess one
to three lipoyl-domains depending on the complex and organism they occur in. In in vitro
assays it was shown that the lipoyl-domains alone can be expressed and are recognised
by the lipoic acid attaching enzymes, and thus become post-translationally lipoylated (Ali
and Guest, 1990, Dardel et al., 1990, Quinn et al., 1993). Figure 1.6 displays a schematic
diagram of the P. falciparum KADH-E2 subunits and the H-protein, which is part of the
glycine cleavage system described below.
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Figure 1.6.: Schematic diagram of P. falciparum H-protein and KADH-E2 subunits
This figure displays schematically the structure of P. falciparum H-protein (A), PDH-E2 (B),
BCDH-E2 (C) and KGDH-E2 (D). The KADH-E2 subunits consist of three domains, the lipoyl
domains at the N-terminus (yellow), a substrate binding domain (green) and the catalytic domain
at the C-terminus (red). The PDH-E2 possesses two lipoyl domains (9 kDa and 16 kDa in size)
whereas the BCDH-E2 and KGDH-E2 only possess one lipoyl domain each (13 kDa and 12 kDa).
The H-protein only consists of lipoyl-domain.
The E1 proteins confer substrate specificity to the complexes and require TPP and Mg2+
as cofactors for their activity. The dihydrolipoamide dehydrogenase (E3) is a flavopro-
tein, which is responsible for the re-oxidation of dihydrolipoamide. In most organisms,
the dihydrolipoamide dehydrogenase is shared between the different multienzyme com-
plexes (Bourguignon et al., 1996). However, some organisms contain KADH specific E3
subunits (Lutziger and Oliver, 2000).
The PDH catalyses the oxidative decarboxylation of pyruvate to acetyl-CoA. The enzyme
complex is generally found in the mitochondrion where it links glycolysis with the TCA
cycle. Plants possess an additional PDH enzyme complex, which is present in the plas-
tid, where it provides acetyl-CoA and NADH for fatty acid biosynthesis (Mooney et al.,
2002). The situation in apicomplexan parasites is unique since these parasites possess
only one PDH, which is present in the apicoplast (Foth et al., 2005). Accordingly, they
possess two organelle specific E3 proteins (McMillan et al., 2005).
BCDH is located to the mitochondrion where it is involved in the degradation of the
branched-chain amino acids valine, leucine and isoleucine. First, the branched-chain
amino acid transaminase catalyses the production of the branched chain α-keto acids.
Valine is converted into α-ketoisovaleric acid, leucine into α-ketoisocaproic acid and
isoleucine into α-keto-β -methylvaleric acid. These α-keto acids are then oxidative decar-
boxylated by BCDH generating isobutyryl-CoA, isovaleryl-CoA and α-methylbutyryl-
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CoA, respectively. Eventually, the acyl-CoA products can be converted to acetyl-CoA
and/or succinyl-CoA for usage in the TCA cyle (Anderson et al., 1998). Homologues of
BCDH-E1 and BCDH-E2 were identified in P. falciparum, and it has been shown that this
enzyme complex is present in the mitochondrion (Günther et al., 2005, McMillan et al.,
2005).
The KGDH is also found in the mitochondrion where it catalyses the oxidative decarboxy-
lation of α-ketoglutarate to succinyl-CoA as an integral part of the TCA cycle. Succinyl-
CoA is also used for the biosynthesis of haem, whereas NADH is fed into the respiratory
chain via complex I (NADH dehydrogenase). P. falciparum also possesses a KGDH,
which is located in the mitochondrion (Günther et al., 2005, McMillan et al., 2005).
1.7.2.2. Glycine cleavage system
The glycine cleavage system (GCV) represents another mitochondrial multienzyme com-
plex, which is dependent on lipoic acid. It catalyses the oxidative decarboxylation and
deamination of glycine, generating CO2, NH3, NADH and N5,N10-methylene tetrahydro-
folate (CH2-THF), and the reaction mechanism is shown in Figure 1.7. The GCV consists
of multiple copies of four protein subunits, namely P-protein, H-protein, T-protein and
L-protein. The P-protein is a pyridoxal phosphate dependent decarboxylase, which catal-
yses the decarboxylation of glycine and the reductive methylamination of the lipoamide,
which is covalently attached to the H-protein. The T-protein requires THF for its activity,
and catalyses the transfer of methylene to THF and the subsequent release of NH3. The
H-protein then reacts with the L-protein, the dihydrolipoamide dehydrogenase described
above, to oxidise the dihydrolipoamide with NAD+ as the final electron acceptor. The
released CH2-THF reacts with another glycine molecule, resulting in the formation of
serine, a reaction that is catalysed by serine hydroxymethyltransferase (SHMT), which is
closely associated with the GCV (Douce et al., 2001).
Overall, the reaction mechanism of the GCV is very similar to the one observed in
KADHs, with lipoic acid function as a shuttle transporting reaction intermediates to the
different active sites in the complex. As the lipoyl-moieties in the KADH-E2 subunits,
lipoic acid is covalently attached via an amide linkage to the ε-amino group of a conserved
lysine residue of the H-protein. Structurally, the H-protein is related to the lipoyl-domains
of the KADH-E2 subunits and could be seen as the "lipoyl-domain" of the GCV (Figure
1.6).
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Figure 1.7.: Reaction mechanism of the glycine cleavage system
The P-protein, a pyridoxal phosphate dependent decarboxylase, catalyses the decarboxylation of
glycine and the subsequent transfer of the methylamine-group to the lipoamide-group of the H-
protein. The methylamine-group is passed on the T-protein, which catalyses its deamination.
The L-protein is responsible for the re-oxidization of the dihydrolipoamide of the H-protein with
NAD+ as the final electron acceptor. A serine hydroxymethyltransferase associated with the
glycine cleavage system catalyses the reaction of glycine with the methyl-group bound to tetrahy-
drofolate to form serine. The image is taken from Douce et al. (2001) with permission from
Elsevier.
Abbreviations: P, P-protein; H, H-protein; T, T-protein; L, L-protein, SHMT, serine hydrox-
ymethyltransferase; THF, tetrahydrofolate; Hmet , methylaminated H-protein; Hred , reduced form
of H-protein; Hox, oxidized form of H-protein
A detailed structure of the GCV is not known, but the subunit stoichiometry of plant
GCV was investigated and it was shown to contain four P-protein homo-dimers, 27 H-
protein monomers, nine T-protein monomers and two L-protein homo-dimers, with the
H-proteins forming the core of this complex (Oliver et al., 1990). Homologues of all sub-
units, except for the P-protein, have been identified in the P. falciparum genome. Further
analyses suggest that the GCV is present in the mitochondrion, since all identified sub-
units possess potential mitochondrial transit peptides at their N-termini (Salcedo et al.,
2005).
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1.7.3. Lipoic acid metabolism
Lipoic acid is post-translationally attached to the KADH-E2 subunits and to the H-protein
of the GCV. It is ligated to the ε-amino group of a conserved lysine residue of the KADH-
E2 and the H-protein (Reche and Perham, 1999, Douce et al., 2001). This is achieved
by either of the pathways displayed in Figure 1.8. Lipoic acid can be synthesised de
novo and biosynthesis requires two enzymes. First, the octanoyl-ACP:protein N-octanoyl
transferase (LipB) covalently attaches octanoyl-acyl carrier protein (ACP) to the enzyme
complexes (Cronan et al., 2005, Zhao et al., 2005). The octanoyl-ACP used as a precur-
sor for lipoic acid synthesis is provided by fatty acid biosynthesis (Gueguen et al., 2000,
Miller et al., 2000). In a second step, two sulphurs are inserted into the C8-chain of the
octanoyl-moiety at positions six and eight, to form the lipoyl-arm. This reaction is catal-
ysed by lipoic acid synthase (LipA), an S-adenosyl-methionine (AdoMet)-dependent, [Fe-
S] cluster-containing enzyme, which shows a high degree of mechanistic similarity to bi-
otin synthase (Miller et al., 2000, Zhao et al., 2003, Cicchillo et al., 2004a). Lipoic acid
can also be salvaged from the environment, and scavenged lipoic acid is ligated directly
to the enzyme complexes by either of the two known salvage pathways. The first involves
one enzyme, a lipoic acid protein ligase A (LplA), which attaches scavenged lipoic acid
in a single ATP-dependent reaction (Cronan et al., 2005). The second salvage pathway
consists of two enzymes that catalyse the attachment of lipoic acid to the enzyme com-
plexes. Lipoic acid is initially activated by the lipoate-activating enzyme using ATP or
GTP, and is then ligated to the enzyme complexes by a lipoyltransferase (Fujiwara et al.,
1999, 2001, 2007).
Almost all organisms are able to synthesise lipoic acid using the above described biosyn-
thesis pathway, generally found in their mitochondrion. Plants possess two biosynthesis
pathways, one being present in the mitochondrion and the other found in the plastid (Ya-
suno and Wada, 2002). Mammals possess the genes encoding for the proteins comprising
the biosynthesis pathway, and lipoic acid synthase has been shown to be essential for em-
bryogenic development (Yi and Maeda, 2005). However, later on, mammals seem to rely
primarily on the uptake of lipoic acid through vitamin transporters (Prasad and Ganap-
athy, 2000). The scavenged lipoic acid is then ligated to the enzyme complexes by the
salvage 2 pathway. In contrast, bacteria possess the salvage 1 pathway and scavenged
lipoic acid is attached to the enzyme complexes in a single reaction catalysed by LplA
(Cronan et al., 2005). Plants also possess a functional LplA-like protein, which is pre-
dicted to be mitochondrial but its importance in vivo has not yet been analysed (Kang
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Figure 1.8.: Lipoic acid metabolism
Three lipoylation pathways are known. The biosynthesis pathway consists of octanoyl-
ACP:protein N-octanoyl transferase (LipB), which attaches octanoyl-ACP to a specific lysine
residue of the acyltransferase (E2) subunit of KADHs. Subsequently, lipoic acid synthase (LipA),
a [Fe-S] cluster-containing, S-adenosylmethionine (AdoMet)-dependent enzyme, introduces two
sulphurs into the octanoyl-moiety, resulting in protein bound lipoic acid. Salvage 1 consists of one
enzyme, a lipoic acid protein ligase (LplA), which catalyses the attachment of scavenged lipoic
acid to the E2 subunit in a single, ATP-dependent step. Salvage 2 consists of two enzymes that are
responsible for the ligation of scavenged lipoic acid to the KADHs. First, lipoic acid activating en-
zyme activates lipoic acid using ATP or GTP and subsequently, activated lipoic acid is transferred
to the E2 subunit by a lipoyltransferase.
et al., 2007).
1.7.3.1. Lipoic acid synthase
LipA catalyses the production of lipoic acid from octanoic acid, by inserting two sulphur
atoms at position six and eight. The octanoic acid is provided by fatty acid biosynthesis
in the form of octanoyl-ACP, and it was shown that LipA actually uses the protein-bound
octanoyl-moiety as a substrate rather than free octanoyl-ACP (Miller et al., 2000, Zhao
et al., 2003). LipA belongs to an enzyme superfamily that uses AdoMet and a specialised
[4Fe-4S] cluster to cleave non-activated carbon-hydrogen (C-H) bonds (Wang and Frey,
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2007). The [4Fe-4S] cluster is specialised in that three irons are ligated to conserved cys-
teine residues of the enzyme and one is ligated to AdoMet (Wang and Frey, 2007). The
[4Fe-4S] cluster induces the reductive cleavage of the AdoMet C-S bond, generating me-
thionine and 5’-deoxyadenosyl radical, which is required for the further reaction. It was
shown that generation of one molecule of lipoic acid requires two molecules of AdoMet
(Cicchillo et al., 2004a). Controversial is the source of sulfur used by LipA. The enzyme
contains a second [4Fe-4S] cluster, which is distinct from the [4Fe-4S] AdoMet cluster
(Cicchillo et al., 2004b). The enzyme forms a homo-dimer, and it was suggested that one
of the additional [4Fe-4S] cluster supplies the two sulfur atoms, which are inserted into
the C8-chain (Cicchillo and Booker, 2005). It was hypothesised that both the C6 and C8
alkyl radicals, which are generated by removing the hydrogen atom from the respective
C-H bond by the 5’-deoxyadenosyl radical, attack a sulphur atom of this [4Fe-4S] cluster
with subsequent reduction of Fe3+ to Fe2+ and formation of the C-S bond (Booker et al.,
2007).
LipA shares some mechanistic features with biotin synthase. Generally, lipoic acid
metabolism and biotin metabolism are closely related in terms of reaction mechanisms
carried out by the respective enzymes (Perham, 2000, Reche, 2000). Biotin is an essential
cofactor of several enzyme complexes including acetyl-CoA carboxylase and pyruvate
carboxylase (Pacheco-Alvarez et al., 2002, Nikolau et al., 2003). Bacteria, plants and
some fungi are able to synthesise biotin in contrast to mammals, which rely on the uptake
of this vitamin. Like LipA, biotin synthase belongs to the AdoMet radical superfamily
and catalyses the generation of biotin from desthiobiotin. During this reaction, two C-H
bonds are cleaved and one sulfur atom is inserted. Like LipA, biotin synthase forms a
homo-dimer and requires two AdoMet molecules to form one molecule of biotin (Shaw
et al., 1998). The protein also contains a second [Fe-S] cluster, which is thought to pro-
vide the inserted sulfur atom, but in contrast to LipA, this is a [2Fe-2S] cluster rather than
a [4Fe-4S] cluster (Ugulava et al., 2001, Lotierzo et al., 2005, Bui et al., 2006).
1.7.3.2. Lipoic acid ligases
As LipA, which shows mechanistic similarities to biotin synthase, the ligases LplA and
LipB involved in lipoic acid metabolism possess a high degree of similarity to biotin pro-
tein ligase (BPL). LplA, LipB and BPL even belong to the same protein family (Perham,
2000, Reche, 2000). Although sequence conversation between these proteins is very poor,
a single lysine residue is highly conserved. It was suggested that this lysine is involved
in the transfer of lipoic acid/biotin to the ε-amino group of a lysine residue in the apo-
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domain of the respective enzyme complex (Reche, 2000, Bagautdinov et al., 2005, Ma
et al., 2006, McManus et al., 2006).
The reaction catalysed by LipB differs in several aspects from the reactions performed
by LplA and also BPL. Firstly, bacterial LipB is not able to transfer free lipoic acid to a
lipoyl-domain of an enzyme complex, it requires the ACP-bound form as substrate (Jor-
dan and Cronan, 2002). LipB is able to transfer lipoyl-ACP as well as octanoyl-ACP,
but keeping in mind that the substrate of LipA is protein-bound octanoate rather than
free octanoyl-ACP, it is suggestive that the physiological substrate of LipB is octanoyl-
ACP. Octanoyl-ACP is a product of fatty acid biosynthesis and as already explained in
Chapter 1.5.1, two distinct fatty acid biosynthesis pathways exist. Generally, type I fatty
acid biosynthesis results in the generation of palmitate (C16), whereas type II fatty acid
biosynthesis is capable of producing a variety of fatty acids differing in length, including
octanoyl-ACP (White et al., 2005). In the transfer reaction catalysed by LipB, octanoyl-
ACP is covalently attached to the enzyme as an acyl-intermediate before it is transferred
to the apo-lipoyl-domain (Zhao et al., 2005). It was proposed that LipB functions in a
two step reaction as a cysteine/lysine dyad acyltransferase (Ma et al., 2006). In the first
step, the octanoyl-moiety forms a thioester with a conserved cysteine residue, while the
conserved lysine of LipB activates the ε-amino group of the target lysine in the lipoyl-
domain by deprotonation. The thioester between the octanoyl-chain and LipB is then
cleaved by nucleophilic attack of the activated ε-amino group of the target lysine, and the
amide linkage to the lipoyl-domain lysine is formed (Ma et al., 2006).
In contrast to LipB, LplA catalyses the attachment of scavenged lipoic acid to the apo-
enzyme complexes. It was shown that LplA is able to use the ACP thioester forms of oc-
tanoic acid and lipoic acid as substrates, although only poorly in comparison to lipoic acid
(Jordan and Cronan, 2002). Lipoic acid is the preferred substrate of LplA (Green et al.,
1995), and it is thought that the transfer of lipoic acid happens in two steps. First, lipoic
acid becomes activated by ATP, forming the reaction intermediate lipoyl-AMP and re-
leasing pyrophosphate (PPi). The activated form then is ligated to the apo-lipoyl-domain
in a second step (Fujiwara et al., 2005, Kim et al., 2005, McManus et al., 2006). Thus,
ligation of exogenously scavenged lipoic acid to the enzyme complexes by the salvage
1 pathway comprising LplA, occurs in the same way as it is catalysed by the salvage 2
pathway (see Figure 1.8). Here, two enzymes are required for the post-translational lipoy-
lation, first for activation using ATP or GTP (Fujiwara et al., 2001) and second for transfer
to the apo-protein (Fujiwara et al., 1997, 1999, 2007). This reaction mechanism of LplA
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is also analogous to the BPL reaction mechanism in which biotin is first activated by
ATP and subsequently transferred to the target lysine residue of the apo-enzyme complex
(Chapman-Smith et al., 2001). Structural analyses of the Escherichia coli and Thermo-
plasma acidophilum LplA, and the bovine lipoyltransferase helped to better understand
the reaction mechanism performed by lipoic acid ligases and also showed structural sim-
ilarities to BPL (Fujiwara et al., 2005, Kim et al., 2005, McManus et al., 2006, Fujiwara
et al., 2007). Moreover, similarities between the three proteins, but also differences be-
tween LplA and lipoyltransferase, and between the LplA proteins themselves were high-
lighted. From the structural analyses it was concluded that two different size categories
of LplA exist, comprising the short forms (∼260-270 amino acids in length) and the long
forms (∼330-340 amino acids in length) (Kim et al., 2005, McManus et al., 2006). The
archaebacterium T. acidophilum was shown to possess a short form LplA whereas E. coli
possesses a long LplA (Kim et al., 2005, McManus et al., 2006). It was further suggested
that LplA enzymes contain two domains, a large N-terminal domain responsible for lipoic
acid binding and activation, and a smaller C-terminal domain, whose precise function is
not known (Fujiwara et al., 2005, Kim et al., 2005, McManus et al., 2006). The struc-
turally related BPL protein contains a similar C-terminal domain, which contributes to
the interaction with ATP and protein substrate (Chapman-Smith et al., 2001) and thus a
similar function of the C-terminal domain in LplA enzymes was suggested (McManus
et al., 2006). Interestingly, the short form T. acidophilum LplA does not possess the C-
terminal domain and McManus et al. (2006) suggested that a second enzyme is required
for the transfer of activated lipoic acid since their recombinant expressed protein showed
no activity. However, Kim et al. (2005) also used T. acidophilum LplA in their studies
but did not mention whether their protein was active or not. The N-terminal domain of
both E. coli and T. acidophilum LplA was shown to possess three highly conserved se-
quence motifs, which contain key residues involved in the formation of the lipoyl-AMP
binding pocket (Fujiwara et al., 2005, Kim et al., 2005, McManus et al., 2006). Lipoic
acid is bound in a hydrophobic cavity causing a U-shape formation of the lipoyl-AMP,
and it is believed that the binding and activation of lipoic acid with ATP takes place at the
same site, because (1) no large conformational changes were observed after lipoic acid
binding and activation and (2) ATP was found in the same position as AMP (Fujiwara
et al., 2005, Kim et al., 2005). Furthermore, a conserved lysine residue was present in
both LplAs, which was shown to directly interact with the carboxy-group of lipoic acid
(Fujiwara et al., 2005, Kim et al., 2005, McManus et al., 2006). This lysine residue is
highly conserved in all members of this protein family including LipB and BPL (Reche,
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2000). It was suggested that this residue also interacts with the apo-protein substrate and
promotes the nucleophilic attack of the target lysine to form the amide linkage (Ma et al.,
2006). Other structural similarities were observed between LplAs and E. coli BPL. Su-
perimposing the LplA structures with BPL showed that biotin and lipoic acid are bound in
the same position of the respective enzyme (Fujiwara et al., 2005, McManus et al., 2006).
By comparing BPL with T. acidophilum LplA, areas in the LplA enzyme were identified,
which might be involved in conferring substrate specificity to the enzyme. It is known that
BPL enzymes contain four unstructured loops, of which two are potentially participating
in biotin and/or ATP binding (Streaker and Beckett, 1999). One of these loops becomes
ordered upon biotin binding and interacts with biotinyl-AMP. T. acidophilum LplA con-
tains a similar unstructured loop and superposition showed that this loop is in the same
position as the one of BPL (McManus et al., 2006). The loop contains highly conserved
amino acids and it was already proposed that this region might be important for lipoic
acid binding (Reed et al., 1994, Morris et al., 1995). Thus, superimposing T. acidophilum
LplA with E. coli BPL further supports this theory (McManus et al., 2006).
The bovine lipoyltransferase also consists of a large N-terminal and a short C-terminal
domain, with lipoyl-AMP being bound in a U-shaped conformation in the N-terminal do-
main (Fujiwara et al., 2007). Comparing the structure of E. coli LplA with the bovine
lipoyltransferase shows that the N-terminal domains superimpose very well, whereas the
C-terminal domains, although similarly folded, are rotated to each other by about 180◦C
(Fujiwara et al., 2007). As mentioned before, it was suggested that the C-terminal domain
of LplA might be involved in ATP binding, and thus the different conformation found in
the lipoyltransferase might prevent ATP binding. This could possibly be the reason why
mammalian lipoyltransferases are not able to activate lipoic acid (Fujiwara et al., 2007).
Another difference identified between E. coli LplA and bovine lipoyltransferase is the
"adenylate binding loop" (Fujiwara et al., 2007). In contrast to the LplA enzymes, re-
combinant lipoyltransferase generated in a prokaryotic expression system, was purified
with endogenous lipoyl-AMP bound, suggesting a stronger interaction with the lipoyl-
mononucleotide in comparison to LplA (Fujiwara et al., 2007). The "adenylate binding
loop" is thought to function as a lid in the lipoyltransferase, interacting with the ribose-
ring and phosphate-group of lipoyl-AMP. This loop is also present in the E. coli enzyme,
however, it is disordered and not obviously associated with the substrate binding site (Fu-
jiwara et al., 2007).
Post-translational modification of enzyme complexes by LplA, LipB and also BPL occurs
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at a highly conserved lysine residue. The target lysine for both lipoylation and biotiny-
lation is found in a special domain, the lipoyl- or biotinyl-domain, of the respective en-
zyme complex. Despite low amino acid sequence similarity between lipoyl- and biotinyl-
domains, both share a common structure (Brocklehurst and Perham, 1993). Both domains
consist of two anti-parallel organised four-stranded β -sheets, with the conserved lysine
residue at the tip of one β -turn (Perham, 2000). The exact positioning of lysine in the
domain is crucial for the apo-domain to be recognised and to become post-translationally
modified (Wallis and Perham, 1994, Reche et al., 1998). However, it was shown that re-
placing the DKA/V motif of a lipoyl-domain with the MKM motif of a biotinyl-domain
was not sufficient to cause biotinylation of the domain (Wallis and Perham, 1994). Al-
beit replacing the MKM motif of a biotinyl-domain with the DKA/V motif of a lipoyl-
domain was enough for this domain to be recognised by LplA and to become lipoylated,
but only poorly (Reche et al., 1998). These findings suggest that not only the position-
ing of lysine, but also of surrounding amino acids in each domain are crucial for cor-
rect post-translational modification. It appears that small structural differences between
the domains are responsible for specific lipoylation or biotinylation (Reche and Perham,
1999). Recently, it was shown that removal of several amino acids in a loop adjacent
to the β -turn containing the lysine in a lipoyl-domain caused major structural changes
and decreased the lipoylation efficiency, highlighting the importance of the lipoyl-domain
structure for complete post-translational modification (Jones and Perham, 2007). The
biotinyl-domain of the E. coli biotin carboxy carrier protein of the acetyl-CoA carboxy-
lase possesses an additional loop ("protruding thumb"), which is thought to prevent this
domain from lipoylation in vivo (Reche and Perham, 1999, Kim et al., 2005). However,
this effect may be limited to only some proteins because this extra loop is not present in
most other biotinyl-domains (Reddy et al., 1998). The negatively charged side chain of
aspartate in the DKA/V lipoylation motif may prevent recognition and binding of BPL
to this domain, and thus potentially prevents unspecific biotinylation of a lipoyl-domain
(Reche and Perham, 1999).
1.7.4. Lipoic acid metabolism in apicomplexan parasites
Apicomplexan parasites like T. gondii and P. falciparum possess all KADHs and the
GCV that require post-translational lipoylation for their activity. The BCDH, KGDH
and the GCV are found in the mitochondrion, whereas only one copy of the PDH is
present, which is located in the apicoplast of these parasites (Foth et al., 2005, Günther
et al., 2005, McMillan et al., 2005, Salcedo et al., 2005). The lipoylation of these com-
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plexes thus requires lipoylation pathways to be present in the mitochondrion and in the
apicoplast. Indeed, it was shown that apicomplexan parasites possess organelle specific
lipoylation pathways. Biosynthesis of lipoic acid catalysed by LipB and LipA occurs in
the apicoplast, with fatty acid biosynthesis providing the precursor octanoyl-ACP. Scav-
enged lipoic acid is used in the mitochondrion and is covalently attached to the enzyme
complexes by the salvage 1 pathway compromising LplA (Thomsen-Zieger et al., 2003,
Wrenger and Müller, 2004). It appears that the two pathways act independently from
each other as salvaged lipoic acid appears to only be used by the mitochondrial path-
way, whereas lipoylation in the apicoplast solely relies on de novo biosynthesis using
octanoyl-ACP as a precursor (Crawford et al., 2006, Mazumdar et al., 2006, Allary et al.,
2007). Knock-down of ACP in T. gondii affects parasite growth and virulence, and also
suggests that the main function of type II fatty acid biosynthesis in the apicoplast is to
provide octanoyl-ACP for the lipoylation of PDH (Mazumdar et al., 2006). Additionally,
salvage of lipoic acid in P. falciparum and T. gondii was shown to be crucial for para-
site viability (Crawford et al., 2006, Allary et al., 2007). These data suggest that both
pathways act independently and that both are required for parasite survival. However,
a second gene coding for a LplA-like protein (LplA2) was identified in P. falciparum
during the course of this thesis and I could show that it localises to both the mitochon-
drion and apicoplast (Allary et al., 2007, Günther et al., 2007). This raises the questions
whether lipoic acid metabolism in Plasmodium is more complicated than the two indepen-
dent pathways described above. Interestingly, Listeria monocytogenes, a Gram-positive
intracellular pathogen, is a lipoic acid auxotroph but possesses two distinct genes both en-
coding LplAs (Glaser et al., 2001, O’Riordan et al., 2003). It was suggested that the two
LplA proteins are non-redundant during intracellular growth, because a lplA1 knock-out
strain was not able to replicate intracellularly despite the presence of lplA2 (O’Riordan
et al., 2003). Recently it was shown, that indeed L. monocytogenes LplA1 is required for
intracellular growth since only LplA1 and not LplA2 is able to scavenge degraded host
lipoyl-proteins as a source of lipoic acid (Keeney et al., 2007). This suggests, that these
bacteria are highly adapted to their host-cell and that host derived lipoic acid is essential
for Listeria virulence. The presence of two LplAs in Plasmodium could also be an adap-
tation of the parasites to the different environments they are exposed to during the course
of their life cycle, and could confer, for instance, substrate specificity and/or be important
in different stages of parasite development.
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1.8. Aims of this study
• Validation of LplA1 and LplA2 as potential drug targets by reverse genetic approaches
in P. falciparum and the rodent malaria parasite P. berghei.
• Analyses of potential redundancy between the three ligases (LipB, LplA1 and LplA2).
• Confirmation of P. falciparum LplA2 functionality and determination of its localisa-
tion within the parasite.
• Biochemical characterisation of P. falciparum LplA1 and LplA2 by developing a spec-
trophotometric assay system for the determination of lipoic acid protein ligase activity.
This thesis is divided into three result chapters covering LplA1 (Chapter 3), LplA2
(Chapter 4) and the biochemical characterisation of both proteins (Chapter 5). The re-
sults presented in these chapters and their implications will be discussed in Chapter 6.
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2. Material and methods
2.1. Biological and chemical reagents
General chemicals were either purchased from BDH, Fisher Scientific or VWR.
Abcam anti-rat IgG (HRP conjugated)
Amaxa Human T cell Nucleofector kit
BD Biosciences anti-His-tag antibody
BDH Giemsa stain, saponin
Bio-Rad Precision plus all blue protein standards, Bradford protein
assay reagent
Blood transfusion
service
Human full blood
BOC Malaria culture gas (5% CO2, 1% O2 and 94% N2)
Braun Heparin
Calbiochem anti-Lipoic acid antibody
Eurogentec Custom antibody production, oligonucleotides
Fermentas GeneRuler 1 kb DNA ladder
Fisher Scientific 10x phosphate buffered saline (PBS)
GE Healthcare Rainbow protein marker, Gene Images CDP-Star detection
module, Gene Images Random Prime Labelling Module
IBA anti-Strep-tag antibody, Strep-Tactin Sepharose, D-
Desthiobiotin, Strep-tag regeneration buffer with 2-[4’-
hydroxy-benzeneazo]benzoic acid (HABA)
ICN Biomedicals
Inc.
Lipoic acid
Invitrogen Accuprime Pfx SuperMix, PCR SuperMix, TOPO TA
cloning kit, ZERO BLUNT PCR cloning kit, chemically
competent E. coli TOP10 and DB3.1, RPMI 1640 (with 25
mM HEPES, L-glutamine, without NaHCO3), Albumax II,
gentamycin, dNTP mix, 20x MOPS buffer, Hanks’balanced
salt solution (HBSS), SYBR safe (10000x stock), agarose,
low melting point agarose, gentamycin
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Jacobus pharmaceu-
ticals
WR99210
Melford Ampicillin, carbenicillin, isopropyl-β -D-
thiogalactopyranoside (IPTG), adenosine triphosphate
(ATP), dithiothreitol (DTT), proteinase K
Millipore Immobilon Western blot detection kit
Molecular Probes Mitotracker CMXRos, anti-rat IgG (Alexa fluor 488 conju-
gated), anti-rabbit IgG (Alexa fluor 594 conjugated)
New England Bio-
labs
All restriction endonucleases
Novagen BugBuster protein extraction solution, benzonase, chemi-
cally competent E. coli BLR(DE3)
Pierce Restore Western blot stripping buffer
Promega 1 kb DNA ladder, anti-mouse IgG (HRP conjugated), anti-
rabbit IgG (HRP conjugated)
Qiagen Qiaprep spin DNA miniprep kit, Hi-speed plasmid maxi
kit, Qiaquick gel extraction kit, QIAamp DNA mini kit,
QIAamp DNA blood mini kit, RNeasy mini kit, nickel-
nitrilotriacetic acid (Ni-NTA) agarose, RNaseA
Roche Rapid DNA ligation kit, Expand High Fidelity PCR system
Thermo electron Oligonucleotides
Schleicher Schuell Protran nitrocellulose, fibrous cellulose powder CF11
Sigma Hypoxanthine, E. coli inorganic pyrophosphatase, am-
monium molybdate, trizol, Ponceau S Solution, 4-
aminobenzoic acid, Alsever’s solution, glass beads,
L-polylysine, sarkosyl, bovine serum albumin (BSA),
lysozyme, phenylmethylsulfonylfluoride (PMSF),
leupeptin, pepstatin-A, E-64, 1,10-phenantholine,
xanthurenic acid, penicillin/streptomycin, 4’,6-
Diamidino-2-phenylindole dihydrochloride (DAPI),
1,4-Diazabicyclo[2.2.2]octane (DABCOT M)
Stratagene Chemically competent E. coli XL10-Gold
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2.1.1. Buffers, solutions and media
General buffers
1x PBS 140 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 1.8 mM
KH2PO4, pH 7.4
1x TAE 40 mM Tris-Acetate, 1 mM EDTA pH 8.0
0.5x TBE 45 mM Tris-Borate, 1 mM EDTA pH 8.0
TE 10 mM Tris/HCl pH 8.0, 1 mM EDTA pH 8.0
DNA analyses
DNA loading dye 0.25% (w/v) bromophenol blue, 0.25% (w/v) orange-G,
40% (w/v) sucrose
Buffer A 100 mM Tris/HCL, 300 mM NaCl, pH 9.5
1x SSC 15 mM Tri-sodium citrate, 150 mM NaCl, pH 7-8
PFGE-lysis buffer 0.5 M EDTA, 10 mM Tris pH 8.0, 1% (v/v) sarkosyl, 2
mg/ml proteinase K (added fresh prior use)
PFGE-storage buffer 50 mM EDTA, 10 mM Tris pH 8.0
Protein analyses
6x loading buffer 62.5 mM Tris/HCl pH 6.8, 2% (w/v) SDS, 10% (v/v)
glycerol, 0.001% (w/v) bromophenol blue, 5% (v/v) 2-
mercaptoethanol
2x native loading
buffer
62.5 mM Tris/HCl pH 6.8, 10% (v/v) glycerol, 0.001%
(w/v) bromophenol blue
1x running buffer 25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS
1x MOPS buffer 50 mM 3-[N-morpholino]propane sulphonic acid, 50 mM
Tris, 3.5 mM SDS, 1 mM EDTA
1x native running
buffer
25 mM Tris, 192 mM glycine
Coomassie stain 40% (v/v) methanol, 10% (v/v) acetic acid, 0.1% (w/v)
Coomassie brilliant blue R-250
Destain 20% (v/v) methanol, 10% (v/v) acetic acid
Towbin buffer 25 mM Tris, 192 mM glycine, 20% (v/v) methanol
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2D-lysis buffer 100 mM HEPES pH 7.4, 5 mM MgCl2, 10 mM EDTA,
0.5% (v/v) Triton X-100, 5 µg/ml RNAse A, 1 mM PMSF,
1 mM benzamidine, 2 µg/ml leupeptin, 10 µM E-64, 2 mM
1,10-phenanthroline, 4 µM pepstatin A (protease inhibitors
were added prior to use)
Bacteria culture
Luria-Bertani (LB)
medium
10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl (add 15 g/L
agar for LB plates)
M9 minimal
medium
10x M9 salt stock: 58 g/L Na2HPO4, 30 g/L KH2PO4, 5
g/L NaCl, 10 g/L NH4Cl
Working solution: 1x M9 salts, 0.2% (w/v) glucose, 1 mM
MgSO4, 0.001% (w/v) thiamine (add 15 g/L agar for M9
plates)
Ampicillin 100 mg/ml in ddH2O; stored at -20◦C
Carbenicillin 100 mg/ml in ddH2O; stored at -20◦C
Kanamycin 50 mg/ml in ddH2O; stored at -20◦C
Tetracycline 5 mg/ml in ethanol; stored at -20◦C
Chloramphenicol 34 mg/ml in ethanol; stored at -20◦C
P. falciparum culture
Complete RPMI
medium
15.9 g/L RPMI 1640 (containing 25 mM HEPES and L-
glutamine), 0.1% (w/v) sodium bicarbonate, 10 mM glu-
cose, 200 µM hypoxanthine, 20 µg/ml gentamycin, 0.5%
(w/v) Albumax II, pH 7.4
Blood-wash medium 15.9 g/L RPMI 1640 (containing 25 mM HEPES and L-
glutamine), 0.1% (w/v) sodium bicarbonate, 10 mM glu-
cose, 200 µM hypoxanthine, 20 µg/ml gentamycin, pH 7.4
Cytomix 120 mM KCl, 0.15 mM CaCl2, 2 mM EGTA, 5 mM MgCl2,
10 mM K2HPO4/KH2PO4 pH 7.6, 25 mM Hepes pH 7.6
WR99210 Stock: 20 mM in dimethylsulphoxide (DMSO) stored at -
80◦C
Working solution: 20 µM diluted in blood-wash medium
Blasticidin 10 mg/ml in blood-wash medium
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Freezing solution 30% (v/v) glycerol in PBS
MACS buffer 0.5% (w/v) BSA, 2 mM EDTA pH 8.0 in PBS
P. berghei culture
Transfection
medium
20% (v/v) foetal calf serum (heat inactivated for 30 min at
56◦C), 14 µg/ml gentamycin in RPMI 1640 (containing 25
mM HEPES and L-glutamine)
Freezing solution 10% (v/v) glycerol in Alsever’s solution (Sigma)
Dissection medium 3% (w/v) BSA in RPMI 1640 (containing 25 mM HEPES
and L-glutamine)
Nycodenz Stock: 5 µM Tris pH 7.5, 3 mM KCl, 0.3 mM EDTA, 276
mg/ml Nycodenz
Working solution: 55% (v/v) Nycodenz stock in PBS
Pyrimethamine Stock: 7 mg/ml in DMSO stored at 4◦C
Working solution: 10 ml/L pyrimethamine stock in tap wa-
ter, pH 3.5-5.5
Ookinete culture
medium
25% (v/v) foetal calf serum (heat inactivated for 30
min at 56◦C), 50 µM xanthurenic acid, 1% (v/v) peni-
cillin/streptomycin in RPMI 1640 (containing 25 mM
HEPES and L-glutamine)
Mosquito breeding
Breeding water 0.1% (w/v) sea salt in dH2O
Sucrose solution 10% (w/v) sucrose, 0.2 µg/ml 4-aminobenzoic acid in
dH2O
2.1.2. Bacteria strains
XL10-Gold (Stratagene)
Tetr 4(mcrA)1834(marc-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac
Hte [F’ proAB lacIqZ4M15 Tn10 (Tetr) Amy Camr]a
TOP10 (Invitrogen)
F− mcrA 4(mrr-hsdRMS-mcrBC) φ80lacZ4M15 4lacX74 recA1 arcD139 4(arc-
leu)7697 galU galK rpsL (StrR) endA1 nubG
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DB3.1 (Invitrogen)
F− gyrA462 endA1 4(sr1-recA) mcrB mrr hsdS20(rB-, mB-) supE44 ara-14 galK2
lacY1 proA2 rpsL20(SmR) xyl-5 λ -leu mtl1
BLR(DE3) (Novagen)
F− ompT hsdSB(rB- mB-) gal dcm (DE3) 4(srl-recA)306::Tn10 (TetR)
Ker184 (lipB−) (Reed and Cronan, 1993)
rpsL lipB182::Tn1000dKn
Tm134 (lplA−) (Morris et al., 1994)
rpsL lplA148::Tn10dTc
Tm136 (lipB−/lplA−) (Morris et al., 1995)
rpsL lipB182::Tn1000dKn lplA48::Tn10dTc
2.1.3. Plasmodium falciparum strains
3D7 The Netherlands
D10 Papua New Guinea
2.1.4. Plasmodium berghei strains
NK65 NYU, New York
2.1.5. Mice and rat strains
NMRI Naval Medical Research Institute, outbred mice, Charles
River Laboratory, Sulzfeld, Germany
C57BL/6 Inbred mice, Charles River Laboratory, Sulzfeld, Germany
SD Sprague-Dawley, outbred rats, Charles River Laboratory,
Sulzfeld, Germany
The animals were kept in Makrolon cages. Usually five mice or two rats were kept per
cage. The cages were stored in the animal facility at constant temperature (22◦C) and
humidity of 50% to 60%. The light-dark cycle was constant with 12h.
Animals were fed with standard diet pellets (SSNIFF).
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2.1.6. Mosquito strains
Anopheles stephensi Nijmegen, The Netherlands
EMBL, Heidelberg, Germany
2.1.7. Oligonucleotide primers
Oligonucleotide primers were designed to amplify genes for recombinant protein expres-
sion, knock-out studies and localisation studies. To allow sub-cloning of the PCR frag-
ments into the relevant destination plasmids, oligonucleotide primers had a 5’ extension
including the appropriate restriction sites. The oligonucleotide primers used in this study
are listed below.
Recombinant protein expression
H-protein-S 5-GCGCCATATG GAA TAT ATA AAA ATT GAG GAT GG-3
(NdeI)
H-protein-AS 5-GCGCGGATCC TTA TTT CCC CCC TTG CCC TTT ATT
TTC-3 (BamHI)
pdhE2-lipoyl1-S 5-GCGCCATATG AGA AAA AAT GTT GTT TTT TCA AAA
ATA G-3 (NdeI)
pdhE2-lipoyl1c-AS 5-GCGCGGATCC TTA GAC ATC TCC AAC ATT TGC TTC
ACA TCC-3 (BamHI)
pdhE2-lipoyl2-S 5-GCGCCATATG AAG AAG CAT ATA AAT GAT GAT G-3
(NdeI)
pdhE2-lipoyl2-AS 5-GCGCGGATCC TTA CCT TAA ATT TTT TAA AAA CTT
TCT TCC C-3 (BamHI)
PM 26 5- GCGCCATATG GAG GGA AAA TCA TTT AAA GGG-3
(NdeI)
bcdhE2-lipoyl-AS 5-GCGCGGATCC TTA CTC CTT TTC TAC TTC TTC TTC
ATC TC-3 (BamHI)
kgdhE2-lipoyl-S 5-GCGCCATATG ATT AAA GTA CCT AGA CTT GG-3 (NdeI)
kgdhE2-lipoyl-AS 5-GCGCGGATCC TTA ATG TGC TTC ATC TTT AAT ATC
TC-3 (BamHI)
PfLplA-NdeI-S 5-GCGCCATATG GAA AAA AGG ACA AAT GGA CCT TTG-
3 (NdeI)
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PfLplA-BamHI-AS 5-GCGCGGATCC CTA AAG TTC TTG TAA TAT CCA TGA
ACG-3 (BamHI)
PfLplA2-FL-NdeI-S 5-GCGCCATATG AGA ATT ATA AAG TGC CTG GAT CAA
ATA TTC AGG CC-3 (NdeI)
PfLplA2-S1-NdeI-S 5-GCGCCATATG AAA AAA ATA AAC ATT CTT TAT TTT
ATT GAT GTC AGC-3 (NdeI)
PfLplA2-S2-NdeI-S 5-GCGCCATATG AAT GAG TCC AAA GGA AAC GAA TGC-
3 (NdeI)
PfLplA2-BamHI-
AS
5-GCGCGGATCC TTA TAG AAA ATA TGT TGG TAT ATC
GTA ATA CC-3 (BamHI)
PfLplA2-IBA3-1-
fwd
5-GCGCGCGGTCTCGA ATG AGA ATT ATA AAG TGC CTG
GAT C-3 (BsaI)
PfLplA2-IBA3-2-
fwd
5-GCGCGCGGTCTCGA ATG AAA AAA ATA AAC ATT
CTT TAT TTT ATT GAT GTC AGC-3 (BsaI)
PfLplA2-IBA3-3-
fwd
5-GCGCGCGGTCTCGA ATG AAT GAG TCC AAA GGA
AAC GAA TGC-3 (BsaI)
PfLplA2-IBA3-rev 5-GCGCGCGGTCTCAGC GCT TAG AAA ATA TGT TGG
TAT ATC GTA ATA CC-3 (BsaI)
KO studies in P. falciparum - cloning and analyses
Pf-LplA2-KO-
pHH1-fwd
5-GCGCAGATCT GTC ATT GTA AAT AAT ACA TGT GAA
GAA ATG-3 (BglII)
Pf-LplA2-KO-
pHH1-rev
5-GCGCCTCGAG TTA GTG TTC CGA ATT TCT TAA TAT
ATG ATC-3 (XhoI)
LplA-pHH1-rescue-
fwd
5-GCGCAGATCT GGA GAA ATA ACC GAT CTA TAA TTA
TAG G-3 (BglII)
LplA-KOkon-rev 5-GCGCCTCGAG CTA AAG TTC TTG TAA TAT CCA TGA
ACG-3 (XhoI)
Pb-LplA-BglII-S 5-GCGCAGATCT ATG CCA GGT ATA TCC TGT TTT GTA
AAA CGA TGT TAT GG-3 (BglII)
Pb-LplA-NotI-AS 5-GCGCGCGGCCGC TTA GAG TTC TTC TAA TAT CCA
TGA AGT TAT TTC TTC TAA GG-3 (NotI)
LplA2-fwd 5-cacc ATG AGA ATT ATA AAG TGC CTG G-3
LplA2-rev 5-TAG AAA ATA TGT TGG TAT ATC GTA ATA CC-3
CAM5’-check-F 5-GCGC CCA ATA GAT AAA ATT TGT AGA G-3
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PbDT3’-check-R 5-GCGC CGA ACA TTA AGC TGC CAT ATC C-3
KO studies in P. berghei - cloning and analyses
Pf-LplA-ORF-fwd 5-GCGCCTCGAG ATG AAA CGA ATA TTC AGG TTG GTA
AG-3 (XhoI)
Pf-LplA-ORF-rev 5-GCGCCTGCAG CTA AAG TTC TTG TAA TAT CCA TGA
ACG-3 (PstI)
Pf-LplA2-ORF-fwd 5-GCGCCTCGAG ATG AGA ATT ATA AAG TGC CTG GAT
C-3 (XhoI)
Pf-LplA2-ORF-rev 5-GCGCCTGCAG TTA TAG AAA ATA TGT TGG TAT ATC
G-3 (PstI)
Pb-LplA-5’-fwd 5-GCGCGGTACC TAC TAT ATA TTT AAT ATA TAA CAG
GG-3 (KpnI)
Pb-LplA-5’-rev 5-GCGCAAGCTT CCA ACG ATA AAT TAA AGT AAA TAT
TTT G-3 (HindIII)
Pb-LplA-3’-fwd 5-GCGCGCGGCCGC CCA ATA CTT TAA AAC ATT TAA
CAA TC-3 (NotI)
Pb-LplA-3’-rev 5-GCGCCCGCGG GGA CAA GCA TAG CTT ATG CCC GAT
C-3 (SacII)
Pb-LplA-int-fwd 5-GCGCGGATCC CAA AAT ATT TAC TTT AAT TTA TCG
TTG G-3 (BamHI)
Pb-LplA-int1-rev 5-GCGCCCGCGG TTA GTC TAA TGC ATC TGA AAA AAC
ATT TCC-3 (SacII)
Pb-LplA2-5’-fwd 5-GCGCGGTACC GAG CAT TGT ATT ATT AAT GAG CTC
C-3 (KpnI)
Pb-LplA2-5’-rev 5-GCGCAAGCTT GTA TGT ATC ATT ATA AGT TTT AAA
TGG-3 (HindIII)
Pb-LplA2-3’-fwd 5-GCGCGCGGCCGC GCA TGC ATT TAT TAG GTA CTT
TTC CC-3 (NotI)
Pb-LplA2-3’-rev 5-GCGCCCGCGG CGA TGT GGT GGG CAG GGA AGG
AAT TGG-3 (SacII)
Pb-LplA2-int-fwd 5-GCGCGGATCC CAT ATT TAT GAA CAA TTA TTA ATC
G-3 (BamHI)
Pb-LplA2-int1-rev 5-GCGCCCGCGG TTA GTG ATC AAA TAT ATC ACA TGT
ACT AAA TGG-3 (SacII)
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Pb-LplA2-NdeI-fwd 5-CATATG GAT TTT GAA AAA GAA ACT AGA CTT TAT
CC-3 (NdeI)
Pb-LplA2-NdeI-rev 5-TCTAGA CATATG GTT TGG AAG AAT AAA CGA AGT
TAA TAT AC-3 (XbaI, NdeI)
PfCAM5’-F2 5-GCGC GGTACC GGATCC GCG AAT TAG CTA AGC ATG
CAA GC-3 (KpnI, BamHI)
PfCAM5’-R1 5-GCGCCTCGAG CCT GAT ATA TTT CTA TTA GGT ATT
TAT TAT TAT AAA ATA TAA ATC-3 (XhoI)
PfHRPII3’-F1 5-GCGCCTGCAG CCC GCC ATT AAA TTT ATT TAA TAA
TAG-3 (PstI)
PfHRPII3’-R1 5-GCGCGCGGCCGC GTA CCT CTA GAT TTC TCT GCG G-
3 (NotI)
Tg-for 5-CCC GCA CGG ACG AAT CCA GAT GG-3
b3D-rev 5-GCGC CGA CGT TGT AAA ACG ACG GCC-3
Tg-rev 5-CGC ATT ATA TGA GTT CAT TTT ACA CAA TCC-3
PbLplA1-test-fwd 5-GGA TAA TGT AAT AAA ATC TAG CCA TTT AAC TC-3
PbLplA1-test-rev 5-GTG TTG GTG TGT ATA TGA GAA ATT CC-3
Pb-LplA1-REP-rev 5-GCGC GTG TTG GTG TGT ATA TGA GAA ATT CC-3
LplA2-test-for 5-CTT AAT TTA TGC TTT TTT AAA GGC CCC G-3
LplA2-test-rev 5-GCA TTT GTT TTT CCA CAT GAT AGG GGC-3
Pb-LplA2-REP-rev 5-GCGC CGA AAT AAG CAA AGA CAT GCA TGG ATG-3
Localisation studies
LplA2-fwd 5-cacc ATG AGA ATT ATA AAG TGC CTG G-3 (for directional
TOPO cloning)
LplA2-rev 5-TAG AAA ATA TGT TGG TAT ATC GTA ATA CC-3
H-protein-fwd 5-cacc ATG ATA AAT ATA AGA AAA GTG CTT C-3 (for di-
rectional TOPO cloning)
H-protein-rev 5-TTT CCC CCC TTG CCC TTT ATT TTC-3
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2.1.8. Antibodies
Table 2.1.: Primary antibodies and their dilutions
Western blot IFA Source
anti-His-tag (mouse) 1:10000 BD Biosciences
anti-Strep-tag (rabbit) 1:2000 IBA
anti-Lipoic acid (rabbit) 1:500 (parasite extract) Calbiochem
1:2000 (recombinant protein)
anti-LplA1 (rabbit) 1:1000 Eurogentec
anti-LplA2 (rat) 1:500 1:500 Eurogentec
anti-BCDH E2 (rabbit) 1:5000 Eurogentec
anti-KGDH E2 (rat) 1:100 Eurogentec
anti-H-protein (rabbit) 1:2000 Eurogentec
anti-aE3 (rabbit) 1:200 Eurogentec
anti-TrxPx1a (rabbit) 1:5000 Eurogentec
a Akerman and Müller (2003)
Table 2.2.: Secondary antibodies and their dilutions
Western blot IFA Source
anti-mouse IgG (H+L), HRP (goat) 1:5000 Promega
anti-rabbit IgG (H+L), HRP (goat) 1:10000 Promega
anti-rat IgG (H+L), HRP (goat) 1:5000 Abcam
anti-rat IgG (H+L), Alexa fluor 488 1:500 Molecular Probes
(chicken)
anti-rabbit IgG (H+L), Alexa fluor 594 1:500 Molecular Probes
(goat)
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2.2. P. falciparum cell culture
2.2.1. Culturing of P. falciparum erythrocytic stages
Parasites were cultured in complete RPMI 1640 medium with 5% (v/v) human erythro-
cytes (Trager and Jensen, 1976). The cultures were maintained at 37◦C under an atmo-
sphere of reduced oxygen (5% CO2, 1% O2 and 94% N2). The medium was changed
daily, and the parasitemia was kept between 1-5%. If a higher parasitemia was required
the medium was changed twice a day. Parasitemia was determined by counting the in-
fected erythrocytes in Giemsa stained blood smears. Smears were fixed in methanol fol-
lowed by staining in Giemsa diluted 1:10 in H2O for 10-20 min. The stained blood smears
were analysed by light microscopy with an objective magnification of 100 fold.
2.2.2. Synchronisation of parasite culture
Parasites were synchronised using sorbitol according to Lambros and Vanderberg (1979).
Cultures with mainly parasites in the ring stage were used for synchronisation. The culture
was centrifuged at 1500 rpm (Jouan CR3i centrifuge with T4 rotor), 25◦C for 5 min and
the supernatant was discarded. The pellet was resuspended in 5 pellet volumes of 5%
(w/v) sorbitol (in 10 mM potassium phosphate pH 7.2), incubated at 37◦C for 10 min and
then centrifuged as above. The supernatant was discarded, and the pellet was resuspended
in RPMI 1640 complete medium and cultured as described above (see 2.2.1).
2.2.3. Preparation of P. falciparum stabilates
Stabilates were generated of cultures containing approximately 3-5% ring stage parasites.
The infected erythrocytes were pelleted by centrifugation at 1500 rpm (Jouan CR3i cen-
trifuge with T4 rotor), 4◦C for 5 min. The supernatant was aspirated and the pellet was
resuspended in one pellet volume of complete RPMI 1640 medium, and two pellet vol-
umes of freezing solution (30% (v/v) glycerol in PBS). 600 µ l aliquots were transferred
to 1 ml cryotubes (Nalgene), incubated on ice for 10 min and subsequently transferred to
liquid nitrogen.
2.2.4. Thawing of P. falciparum stabilates
Stabilates were thawed by constant shaking in a 37◦C waterbath. Once thawed, the stabi-
lates were transferred to a 15 ml tube and placed on ice. Two volumes of cold 27% (w/v)
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sorbitol (in 10 mM potassium phosphate buffer pH 7.2) were added drop-wise with con-
stant shaking and incubation on ice. After 13 min, two volumes of cold 5% (w/v) sorbitol
(in 10 mM potassium phosphate buffer pH 7.2) were added as before and incubated on
ice for 10 min. The solution was centrifuged at 1500 rpm (Jouan CR3i centrifuge with T4
rotor), 4◦C for 5 min and the supernatant was discarded. The pellet was carefully resus-
pended in 5 ml cold 5% (w/v) sorbitol (in 10 mM potassium phosphate buffer pH 7.2) and
incubated for a further 8 min on ice. The resuspended cells were centrifuged as above and
the supernatant was discarded. The pellet was washed twice with cold complete RPMI
1640 medium before it was resuspended in warm complete RPMI 1640 medium and taken
into culture with an initial haematocrit of 2.5%. Once the culture had a parasitemia of 4%,
the haematocrit was increased to 5% and the appropriate drug selection was applied when
transfected parasite lines were thawed.
2.2.5. Parasite extraction from infected erythrocytes
Parasites were extracted from erythrocytes using saponin as described by Umlas and Fal-
lon (1971). The infected erythrocytes were lysed by addition of 1/10 of the culture volume
of saponin (2% (w/v) in PBS). The culture-saponin mixture was incubated on ice for 10
min and was then centrifuged for 10 min at 3500 rpm (Jouan CR3i centrifuge with T4
rotor) and 4◦C. The supernatant was discarded and the parasite pellet was washed in cold
PBS. After the wash step, the isolated parasites were centrifuged as above and the result-
ing pellet was resuspended in the appropriate buffer. To prepare DNA from the parasite
pellet it was resuspended in 200 µ l PBS, for RNA it was resuspended in 1 ml Trizol and
for protein preparation the parasite pellet was resuspended in one pellet volume 2D-lysis
buffer.
2.2.6. Genomic DNA (gDNA) preparation of parasites
After saponin lysis (see 2.2.5) of a 50 ml culture, the parasite pellet was resuspended in
200 µ l PBS. The following gDNA preparation was carried out using the QIAamp DNA
mini kit (Qiagen) according to manufacturer’s instructions.
2.2.7. Protein preparation of parasites
A 50 ml parasite culture was saponin-lysed (see 2.2.5) and the pellet was resuspended in
one pellet volume of 2D-lysis buffer. The resuspended parasite pellet was stored at -80◦C.
To prepare the protein extract, the resuspended parasite pellet was thawed at room tem-
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perature and frozen again using dry ice. This was repeated three times. Afterwards, the
resuspended pellet was sonicated in a sonicating waterbath for 5 min followed by centrifu-
gation at 13000 rpm (Fisher Scientific accuSpin MicroR with 24-place rotor), at 4◦C for
5 min. The supernatant was transferred into a fresh tube and its protein concentration was
determined using Bradford reagent and a standard curve of known BSA concentrations
(see 2.6.6).
2.2.8. Preparation of chromosome blocks
To resolve chromosomal DNA of P. falciparum by pulse field gel electrophoresis (PFGE,
see 2.5.12), chromosomal DNA was embedded into agarose plugs. A 10 ml parasite
culture containing 5-7% trophozoites was saponin-lysed (see 2.2.5) and the parasites were
pelleted by centrifugation. To prepare the blocks, the parasite pellet was resuspended in
three times the pellet volume of warm (50◦C) PBS. The same volume of warm (50◦C) 2%
(w/v) low melting point agarose in PBS was added and the mixture was transferred into
the plug molds (Bio-Rad) and allowed to set on ice. Once set, the blocks were transferred
into PFGE-lysis buffer and incubated at 37◦C for 48 hours. Chromosome blocks were
stored in PFGE-storage buffer at 4◦C for at least 7 months.
2.2.9. Gene knock-out in P. falciparum
For knock-out studies in P. falciparum the plasmid pHH1 was used (Reed et al., 2000)
(Figure 2.1). The knock-out fragments were cloned into the plasmid using the restric-
tion sites BglII and XhoI. The knock-out fragment was truncated at the N-terminus thus
missing the ATG-start codon. The fragment was also truncated at the C-terminus and con-
tained an artificial stop codon to ensure the disruption of the gene. Disruption of the gene
was achieved by single cross-over recombination of the knock-out plasmid with the gene
locus, which should result in the formation of two truncated, non-functional copies of
the gene. The plasmid contains the human dihydrofolate reductase (hDHFR) gene which
allowed for the selection of transfected parasites with WR99210 (Waterkeyn et al., 1999).
To select this plasmid in bacteria it also contained the ampicillin resistance gene.
2.2.10. Transfection of P. falciparum
Two methods were used to transfect P. falciparum. The first method, according to Deitsch
et al. (2001), included the transfection of uninfected erythrocytes and the spontaneous up-
take of DNA by the parasites. 100 µg plasmid DNA were resuspended in 50 µ l TE buffer
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Figure 2.1.: Vector map of pHH1
This figure displays the important features of the pHH1 plasmid, which was used for knock-out
studies in P. falciparum. The plasmid contains the ampicillin resistance cassette (AmpR; 861 bp)
for selection in E. coli and the human dihydrofolate reductase gene (hDHFR; 569 bp) for selection
in P. falciparum. The hDHFR is under control of the P. falciparum calmodulin promoter (PfCAM
5’; 631 bp) and flanked by the P. falciparum histidine-rich protein 2 3’ UTR (PfHRPII 3’; 574 bp).
The multiple cloning site consists of XhoI and BglII and is flanked by the P. berghei dihydrofolate
reductase / thymilidate synthase 3’ UTR (PbDHFR/TS 3’; 855 bp).
and were added to 450 µ l uninfected erythrocytes that were previously washed with cy-
tomix. The plasmid DNA was transfected by electroporation (310 V, 950 F; time constant
should be about 30 ms) using the Gene Pulser Xcell electroporator (Bio-Rad). Subse-
quently, 10 ml complete RPMI 1640 medium and erythrocytes infected with schizonts
were added to a final parasitemia of 1% and haematocrit of 5%. After 48 hours, the drug
for selection of transfectants was added to the culture (either 5 nM WR99210 or 2 µg/ml
blasticidin). After addition of the drug most parasites died and transfectants appeared
three weeks to four months after the transfection.
Using the second transfection method, erythrocytes infected with P. falciparum ring stages
of a parasitemia between 4-7% were transfected (Crabb and Cowman, 1996, Wu et al.,
1996). For electroporation, 100 µg plasmid DNA were resuspended in 30 µ l TE buffer
and were mixed with 270 µ l cytomix and 200 µl of the infected erythrocytes. After elec-
troporation at 310 V and 950 µF (the time constant should be about 10 ms) the mixture
was transferred into a culture flask and 200 µl uninfected erythrocytes were added. After
6 hours the medium was changed and the appropriate drug was added. Similarly, it took
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three weeks to four months before transfected parasites were visible in Giemsa stained
blood smears. Parasites used for transfection were either 3D7 (The Netherlands) or D10
(Papua New Guinea).
2.2.11. Cloning of P. falciparum by limiting dilution
Parasites were cloned according to Kirkman et al. (1996). The erythrocyte number of a
culture with 3% parasitemia was determined and diluted in complete RPMI 1640 medium
so that 10 ml contained 106 cells. 12.5 µ l of these were transferred to 30 ml complete
RPMI 1640 medium with 1% haematocrit. For cloning, 200 µl were transferred to each
well of a 96 well plate which equals 0.25 parasites per well. After 5-6 days the medium
was changed. After another 5-6 days the medium was changed again and was comple-
mented with 1% (v/v) erythrocytes and the appropriate drug to select for transfectants.
Following the third medium change 5-6 days later, the plates were monitored daily and
wells in which the colour of the medium changed to yellow were transferred to a 12 well
plate (2 ml cultures per well with 2% haematocrit and the appropriate drug). In the 12
well plate the cultures were monitored by blood smears and Giemsa staining until par-
asites were visible. These were transferred to 10 ml cultures with 5% haematocrit and
were cultured for further analyses.
2.2.12. Growth rate assay
Cultures containing ring stage parasites were sorbitol-synchronised (see 2.2.2) twice
within 4 hours and diluted to 1% parasitemia and 5% haematocrit. Progression through
the intraerythrocytic developmental cycle was assessed by taking thin-smears every 8
hours over a 48 hour time course. The smears were stained with Giemsa and were anal-
ysed by light microscopy with an objective magnification of 100 fold.
2.2.13. MACS columns
MACS columns were used to obtain a highly synchronised culture of late stage parasites
with parasitemias of ∼90%. These cultures were used to extract protein or to analyse the
lipoic acid content of the parasites.
First, the CS-MACS column (Miltenyi Biotec) was assembled according to manufac-
turer’s instruction using a blunt 0.8 mm needle. The column was placed in the Vari-
oMACS separator (Miltenyi Biotec) and was equilibrated with MACS buffer (0.5% (w/v)
BSA, 2 mM EDTA pH 8.0 in PBS) for 5 min at room temperature followed by washing
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with 50 ml MACS buffer. The medium of a 50 ml culture containing mainly late stage
parasites was removed and the blood was resuspended in 20 ml complete RPMI 1640. The
20 ml were applied to the column and were allowed to drop through the column slowly
(∼1.5 ml/min). During this process late stage parasites bound to the column due to the
paramagnetic haemozoin in the food vacuole of the parasites. Once the whole culture had
entered the column, it was washed with 50 ml MACS buffer. To elute the parasites, the
column was removed from the VarioMACS separator, turned upside down and the late
stage parasites were washed off with 30 ml MACS buffer. The elution fraction was cen-
trifuged at room temperature, 1500 rpm (Jouan CR3i centrifuge with T4 rotor) for 10 min
to pellet the infected erythrocytes. The supernatant was discarded and the pellet was taken
up in 10 ml complete RPMI 1640 and incubated at 37◦C for 30 min to allow the parasites
to regenerate. After incubation the infected erythrocytes were saponin-lysed (see 2.2.5)
and the parasite pellet was used for further analyses.
2.2.14. Immunofluorescence
Immunofluorescence analyses were carried out according to Tonkin et al. (2004). 10 µ l
of culture with 2.5% haematocrit was spotted into each well of Lab-Tek 8-well chamber
slide (Nunc) previously treated with L-polylysine and allowed to dry. The cells were
fixed with 4% (v/v) paraformaldehyde and 0.0075% (v/v) glutaraldehyde in PBS. After
30 min incubation, the cells were washed once with PBS and subsequently permeabilised
in 0.1% (v/v) Triton X-100 in PBS for 10 min. The cells were washed again in PBS
and incubated with 0.1 mg/ml sodium borohydride in PBS for further 10 min. Following
another wash step with PBS cells were blocked overnight in 3% (w/v) BSA in PBS in
a humidity chamber at 4◦C. After blocking, the slide was washed three times with PBS
containing 0.05% (v/v) Tween20. The primary antibodies were used at dilutions of 1:500
- 1:5000 in 3% (w/v) BSA in PBS (see Table 2.1). The first antibody was incubated for 1
hour at 4◦C followed by three wash steps with PBS containing 0.05% (v/v) Tween20. The
secondary antibody was applied at 1:500 dilution in 3% (w/v) BSA in PBS for one hour
at 4◦C. The second antibody was specific against the animal in which the first antibody
was raised and was conjugated to either Alexa fluor 594 or 488 (see Table 2.2). Before
the slide was washed, DAPI (final concentration of 0.5 µg/ml) was added for 5 min.
After three wash steps with PBS containing 0.05% (v/v) Tween20 the plastic well divider
was removed and the slide was mounted with mounting solution (2.5% (v/v) DABCOT M,
50% (v/v) glycerol in PBS). The samples were analysed using an Axioskop-2 mot plus
microscope (Zeiss) equipped with a Hamamatsu C4742-95 CCD camera.
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2.2.15. Fluorescent microscopy
The subcellular localisation of parasite proteins was analysed either by immunofluores-
cence analyses (IFA), or by analysing live parasites expressing proteins fused to green
fluorescent protein (GFP). The microscope used was an Axioskop-2 mot plus microscope
(Zeiss) equipped with a Hamamatsu C4742-95 CCD camera.
Images were captured at 100 fold magnification using differential interference contrast
(DIC) microscopy. The GFP-fusion proteins, as well as antibodies coupled with Alexa
fluor 488, were observed using the fluorescent filter FITC (excitation at 494 nm and emis-
sion at 518 nm). In live cell imaging the mitochondrion was selectively stained using
Mitotracker CMXRos (Molecular Probes), and was visualised using the fluorescent filter
for rhodamine (excitation at 570 nm and emission at 590 nm). The same filter was used
to visualise antibodies coupled with Alexa fluor 594.
Staining of the mitochondrion was performed by incubating 1 ml parasite culture (6%
parasitemia, 5% haematocrit) with 25 nM Mitotracker CMXRos for 5 min at 37◦C, be-
fore washing with 10 ml warm complete RPMI 1640. The culture was centrifuged at 1500
rpm (Jouan CR3i centrifuge with T4 rotor) for 10 min at 25◦C, and the supernatant was
discarded. The infected erythrocytes were resuspended in 1 ml warm complete RPMI
1640 medium before being analysed as described above.
2.3. P. berghei cell culture
2.3.1. In vitro culture of P. berghei
Parasites were maintained in vitro only for one developmental cycle to obtain mature
schizonts for transfection. The culture was set up by collecting the blood of an infected
rat by cardiac puncture at a parasitemia of 1-4%. The blood was transferred to 10 ml
transfection medium containing 250 µ l of the heparin stock solution (200 I.U./ml) and
was centrifuged 10 min at 1000 rpm (Jouan CR3i centrifuge with T4 rotor). The super-
natant was discarded, then the blood pellet was carefully resuspended in 25 ml transfec-
tion medium and transferred to a sterile 500 ml Erlenmeyer flask. 125 ml transfection
medium was added without disturbing the blood layer at the bottom of the flask. The
culture was incubated at 36.5◦C with gentle shaking under an atmosphere of reduced
oxygen (5% CO2, 10% O2 and 85% N2), overnight. The following day the parasites had
developed into mature schizonts, which were not released from their host cells in vitro.
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2.3.2. Purification of mature P. berghei schizonts
A 55% Nycodenz working solution (in PBS) was used to purify mature schizonts. The 150
ml parasite culture (see 2.3.1) was split into five 50 ml tubes. 10 ml of 55% Nycodenz
was carefully layered underneath the culture and centrifugation was performed at 1200
rpm (Jouan CR3i centrifuge with T4 rotor) for 30 min at room temperature without brake.
During centrifugation, the uninfected erythrocytes moved through the Nycodenz to the
bottom of the tube, whereas the mature schizonts assembled in a brown layer on top of
the Nycodenz. The brown layer was collected with a Pasteur pipette and transferred to
a fresh 50 ml tube. From a 150 ml culture 30-40 ml were collected. The Nycodenz was
washed away by addition of transfection medium followed by centrifugation at 1000 rpm
(Jouan CR3i centrifuge with T4 rotor) for 8 min at room temperature. The schizont pellet
was resuspended in 15 ml transfection medium, and 1 ml aliquots were used for each
transfection.
2.3.3. Transfection of P. berghei
Parasites were transfected according to Janse et al. (2006). Transfection was performed
by electroporation using the Nucleofector II device and "Human T cell Nucleofector
kit" from Amaxa biosystems. 5 µg of plasmid DNA was used per transfection. Be-
fore transfection, the plasmid was digested overnight to obtain linearised DNA. The di-
gested DNA was ethanol precipitated (see 2.5.7) and resuspended in 10 µ l ddH2O. 100
µl of the Human T cell Nucleofector solution (Amaxa biosystems) were added to the
DNA. The schizonts were pelleted by centrifugation at 13200 rpm in an Eppendorf mi-
crocentrifuge (F45-24-11 rotor) for 5 sec, and the parasite pellet was resuspended in
the DNA-Nucleofector mixture. Electroporation was performed using the Nucleofec-
tor II device and protocol U33. 50 µ l of culture medium were added to the cuvette
and the transfected parasites were intravenously injected into a mouse. 24 hours later
the drug selection started. The animals were provided with drinking water containing
pyrimethamine (70 µg/ml), the drug used to select for the Toxoplasma gondii dihydrofo-
late reductase/thymilidate synthase (DHFR/TS). The parasitemia was assessed daily, and
the parasites were collected for further analyses at a parasitemia of 1-5%.
2.3.4. Gene knock-out in P. berghei
For knock-out studies in P. berghei the plasmid b3D.DT∧H.∧D was used (kindly provided
by A. P. Waters, Leiden University, The Netherlands) (Figure 2.2). The plasmid contained
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the T. gondii DHFT/TS as a selectable marker referring resistance to pyrimethamine.
The TgDHFR/TS expression cassette was flanked by two multiple cloning sites (MCS),
allowing knock-out of genes by either replacement (double cross-over recombination),
or integration (single cross-over recombination). The plasmid backbone was based on
the pBluescript plasmid (Stratagene) containing the beta-lactamase gene conferring resis-
tance to ampicillin for selection in E. coli.
Figure 2.2.: Vector map of b3D.DT∧H.∧D
This figure displays the important features of the plasmid b3D.DT∧H.∧D, which was used for
knock-out studies in P. berghei. The plasmid contains the ampicillin resistance cassette (AmpR;
861 bp) for selection in E. coli, and the T. gondii dihydrofolate reductase / thymilidate synthase
expression cassette (TgDHFR/TS (1803 bp) flanked by the P. berghei DHFR/TS 5’ (2279 bp) and
3’ UTR (481 bp)) for selection in P. berghei. Further, the plasmid contains two multiple cloning
sites (KpnI-SbfI and EcoRV-SacII).
For the replacement strategy, 5’ and 3’ flanks (∼500 bp in size) of the gene of interest
were amplified by PCR and cloned in the two MCSs. Prior to transfection, the plasmid
was digested so that only the 5’ flank, the TgDHFT/TS expression cassette, and the 3’
flank were used for transfection.
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The integration strategy is similar to the method used to knock-out genes in P. falciparum
(see 2.2.9). The knock-out fragments were amplified by PCR (∼1000 bp in size) and
cloned into the second multiple cloning site using the restriction enzymes BamHI and
SacII. The knock-out fragments were truncated at the N- and C-terminus. An artificial
stop codon was introduced at the 3’ end of the PCR product to ensure the disruption of
the gene locus. Prior to transfection, the plasmid was linearised using a restriction enzyme
which cut within the knock-out fragment.
2.3.5. Preparation of P. berghei stabilates
To prepare stabilates of P. berghei cultured in rats, 300 µl infected blood was added to
600 µl freezing solution (10% (v/v) glycerol in Alsever’s solution (Sigma)). Stabilates
prepared from mice were smaller. 100 µ l infected blood was added to 200 µ l freezing
solution. The blood was gently mixed with the freezing solution and stored in liquid
nitrogen immediately.
2.3.6. Extraction of P. berghei parasites from infected blood
The blood of an infected rat or mouse was collected by cardiac puncture at a parasitemia
of 1-5%. To separate erythrocytes from lymphocytes and platelets, the blood was first
purified using a cellulose column. For rats a 20 ml syringe, and for mice a 5 ml syringe
was used as a column containing cotton, cellulose powder and glass beads. The glass
beads removed platelets and the lymphocytes bound to the cellulose. The column was
equilibrated with 10 ml PBS before the blood was applied. After the blood entered the
column, it was washed with PBS and the eluate was collected once the first blood drop
left the column. For rats 50 ml and for mice 14 ml were collected. The collected fraction
was centrifuged at 1500 rpm (Jouan CR3i centrifuge with T4 rotor) for 8 min at room
temperature and the supernatant was discarded. The pellet was resuspended in 0.2% (w/v)
saponin (in PBS) and mixed by shaking until lysis of the erythrocytes was complete.
The parasites were pelleted at 2800 rpm (Jouan CR3i centrifuge with T4 rotor) for 8
min at room temperature. The resulting parasite pellet was resuspended in 1 ml PBS,
transferred into a 1.5 ml tube and centrifuged at 7000 rpm (Eppendorf microcentrifuge
with F45-24-11 rotor) for 2 min at room temperature. The supernatant was discarded
and the parasite pellet was resuspended in the appropriate buffer. For gDNA isolation
the parasite pellet was resuspended in 200 µl PBS and stored at -20◦C until gDNA was
prepared. For protein analyses, the pellet was resuspended in the same volume of 2x SDS
buffer (250 mM Tris pH 6.8, 6.6% (w/v) SDS, 24% (v/v) glycerol, 10 mM EDTA, 6%
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(v/v) mercaptoethanol, bromophenolblue) and stored at -20◦C. To prepare RNA, the pellet
was resuspended in 350 µl lysis buffer of the RNeasy mini kit from Qiagen. The parasite
pellet was homogenized by passing it through a 20-gauge needle at least five times before
it was stored at -80◦C until RNA was prepared according to manufacturer’s guidelines.
2.3.7. Genomic DNA (gDNA) preparation from P. berghei parasites
Parasites were isolated from infected erythrocytes as described above (see 2.3.6) and the
parasite pellet was resuspended in 200 µl PBS. gDNA was then extracted using the QI-
Aamp DNA blood mini kit (Qiagen) according to manufacturer’s guidelines.
2.3.8. Protein preparation from P. berghei parasites
Parasites, isolated by saponin lysis from erythrocytes (see 2.3.6), were resuspended in one
pellet volume 2x SDS buffer (250 mM Tris pH 6.8, 6.6% (w/v) SDS, 24% (v/v) glycerol,
10 mM EDTA, 6% (v/v) mercaptoethanol, bromophenolblue). The resuspended parasites
were boiled at 100◦C for 5 min before being loaded onto a 12% SDS-polyacrylamide gel.
2.3.9. Cloning of P. berghei parasites
The blood of an infected mouse was collected by cardiac puncture at a parasitemia be-
tween 0.1 and 1%. The blood was diluted with RPMI 1640 (containing 25 mM HEPES
and L-glutamine) so that 100 µ l contained one parasite. These were then injected in-
travenously into 15 NMRI mice. After 7 days the parasitemia was monitored daily by
Giemsa stained blood smears. Once the parasitemia was above 1%, the blood was col-
lected by cardiac puncture. Stabilates and gDNA were made and the gDNA was analysed
by PCR using primer sets diagnostic for integration, plasmid and wild-type.
2.3.10. Growth rate assay
The parasitemia of an infected mouse was determined and the blood was collected by
cardiac puncture at a parasitemia between 0.1 and 1%. The blood was diluted with RPMI
1640 (containing 25 mM HEPES and L-glutamine) so that 100 µ l contained 1000 par-
asites. These were injected intravenously into five NMRI mice. Parasitemia of the five
mice was monitored and determined daily for eight days.
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2.3.11. Transfer assay
To test whether a mutant parasite line showed a growth defect, the transfer assay was
performed. The parasitemia of mice infected with mutant and wild-type parasites was
determined and the blood was collected by cardiac puncture at a parasitemia between 0.1
and 1%. The infected blood was diluted with RPMI 1640 (containing 25 mM HEPES and
L-glutamine) so that 100 µ l contained 1000 mutant and 1000 wild-type parasites. These
were injected intravenously into two NMRI mice. After three to four days, the blood of
the mice was collected by cardiac puncture and 100 µl were transferred intraperitoneally
into two naive mice. This was repeated five times. From the first and last two mice,
parasites were extracted by saponin lysis (see 2.3.6) and gDNA was prepared (see 2.3.7).
The gDNA was analysed by PCR using primer sets diagnostic for integration, plasmid
and wild-type.
2.3.12. Exflagellation of P. berghei gametocytes
Exflagellation of male gametocytes in a parasite population was analysed before Anophe-
les mosquitoes were infected with P. berghei. Usually exflagellation occurs in the midgut
of the mosquito and is the differentiation of a microgamont into four to eight microga-
metes. Among other things, this can be induced in vitro by a temperature drop of at least
2-5◦C (Sinden and Croll, 1975).
A drop of blood was removed from an infected mouse by tale puncture and transferred
to a slide covered with a cover slip. After 10 min the slide was checked microscopi-
cally for exflagellation. The temperature drop from 37◦C to room temperature induces
exflagellation. The slide was examined by phase contrast microscopy using an objective
magnification of 40 fold. If four to six exflagellating microgamonts were visible in each
field of view, the animal was used for a blood meal.
2.3.13. In vitro ookinete culture
Mice with a parasitemia above 1% were used for ookinete cultures. The exflagellation
was examined (see 2.3.12) and animals with sufficient exflagellating parasites were bled
by cardiac puncture. The blood was taken into culture using 10 ml of ookinete culture
medium per 1 ml of fresh blood. The culture was incubated at 20◦C for 20-24 hours.
The ookinetes were purified using magnetic beads labeled with an antibody against the
ookinete surface protein p28. The culture was centrifuged at 1700 rpm (Jouan CR3i cen-
trifuge with T4 rotor) for 8 min at room temperature and the supernatant was discarded.
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The blood pellet was resuspended in 500 µ l PBS and transferred into a fresh 1.5 ml re-
action tube. 3 µl anti-p28 labeled magnetic beads were added and gently mixed for 5
min. After mixing, the tube was placed into a magnetic rack and left for 2 min to al-
low the ookinetes bound to the magnetic beads to separate from the remaining blood
and culture medium. The remaining blood and medium was removed and the ookinetes
were washed twice with PBS. After the final wash step, the ookinetes were centrifuged
at 7000 rpm (Eppendorf microcentrifuge with F45-24-11 rotor) for 2 min at room tem-
perature. The supernatant was discarded and the ookinetes were resuspended in 100 µ l
HBSS (Hanks’balanced salt solution). To determine the number of ookinetes in the cul-
ture, they were counted using a hemocytometer and phase contrast microscopy (40 fold
magnification).
2.3.14. Breeding of A. stephensi
Female mosquitoes require a blood meal before egg production. To feed mosquitoes,
two mice or one rat were anaesthetised using ketamin/xylazinhydrochloride and placed
on a cage containing two to seven days old mosquitoes. After 15 min the animals were
removed. Four days later the oviposition took place. For that, a petridish filled with
breeding water containing a fluted filter was placed in the cage. The eggs were removed
and washed using the fluted filter with breeding water, followed by 70% (v/v) ethanol.
The washed eggs were put in a larvae tank. Hatched larvae were washed every second
day and diluted if required. They were fed daily using a third of a cat-food pellet. From
day nine onwards the pupae were collected, placed in a petridish with breeding water and
put into a mosquito cage to hatch.
Mosquitoes were fed daily using two pieces of cotton wool, one soaked with sucrose
solution and the other soaked with breeding water. The mosquitoes were kept at 21◦C
(insectary) or 28◦C (breeding room) and 80% humidity. The light-dark cycle was 14h to
10h.
2.3.15. Mosquito midgut infectivity with P. berghei oocysts
Midgut infectivity was screened at day 10-14 post blood feeding when oocysts were devel-
oped and contained either sporoblasts or sporozoites. A midgut was recorded as infected
when at least one oocyst was detected. A minimum of 10 midguts were analysed, and
the oocyst number in each midgut was determined. The mean total number of oocysts
per midgut was then calculated from all separate counts of infected midguts. Midguts
used were freshly dissected in dissection medium and were analysed by phase contrast
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microscopy with 40 fold magnification.
2.4. Bioinformatics
2.4.1. Identifying genes in the P. falciparum genome
The lplA2 gene was identified in the P. falciparum genome by TBlastN searching the Plas-
modium genome database PlasmoDB (Bahl et al., 2003) with the Arabidopsis thaliana
LplA sequence.
2.4.2. Multiple sequence alignments
Multiple protein alignments were performed using ClustalW (Thompson et al., 1994)
with predicted P. falciparum protein sequences and sequences of orthologues proteins
from other organisms. Orthologues were identified by BlastP searching the OrthoMCL
database (Chen et al., 2006). Sequence similarities were determined based on the chemi-
cal properties of the amino acids using Vector NTI software (Invitrogen).
2.4.3. Subcellular localisation predictions
Subcellular localisation predictions using the predicted protein sequences were performed
using MitoProt (Claros and Vincens, 1996), PATS (Zuegge et al., 2001), PlasMit (Bender
et al., 2003), Predotar (Small et al., 2004) and SignalP (Nielsen et al., 1997).
2.5. Methods in molecular biology
2.5.1. Polymerase chain reaction (PCR)
Plasmodium genes were amplified from gDNA using the following PCR systems.
2.5.1.1. PCR SuperMix
The PCR SuperMix (Invitrogen) is a ready to use mix containing 1.65 mM MgCl2, 220
µM dNTP and 22 U/ml Taq DNA polymerase. The SuperMix was mixed with 100 ng
gDNA and 400 nM of each oligonucleotide to a final volume of 25 µl. The PCR was
performed under the following conditions:
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Initial Denaturation 94◦C, 5 min
30 cycles of:
Denaturation 94◦C, 1 min
Annealing oligonucleotide specific temperature, 1 min
Elongation 60◦C, 1 min per kb to be amplified
Final Elongation 60◦C, 10 min
The PCR products were analysed on a 1% agarose gel and fragments of the expected
size were cloned into pCR 2.1-TOPO using the TOPO TA PCR cloning kit (see 2.5.2.1).
2.5.1.2. AccuPrime Pfx SuperMix
The AccuPrime Pfx SuperMix (Invitrogen) contained 1.1 mM MgSO4, 330 µM dNTPs
and 22 U/ml Pfx DNA polymerase. The PCR was set up using 100 ng gDNA and 400
nM of each oligonucleotide. The final volume per PCR reaction was 25 µl and PCR was
performed under the following conditions:
Initial Denaturation 94◦C, 5 min
30 cycles of:
Denaturation 94◦C, 1 min
Annealing oligonucleotide specific temperature, 1 min
Elongation 68◦C, 2 min per kb to be amplified
Final Elongation 68◦C, 10 min
The PCR products were analysed on a 1% agarose gel and fragments of the expected
size were cloned into pCR-BluntII-TOPO using the Zero Blunt TOPO PCR cloning kit
(see 2.5.2.1).
2.5.1.3. Expand High Fidelity PCR kit
The Expand High Fidelity PCR kit (Roche) was set up in two master-mixes. The first mix
contained 200 µM dNTPs, 400 nM of each oligonucleotide and 100 ng gDNA in a final
volume of 12.5 µ l. The second mix contained the reaction buffer with 1.5 mM MgCl2 and
2.5 U of the Expand HiFiPLUS enzyme blend in a final volume of 12.5 µl. The enzyme
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blend contained a Taq DNA polymerase and a thermostable proofreading protein without
polymerase activity. The two master-mixes were mixed and the PCR was performed un-
der the following conditions:
Initial Denaturation 94◦C, 5 min
10 cycles of:
Denaturation 94◦C, 1 min
Annealing oligonucleotide specific temperature, 1 min
Elongation 68◦C, 2 min per kb to be amplified
20 cycles of:
Denaturation 94◦C, 1 min
Annealing oligonucleotide specific temperature, 1 min
Elongation 68◦C, 2 min per kb to be amplified + 5 sec per cycle
Final Elongation 68◦C, 10 min
The PCR products were analysed on a 1% agarose gel and fragments of the expected
size were cloned into pCR-BluntII-TOPO using the Zero Blunt TOPO PCR cloning kit
(see 2.5.2.1).
2.5.2. Cloning techniques
2.5.2.1. TOPO cloning of PCR products
All PCR products amplified were initially cloned into the TOPO vectors (Invitrogen).
Different types of TOPO vectors were used depending on the polymerase used in the PCR
reaction. Taq polymerases produced adenine overhangs at the 3’ ends of PCR products
and required therefore the TOPO TA PCR cloning kit with the vector pCR 2.1-TOPO
(Figure 2.3). PCR products amplified with a Pfx/Pfu polymerase had blunt ends and were
therefore cloned using the Zero Blunt TOPO PCR cloning kit containing the vector pCR-
BluntII-TOPO (Figure 2.4).
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Figure 2.3.: Vector map of pCR2.1-TOPO
This figure displays the important features of the pCR2.1-TOPO plasmid (Invitrogen), which was
used to clone PCR products amplified with Taq based polymerase. The plasmid contains the
kanamycin (KanR; 795 bp) and ampicillin resistance cassette (AmpR; 861 bp) for selection in
E. coli. The topoisomerase I is covalently bound to the TOPO binding sites. After cloning, the
generated construct was analysed by diagnostic digests using the restriction sites shown, and the
sequence of the cloned PCR product was verified by sequencing using the primers M13F and
M13R.
Figure 2.4.: Vector map of pCR-BluntII-TOPO
This figure displays the important features of the pCR-Blunt II-TOPO plasmid (Invitrogen), which
was used to clone PCR products amplified with polymerases with proofreading abilities. The
plasmid contains the kanamycin (KanR; 795 bp) and zeocin resistance cassette (ZeoR; 375 bp) for
selection in E. coli. The topoisomerase I is covalently bound to the TOPO binding sites. After
cloning, the generated construct was analysed by diagnostic digests using the restriction sites
shown, and the sequence of the cloned PCR product was verified by sequencing using the primers
M13F and M13R.
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Directional TOPO cloning was performed if the amplified PCR product was used for
Gateway cloning (see 2.5.2.3). The plasmid pENTR/D-TOPO (part of the pENTR/D-
TOPO cloning kit) (Figure 2.5) was used, which contained a 5’ directional GTGG over-
hang. Therefore, the PCR product was amplified with a forward oligonucleotide primer
that introduced a CACC overhang to allow directional cloning.
The ligation reactions for all kits were performed as per manufacturer’s instruction, were
subsequently transformed into chemically competent E. coli TOP10 cells (Invitrogen)
and were plated on LB-plates containing 50 µg/ml kanamycin. Single bacteria colonies
were used to inoculate 3 ml LB-medium containing 50 µg/ml kanamycin and were grown
overnight at 37◦C. The following day the bacteria were pelleted, plasmid DNA was ex-
tracted (see 2.5.5) and analysed by digest with appropriate restriction enzymes (see 2.5.6).
Before inserts were sub-cloned into a destination plasmid, the sequence was verified.
Figure 2.5.: Vector map of pENTR/D-TOPO
This figure displays the important features of the pENTR/D-TOPO plasmid (Invitrogen), in which
PCR products were cloned directional. The plasmid contains the kanamycin resistance cassette
(KanR; 810 bp) for selection in E. coli. The topoisomerase I is covalently bound to the TOPO
binding sites and the directional TOPO overhang (GTGG) ensures that the PCR product is cloned
directional. Further, the plasmid contains attL1 and attL2 sites for MultiSite Gateway LR re-
combination. After cloning, the generated construct was analysed by diagnostic digests using the
restriction sites shown, and the sequence of the cloned PCR product was verified by sequencing
using the primers M13F and M13R.
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2.5.2.2. Sub-cloning into destination plasmids
Inserts of correct TOPO-clones were used and sub-cloned into the respective destination
plasmid. The insert was isolated from the TOPO plasmid using the appropriate restriction
endonucleases (see 2.5.6). The destination plasmid was linearised using the same restric-
tion enzymes and the digests were separated by agarose gel electrophoresis (see 2.5.10).
The insert and digested destination plasmid were excised from the gel and purified using
the Qiagen Gel Extraction kit as per manufacturer’s instructions. The DNA was eluted in
30 µ l ddH2O.
The insert was then ligated into the destination plasmid using the Rapid DNA Ligation kit
(Roche). Molar vector to insert ratios from 1:3 to 1:10 were used in the ligation reactions
which were performed as per manufacturer’s instruction. 10 µ l of the ligation reaction
was subsequently transformed into chemically competent E. coli and plated on LB-plates
containing the appropriate antibiotics. Single colonies were analysed by DNA miniprep
(see 2.5.5) and restriction endonuclease digestion (see 2.5.6). Plasmids containing the
correct insert size were analysed by DNA sequencing.
2.5.2.3. Gateway cloning
The Gateway cloning technology (Invitrogen) is based on the site-specific recombination
system of phage l. The recombination occurs at the "att" sites which contain the bind-
ing sites for the proteins that mediate phage l recombination. Via the BP reaction, the
prophage integrates into the genome of E. coli and via the LR reaction, the lambda-DNA
is excised from the E. coli genome.
Only LR cloning reactions were carried out according to manufacturer’s guidelines. Sin-
gleSite Gateway cloning was used to generate an over-expression plasmid of P. berghei
LplA1. The entry plasmid pHGB and the destination plasmid pHrBI-1/2 with the
blasticidin-S-deaminase (BSD) as a selectable marker were used (Tonkin et al., 2004)
(Figure 2.6). P. berghei lplA1 was amplified by PCR and directly cloned into the entry
plasmid pHGB as described in 2.5.2.2 using the restriction endonucleases BglII and NotI.
Once cloned into the entry vector the lplA1 expression cassette (under control of the P.
falciparum Hsp86 promotor) was cloned into pHrBI-1/2 by site specific recombination of
the attL and attR sites.
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Figure 2.6.: Vector maps of pHGB and pHrBI-1/2
This figure displays the important features of the SingleSite gateway vectors pHGB and pHrBI
(according to Tonkin et al. (2004)). The entry vector pHGB contains the kanamycin resistance
cassette (KanR; 810 bp) for selection in E. coli. The attL1 and attL2 sites flank the expression
cassette into which the gene of interest is cloned. The expression cassette is under control of the
P. falciparum heat shock protein 86 promoter (PfHsp86 5’; 857 bp) and the P. berghei dihydro-
folate reductase/thymilidate synthase 3’ UTR (PbDHFR/TS 3’; 481 bp). The destination vector
pHrBI-1/2 contains the ampicillin resistance cassette (AmpR; 861 bp) for selection in E. coli and
the blasticidin-S-deaminase gene (BSD; 399 bp) for selection in P. falciparum. The blasticidin-S-
deaminase is flanked by the UTR’s of the P. falciparum histidine-rich protein 3 (PfHrpIII 5’/3’).
pHrBI-1/2 contains attR1 and attR2 sites, which flank a selection cassette containing the ccdB
death gene (306 bp) which interferes with DNA gyrase and thus allows negative selection in bacte-
ria. A chloramphenicol resistance cassette is also present (CmR; 660 bp). After the recombination
reaction the selection cassette is replaced with the expression cassette.
MultiSite gateway cloning was performed to generate GFP-tagged fusion cassettes. The
PCR product of the gene of interest was cloned directionally into the plasmid pENTR/D-
TOPO (see 2.5.2.1). The cloning of the constructs was performed as described by van
Dooren et al. (2005). Two entry plasmids were used that introduced different promoters
to the GFP-tagged fusion cassette. The PfHsp86 5’-pDONR4/1 contains the P. falciparum
Hsp86 5’ UTR and the PfCRT 5’-pDONR4/1 possesses the P. falciparum CRT 5’ UTR
(Figure 2.7). The C-terminal tag was provided by GFPmut2-pDONR2/3 (Figure 2.8).
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Figure 2.7.: Vector maps of PfHsp86 5’-pDONR4/1 and PfCRT 5’-pDONR4/1
This figure displays the important features of the 5’ element entry vectors Hsp86 5’-pDONR4/1
(Panel A) and CRT 5’-pDONR4/1 (Panel B). Both contain the kanamycin resistance cassette
(KanR; 810 bp) for selection in E. coli. The 5’ elements, Hsp86 5’ (857 bp) (A) and CRT 5’ (1481
bp) (B), are flanked by the attL4 and attR1 recombination sites which fuse the 5’ element in the
LR recombination reaction at the N-terminus of the gene of interest.
Figure 2.8.: Vector map of GFPmut2-pDONR2/3
This figure displays the important features of the 3’ element entry vector GFPmut2 in pDONR2/3.
It contains the kanamycin resistance cassette (KanR; 810 bp) for selection in E. coli. GFPmut2
(714 bp) is flanked by the attR2 and attL3 recombination sites which fuse the 3’ element in the LR
recombination reaction at the C-terminus of the gene of interest.
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The destination plasmid used was pCHDR-3/4 which contains the human dihydrofolate
reductase (hDHFR) as a selectable marker conferring resistance to WR99210 (Figure
2.9). Thus, four plasmids (either PfHsp86 5’-pDONR4/1 or PfCRT 5’-pDONR4/1, the
gene of interest in pENTR/D-TOPO, GFP-pDONR2/3 and pCHDR-3/4) were incubated
in the LR MultiSite cloning reaction according to manufacture’s guidelines to generate
the expression plasmid.
The Gateway cloning reactions were transformed into chemically competent E. coli
TOP10 cells (Invitrogen) and were plated on LB-plates containing 100 µg/ml ampicillin.
Single bacteria colonies were used to inoculate 3 ml LB-medium containing 100 µg/ml
ampicillin and were grown overnight at 37◦C. The bacteria were pelleted, plasmid DNA
was extracted (see 2.5.5) and analysed by digestion with appropriate restriction enzymes
(see 2.5.6). Plasmids with the expected insert size were analysed by DNA sequencing.
Figure 2.9.: Vector map of pCHD-3/4
This figure displays the important features of the pCHD-3/4 destination plasmid. These include the
ampicillin resistance cassette (AmpR; 861 bp) for selection in E. coli and the human dihydrofolate
reductase gene (hDHFR; 564 bp) for selection in P. falciparum. The hDHFR is under control
of the P. falciparum calmodulin promoter (PfCAM 5’; 631 bp) and flanked by the P. falciparum
histidine-rich protein 2 3’ UTR (PfHRPII 3’; 574 bp). pCHD-3/4 contains attR4 and attR3 sites,
which allow generation of an expression vector by recombining with three entry plasmids in a
MultiSite Gateway LR reaction. The attR4 and attR3 site flank a selection cassette containing the
ccdB death gene (306 bp) which interferes with DNA gyrase and thus allows negative selection
in bacteria, and the chloramphenicol resistance cassette (CmR; 660 bp). After the recombination
reaction, the selection cassette is replaced with the expression cassette flanked by the P. berghei
dihydrofolate reductase / thymilidate synthase 3’ UTR (PbDHFR/TS 3’; 853 bp).
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2.5.3. E. coli transformation
Chemically competent E. coli were used to transform either plasmid DNA or ligation
reactions. The DNA was added to the bacteria and incubated on ice for 30 min. The
bacteria were then heat shocked at 42◦C for 30-40 sec. To regenerate the bacteria, 500 µl
LB-medium was added and they were incubated at 37◦C for one hour in a shaking incuba-
tor before they were plated on LB-agar plates containing the appropriate antibiotics. The
plates were incubated at 37◦C overnight, and single colonies were analysed by miniprep
DNA extraction (see 2.5.5) and restriction endonuclease digestion (see 2.5.6).
2.5.4. Preparing competent cells
Competent bacteria used during this work were either bought from Invitrogen, Novagen
or Stratagene, or were made chemically competent using the following protocol.
A 5 ml overnight culture of the appropriate E. coli strain was used to inoculate 200 ml
LB-medium without antibiotics. This culture was grown at 37◦C and 220 rpm until OD600
reached 0.6. The culture was placed on ice for 10 min before it was centrifuged at 3000
rpm (Jouan CR3i centrifuge with T4 rotor), 4◦C for 10 min. The supernatant was dis-
carded and the pellet was placed back on ice and was resuspended in 50 ml cold 80 mM
CaCl2. The resuspended bacteria were incubated 30 min on ice before they were cen-
trifuged as before. The pellet was resuspended in 10 ml cold 80 mM CaCl2, 20% (v/v)
glycerol and 200 µl aliquots of the bacteria were frozen using dry ice and stored at -80◦C.
2.5.5. Plasmid DNA isolation from E. coli
Plasmid DNA was isolated from E. coli culture using two different methods depending
on the required plasmid DNA amount.
For small scale isolations the Qiaprep Spin Miniprep kit from Qiagen was used. 3 ml
LB-medium containing the appropriate antibiotics was inoculated with a single bacteria
colony and grown overnight at 37◦C in a shaking incubator (200 rpm). The bacteria were
pelleted and plasmid DNA was extracted according to manufacture’s guidelines. The
plasmid DNA was eluted in 50 µl ddH2O and was further analysed by digestion with the
appropriate restriction endonucleases (see 2.5.6).
Large quantities of plasmid DNA were required of constructs that were used for trans-
fection of P. falciparum. To prepare the plasmid DNA the Hi-Speed Plasmid Maxi kit
from Quiagen was used. A 3 ml day culture was set up using a single bacteria colony and
was grown at 37◦C for 8 hours. This culture was used to inoculate 250 ml LB-medium
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containing the appropriate antibiotics and was grown overnight at 37◦C and 200 rpm. The
following day, the bacteria were centrifuged at 3000 rpm (Sigma 6K15 centrifuge with
12500 rotor) at 4◦C for 20 min. Plasmid DNA was then extracted following the manufac-
ture’s guidelines. Finally, the plasmid DNA was eluted in 500 µl ddH2O and the DNA
concentration was quantified by spectrophotometric analyses (see 2.5.8). Furthermore,
the plasmid DNA was analysed by restriction endonuclease digestion (see 2.5.6).
2.5.6. Restriction endonuclease digestion
Plasmid DNA was routinely analysed by digestion with restriction endonucleases. Unless
otherwise stated, 3 µ l of plasmid DNA was added to 2 µl of the appropriate buffer, 0.2
µl BSA and 0.5 µ l of each enzyme. ddH2O was used to fill up the reaction mix to a final
volume of 20 µ l. The digestion took place at 37◦C degree (or 50◦C if BsaI was used) for
1-2 hours. 4 µ l of 6x DNA loading dye was added, mixed, and then loaded onto a 1%
(w/v) agarose gel.
2.5.7. Ethanol precipitation of genomic and plasmid DNA
To precipitate DNA, 1 µ l glycogen and 0.1 volumes of 3 M NaAc pH 5.2 were added to
the DNA solution before 2.5 volumes of cold 100% ethanol were added. The resulting
mix was incubated at -20◦C for at least one hour. The precipitated DNA was pelleted by
centrifugation at 13000 rpm (Fisher Scientific accuSpin MicroR with 24-place rotor), 4◦C
for 30 min. The supernatant was discarded, and the DNA pellet was washed with cold
70% (v/v) ethanol and centrifuged as before. The supernatant was removed and the pellet
air-dried before it was resuspended in the appropriate buffer.
2.5.8. Determining DNA and RNA concentration
The concentration of nucleic acid solutions was determined by measuring the OD260 of
the solution using a UV-spectrophotometer (Shimadzu). An OD260 of 1 corresponded to
a concentration of 50 µg/ml for double stranded DNA, 37 µg/ml for single stranded DNA
and 40 µg/ml for RNA.
2.5.9. DNA sequencing
DNA sequencing was performed by The Sequencing Service, School of Life Sciences,
University of Dundee (www.dnaseq.co.uk) using Applied Biosystems Big-Dye Ver 3.1
chemistry on an Applied Biosystems model 3730 automated capillary DNA sequencer.
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The sequencing reaction required 200-300 ng of plasmid DNA and 3.2 pmoles of se-
quencing primer per reaction.
2.5.10. Agarose gel electrophoresis
The quality and quantity of DNA was routinely examined by agarose gel electrophoresis
using the Sub-Cell GT system (Bio-Rad). 1% (w/v) agarose was dissolved in 1x TAE
buffer by boiling the mixture in a microwave. Once the agarose cooled down to 50◦C,
SYBR safe (1:10000) (Invitrogen) was added and it was poured into gel trays with the
appropriate size comb. The DNA samples were mixed with 6x DNA loading dye and
electrophoresis was performed at 80-110 V for 30-60 min in 1x TAE buffer. 1 kb ladder
(Promega) was run with DNA samples to allow the size determination of the bands visu-
alised by UV illumination at 302 nm or 365 nm using the Gel Doc XR system (Bio-Rad).
2.5.11. Southern blot analysis
To analyse parasite DNA, digests with specific restriction enzymes led to a specific pattern
of bands detectable on a Southern blot. 1-5 µg DNA was digested with the appropriate
restriction enzymes at 37◦C overnight. The following day the digested DNA was loaded
onto a 0.8% (w/v) agarose gel and the gel was run at 15-20 V overnight. The DNA was
then transferred to the positively charged nylon membrane Hybond-N+ (GE Healthcare).
For the transfer the membrane was placed on the VacuGene XL apparatus (GE Health-
care) and was covered with 0.25 N HCl. The gel was put on top of the membrane and
the vacuum pump was turned on (with the pressure between 50 and 60 mbar). The gel
was covered with the depurination solution (0.25 N HCl) for 25 min until the colour of
the loading dye changed from blue to yellow. The HCl was removed and the gel was
covered with the denaturation solution (1.5 M NaCl and 0.5 M NaOH) for approximately
25 min until the loading dye colour changed back to blue. The denaturation solution
was removed and 20x SSC was poured on the gel. The transfer took one hour during
which the gel remained covered with 20x SSC. By using the UV crosslinker, the DNA
was crosslinked with the membrane. To analyse the Southern blot the Gene Images CDP-
Star detection module from GE Healthcare was used. The membrane was blocked with
the pre-hybridisation buffer (5x SSC, 0.1% (w/v) SDS, 5% (w/v) dextran sulphate and
1:20 dilution of GI liquid block) for at least two hours at 60◦C. The pre-hybridisation
buffer was warmed to 60◦C before it was added to the membrane. After pre-hybridising,
a fluorescein-labelled probe was added. The probe of the gene of interest was synthesized
using the Gene Images Random Prime Labelling Module from GE Healthcare. During
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the PCR reaction fluorescein-11-dUTP partially replaced the dTTP so that a fluorescein-
labelled probe was synthesized. 2 µ l/ml hybridisation buffer of freshly made probe was
added and was incubated with the membrane at 60◦C overnight. Before adding to the
membrane, the probe was denatured at 90◦C for 5 min. After incubation with the probe
the blot was washed twice for 10 min with 1x SSC + 0.1% SDS at 60◦C and twice for
10 min with 0.5x SSC + 0.1% SDS at 60◦C. After washing, the membrane was blocked
in a 1:10 dilution of GI liquid block in buffer A (100 mM Tris/HCl, 300 mM NaCl, pH
9.5) for one hour at room temperature followed by incubation with the anti-fluorescein
alkaline phosphatase (AP) conjugated antibody for at least one hour at room temperature.
The antibody was diluted 1:5000 in buffer A with 0.5% (w/v) BSA. Then, the blot was
washed three times for 30 min in buffer A with 0.3% (v/v) Tween20 and the detection
reagent was added. The light produced in the reaction catalysed by the alkaline phos-
phatase (decomposition of the detection reagent) was detected on autoradiography film
(Kodak).
2.5.12. Pulse field gel electrophoresis
To separate chromosomes from each other in an agarose gel, pulse field gel electrophore-
sis (PFGE) was performed using the CHEF-DR III Variable Angle System (Bio-Rad).
Before the gel was run, the apparatus had to be washed and equilibrated. First, it was
washed with 0.1% (w/v) SDS at room temperature overnight (pump setting: 60). The
following day, the machine was washed twice with ddH2O at 13◦C followed by equilibra-
tion with 2 L of the appropriate running buffer (0.5x TBE for separation of chromosomes
1-10, or 1x TAE for separation of chromosomes 11-14) overnight at 13◦C. The following
day the running buffer was changed and the PFGE was performed. To prepare the gel, 1%
(w/v) agarose was dissolved in 0.5x TBE (or 1x TAE for separation of chromosomes 11-
14) and poured into a gel casting stand with the appropriate comb (Bio-Rad). Once set, the
comb was removed and the equilibrated chromosome blocks (see 2.2.8) were loaded. The
chromosome blocks were equilibrated for at least 30 min in the running buffer at room
temperature before they were loaded on the gel. After loading, the wells were sealed with
1% (w/v) low melting point agarose in 0.5x TBE (or 1x TAE for separation of chromo-
somes 11-14) and the gel was run at the appropriate running conditions (see below). After
the run was complete, the gel was removed and the apparatus was washed with ddH2O,
0.1% (w/v) SDS and ddH2O again. The gel was stained with SYBR safe (Invitrogen).
DNA was visualised using the Gel Doc XR system (Bio-Rad) and analysed by Southern
blotting as described in 2.5.11.
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Conditions for resolution of chromosomes 1-5:
1% (w/v) agarose in 0.5x TBE, 60-120 sec pulse, 6 V/cm (200 volts), 24 hour run.
Conditions for resolution of chromosomes 1-10:
1% (w/v) agarose in 0.5x TBE, 225 sec pulse, 4.2 V/cm (140 volts), 60 hour run.
Conditions for resolution of chromosomes 11-14:
1% (w/v) agarose in 1x TAE, 360-800 sec pulse, 3 V/cm (100 volts), 96 hour run.
2.6. Methods in biochemistry
2.6.1. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
Proteins were separated by polyacrylamide gel electrophoresis (PAGE) as described by
Laemmli (1970). The NuPAGE electrophoresis system (Invitrogen) was used with ei-
ther 4-12% Novex Bis/Tris pre-cast gels or self-made polyacrylamide gel. Gradient
gels were utilised for the analyses of parasite extract whereas 15% and 12.5% poly-
acrylamide gels were used for examining purity of recombinant protein and enzyme
assays. The running gel consisted of 6 ml running gel buffer (375 mM Tris pH 8.9,
0.1% (w/v) SDS, 12.5-15% (v/v) acrylamide) which was polymerised by addition of 5
µl N,N,N’,N’-Tetramethylethylenediamine (TEMED) and 25 µ l ammonium persulphate
(APS) (10 mg/ml). The gel was poured into empty plastic cassettes (Invitrogen) and al-
lowed to set. The stacking gel, consisting of 2 ml stacking gel buffer (122 mM Tris pH
6.7, 0.1% (w/v) SDS, 5% (v/v) acrylamide) was poured on top of the running gel and an
appropriate comb was placed in the stacking gel. While the stacking gel was allowed to
set protein samples were prepared. 15 µg parasite extract or 5 µg recombinant protein
was mixed with 6x loading buffer and denatured at 100◦C for 5 min. The samples were
loaded and the self-made polyacrylamide gels were run in 1x running buffer and pre-cast
gels in 1x MOPS buffer (Invitrogen) at 40 mA and 200 V. Following electrophoresis, gels
were either stained with Coomassie blue (see 2.6.3), silver (see 2.6.4) or were analysed
by western blotting (see 2.6.5).
2.6.2. Native polyacrylamide gel electrophoresis
For native PAGE, proteins were not denatured before or during electrophoresis and were
therefore separated according to their charge. The NuPAGE electrophoresis system (In-
vitrogen) was used with 20% polyacrylamide gels. The running gel consisted of 6 ml
native running buffer (125 mM Tris pH 8.9, 20% (v/v) acrylamide) and the stacking gel
of 2 ml native stacking buffer (125 mM Tris pH 6.7, 5% (v/v) acrylamide). Samples
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were prepared using 2x native loading buffer and were kept on ice until loading onto the
gel. Gels were run in 1x native running buffer at 20 mA and 4◦C until the loading buffer
reached the bottom of the gel. The gel was removed from the cassette and either stained
with Coomassie blue (see 2.6.3) or analysed by western blotting (see 2.6.5).
2.6.3. Coomassie blue staining of polyacrylamide gels
After electrophoresis, the gel was removed from the cassette and covered with Coomassie
stain for at least 1h at room temperature. For destaining, the Coomassie blue solution was
removed and the gel was incubated in destain for 2-3 hours.
2.6.4. Silver staining of polyacrylamide gels
Silver staining was performed according to Shevchenko et al. (1996). Following elec-
trophoresis, the gel was taken out of the cassette and was fixed in 45% (v/v) methanol
and 5% (v/v) acetic acid for 30 min. The gel was washed twice for 10 min in ddH2O
before it was treated with 0.02% (w/v) sodium thiosulphate for 1-2 min. After washing
the gel twice in ddH2O for 1 min, it was impregnated with 0.1% (w/v) silver nitrate at
4◦C for 20-30 min. It was rinsed twice with ddH2O and the developing solution (0.04%
(v/v) formaldehyde, 2% (w/v) Na2CO3) was added until protein became visible. The
color development was stopped by adding 5% (v/v) acetic acid, in which the gel was also
stored.
2.6.5. Western blot analyses
By western blotting, proteins previously separated in a polyacrylamide gel were trans-
ferred to a nitrocellulose membrane (Schleicher & Schuell). Transfer was performed
using the Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell (Bio-Rad). The blot was
built from the bottom to the top consisting of five layers of filter paper, nitrocellulose
membrane, polyacrylamide gel and five layers of filter paper. Before set up, the filter pa-
per, nitrocellulose membrane and the polyacrylamide gel were soaked in Towbin buffer.
Transfer took place at 20 V for 35 min for one gel. Transfer of more than one gel in-
creased the transfer time by 10 min for each additional gel. After transfer the membrane
was stained with Ponceau S Solution (Sigma) which detected all proteins bound to the
membrane. The blot was destained using PBS.
Western blots were analysed using the Immobilon Western kit from Millipore. First, the
membrane was blocked in 5% (w/v) milk in PBS for at least two hours at room tem-
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perature. After blocking the membrane was washed three times for 10 min with PBS
containing 0.1% (v/v) Tween20 followed by incubation with the first antibody. The an-
tibody was diluted in 1% or 2% (w/v) milk in PBS containing 0.1% (v/v) Tween20 and
incubation took place for at least one hour at room temperature. The first antibodies and
their dilutions used are listed in Table 2.1. After incubation, the membrane was washed
as described above and the second antibody was added. The second antibodies used and
their dilutions can be found in Table 2.2. The antibodies were diluted in 1% or 2% (w/v)
milk in PBS containing 0.1% (v/v) Tween20 and the membrane was incubated for one
hour at room temperature. The second antibody was specific against the animal in which
the first antibody was raised and was conjugated to horseradish peroxidase (HRP). Af-
ter incubation with the second antibody, the membrane was washed as described before
and the detection reagents of the Immobilon Western blot detection kit (Millipore) were
added. The kit contained two solutions; the HRP Substrate Peroxide Solution and the
HRP Substrate Luminol Reagent. Equal volumes of both were mixed and added to the
membrane. The reagents reacted with the HRP and produced a chemiluminescent signal
with a maximum emission at 430 nm. The resulting light was detected on autoradiography
film (Kodak).
2.6.6. Determining protein concentration
The protein concentration of parasite extract was determined by the Bradford assay (Brad-
ford, 1976), using the Bio-Rad protein assay reagent. The absorbance of a protein solution
mixed with Bradford reagent (Bio-Rad) was measured at 595 nm and the protein concen-
tration was determined in reference to a standard curve of known BSA concentrations.
The concentration of purified recombinant protein was analysed by measuring the ab-
sorbance of the solution at 280 nm. The protein concentration was then calculated using
a protein specific extinction coefficient that was calculated using Vector NTI software
(Invitrogen).
2.6.7. Generation of polyclonal antibodies
Polyclonal antibodies were generated from purified recombinantly expressed proteins by
Eurogentec (Belgium), following their standard immunisation protocols. 400 µg of re-
combinant LplA1 and H-protein, and 100 µg of recombinant LplA2 were separated by
SDS-PAGE, cut out and sent to Eurogentec for immunisation of either rabbits or rats, re-
spectively. Each bleed was tested on recombinant protein and parasite extract to test for
specificity.
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2.6.8. BugBuster Protein Extraction
To establish optimal expression conditions for a recombinant protein expression construct,
the BugBuster protein extraction kit from Novagen was used. 100 ml LB-medium con-
taining the appropriate antibiotics were inoculated with 1-5 ml of an overnight culture
of bacteria transformed with the construct of interest. The bacteria were grown at 37◦C
until OD600 was 0.6 and were induced with 1 mM isopropyl-ß-D-thiogalactoside (IPTG)
or 200 ng/ml anhydrotetracycline (AHT), depending on the plasmid used. Expression
took place at different temperatures (37◦C, 30◦C, 23◦C and 18◦C). For protein extrac-
tion, 1 ml samples of each culture were taken before induction, each hour after induction
and after overnight expression. For analyses, the samples were centrifuged for 1 min at
13200 rpm (Eppendorf microcentrifuge with F45-24-11 rotor), the supernatant was dis-
carded and the pellet was resuspended in 100 µl BugBuster Protein Extraction Reagent.
To digest bacterial DNA, 0.5 µ l benzonase were added and the mixture was incubated at
room temperature with constant shaking. After 15 min, the mixture was centrifuged for
15 min at 13000 rpm (Fisher Scientific accuSpin MicroR with 24-place rotor) and 4◦C.
The supernatant was transferred into a fresh tube, and the pellet was resuspended in 100
µl PBS. For analyses, 5 µl of the pellet fractions and 15 µl of the supernatant fractions
were separated by SDS-PAGE (see 2.6.1) and evaluated by western blotting using specific
antibodies against the protein or protein-tag (see 2.6.5).
2.6.9. Expression and purification of proteins with a His-tag
The plasmid pJC40 was used to attach a N-terminal (His)10-tag to recombinantly ex-
pressed proteins (Figure 2.10) (Clos and Brandau, 1994). Proteins recombinantly ex-
pressed using this plasmid were P. falciparum LplA1 (see 5.2), P. falciparum LplA2 (see
5.3) and P. falciparum H-protein and the lipoyl-domains of the KADH-E2 subunits (see
5.5). For expression, 4x 500 ml LB-medium containing 100 µg/ml ampicillin were inoc-
ulated with 10-15 ml of a bacteria overnight culture. The bacteria were grown at 37◦C
and 220 rpm in a shaking incubator until OD600 was between 0.5 and 0.6 followed by in-
duction of recombinant protein expression with 1 mM IPTG. The protein was expressed
at optimal conditions, which were determined previously using the BugBuster protein ex-
traction kit (see 2.6.8). After the optimal time of expression, the culture was centrifuged
for 20 min at 3500 rpm (Sigma 6K15 centrifuge with 12500 rotor) and 4◦C. The super-
natant was discarded, and the pellet was resuspended in Tris-lysis buffer (50 mM Tris/HCl
(pH 7.5), 300 mM NaCl, 10 mM imidazole and 1 mM DTT) or LplA-lysis buffer which
contained in addition 10% (v/v) glycerol. The resuspended pellet was stored at -20◦C.
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Figure 2.10.: Vector map of pJC40
This figure displays the important features of the pJC40 recombinant expression plasmid. These
include the ampicillin resistance cassette (AmpR; 861 bp) and the multiple cloning site (NdeI-
ApaI). Recombinant expression using this plasmid is under control of the T7 promoter and attaches
a (His)10-tag at the N-terminus of the recombinant protein which can be cleaved off with factor
Xa.
For purification, the pellet was thawed and 50 µg/ml lysozyme was added. The pellet was
incubated for 30 min on ice. Before the bacteria were disrupted the protease inhibitors
phenylmethylsulfonylfluoride (PMSF, 1 mM), leupeptin (2 µg/ml) and pepstatin-A (1.5
µM) were added. To disrupt the bacteria they were either sonicated 5-10 times for 30 sec
with 30 sec breaks or the one shot cell disrupter (Constant Systems) was used at 15 kpsi.
Subsequently, the disrupted bacteria were centrifuged for 60 min at 20000 rpm (Beckman
J2-H5 centrifuge with a JA-20 rotor) and 4◦C, before the recombinant protein was puri-
fied by either batch nickel affinity chromatography (see 2.6.9.1), or FPLC nickel affinity
chromatography (see 2.6.9.2).
2.6.9.1. Batch nickel affinity chromatography
After centrifugation, as described above, the supernatant was filtered through a 0.45
µm syringe filter (Sartorius). The following purification was performed using nickel-
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nitrilotriacetic acid (Ni-NTA) agarose from Qiagen, which interacted with the His-tag.
Approximately 5-10 mg of His-tagged protein bound to 1 ml Ni-NTA agarose. The su-
pernatant of the centrifugation step was transferred onto Ni-NTA agarose, which was
equilibrated with the appropriate lysis buffer before (Tris-lysis buffer contained 50 mM
Tris/HCl (pH 7.5), 300 mM NaCl, 10 mM imidazole and 1 mM DTT; LplA-lysis buffer
also contained 10% (v/v) glycerol). The binding was conducted at 4◦C for one hour, ro-
tating on a blood wheel, followed by centrifugation for 5 min at 600 rpm (Sigma 6K15
centrifuge with 11150 rotor) and 4◦C. The pelleted Ni-NTA agarose beads with the bound
protein were washed four times. Twice with the appropriate lysis buffer, followed by two
wash steps with the appropriate wash buffer (50 mM Tris/HCl (pH 7.5), 300 mM NaCl,
20 mM imidazole and 1 mM DTT; LplA-wash buffer also contained 10% (v/v) glycerol).
Each wash step was carried out at 4◦C for 10 min, rotating on a blood wheel, followed by
centrifugation as explained above. The last wash step was poured into a Econo-Pac col-
umn (Bio-Rad) and the resin was allowed to set. The protein was eluted from the agarose
with elution buffer (50 mM Tris/HCl (pH 7.5), 300 mM NaCl, 500 mM imidazole and 1
mM DTT; LplA-elution buffer also contained 10% (v/v) glycerol). The elution volume
varied depending on the recombinant protein and the amount of starting material. The
volumes used were between 2 ml and 10 ml elution buffer. The protein concentration was
determined by measuring the absorbance of the solution at 280 nm (see 2.6.6). Finally,
SDS-PAGE (see 2.6.1) of all samples taken during the purification was carried out and
was analysed by Coomassie blue staining (see 2.6.3) or western blotting (see 2.6.5).
2.6.9.2. FPLC nickel affinity chromatography
For FPLC nickel affinity chromatography, HiTrap chelating HP columns (1 ml; GE Health-
care) were used. HiTrap columns were washed sequentially with sterile filtered ddH2O,
100 mM NiSO4, ddH2O and LplA-lysis buffer (50 mM Tris/HCl (pH 7.5), 300 mM NaCl,
10% (v/v) glycerol, 10 mM imidazole and 1 mM DTT), before protein samples were pre-
loaded onto a HiTrap chelating column. The protein samples were filtered using a 0.2
µm syringe filter (Sartorius) before being loaded onto the column. The column was then
attached to a BioLogic DuoFlow (Bio-Rad), washed with 10 column volumes of LplA-
lysis buffer before the sample was eluted using a linear gradient of 10-500 mM imida-
zole. The linear gradient of imidazole was prepared by the BioLogic DuoFlow by mixing
LplA-lysis buffer (10 mM imidazole) with LplA-elution buffer (500 mM imidazole). The
elution profile of the proteins loaded onto the column was followed spectrally at 280 nm.
Samples from OD280 peaks were analysed by SDS-PAGE (see 2.6.1) and western blotting
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(see 2.6.5).
2.6.10. Expression and purification of proteins with a Strep-tag
The plasmid pASK-IBA3 (IBA) was used to attach a C-terminal Strep-tag to recom-
binantly expressed proteins (Figure 2.11). Proteins recombinantly expressed using this
plasmid were P. falciparum LplA1 (see 5.2) and P. falciparum LplA2 (see 5.3).
Figure 2.11.: Vector map of pASK-IBA3
This figure displays the important features of the pASK-IBA3 recombinant expression plasmid.
These include the ampicillin resistance cassette (AmpR; 861 bp) and the multiple cloning site
(BsaI-BsaI). Recombinant expression using this plasmid is under control of the Tet-promoter
which is switched off by the Tet-repressor (624 bp) until induction. The Strep-tag is attached
to the C-terminus of the recombinant protein.
For expression of recombinant protein, 500 ml LB-medium containing 100 µg/ml ampi-
cillin were inoculated with 10 ml of overnight bacteria culture. The bacteria were grown
at 37◦C and 220 rpm in a shaking incubator until OD600 was between 0.5 and 0.6. The
expression of the recombinant protein was induced by addition of 200 ng/ml AHT. The
protein was expressed at optimal conditions, which were determined previously using the
BugBuster protein extraction kit (see 2.6.8). After the optimal time of expression, the
culture was centrifuged for 20 min at 3500 rpm (Sigma 6K15 centrifuge with 12500 ro-
tor) and 4◦C. The supernatant was discarded, and the pellet was resuspended in a small
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volume of pre-cooled buffer W (100 mM Tris/HCl (pH 8.0), 150 mM NaCl). The resus-
pended pellet was stored at -20◦C.
For purification, the pellet was thawed and 50 µg/ml lysozyme was added. The pellet was
incubated for 30 min on ice. Before the bacteria were disrupted, the protease inhibitors
PMSF (1 mM), leupeptin (2 µg/ml) and pepstatin-A (1.5 µM) were added. To disrupt the
bacteria they were either sonicated 5-10 times for 30 sec with 30 sec breaks or the one
shot cell disrupter (Constant Systems) was used at 15 kpsi. Subsequently, the disrupted
bacteria were centrifuged for 60 min at 20000 rpm (Beckman J2-H5 centrifuge with a JA-
20 rotor) and 4◦C. The purification was accomplished using Strep Tactin Sepharose (IBA)
in a column procedure. While the bacteria were centrifuged, the column was prepared.
500 µ l of Strep Tactin Sepharose was transferred into a Econo-Pac column (Bio-Rad) and
was equilibrated with buffer W. The bacterial supernatant was filtered through a 0.45 µm
syringe filter (Sartorius) and added onto the Strep-Tactin Sepharose. Samples were taken
from the pellet and the supernatant fraction for further analyses. After the supernatant
had completely entered the resin by gravity-flow, it was washed with 10 column volumes
of buffer W. Again, samples were taken for further analyses. For elution of the protein,
3 ml of elution buffer (buffer W with 2.5 mM desthiobiotin) were used. The eluate was
collected in six tubes, each containing 0.5 ml of the elution fraction. The protein con-
centration of each elution fraction was determined by measuring the absorbance of each
fraction at 280 nm (see 2.6.6). Finally, SDS-PAGE (see 2.6.1) of all samples taken dur-
ing the purification and elution fractions was carried out and analysed by Coomassie blue
staining (see 2.6.3) or western blotting (see 2.6.5).
2.7. Functionality and enzyme assays
2.7.1. Complementation assay to confirm P. falciparum LplA2 functionality
Three LplA2 expression constructs were generated using the plasmid pASK-IBA3 (see
Figure 2.11). The constructs differed in length at their N-termini. The first construct
was lplA2 full length (base pairs 1-1152). Construct S1 consisted of base pairs 79-1152
and construct S2 of base pairs 235-1152. The constructs were transformed into the lipB
deficient E. coli strain Ker184 (Reed and Cronan, 1993) and the lipB/lplA deficient E. coli
strain Tm136 (Morris et al., 1995), to assess whether LplA2 can complement the growth
defect of the bacterial lines when grown on minimal medium. The transformed Ker184
were plated on M9 minimal plates containing 100 µg/ml ampicillin, 50 µg/ml kanamycin
and 200 ng/ml AHT to induce the expression. The transformed Tm136 were plated on
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minimal plates containing the M9 minimal medium salts, 0.4% (w/v) glucose, 7.5 µ /ml
FeSO4, 1 µ/ml casein (vitamin free), 0.002% (w/v) thiamine, 1 mM MgSO4, 100 µg/ml
ampicillin, 50 µg/ml kanamycin, 15 µg/ml tetracycline and 200 ng/ml AHT. The bacteria
were incubated at 37◦C until growth was detected.
2.7.2. Lipoylation assay followed by PAGE and western blotting - "Gel assays"
Lipoate protein ligases (LplA) catalyse the attachment of lipoic acid to the lipoyl-domains
of the KADH-E2 subunits and to the H-protein of the GCV using ATP and releasing AMP
and inorganic pyrophosphate (PPi) as shown in the following equation:
Lipoyl-domain + lipoic acid + ATP → lipoylated-domain + AMP + PPi
In this assay, LplA activity was qualitatively analysed by examining the lipoylation state
of the protein substrate - the lipoyl-domain. In native PAGE, the lipoylated form of the
protein migrates faster than the non-lipoylated form resulting in a shift of the protein
band (Fujiwara et al., 1992). Using SDS-PAGE, the lipoylation state was determined by
western blotting using an antibody against protein bound lipoic acid (see Table 2.1).
The lipoylation reaction was performed in a final volume of 30 µ l containing 100 mM
phosphate buffer (pH 7.4), 2 mM MgCl2, 1 mM DTT, 2 mM ATP, 0.5 mM lipoic acid, 2-
4.4 µM protein substrate and varying concentrations of recombinant LplA between 0-3.5
µM. The reaction was carried out at 37◦C for 30 min for E. coli LplA, and for 60 min for
P. falciparum LplA1.
If separated by native PAGE, the reaction was terminated by the addition of 2x native
sample buffer and the reaction was transferred onto ice. Half of the reaction was separated
by 20% native PAGE at 4◦C overnight. If separated by SDS-PAGE, the reaction was
terminated by the addition of 6x loading buffer. The samples were boiled for 5 min before
half of the reaction was separated by 15% SDS-PAGE. The gel was analysed by western
blotting using an antibody directed against protein-bound lipoic acid (see Table 2.1).
2.7.3. Spectrophotometric assay
Using the spectrophotometric assay to determine LplA activity, the release of PPi during
the reaction was determined as a measure of LplA activity. As shown in Figure 2.12,
the spectrophotometric assay is a coupled enzyme assay in which an inorganic pyrophos-
phatase converts the released PPi to inorganic phosphate (Pi2−). The Pi2− reacts with
ammonium molybdate and forms a blue coloured complex which can be detected spec-
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trophotometrically at 710 nm. After complex formation, a solution containing bismuth
citrate is added to stabilise the formed complexes (Cariani et al., 2004).
Lipoyl-domain + lipoic acid  + ATP lipoylated-domain + AMP + PPi 
(PPiMg)
2-
blue-colored complex [710nm]
+ ammonium molybdate
2 Pi
2-
 + Mg
2+
LplA
inorganic pyrophosphatase
Figure 2.12.: Schematic diagram of spectrophotometric assay
The lipoyl-domains of the KADH-E2 subunits and the H-protein of the GCV are post-
translationally lipoylated by LplA. During the LplA reaction ATP is used and AMP and pyrophos-
phate (PPi) are released. In the spectrophotometric assay, PPi is converted to 2 Pi2− by an inor-
ganic pyrophosphatase. The Pi2− reacts with ammonium molybdate and forms a blue-coloured
complex which can be detected spectrophotometrically at 710 nm.
Beside the actual LplA reaction mixture (see below), two solutions were required for this
assay.
Solution 1: 3 g ascorbic acid was dissolved in 35 ml ddH2O. 50 ml of 1 M HCl was
added once the ascorbic acid was dissolved, and the solution was cooled down to 0◦C on
ice. 5 ml of 10% (w/v) ammonium molybdate and 15 ml of 20% (w/v) SDS were added
whilst stirring continuously. The solution turned yellow. Kept on ice, solution 1 was sta-
ble for four hours.
Solution 2: 3.5 g bismuth citrate was dissolved in 100 ml 1 M HCl. 3.5 g sodium citrate
was added. This solution was stable for one week, if protected from light.
To analyse the linearity of this assay and to quantify the released PPi during the LplA re-
action, a standard curve of known Pi2− concentrations was generated. A 1 mM K2HPO4
solution was used to make up solutions containing 0-30 nmol Pi2− in 30 mM Tris/HCl
(pH 7.5), 2 mM MgCl2, 1 mM DTT and 0.5 mM lipoic acid in a final volume of 200
µl. To determine the Pi2− concentration, 400 µ l of solution 1 was added and the mixture
was incubated on ice. After 10 min, 600 µ l of solution 2 was added and the mixture
was incubated for a further 10 min at 37◦C. Absorbance at 710 nm was measured using a
UV-2501PC (Shimadzu) after an additional 20 min at room temperature.
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To determine LplA activity using the spectrophotometric assay, the reaction was carried
out in a final volume of 200 µ l containing 30 mM Tris/HCl (pH 7.5), 2 mM MgCl2, 1
mM DTT, 2.5 U inorganic pyrophosphatase, 0.5 mM lipoic acid, 2 mM ATP and 0-40
µM of protein substrate. The reaction was started by addition of varying concentrations
of LplA between 0-1.6 µM, and was incubated at 37◦C for 30 min for E. coli LplA and 10
min - 30 min for P. falciparum LplA1. The reaction was stopped by addition of solution
1 and 2 as described above. Measured absorbance was first converted into Pi2− using the
standard curve and was than converted into released PPi. Data were analysed using Prism
3.0 (GraphPad software) and Grafit 5.0 (Erithacus software).
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3. LplA1
3.1. Introduction
Apicomplexan parasites possess two machineries to lipoylate the KADH-E2 subunits
and the H-protein of the GCV, which require the cofactor lipoic acid for their activity
(Perham, 2000, Douce et al., 2001). The apicoplast contains a lipoic acid biosynthesis
pathway and the mitochondrion a lipoic acid salvage pathway (Thomsen-Zieger et al.,
2003, Wrenger and Müller, 2004). The biosynthesis of lipoic acid is catalysed by two
proteins, a octanoyl-[acyl carrier protein]: protein N-octanoyltransferase (LipB) and a
lipoic acid synthase (LipA) (Zhao et al., 2003, 2005). LipB attaches octanoyl-ACP pro-
vided by fatty acid biosynthesis to the E2 subunit of the PDH and LipA then catalyses the
insertion of two sulphur atoms to form the lipoyl moiety. The salvage pathway consists
of LplA, a functional lipoate protein ligase, which ligates scavenged lipoic acid to the H-
protein and KADH-E2 subunits in the mitochondrion (Wrenger and Müller, 2004, Allary
et al., 2007).
In this chapter, the role of LplA1 in P. falciparum and P. berghei is analysed, and it is
assessed whether LplA1 is crucial for parasite survival by reverse genetic approaches.
3.2. Sequence considerations
Structural information about lipoate protein ligases is available from the E. coli and T.
acidophilum proteins (Fujiwara et al., 2005, Kim et al., 2005, McManus et al., 2006).
Comparison of P. falciparum and P. berghei LplA1 with the two bacterial proteins shows
only modest sequence similarities to T. acidophilum LplA, but higher similarities to the
E. coli protein (Table 3.1).
Table 3.1.: Sequence similarities of P. falciparum and P. berghei LplA1 with bacterial
LplAs
E. coli LplA T. acidophilum LplA
P. falciparum LplA1 39.4% 25.5%
P. berghei LplA1 38.4% 23.8%
3. LplA1 86
For further analysis, amino acid sequence alignment of P. falciparum and P. berghei
LplA1 with the two bacterial proteins was performed. The alignment was carried out
by combining ClustalW alignments of the bacterial proteins and the Plasmodium proteins
using the program T-Coffee (Notredame et al., 2000, Poirot et al., 2003) (Figure 3.1).
Three sequence motifs (highlighted in red), which are highly conserved in other LplAs,
are also found in both Plasmodium LplA1s, highlighting the importance of these amino
acids for LplA activity. It was shown that these motifs are involved in the formation
of the lipoyl-AMP binding pocket, the reaction intermediate which is formed during the
LplA reaction. The alignment also shows that the Plasmodium proteins possess an ap-
proximately 50 amino acid long insertion in comparison to the bacterial proteins. Further,
both Plasmodium proteins contain an 18 amino acid long N-terminal extension which is
likely responsible for targeting the proteins to the mitochondrion. Although 47% of the
N-terminal extensions are identical, only the potential cleavage site of the targeting pep-
tide for P. falciparum LplA1 can be predicted by MitoProt (indicated by arrow).
P. falciparum and P. berghei LplA1 are very similar to each other with 78% amino acid
sequence similarity. Additionally, the gene loci are syntenic, except for three small hy-
pothetical proteins in the P. berghei lplA1 locus (Figure 3.2). These, however, could be
a result of miss-annotation and they could actually be exons of the cop-coated vesicle
membrane protein p24 precursor, lplA1 or a conserved hypothetical protein. However,
further investigations are required to determine whether these transcripts are present in P.
berghei RNA.
The following experiments described in this chapter were all performed based using the
annotated lplA1 genes.
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Figure 3.1.: Amino acid sequence alignment of P. falciparum and P. berghei LplA1 with
bacterial LplA
Separate ClustalW alignments of E. coli (Ec) / T. acidophilum (Tc) LplA and P. falciparum (Pf) /
P. berghei (Pb) LplA1 were combined using the program T-Coffee (Notredame et al., 2000, Poirot
et al., 2003) showing (*) identical residues, (:) conserved residues and (.) homologous residues.
Three highly conserved sequence motifs, which contain key residues involved in the formation
of the lipoyl-AMP binding pocket, are highlighted in red. Residues outside these three motifs
involved in lipoic acid binding are highlighted in yellow for the E. coli protein and green for the T.
acidophilum protein. Both Plasmodium LplA1s possess a 18 amino acid extension of which 47%
are identical residues (highlighted in blue). Both proteins are predicted to be mitochondrial, but
a potential cleavage site can only be predicted for P. falciparum LplA1 by MitoProt (indicated by
the arrow).
3. LplA1 88
Figure 3.2.: Synteny map of P. falciparum and P. berghei lplA1 gene loci
Synteny map of lplA1 gene loci was taken from the PlasmoDB website (www.plasmodb.org). The
map shows that the gene loci are syntenic except for three small proteins around the annotated
lplA1 gene in P. berghei. It is however possible, that they are miss-annotated and that they actually
belong to the cop-coated vesicle membrane protein p24 precursor, lplA1 and the hypothetical
protein PB000050.02.0. One distinctive feature of both gene loci is that the lplA1 coding sequence
is on the opposite strand in comparison to the other genes present in the loci.
3.3. Lipoic acid dependent proteins in P. falciparum
To confirm that the lipoic acid biosynthesis and salvage pathways are active in P. fal-
ciparum blood stages, western blot analyses of parasite extract using an antibody di-
rected against protein-bound lipoic acid was performed (Figure 3.3, lane 4). Four bands
were detected by the anti-lipoic acid antibody likely corresponding to PDH-E2 (75 kDa),
BCDH-E2 (50 kDa), KGDH-E2 (47 kDa) and H-protein (25 kDa). To further support
this, western blot analyses were performed using antibodies raised against P. falciparum
H-protein, BCDH-E2 and KGDH-E2 (Figure 3.3, lanes 1-3) (for antibody dilutions see
Table 2.1). The apparent sizes of the proteins detected by the anti-H-protein (26 kDa;
lane 1), anti-BCDH-E2 (50 kDa; lane 2) and anti-KGDH-E2 (47 kDa; lane 3) correlate
nicely with the protein bands detected by the lipoic acid antibody, suggesting that indeed
the mitochondrial KADHs and the H-protein are lipoylated in the erythrocytic stages of
P. falciparum. It was shown previously that the 75 kDa band detected by the lipoic acid
antibody corresponds to the PDH-E2 subunit (Allary et al., 2007).
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Figure 3.3.: Lipoylation pattern in wild-type parasites
Western blots of P. falciparum protein extract (15 µg) were separated on a 4-12% gradient gel and
were analysed using four different antibodies: (lane 1) anti-H-protein recognising a 26 kDa band;
(lane 2) anti BCDH-E2 recognising a 50 kDa band; (lane 3) anti KGDH-E2 recognising a 47 kDa
band; (lane 4) anti-lipoic acid recognising four major protein bands corresponding to PDH-E2 (75
kDa), BCDH-E2 (50 kDa), KGDH-E2 (47 kDa) and H-protein (25 kDa).
Plasmodium PDH is solely found in the apicoplast, whereas the the BCDH and KGDH
are present in the mitochondrion (Foth et al., 2005, Günther et al., 2005, McMillan et al.,
2005). The H-protein is predicted to be in the mitochondrion as part of the GCV (Sal-
cedo et al., 2005), but there is no experimental support for this prediction. Therefore,
H-protein-GFP fusion proteins were generated to investigate H-protein localisation ex-
perimentally. Full length H-protein was amplified using the primers H-protein-fwd and
H-protein-rev (see 2.1.7) and was cloned in frame with GFP using the MultiSite Gateway
plasmids described in Chapter 2.5.2.3 (van Dooren et al., 2005). The destination plas-
mid pCHD-3/4 (see Figure 2.9) confers resistance to WR99210 and the expression of the
fusion protein was controlled by either the P. falciparum Hsp86 or CRT promotor. Trans-
fected parasites were analysed by fluorescence microscopy, and to visualise the mito-
chondrion the parasites were additionally stained with Mitotracker CMXRos (Molecular
Probes). Merged images showed clearly that the H-protein is located in the mitochon-
drion supporting its predicted localisation (Figure 3.4, Panel A). Parasite lines expressing
the bipartite leader sequence of the PDH-E2 (amino acids 1-166) cloned in frame with
GFP (Panel B) and lines expressing the mitochondrial targeting sequence of the BCDH-
E2 (amino acids 1-106) (Panel C) and KGDH-E2 (amino acids 1-114) (Panel D) cloned
in frame with GFP were previously analysed in the laboratory (McMillan and Müller,
unpublished data). Images of these parasites confirm localisation of the PDH-E2 to the
apicoplast, and BCDH-E2 and KGDH-E2 to the mitochondrion.
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A H-protein
B PDH-E2 C BCDH-E2 D KGDH-E2
Figure 3.4.: Subcellular localisation of P. falciparum H-protein and KADH-E2 subunits
(Panel A) The subcellular localisation of H-protein was investigated by expressing GFP fusion
proteins in the erythrocytic stages of P. falciparum. Full length H-protein was cloned in frame
with GFP and expression was controlled by either the Hsp86 or CRT promoter. Parasites mito-
chondria were selectively stained with Mitotracker CMXRos (Molecular Probes) and images of
live cells were obtained by DIC microscopy (Phase) or in the FITC (H-protein-GFP) or rhodamine
(Mitotracker) fluorescent channels. Overlays of the images are displayed to determine possible
co-localisation (Merge). Merged images clearly show co-localisation of H-protein-GFP and Mito-
tracker, suggesting mitochondrial localisation of the protein. Panels B-D display merged images
of parasites expressing the bipartite leader sequence of PDH-E2 (amino acids 1-166) in frame
with GFP, the target peptide of BCDH-E2 (amino acids 1-106) in frame with GFP and the target
peptide of KGDH-E2 (amino acids 1-114) in frame with GFP stained with Mitotracker CMXRos
(McMillan and Müller, unpublished data). Scale bars equal 5 µm.
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3.4. Knock-out studies in P. falciparum
3.4.1. Knock-out studies via single cross-over recombination
To analyse the role of P. falciparum LplA1 and to genetically assess it as a potential drug
target, knock-out studies in P. falciparum were performed using the plasmid pHH1 (see
Figure 2.1) (Reed et al., 2000). Using this plasmid, knock-out of the gene is achieved
via single cross-over of the knock-out plasmid with the gene locus, which causes an in-
terruption of the endogenous locus and should result ideally in two non-functional copies
of the gene (Figure 3.5, Panel B). The plasmid was generated in the laboratory (Figure
3.5, Panel A) and was transfected into 3D7 wild-type parasites according to Deitsch et al.
(2001). I took over the transfected parasites and "cycled" them with WR99210 to se-
lect for parasites where the transfected plasmid had targeted the lplA1 gene locus. In the
course of one cycle, parasites that were selected for the presence of the marker hDHFR
with WR99210 were cultured without drug pressure for three weeks to encourage loss of
episomal plasmid. Subsequently, drug pressure was applied again and only those para-
sites containing either plasmid or selectable marker integrated into their genome survived
this treatment. It is believed that the "on-and-off" drug cycles help for a faster selec-
tion of stable transfectants. The parasites transfected with the lplA1 knock-out plasmid
were taken through three cycles and gDNA was analysed by Southern blotting to judge
whether a disruption of the endogenous gene had occurred (Figure 3.5, Panel C). Probing
the Southern blot with P. falciparum lplA1 showed that no integration into the gene locus
had occurred. Gene (1906 bp) and plasmid specific bands (6018 bp) were visible on the
Southern blot suggesting that P. falciparum lplA1 is either essential for parasite survival,
and thus knock-out cannot be achieved, or the gene locus cannot be targeted.
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Figure 3.5.: Knock-out studies of P. falciparum lplA1
For knock-out studies the plasmid pHH1 was used. (Panel A) The 990 bp lplA1 knock-out frag-
ment was cloned into pHH1 (5760 bp) using the restriction enzymes BglII and XhoI. (Panel B)
The lplA1 knock-out fragment lacks the ATG-start codon and is truncated at the C-terminus where
in addition an artificial stop-codon is introduced. Knock-out is achieved by single cross-over of
this plasmid with the gene locus, which should result in an interruption of the locus generating two
non-functional copies of the gene. Digest with the restriction enzyme NdeI results in a specific
banding pattern on a Southern blot when probed with P. falciparum lplA1 (WT: 1906 bp, plasmid:
6018 bp, integration 5’: 4428 bp, integration 3’: 3496 bp). Panel C displays a Southern blot of
parasite gDNA digested with NdeI and probed with P. falciparum lplA1. Lane 1 contains 3D7
wild-type gDNA and lane 2 gDNA of parasites transfected with the knock-out construct taken
through three cycles of WR99210 selection. Arrows indicate plasmid and wild-type bands visible
on the Southern blot.
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3.4.2. Complementation studies
To address the possibility that P. falciparum LplA1 is essential for parasite survival, the
parasites already bearing the knock-out plasmid were transfected with a complementa-
tion construct carrying the lplA1 gene from P. berghei, to overcome the lethal effect that
might occur upon knock-out of the lplA1 gene. The presence of the episomal copy of P.
berghei lplA1 should allow the knock-out of P. falciparum lplA1 (Krnajski et al., 2002).
P. berghei lplA1 was amplified using the oligonucleotide primers Pb-LplA-BglII-S and
Pb-LplA-NotI-AS (see 2.1.7), introducing a BglII and NotI site for cloning into the sin-
gle side gateway entry vector pHGB (Tonkin et al., 2004). After sequence verification,
P. berghei lplA1 was sub-cloned into the destination plasmid pHrBI-1/2 which possesses
a second selectable marker, the blasticidin-S-deaminase (BSD) conferring resistance to
blasticidin (see 2.5.2.3) (Figure 3.6, Panel A). Using this plasmid, the expression of P.
berghei LplA1 is controlled by the P. falciparum Hsp86 promotor, a strong promotor
expressing throughout the blood stages (Wu et al., 1995, Militello et al., 2004). The over-
expression plasmid was twice transfected into parasites carrying the knock-out plasmid
(Crabb and Cowman, 1996, Wu et al., 1996), and the two independent parasite popula-
tions obtained were named KO+Pb-1 and KO+Pb-2. The populations were cultured in
the presence of WR99210 and blasticidin to select for the two plasmids. Both parasite
lines were taken through two WR99210 cycles with continuous blasticidin selection to
maintain the episomal over-expression plasmid. gDNA was prepared and Southern blot
analyses were performed for both parasite populations. Figure 3.6 (Panel B and C) show
the Southern blots of KO+Pb-1 exemplary for both populations. Southern blot analyses
revealed that the gene locus (1906 bp) was not targeted. Probing the blot with P. falci-
parum lplA1 (Panel B) showed that after transfection (cycle 0), the parasites carried the
knock-out plasmid (6018 bp) and over-expression plasmid (9000 bp) episomally (lane
2). However, after the first WR99210 cycle, the band corresponding to the knock-out
plasmid disappeared and only the wild-type (1906 bp) and the band likely to correspond
with the over-expression plasmid were visible (lane 3). This pattern did not change af-
ter the second cycle (lane 4). Probing a blot of wild-type, cycle 0 and cycle 1 gDNA
with a hDHFR specific probe (Panel C) showed that the two plasmids apparently had re-
combined after transfection of the over-expression construct, because the 9000 bp band
was also recognised by the hDHFR probe, although the selectable marker of the plas-
mid is the blasticidin-S-deaminase (BSD). Finally, both parasite populations were taken
through a third cycle of drug selection in which both drugs (WR99210 and blasticidin)
were removed in an attempt to loose the recombined plasmid and to select for parasites
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that potentially had integrated the recombined plasmid. After six weeks, drug pressure
(WR99210 and blasticidin) was applied again and parasites were analysed by Southern
blotting (Panel B, lane 5). The Southern blots showed the same pattern as before, sug-
gesting that despite the presence of an extra copy of P. berghei LplA1, the P. falciparum
lplA1 gene could not be disrupted.
A
B Pf lplA1-probe C hDHFR-probe
Figure 3.6.: Complementation studies to potentially allow knock-out of P. falciparum
lplA1
To potentially allow the knock-out of P. falciparum lplA1 a construct was designed which over-
expresses P. berghei LplA1, to complement for the loss of P. falciparum LplA1 in case of an
integration of the knock-out construct. Panel A, lane 1 displays full length P. berghei lplA1 (1245
bp) cloned into the entry-plasmid pHGB (4000 bp) using the restriction enzymes BglII and NotI.
Cloning into the destination plasmid pHrBI-1/2 (7800 bp) was performed by single side Gateway
cloning (lane 2). Panel B and C display Southern blots of the parasite population KO+Pb-1.
Lane 1 in both blots corresponds to 3D7 wild-type parasites, lane 2 to parasites after transfection
of the over-expression plasmid (cycle 0) and lane 3 after the first WR99210 cycle. Lane 4 in
Panel B corresponds to parasites after the second WR99210 cycle and lane 5 to parasites after a
cycle in which WR99210 and blasticidin were removed (cycle 3). The Southern blot probed with
P. falciparum lplA1 shows that the endogenous lplA1 gene is present after all cycles (1906 bp),
showing that the gene locus was not targeted. The 6018 bp band corresponding to the knock-out
plasmid is present after transfection in cycle 0 (lane 2), but disappears after cycle 1 (lanes 3-5).
The over-expression plasmid (9000 bp) is present in all cycles (lanes 2-5). Probing the blot with
the hDHFR suggests that the knock-out and over-expression plasmid recombined, because the
over-expression plasmid was detected by the hDHFR probe. It was surprising that the recombined
plasmid was still present after the third cycle in which WR99210 and blasticidin were removed. It
suggests that maybe the band at 9000 bp corresponds to an unspecific integration event.
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This was somewhat surprising because it was expected that parasites would lose any epi-
somally carried recombined plasmid in the long "off-cycle", and that the third selection
would specifically enrich parasites where the target locus was disrupted. Another pos-
sible explanation for the presence of the 9000 bp band could be, that the recombined
knock-out and over-expression plasmid had integrated into the P. falciparum genome
non-specifically, and that the observed restriction pattern in the Southern blot band cor-
responds to this unspecific integration event. To further analyse this possibility, PFGE
analyses was performed using wild-type parasites and transfected parasites in cycle 1 and
cycle 3 (Figure 3.7). The gene specific P. falciparum lplA1 probe indicates the presence
of the gene on chromosome 13 (Panel A). The hDHFR probe (the selectable marker of
the knock-out plasmid) (Panel B) as well as the BSD probe (the selectable marker of the
over-expression plasmid) (Panel C) did not detect chromosome 13, indicating that the
plasmids had not integrated into the lplA1 gene locus. However, bands at the bottom
of the blot were detected with all three probes used. This is unusual, because episomal
plasmids generally run off the gel during PFGE if chromosomes 11-14 are separated (see
2.5.12). The presence of this strong signal however suggests that unspecific integration
somewhere on chromosomes <10 had occurred. It also supports recombination of the two
plasmids prior to integration, since the hDHFR and BSD probes detect the same bands.
A Pf lplA1-probe B hDHFR-probe C BSD-probe
Figure 3.7.: PFGE of KO+Pb-1
PFGE of KO+Pb-1 parasite population was performed and analysed using P. falciparum lplA1
(Panel A), hDHFR (Panel B) and BSD probes (Panel C). Lane 1 corresponds to wild-type para-
sites, lane 2 to KO+Pb-1 cycle 1 and lane 3 to KO+Pb-1 cycle 3. The P. falciparum lplA1 probe
detected lplA1 on chromosome 13. The hDHFR and BSD probes did not detect chromosome 13
showing that no integration into the lplA1 gene locus had occurred. However, additional bands
were detected corresponding to chromosomes <10, suggesting that unspecific integration some-
where on these chromosomes had occurred.
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There are two possible explanations as to why the recombined plasmid did not integrate
into the lplA1 gene locus. Either P. berghei lplA1 was not expressed and thus did not
complement the possible lethal effect of P. falciparum lplA1 knock-out, or the gene lo-
cus could not be targeted. Therefore, it was first analysed whether P. berghei LplA1 was
expressed to potentially complement for the loss of P. falciparum LplA1 in the event of
integration. Western blot analyses of parasite extract using an antibody against P. falci-
parum LplA1 were performed. The predicted size of the annotated P. falciparum LplA1 is
45.5 kDa and slightly larger for P. berghei LplA1 with 45.8 kDa. Two protein bands were
detected by the anti-LplA1 antibody in those parasite lines that harbour the P. berghei
LplA1 over-expression plasmid whereas in wild-type parasites only the lower molecular
weight band was detected (Figure 3.8, Panel A). The intensity of the bands are compa-
rable, suggesting that the use of the heterologous promotor might not effect expression
levels of the P. berghei protein. However, overall it appears that the parasites expressing
both LplA1s − endogenous and P. berghei − contain ∼twice the normal amount of the
protein which might result in some changes in lipoylation of mitochondrial KADH and
H-protein. Therefore, total lipoic acid levels of KO+Pb-1 and KO+Pb-2 were determined
in collaboration with Dr Terry K. Smith, University of Dundee, by gas chromatography-
mass spectrometry (GC-MS) (Figure 3.8, Panel B). Analyses revealed that compared to
wild-type parasites, there seems to be the tendency for a slight increase of the cofactor
bound to protein. This could either be due to more lipoic acid bound to the mitochondrial
complexes, or to lipoic acid sequestered by the LplA1 proteins themselves (see 5.6.2).
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Figure 3.8.: Phenotypical analyses of parasites transfected with the knock-out and over-
expression construct
Panel A displays western blots of parasite extract. Lane 1 corresponds to wild-type parasites,
lane 2 to KO+Pb-1 and lane 3 to KO+Pb-2. The blots were probed with an antibody against
P. falciparum LplA1. Western blot analyses revealed that P. berghei LplA1 is expressed in the
parasites transfected with the over-expression plasmid. A doublet is visible in these blots (lane
2 and 3) in comparison to wild-type (lane 1) indicating that both P. falciparum LplA1 (expected
size 45.5 kDa) and P. berghei LplA1 (expected size 45.8 kDa) are expressed. The blots were
stripped and re-probed with anti-TrxPx1, a peroxiredoxin, as a loading control (Akerman and
Müller, 2003). (Panel B) The lipoic acid (LA) content of the mutant parasite lines was analysed
by GC-MS in collaboration with Dr Terry K. Smith, University of Dundee. Initial results suggest
that there are slight variations between the independently transfected parasite lines. The lipoic
acid level of KO+Pb-1 is comparable to the lipoic acid level determined for wild-type parasites
(39.8 nmoles / 108 cells and 40 nmoles / 108 cells, respectively). The lipoic acid level in KO+Pb-2
is higher than that of wild-type parasites (47 nmoles / 108 cells). The data represent the mean ±
standard error of three separate measurements on the same parasite batch.
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3.4.3. Knock-out control studies
To investigate whether the lplA1 gene locus could be targeted, a knock-out control con-
struct was designed using the plasmid pHH1. The control construct was amplified using
the oligonucleotide primers LplA-pHH1-rescue-fwd and LplA-KOkon-rev (see 2.1.7) in-
troducing a BglII and XhoI site, respectively (Figure 3.9, Panel A). The construct was
truncated at the N-terminus, but was full length at the C-terminus including the endoge-
nous stop codon. Thus, integration of the control construct into the gene locus via single
cross-over recombination should result in a functional copy of the gene (Figure 3.9, Panel
B). 3D7 wild-type parasites were transfected twice with the control construct as described
before (Crabb and Cowman, 1996, Wu et al., 1996), and the obtained parasite populations
were taken through three WR99210 cycles to select for parasites that had the plasmid
integrated into the correct gene locus. Transfectants were analysed by Southern blotting
using gDNA that was digested with the restriction enzyme NdeI. Southern blots shown in
Figure 3.9 (Panel C and D) were analysed using P. falciparum lplA1 and hDHFR probes,
and are exemplary for both transfected parasite populations. The blots show that the lplA1
gene locus was not targeted by the knock-out control construct. Parasites after transfec-
tion (lane 2), after two WR99210 cycles (lane 3) and after three WR99210 cycles (lane 4)
still contained the endogenous lplA1 gene (1906 bp) (Panel C). A faint band correspond-
ing to episomal plasmid was also detected (6050 bp). In addition, a band at 9000 bp was
visible in parasites taken through two and three WR99210 cycles (lanes 3-4) when probed
with either probe, and a band at 500 bp was visible in these parasites when probed with
the hDHFR probe (Panel C). The presence of these bands and especially the 9000 bp band
strongly suggested that the knock-out control construct integrated into the P. falciparum
genome unspecifically possibly at the same position where integration had occurred of
the knock-out/recombined plasmid described above. This was further analysed by PFGE
(Figure 3.10). Probing with P. falciparum lplA1 (Panel A) and hDHFR (Panel B) in-
deed showed that no integration into chromosome 13 had occurred. Moreover, a band
was detected corresponding to chromosomes <10 suggesting unspecific integration of
the knock-out control construct on one of these chromosomes.
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Figure 3.9.: Knock-out control studies of P. falciparum lplA1
Panel A shows the 1022 bp lplA1 control fragment cloned into pHH1 (5760 bp) using the re-
striction enzymes BglII and XhoI. Panel B displays a schematic diagram of the lplA1 knock-out
control integration event. The control fragment is, like the knock-out construct truncated at the
N-terminus, but is in contrast full length at the C-terminus retaining the endogenous stop codon.
Integration of the knock-out control construct into the gene locus should thus result in the dis-
ruption of the locus generating a functional copy of the gene. Digest with the restriction enzyme
NdeI results in a specific banding pattern on a Southern blot when probed with P. falciparum lplA1
(WT: 1906 bp, plasmid: 6050 bp, integration 5’: 4662 bp, integration 3’: 3294 bp). Panel C and
D display Southern blots of parasite gDNA digested with NdeI and probed with P. falciparum
lplA1 and hDHFR. Lane 1 in both blots contains 3D7 wild-type gDNA, lane 2 gDNA of parasites
after transfection (cycle 0), lane 3 gDNA of transfected parasites in cycle 2 and lane 4 gDNA of
transfected parasites in cycle 3. Arrows indicate the endogenous lplA1 (1906 bp) and the plasmid
specific band (6050 bp) showing that no integration into the lplA1 gene locus had occurred. Ad-
ditional bands at ∼9000 bp in both blots and at ∼500 bp in the hDHFR probed blot suggest that
unspecific integration had occurred.
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Figure 3.10.: PFGE of LplA1-KOkon-pHH1 transfected parasites
PFGE of parasites transfected with LplA1-KOkon-pHH1 was performed and analysed using P.
falciparum lplA1 (Panel A) and hDHFR probes (Panel B). Lane 1 corresponds to wild-type para-
sites, lane 2 to transfected parasites in cycle 0 and lane 3 to transfected parasites in cycle 3. The
P. falciparum lplA1 probe detected lplA1 on chromosome 13. The hDHFR probe did not detect
chromosome 13 showing that no integration into the lplA1 gene locus had occurred. However,
an additional band was detected corresponding to chromosomes <10, suggesting that unspecific
integration somewhere on these chromosomes had occurred.
3.5. Over-expression of P. berghei LplA1
3.5.1. Genotypical analyses
D10 wild-type parasites were transfected with the P. berghei lplA1 over-expression con-
struct described in Chapter 3.4.2. Genotypical analyses of two independent transfected
parasite populations named PbLplA1-1 and PbLplA1-2 were performed by Southern blot-
ting, using P. falciparum lplA1 and BSD specific probes (Figure 3.11). gDNA was di-
gested with the restriction enzyme NdeI resulting in a P. falciparum lplA1 gene specific
band of 1906 bp and a plasmid specific band of 9000 bp. The Southern blot probed with
the P. falciparum lplA1 probe only detected the endogenous P. falciparum lplA1 gene, but
did not cross-react with the P. berghei gene in the over-expression plasmid (Panel A). The
presence of plasmid in PbLplA1-1 and PbLplA1-2 was only shown by probing the blot
with the BSD specific probe (Panel B).
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Figure 3.11.: Genotypical analyses of P. berghei LplA1 over-expressing parasites
D10 wild-type parasites were transfected with the P. berghei LplA1 over-expression plasmid and
two independent parasite lines were obtained. The genotype of these lines was analysed by South-
ern blotting using P. falciparum lplA1 (Panel A) and BSD (Panel B) probes. gDNA of wild-type
(lane 1), PbLplA1-1 (lane 2) and PbLplA1-2 (lane 3) was digested using the restriction enzyme
NdeI and analysed by Southern blotting. The P. falciparum lplA1 probe did not cross-react with
the P. berghei lplA1 gene in the plasmid, thus only detecting endogenous P. falciparum lplA1 (1906
bp). Using the BSD probe the over-expression plasmid (9000 bp) was detected.
3.5.2. Phenotypical analyses
For phenotypical analyses of parasites over-expressing P. berghei LplA1, the PbLplA1-
1 population was used. First, western blot analyses were performed using an antibody
against P. falciparum LplA1 (Figure 3.12, Panel A). Western blotting confirmed that both
LplA1s were expressed in the PbLplA1-1 population, showing a doublet correspond-
ing to P. falciparum LplA1 (45.5 kDa) and P. berghei LplA1 (45.8 kDa), in compar-
ison to D10 wild-type parasites. Western blot analyses showed that both proteins are
present in the parasites to equal amounts, suggesting that episomal "over-expression"
of P. berghei LplA1 results in endogenous expression levels. Parasites over-expressing
P. berghei LplA1 thus contain approximately double the amount of LplA1 proteins in
comparison to wild-type parasites. This could have an effect on the lipoylation levels
of mitochondrial KADH and/or H-protein. Thus, the lipoic acid content of PbLplA1-1
was analysed by GC-MS in collaboration with Dr Terry K. Smith, University of Dundee
(Figure 3.12, Panel B). Initial results suggest, that PbLplA1-1 indeed contains more pro-
tein bound lipoic acid in comparison to wild-type parasites (54 nmoles/108 cells and 40
nmoles/108 cells, respectively). However, it is not clear whether this is due to higher
lipoylation levels of the KADH-E2 subunits and H-protein or whether the lipoic acid is
bound to the ligases themselves (see 5.6.2).
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Figure 3.12.: Phenotypical analyses of P. berghei LplA1 over-expression parasites
Panel A displays western blots of parasite extract. Lane 1 corresponds to wild-type parasite and
lane 2 to PbLplA1-1. The blots were probed with an antibody against P. falciparum LplA1. West-
ern blot analyses revealed that P. berghei LplA1 is expressed in the parasite line transfected with
the over-expression plasmid. A doublet is visible in the blot (lane 2) in comparison to wild-type
(lane 1) indicating that both P. falciparum LplA1 (expected size 45.5 kDa) and P. berghei LplA1
(expected size 45.8 kDa) are expressed. The blots were stripped and re-probed with anti-TrxPx1
as a loading control (Akerman and Müller, 2003). (Panel B) The lipoic acid (LA) content of the
mutant parasite line was analysed by GC-MS in collaboration with Dr Terry K. Smith, University
of Dundee. Initial results suggest that PbLplA1-1 contains more lipoic acid than wild-type para-
sites (54 nmoles / 108 cells and 40 nmoles / 108 cells, respectively). The data represent the mean
± standard error of three separate measurements on the same parasite batch.
It was further investigated whether over-expression of P. berghei LplA1 had an effect on
parasite growth. The progression through the intraerythrocytic developmental cycle was
investigated. Thin-smears of highly synchronised PbLplA1-1 and D10 wild-type par-
asites taken every 8 hours in the 48 hour developmental cycle were analysed by light
microscopy (Figure 3.13). In the first 16 hours (Panel A-C), PbLplA1-1 progression was
slightly accelerated through the intraerythrocytic developmental cycle in comparison to
D10, suggesting that the development from ring stage parasites to early trophozoites was
not negatively affected by over-expression of P. berghei LplA1. However, after 24 hours
(Panel D), all D10 parasites were in the trophozoite stage, whereas 7% of PbLplA1-1
were still in the ring stage, suggesting that a small proportion of the over-expressing para-
sites were slowed down in their progression through the developmental cycle. The second
half of the developmental cycle (from trophozoite to schizont) seemed to be more affected
and was slowed down to some extend. After 32 hours (Panel E), 53% of the D10 parasites
were already schizonts whereas only 32% of the over-expresser were in this developmen-
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tal stage. The decelerated progression is particulary obvious after 48 hours (Panel G),
where 85% of the D10 parasites had re-invaded erythrocytes and were in the ring stage.
Only 46% of the parasites analysed of the PbLplA1-1 population were at this time in
the ring stage, suggesting that over-expression of LplA1 had a modest negative effect
on the intraerythrocytic developmental cycle in these parasites lines. These observations
suggest that the correct concentration of LplA1 in the blood stages is important for their
development.
3. LplA1 104
A 0h
I II
ring trophozoite schizont
D10 100% - -
(n=11)
PbLplA1-1 100% - -
(n=12)
B 8h
I II
ring trophozoite schizont
D10 80% 20% -
(n=10)
PbLplA1-1 67% 33% -
(n=9)
C 16h
I II
ring trophozoite schizont
D10 47% 53% -
(n=15)
PbLplA1-1 31% 69% -
(n=13)
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D 24h
I II
ring trophozoite schizont
D10 - 100% -
(n=22)
PbLplA1-1 7% 93% -
(n=14)
E 32h
I II
ring trophozoite schizont
D10 - 47% 53%
(n=15)
PbLplA1-1 4% 64% 32%
(n=22)
F 40h
I II
ring trophozoite schizont
D10 38% - 62%
(n=21)
PbLplA1-1 37% 19% 44%
(n=16)
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I II
ring trophozoite schizont
D10 85% - 15%
(n=20)
PbLplA1-1 46% - 54%
(n=13)
Figure 3.13.: PbLplA1-1 development through the intraerythrocytic cell cycle
Progression through the intraerythrocytic developmental cycle was assessed by taking thin-smears
of highly synchronised cultures which were analysed by light microscopy. The photographs (I)
show Giemsa stained blood smears from PbLplA1-1 and D10 wild-type parasites taken every 8
hours over the 48 hour time course (Panel A-G). (II) gives the percentile portion of the three
different intraerythrocytic developmental stages for each time point. During the first 16 hours
of the intraerythrocytic developmental cycle, the P. berghei LplA1 over-expresser grow slightly
faster than the D10 wild-type parasites (Panel A-C). However, decelerated growth was observed
from 24 hours in the intraerythrocytic developmental cycle, when all wild-type parasites were in
the trophozoite stage whereas PbLplA1-1 still contained ring stage parasites (Panel D). This effect
persisted until the end of the experiment (Panel E-G). Scale bars equal 5 µm.
3.6. Knock-out studies in P. berghei
Knock-out studies of P. berghei lplA1 were performed in collaboration with Prof Kai Ma-
tuschewski, University of Heidelberg, Germany. Two different strategies were utilised to
knock-out lplA1. For both, the plasmid b3D.DT∧H.∧D (see Figure 2.2) was used (kindly
provided by A. P. Waters, Leiden University, The Netherlands). The first knock-out strat-
egy equals the one described for P. falciparum gene knock-out and involves single cross-
over recombination of the knock-out plasmid with the gene locus of interest. The second
strategy involves double cross-over recombination of the knock-out plasmid with the gene
locus, which should result in the replacement of the gene of interest with the selectable
marker of the plasmid, the T. gondii DHFR/TS.
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3.6.1. Knock-out studies via single cross-over recombination
For knock-out studies via single cross-over recombination, the plasmid PbLplA1-KO-
b3D was designed. Similar to knock-out studies in P. falciparum, a 1014 bp fragment
corresponding to nucleotides 88-1098 of P. berghei lplA1 was amplified using the primers
Pb-LplA-int-fwd and Pb-LplA-int1-rev (see 2.1.7). An artificial stop codon was intro-
duced at the 3’ end of the PCR product and the fragment was cloned into the second mul-
tiple cloning site of b3D.DT∧H.∧D using the restriction enzymes BamHI and SacII (Fig-
ure 3.14, Panel A). Integration of PbLplA1-KO-b3D into the lplA1 locus should disrupt
the locus resulting in two non-functional copies of the gene (Figure 3.14, Panel B). For
transfection, PbLplA1-KO-b3D was linearised using the restriction enzyme HpaI which
cuts within the P. berghei lplA1 knock-out fragment (Figure 3.14, Panel A). Linearised
PbLplA1-KO-b3D was transfected three times into NK65 wild-type parasites according
to Janse et al. (2006), and after pyrimethamine selection in mice, the obtained parasite
populations were analysed by PCR, using the gene locus specific primers PbLplA1-test-
fwd and Pb-LplA-REP-rev (black arrows), and the plasmid specific primers Tg-for and
b3D-rev (red arrows). Combinations of these primers were used to amplify 3’ and 5’ spe-
cific integration fragments (Figure 3.14, Panel B) (see 2.1.7). gDNA was prepared of the
three independent parasite populations and Figure 3.14 (Panel C) shows the results of one
parasite population exemplary for all three. PbLplA1-KO-b3D had not integrated into
the gene locus. I was not able to amplify either the 3’ integration specific PCR product
(2375 bp; lane 1) or the 5’ integration specific PCR product (1727 bp; lane 2). How-
ever, recombined plasmid (1628 bp; lane 3) and wild-type P. berghei lplA1 (2479 bp;
lane 4) were present in the parasite populations. These data suggest that either a knock-
out of P. berghei lplA1 is not possible because LplA1 might be essential for P. berghei
blood-stages, or the gene locus is refractory to integration, as it might be the case in P.
falciparum.
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Figure 3.14.: Knock-out studies of P. berghei lplA1 using the integration strategy
(Panel A) The 1014 bp knock-out fragment was amplified from the P. berghei gDNA and was
cloned into b3D.DT∧H.∧D (7514 bp) using the restriction enzymes BamHI and SacII (lane 1).
Before transfection, PbLplA1-KO-b3D was linearised using HpaI, resulting in a 8528 bp fragment
(lane 2). Panel B is a schematic diagram of the integration of PbLplA1-KO-b3D. Transfectants
were analysed by PCR using gene locus specific primers (black arrows) and plasmid specific
primers (red arrows). Panel C displays the PCR analyses of transfected parasites. Lane 1 shows
the 3’ integration specific PCR (2375 bp), lane 2 the 5’ integration specific PCR (1727 bp), lane
3 the plasmid specific PCR (1628 bp) and lane 4 the wild-type specific PCR (2479 bp). The
knock-out plasmid did not integrate into the gene locus. The plasmid was present as an episome.
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3.6.2. Knock-out control studies via single cross-over recombination
To assess whether the P. berghei lplA1 gene locus is refractory to integration, a control
construct was generated which was named PbLplA1-KOkon-b3D. The control fragment
was amplified using the oligonucleotide primer Pb-LplA-int-fwd and Pb-LplA-3’-rev, re-
sulting in a 1734 bp PCR fragment that was cloned directionally into the second multiple
cloning site of b3D.DT∧H.∧D using the restriction enzymes BamHI and SacII (Figure
3.15, Panel A). The control fragment was truncated at the N-terminus therefore miss-
ing the ATG-start codon, but was full length at the C-terminus including the endogenous
stop codon and 3’ UTR. Thus, integration of the control construct into the lplA1 gene
locus should result in a functional copy of the gene (Figure 3.15, Panel B). Prior transfec-
tion PbLplA1-KOkon-b3D was linearised using the restriction enzyme HpaI (Figure 3.15,
Panel A), and the linearised construct was transfected only once into NK65 wild-type par-
asites. After pyrimethamine selection, the obtained parasite population was analysed by
PCR using the primers described above in Chapter 3.6.1 (Figure 3.15, Panel B). Figure
3.15 (Panel C) displays the results of the PCR analyses showing that PbLplA1-KOkon-
b3D had integrated into the gene locus. The 3’ integration specific band (2375 bp; lane 1),
which was also verified by sequencing, and the 5’ integration specific PCR band (2447 bp;
lane 2) were amplified. Recombined plasmid (2348 bp; lane 3) and wild-type P. berghei
lplA1 (2479 bp; lane 4) were also present showing that it was a mixed population. This
clearly shows, that the P. berghei lplA1 locus can be targeted in contrast to the P. falci-
parum lplA1 gene locus. Furthermore, it suggests that LplA1 might be essential for P.
berghei blood stages, because the knock-out construct described above did not target the
lplA1 locus after three independent transfections. To further investigate this possibility,
knock-out studies via double cross-over recombination were carried out additionally.
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Figure 3.15.: Knock-out control studies of P. berghei lplA1 using the integration strategy
(Panel A) The 1734 bp knock-out control fragment was amplified from the P. berghei gDNA and
was cloned into b3D.DT∧H.∧D (7514 bp) using the restriction enzymes BamHI and SacII (lane
1). Before transfection PbLplA1-KOkon-b3D was linearised using HpaI resulting in a 9248 bp
fragment (lane 2). Panel B is a schematic diagram of the integration of PbLplA1-KOkon-b3D.
Transfectants were analysed by PCR using gene locus specific primers (black arrows) and plasmid
specific primers (red arrows). Panel C displays the PCR analyses of the transfectants. Lane 1
shows the 3’ integration specific PCR (2375 bp), lane 2 the 5’ integration specific PCR (2447 bp),
lane 3 the plasmid specific PCR (2348 bp) and lane 4 the wild-type specific PCR (2479 bp). The
knock-out control plasmid did integrate into the gene locus. However, the parasite population was
mixed because episomal plasmid and wild-type P. berghei lplA1 were also detected by PCR.
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3.6.3. Knock-out studies via double cross-over recombination
Double cross-over of the knock-out plasmid with the gene locus should result in the re-
placement of the gene with the selectable marker of the plasmid, the T. gondii DHFR/TS.
For this strategy, the 5’ and 3’ UTRs of P. berghei lplA1 were amplified using the primer
pairs Pb-LplA-5’-fwd / Pb-LplA-5’-rev and Pb-LplA-3’-fwd / Pb-LplA-3’-rev, respec-
tively (see 2.1.7). The 480 bp 5’ UTR fragment was amplified and cloned direction-
ally into the first multiple cloning site of b3D.DT∧H.∧D, using the restriction enzymes
KpnI and HindII. The PCR product amplified using the 3’ UTR primer pair, was 516 bp
in size and was cloned into the second multiple cloning site of the plasmid using NotI
and SacII (Figure 3.16, Panel A). The resulting plasmid was named PbLplA-REP-b3D.
Transfection of this plasmid was performed as described by Janse et al. (2006). Before
transfection, PbLplA-REP-b3D was "linearised" with the restriction enzymes KpnI and
SacII resulting in two fragments, a 5636 bp fragment containing the two P. berghei lplA1
UTRs and the T. gondii DHFR/TS expression cassette, and a 2864 bp fragment con-
taining the plasmid backbone (Figure 3.16, Panel A). Using this construct, knock-out is
achieved by double cross-over of the 5’ and 3’ UTRs of P. berghei lplA1, which should
result in the replacement of the gene with the selectable marker (Figure 3.16, Panel B).
Digested PbLplA-REP-b3D was transfected six times and parasite populations obtained
after pyrimethamine selection in mice were analysed by PCR, using either the gene locus
specific primer combination Pb-LplA-int-fwd / Pb-LplA-REP-rev (1837 bp) or PbLplA1-
test-fwd / PbLplA1-test-rev (2479 bp) (black arrows) and the plasmid specific primers
Tg-for, b3D-rev and Tg-rev (red arrows) (see 2.1.7). In five out of the six independent
transfected lines, PbLplA-REP-b3D had recombined and was amplified, suggesting that
the DNA used for the transfection was not completely digested. If this is the case, the lin-
earised DNA is lost quickly from the parasites, and the presence of pyrimethamine selects
for the plasmid rather than the gene replacement. The sixth parasite population that was
analysed revealed replacement of the lplA1 locus, and the PCR results are shown in Figure
3.16 (Panel C). The replaced 3’ UTR was amplified (1183 bp; lane 1) and sub-cloned to
verify that the PCR product was specific for the replaced gene locus. However, the PCR
fragment could only be obtained after two rounds of amplification, suggesting that only
a minor proportion of the parasite population indeed contained the replaced lplA1 gene
locus. When the parasite population was transferred into a second mouse to generate
more DNA for further analyses, the knock-out population was entirely lost (Figure 3.16,
Panel D; lanes 1 and 2). Only endogenous lplA1 (2479 bp; lane 4) and episomal PbLplA-
REP-b3D (1150 bp; lane 3) was amplified. This clearly suggests that the lplA1 locus in
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P. berghei can be targeted and that lplA1-replacement causes a severe defect on the vi-
ability of blood-stage P. berghei, which results in the selection of parasites that contain
PbLplA-REP-b3D episomally.
A B
C Parasite population after
transfection
D Parasite population after 1
transfer
Figure 3.16.: Knock-out studies of P. berghei lplA1 using the replacement strategy
(Panel A) A 480 bp fragment was amplified as the P. berghei lplA1 5’ UTR and was cloned into
b3D.DT∧H.∧D (8020 bp), using the restriction enzymes KpnI and HindIII (lane 1). The 3’ UTR
PCR fragment (516 bp) was cloned into the plasmid using NotI and SacII (lane 2). Before trans-
fection, PbLplA1-REP-b3D was digested with KpnI and SacII, resulting in a 5636 bp fragment
containing the two UTRs and the T. gondii DHFR/TS expression cassette, and a 2864 bp fragment
containing the plasmid backbone (lane 3). Panel B is a schematic diagram of the replacement of
P. berghei lplA1. Transfectants were analysed by PCR using gene locus specific primers (black
arrows) and plasmid specific primers (red arrows). Panel C displays the PCR analyses of the par-
asite population directly after transfection. Lane 1 shows the 3’ replacement specific PCR (1183
bp), lane 2 the plasmid specific PCR (1150 bp) and lane 3 the wild-type specific PCR (1837 bp).
Panel D displays the PCR analyses of the parasite population after one transfer. Lane 1 shows
the 3’ replacement specific PCR (1183 bp), lane 2 the 5’ replacement specific PCR (1015 bp),
lane 3 the plasmid specific PCR (1150 bp) and lane 4 the wild-type specific PCR (2479 bp). The
parasite population obtained after transfection contained parasites that had the plasmid integrated.
However, this population was lost after transfer of the parasites into another mouse, indicating that
the replacement of lplA1 severely affected parasite growth.
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3.6.4. Knock-out control studies via double cross-over recombination
To complement for the severe effects replacement of P. berghei lplA1 seemed to have, the
complementation plasmid PbLplA1-comp-b3D was designed. The plasmid consisted of
PbLplA1-REP-b3D with an expression cassette of P. falciparum LplA1 cloned in front
of the P. berghei lplA1 3’ UTR. The expression cassette consisted of the P. falciparum
calmodulin (CAM) promotor (amplified using PfCAM5’-F2 and PfCAM5’-R1), P. fal-
ciparum lplA1 (amplified using Pf-LplA-ORF-fwd and Pf-LplA-ORF-rev) and the 3’
UTR of P. falciparum histidine rich protein 2 (HRP2) (amplified using PfHRPII3’-F1 and
PfHRPII3’-R1). For oligonucleotide sequences and introduced restriction sites see 2.1.7.
The expression cassette was first generated in the plasmid pBluescript II SK (Stratagene)
and was then sub-cloned into PbLplA1-REP-b3D using the restriction enzymes BamHI
and NotI (Figure 3.17, Panel A). Before transfection according to Janse et al. (2006), the
plasmid was digested with KpnI and SacII, resulting in a 8114 bp fragment containing
the two P. berghei lplA1 UTRs, the T. gondii DHFR/TS and the P. falciparum LplA1 ex-
pression cassettes, and a 2864 bp fragment containing the plasmid backbone (Figure 3.17,
Panel A). Digested PbLplA1-comp-b3D was transfected only once, and the parasite pop-
ulation obtained after pyrimethamine selection was analysed by PCR using the gene lo-
cus specific primers Pb-LplA-int-fwd and Pb-LplA-REP-rev (black arrows), and plasmid
primers PfHRPII3’-F1, b3D-rev and Pb-LplA-3’-fwd (red arrows) (Figure 3.17, Panel B)
(see 2.1.7). Figure 3.17 (Panel C) shows the results of the PCRs after transfection. The
3’ complementation specific band (1227 bp; lane 1) was amplified from the parasite pop-
ulation, and it was verified by sequencing. In addition, the presence of episomal plasmid
(587 bp; lane 2) and wild-type P. berghei lplA1 (1837 bp; lane 3) was shown. However,
as for the replacement construct, the parasite population that had the complementation
construct integrated into the gene locus was lost after transfer into another mouse (Figure
3.17, Panel D). This is somewhat surprising as the P. falciparum lplA1 copy which was
introduced into P. berghei should be able to complement for the loss of the endogenous
gene. There are a number of potential reasons for this unsuccessful complementation
experiment. First, it is possible that the over-expression of P. falciparum LplA1 is not
entirely beneficial for P. berghei, given that the heterologous protein is not under the con-
trol of the P. berghei lplA1 promoter, but is driven by the P. falciparum CAM promoter.
Should this be the case, it can be postulated that the levels of LplA1 are crucial during par-
asite development. This hypothesis is in some ways supported by the data on P. berghei
LplA1 over-expression in P. falciparum, which seems to have a slight negative effect on
the parasites’ progression through their life cycle (see 3.5.2). A second possibility is that
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maybe P. berghei LplA1 and P. falciparum LplA1 cannot replace each other totally which
might have a negative effect on the viability of transfected P. berghei. Finally, it needs to
be considered that technical problems might have led to this result since the experiment
was only performed once.
Taking all data of the knock-out studies in P. berghei together, they clearly show that
the P. berghei lplA1 gene locus can be targeted in contrast to the P. falciparum lplA1 gene
locus. Moreover, the data strongly suggest that knock-out of lplA1 is likely not possible
because of negative effects on blood stage parasite viability. It can also be concluded,
that these negative effects are unlikely to be due to an alteration of the gene locus upon
recombination, because integration of the knock-out control construct does not result in
any obvious negative effect. The obtained data further allow to speculate that the level of
LplA1 during erythrocytic development might be crucial, given that over-expression of P.
falciparum LplA1 appears to be unable to compensate for P. berghei lplA1 replacement
with a selectable marker.
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Figure 3.17.: Knock-out control studies of P. berghei lplA1 using the replacement strategy
(Panel A) For the control construct, a P. falciparum LplA1 expression cassette was cloned into
PbLplA1-REP-b3D. The expression cassette consisted of the P. falciparum CAM promoter, lplA1
gene and HRP2 3’ UTR. First, the expression cassette (2490 bp) was generated in the plasmid
pBluescript II SK (3000 bp; Stratagene) (lane 1). Using the restriction enzymes BamHI and
NotI, the expression cassette was cloned into PbLplA1-REP-b3D (8500 bp) in front of the P.
berghei lplA1 3’ UTR resulting in the plasmid PbLplA1-comp-b3D (lane 2). Before transfection,
PbLplA1-comp-b3D was digested with KpnI and SacII, resulting in a 8114 bp fragment containing
the 5’ and 3’ P. berghei lplA1 UTRs, the T. gondii DHFR/TS and the P. falciparum LplA1 expres-
sion cassettes, and a 2864 bp fragment containing the plasmid backbone (lane 3). Panel B is a
schematic diagram of the complementation of P. berghei lplA1 replacement. Transfectants were
analysed by PCR using gene locus specific primers (black arrows) and plasmid specific primers
(red arrows). Panel C displays the PCR analyses of the parasite population directly after transfec-
tion and Panel D of the parasite population after one transfer. Lane 1 shows the 3’ replacement
specific PCR (1227 bp), lane 2 the plasmid specific PCR (587 bp) and lane 3 the wild-type spe-
cific PCR (1837 bp). The parasite population obtained after transfection contained parasites that
had the plasmid integrated. However, this population was lost after transfer of the parasites into
another mouse, indicating that the complementation of lplA1 replacement was not successful.
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3.7. Summary
• P. falciparum and P. berghei LplA1 contain highly conserved sequence motifs required
for LplA activity, and the two proteins share high sequence similarities (78%).
• P. falciparum possesses lipoylated H-protein and KADH-E2 subunits. The H-protein, as
well as BCDH-E2 and KGDH-E2 are located in the mitochondrion whereas the PDH-E2
is found in the apicoplast.
• Attempting to knock-out P. falciparum lplA1 by single cross-over recombination was
unsuccessful. The knock-out plasmid was maintained episomally suggesting that P. falci-
parum lplA1 is either essential for parasite survival or the gene locus cannot be targeted.
• A P. berghei LplA1 over-expression plasmid was designed and transfected into P. falci-
parum parasites already bearing the lplA1 knock-out plasmid to complement for the loss
of LplA1, thus potentially allowing the knock-out of P. falciparum lplA1. After trans-
fection both plasmids were present episomally. However, the plasmids recombined and
integrated non-specifically into the P. falciparum genome as shown by Southern blotting
and PFGE. To confirm the presence of both LplA1s, western blot analyses were performed
using an antibody against P. falciparum LplA1, showing that P. falciparum and P. berghei
LplA1 were expressed. Preliminary determination of lipoic acid levels suggested no ma-
jor changes in mutant parasites in comparison to wild-type.
• Knock-out control studies were performed to analyse whether the P. falciparum lplA1
gene locus could be targeted by integration. According to the data obtained from two
independent transfections, the lplA1 locus was not targeted and thus might be refractory.
The knock-out control fragment integrated non-specifically, possibly at the same position
as the knock-out/recombined plasmid. Therefore, it cannot be concluded whether P. fal-
ciparum LplA1 is essential for parasite survival or not.
• P. berghei LplA1 was over-expressed episomally in P. falciparum. The presence of
P. berghei LplA1 was confirmed by western blotting, and initial analyses of lipoic acid
levels in these parasites showed that the transfectants contained slightly higher levels of
lipoic acid than wild-type parasites. This seemed to negatively affect the parasites pro-
gression through the intraerythrocytic developmental cycle.
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• Knock-out studies of lplA1 in P. berghei using different strategies were performed.
Knock-out via single cross-over integration was not achieved. Parasites maintained the
knock-out plasmid episomally, but integration of the PbLplA1-KOkon construct into the
P. berghei lplA1 gene locus showed that the locus was not refractory to integration. Re-
placement of P. berghei lplA1 was achieved initially, but the parasite population that had
the gene replaced with the T. gondii DHFR/TS was lost during attempts to enrich the
population. The parasites were quickly overgrown by parasites still harbouring the en-
dogenous lplA1 gene and carrying the replacement plasmid episomally. This suggested
that LplA1 plays an important role for blood stage viability. Complementation of the re-
placement using P. falciparum LplA1 was, however, also unsuccessful. This is possibly
because the P. falciparum gene was not under the control of the endogenous P. berghei
lplA1 promotor, but was over-expressed, which seems to have a negative effect on parasite
development as also observed by P. berghei LplA1 over-expression in P. falciparum.
• Analyses of the P. falciparum lplA1 and P. berghei lplA1 gene loci suggest that the
two gene loci are syntenic, apart from three small annotated proteins present in the P.
berghei gene locus. However, from the knock-out studies it seems that the P. falciparum
lplA1 gene locus is refractory to integration whereas the P. berghei lplA1 gene locus is
not.
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4. LplA2
4.1. Introduction
The post-translational modification of KADH-E2 subunits and H-protein is performed
by two independent lipoylation pathways present in apicomplexan parasites (Thomsen-
Zieger et al., 2003, Wrenger and Müller, 2004). De novo biosynthesis of lipoic acid occurs
in the apicoplast, consisting of LipB, the octanoyl-ACP transferase, and LipA, the lipoic
acid synthase (Zhao et al., 2003, 2005). This pathway is responsible for lipoylation of the
PDH-E2 subunit. Salvage of the cofactor occurs in the mitochondrion, and lipoate protein
ligase A (LplA1) is responsible for lipoylation of the BCDH-E2, KGDH-E2 and the H-
protein (Wrenger and Müller, 2004). However, analyses of the P. falciparum genome
revealed the presence of a potential second lipoic acid protein ligase A named LplA2. This
raises the question whether the different lipoic acid ligases present in Plasmodium (LipB,
LplA1 and the newly identified LplA2) act independently or are redundant. In this chapter,
this question was addressed by analysing the role of LplA2 in more detail. This chapter
thus describes the identification of lplA2, analyses of its functionality, determination of
its subcellular localisation and assessment of its potential function in P. falciparum and P.
berghei by reverse genetic approaches.
4.2. Identification of lplA2
A second gene potentially encoding a lipoate protein ligase A was identified in P. falci-
parum by TBlastN searching the PlasmoDB database (Bahl et al., 2003) using the Ara-
bidopsis thaliana LplA sequence. The hypothetical protein PFI1160w identified on chro-
mosome 9 was designated LplA2. The sequence similarity of P. falciparum LplA2 to the
Arabidopsis protein was modest with only 20.3% and was only marginally higher for E.
coli LplA, T. acidophilum LplA and P. falciparum LplA1 (Table 4.1).
Table 4.1.: Sequence similarities of P. falciparum LplA2
P. falciparum A. thaliana E. coli T. acidophilum
LplA1 LplA LplA LplA
P. falciparum LplA2 27.2% 20.3% 23.5% 22.4%
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Orthologues of LplA2 are present in other Plasmodium species (Table 4.2), and sequence
alignment of the deduced amino acid sequence of P. falciparum and P. berghei LplA2 with
E. coli and T. acidophilum LplA shows, that despite the modest sequence similarities of
P. falciparum LplA2 with the bacterial proteins, three highly conserved sequence motifs
involved in the formation of the lipoyl-AMP binding pocket are conserved in Plasmod-
ium LplA2, suggesting that LplA2 is a functional protein ligase (Figure 4.1) (Fujiwara
et al., 2005, Kim et al., 2005, McManus et al., 2006). The sequence alignment shows that
the Plasmodium LplA2s contain several insertions in the N-terminal part of the protein
in comparison to bacterial LplA. Additionally, they contain a 28 amino acid extension at
the N-terminus. These extensions possibly correspond to targeting signals required for
subcellular protein localisation and are described in more detail later (see below, Table
4.3). LplA2 orthologues are also found in Theileria and Toxoplasma, other apicomplexan
parasites. Table 4.2 summarises the similarities of the deduced amino acid sequences of
various apicomplexan LplA2s in comparison to P. falciparum LplA2.
Table 4.2.: Sequence similarities of P. falciparum LplA2 to apicomplexan LplA2s
P. falciparum LplA2
Plasmodium berghei 57.7%
Plasmodium chabaudi 56.8%
Plasmodium knowlesi 55.1%
Plasmodium vivax 49.4%
Plasmodium yoelii 57.5%
Theileria annulata 37.0%
Theileria parva 39.0%
Toxoplasma gondii 17.8%
The potential Theileria protein, and the potential LplA2s of other Plasmodium spp. share
a relatively high sequence similarity with P. falciparum LplA2 (between 37% and 57.7%).
In contrast, the sequence similarity of the potential T. gondii LplA2 is lower with 17.8%
when compared to the P. falciparum LplA2. Furthermore, analyses of the T. gondii se-
quence revealed that the first highly conserved sequence motif involved in lipoyl-AMP
binding (see Figure 4.1) is absent in T. gondii LplA2, whereas it is present in all other api-
complexan LplA2 listed in Table 4.2 (Fujiwara et al., 2005, Kim et al., 2005, McManus
et al., 2006). This suggests, that T. gondii LplA2 is likely not to be a functional lipoate
protein ligase. No potential lplA2 was identified in the genome of Cryptosporidium,
4. LplA2 120
Figure 4.1.: Amino acid sequence alignment of P. falciparum and P. berghei LplA2 with
bacterial LplA
Separate ClustalW alignments of E. coli (Ec) / T. acidophilum (Tc) LplA and P. falciparum (Pf) /
P. berghei (Pb) LplA2 were combined using the program T-Coffee (Notredame et al., 2000, Poirot
et al., 2003) showing (*) identical residues, (:) conserved residues and (.) homologous residues.
Three highly conserved sequence motifs which contain key residues involved in the formation
of the lipoyl-AMP binding pocket are highlighted in red. Residues outside these three motifs
involved in lipoic acid binding are highlighted in yellow, for the E. coli protein, and green, for the
T. acidophilum protein. Both Plasmodium LplA2s possess a 28 amino acid extension of which
29% are identical residues (highlighted in blue). This extension likely corresponds to a targeting
sequence responsible for protein import into organelles and is explained later in more detail. In
comparison to the bacterial proteins, Plasmodium LplA2 contain several amino acid insertions.
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another apicomplexan parasite. The genomes of Babesia and Eimeria were also searched
for a potential lplA2 gene. However, their genomes are not annotated yet which makes it
difficult to identify potential candidates.
While this study was performed, Allary and colleagues published the presence of LplA2
in P. falciparum and other Plasmodium spp. (Allary et al., 2007).
4.3. Functionality of LplA2
To experimentally confirm that P. falciparum LplA2 is a functional lipoate protein ligase,
lplA2 was used to complement the growth defect of the lipB deficient E. coli strain Ker184
and the lipB/lplA deficient E. coli strain Tm136 (Reed and Cronan, 1993, Morris et al.,
1995). Three expression constructs of P. falciparum lplA2 were generated using the plas-
mid pASK-IBA3 (see Figure 2.11). The first construct expressed full length (fl) LplA2,
whereas the other two constructs produced N-terminal truncated forms of LplA2 (con-
struct S1 equalled amino acids 27-385 and construct S2 equaled amino acids 79-385) (see
Table 5.1). The different constructs were designed because of the N-terminal extension of
P. falciparum LplA2 described above, which potentially corresponds to a N-terminal tar-
geting sequence that possibly might interfere with protein expression and/or function of
the recombinant protein in the prokaryotic expression system. Cloning of these constructs
is described in Chapter 5.3.1. Bacteria were transformed with the expression constructs,
and were incubated as described in material and methods (see 2.7.1) (Figure 4.2).
A Ker184 B Ker184 C Tm136
Figure 4.2.: Functionality of LplA2
Functionality of P. falciparum LplA2 was assessed by complementation studies of lipB deficient
Ker184 (Panel A and B) and lipB/lplA deficient Tm136 (Panel C) (Reed and Cronan, 1993,
Morris et al., 1995). 1 corresponds to LplA2-fl-pASK-IBA3, 2 to LplA2-S1-pASK-IBA3 and 3 to
LplA2-S2-pASK-IBA3. 4, 5 and 6 are positive and negative controls, and are P. falciparum LplA1-
pASK-IBA3 (4), pASK-IBA3 (5) and untransformed bacteria (6). All three LplA2 constructs (1-3)
are able to complement the growth defect of Ker184 and Tm136.
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Figure 4.2 shows that all three constructs were able to complement the growth defect of
Ker184 and Tm136 when grown on minimal medium without lipoic acid. This suggests
that P. falciparum LplA2 is indeed a functional lipoate protein ligase, able to complement
for E. coli LplA and LipB. This is in contrast to Allary et al. (2007), who suggest that
LplA2 can only complement LplA but not LipB activity. The different results obtained
in the complementation studies may be explained by the different recombinant LplA2
expression constructs used, which differed at their C-termini.
4.4. Localisation of LplA2
The alignment in Figure 4.1 clearly shows that P. falciparum and P. berghei LplA2 possess
a N-terminal extension in comparison to the bacterial proteins. This extension possibly
corresponds to a targeting signal responsible for organellar targeting. Apicoplast targeting
is achieved by a bipartite leader sequence consisting of a signal peptide responsible for
entering the secretory pathway followed by a transit peptide for targeting to the apicoplast
(Waller et al., 2000, Foth et al., 2003). Targeting to the mitochondrion is accomplished
by a N-terminal mitochondrial transit peptide (Bender et al., 2003). Indeed, the enzyme
complexes which require post-translational lipoylation for their activity are found in the
apicoplast and mitochondrion of P. falciparum (Foth et al., 2005, Günther et al., 2005,
McMillan et al., 2005, Salcedo et al., 2005) (see Figure 3.4). Thus, localisation of LplA2
to either of the organelles is likely. To investigate the localisation of LplA2, I first used
the available prediction programs (listed in 2.4.3) to predict the potential subcellular lo-
calisation of this protein, and the results are summarised in Table 4.3.
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Table 4.3.: Predicted LplA2 localisation of Plasmodium spp.
MitoProt PlasMit Predotar PATS SignalP
P. falciparum 0.9328 non-mito 0.03 mito 0.037 no signal peptide
99% 0.00 plastid
P. berghei 0.4511 non-mito 0.01 mito 0.025 0.003
99% 0.01 plastid
P. chabaudi 0.4995 non-mito 0.01 mito 0.023 no signal peptide
99% 0.01 plastid
P. knowlesi 0.8879 non-mito 0.38 mito 0.023 0.404
CSa→34 99% 0.00 plastid
P. vivax 0.9895 non-mito 0.87 mito 0 no signal peptide
CSa→28 99% 0.00 plastid
P. yoelii 0.96 non-mito 0.36 mito 0.657 no signal peptide
99% 0.00 plastid
a predicted cleavage site
Predicting the subcellular localisation of LplA2 is ambiguous. The program MitoProt pre-
dicts P. falciparum LplA2 to be mitochondrial, however, it is predicted non-mitochondrial
by PlasMit and Predotar. P. knowlesi and P. yoelii LplA2 are also predicted to be mito-
chondrial by MitroProt. The program even predicts a potential cleavage site of the transit
peptide for P. knowlesi LplA2, but the results obtained by SignalP for the P. knowlesi
protein and by PATS for the P. yoelii protein indicate a possible apicoplast targeting. The
MitoProt predictions of the other LplA2s also suggest mitochondrial localisation, which
is for P. vivax LplA2 further supported by Predotar. Overall, the localisation predictions
do not fully agree with each other which makes it impossible to predict the localisation of
LplA2 in the parasite.
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4.4.1. Localisation analyses using GFP-fusion proteins
To further determine the subcellular localisation of P. falciparum LplA2, parasites ex-
pressing LplA2-GFP fusion proteins were generated and analysed. Full length lplA2 was
amplified from 3D7 gDNA using the oligonucleotide primers LplA2-fwd and LplA2-rev
(see 2.1.7). The 1152 bp PCR fragment contained a CACC-overhang at the 5’ end for
directional cloning into the entry plasmid pENTR/D-TOPO (Invitrogen). Generation of
the LplA2-GFP expression constructs was performed using MultiSite Gatway cloning de-
scribed in Chapter 2.5.2.3 using the destination plasmid pCHD-3/4 (van Dooren et al.,
2005). Two LplA2-GFP constructs were generated which differed in the promoter driv-
ing the expression of the fusion protein. One was controlled by the stronger P. falciparum
Hsp86 promoter and the second construct was controlled by the weaker P. falciparum CRT
promoter. Both constructs were transfected into D10 wild-type parasites, as described
before (Crabb and Cowman, 1996, Wu et al., 1996), and obtained parasite populations
were analysed by fluorescence microscopy (Figure 4.3). Regardless of the construct used,
no differences in fluorescence were observed in the obtained parasite populations, and
therefore images shown in Figure 4.3 are representative for both LplA2-GFP expression
constructs. To visualise the mitochondria of the parasites, the parasites were treated with
Mitotracker CMXRos (Molecular Probes), a dye to specifically stain mitochondria. The
results suggest that LplA2 is present in two distinct organelles. One organelle is the
mitochondrion since clear co-localisation with Mitotracker can be observed. The other
organelle is distinct from the mitochondrion but closely associated with it, suggesting po-
tential apicoplast localisation (van Dooren et al., 2005). Furthermore, parasites with dual
targeting of LplA2 into both organelles were observed. Quantification of 50 parasites
expressing the LplA2-GFP fusion protein revealed that in 68% LplA2-GFP was found
in the mitochondrion, in 15% LplA2-GFP was present in the organelle distinct from the
mitochondrion likely to be the apicoplast and in 18% it was dual targeted into both or-
ganelles. To experimentally confirm whether the second organelle really is the apicoplast,
immunofluorescence analyses were carried out.
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Figure 4.3.: Localisation of LplA2 using LplA2-GFP expressing parasites
The subcellular localisation of LplA2 was investigated by expressing GFP fusion proteins in the
erythrocytic stages of P. falciparum. Full length LplA2 was cloned in frame with GFP and expres-
sion was controlled by either the Hsp86 or CRT promoter. Parasites mitochondria were selectively
stained with Mitotracker CMXRos (Molecular Probes) and images of live cells were obtained
by DIC microscopy (Phase) or in the FITC (LplA2-GFP) or rhodamine (Mitotracker) fluorescent
channels. Overlays of the images are displayed to determine possible co-localisation (Merge). In
the first two panels, LplA2-GFP clearly co-localises with the mitochondrion. In panel 3 and 4,
the GFP fluorescence is not in the mitochondrion but in a different organelle closely associated
with the mitochondrion, likely to be the apicoplast. The last two panels show parasites in which
LplA2-GFP is present in two organelles, one being the mitochondrion and the other likely being
the apicoplast. Scale bars equal 5 µm.
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4.4.2. Immunofluorescence analyses
Immunofluorescence analyses using 3D7 wild-type parasites were performed to further
investigate the localisation of LplA2. An antibody against apicoplast dihydrolipoamide
dehydrogenase (aE3) which was available in the laboratory was used as an apicoplast
marker (McMillan and Müller, unpublished) together with an antibody against P. falci-
parum LplA2 (Figure 4.4) (for antibody dilutions see Table 2.1). The results show that
in some parasites the two proteins clearly co-localise, suggesting LplA2 localisation in
the apicoplast. In addition, parasites were observed in which the two proteins did not
co-localise, suggesting mitochondrial localisation of LplA2. As already observed in the
LplA2-GFP expressing parasites, parasites with dual targeted LplA2 to both organelles
were present. Analyses of LplA2 localisation by immunofluorescence in 46 parasites
supported the distribution pattern observed in the LplA2-GFP expressing parasites, with
53% of LplA2 not co-localising with aE3 suggesting mitochondrial localisation, 19.6% of
LplA2 co-localising with aE3 suggesting apicoplast localisation and 28% showing dual
targeting of LplA2 to both organelles.
Figure 4.4.: Localisation of LplA2 by immunofluorescence analyses using anti-LplA2
and anti-aE3 antibodies
The subcellular localisation of LplA2 was investigated by immunofluorescence analyses using
anti-LplA2 and anti-apicoplast localised dihydrolipoamide dehydrogenase (aE3) antibodies on
3D7 wild-type parasite. Images of cells were obtained by DIC microscopy (Phase), or in the
FITC (α-LplA2), or rhodamine (α-aE3) fluorescent channels. DNA was stained with DAPI and
overlays of all images taken are displayed to determine possible co-localisation (Merge). In the
first panel, LplA2 does not co-localise with aE3 suggesting mitochondrial localisation. In the sec-
ond panel, LplA2 clearly co-localises with aE3 supporting apicoplast localisation of LplA2. The
last panel displays a parasite in which LplA2 is present in two organelles, one the apicoplast and
the other likely the mitochondrion. Scale bars equal 5 µm.
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These studies strongly suggest that LplA2 is dually targeted to the apicoplast and mito-
chondrion. However, the precise mechanism responsible for dual targeting for this protein
is not known and requires further investigation.
4.5. Knock-out studies in P. falciparum
4.5.1. Knock-out studies via single cross-over recombination
To assess the potential role of LplA2 and to investigate a possible redundancy between
the lipoic acid ligases present in P. falciparum, knock-out studies of lplA2 were performed
using the plasmid pHH1 (see Figure 2.1) (Reed et al., 2000). As described for LplA1 in
Chapter 3.4.1, knock-out is achieved by single cross-over recombination of the knock-
out plasmid with the gene locus (Figure 4.5, Panel B). The 792 bp knock-out fragment
was amplified from 3D7 gDNA using the oligonucleotides Pf-LplA2-KO-pHH1-fwd and
Pf-LplA2-KO-pHH1-rev (see 2.1.7). The knock-out fragment is truncated at the N- and
C-terminus and corresponds to nucleotides 205-993 of lplA2. In addition, an artificial
stop codon was introduced at the 3’ end of the PCR product to ensure the disruption of the
gene locus after integration. The PCR fragment was cloned directionally into pHH1 using
the restriction enzymes BglII and XhoI (Figure 4.5, Panel A), and LplA2-KO-pHH1 was
transfected into P. falciparum D10 wild-type parasites (Crabb and Cowman, 1996, Wu
et al., 1996). The transfected parasite population was cycled with WR99210, to select
for those parasites in which the knock-out plasmid had targeted the lplA2 locus. After
two cycles of drug selection, the parasite population was analysed by Southern blotting
of NdeI digested DNA. The expected band for integration into the lplA2 gene locus (4199
bp) was detected when probes specific for the hDHFR and the P. falciparum CAM 5’ UTR
were used (Figure 4.5, Panel D and E). Additionally, the PfCAM5’ probe detected a weak
band possibly corresponding to plasmid (5820 bp), and a band at 12.4 kb corresponding
to the endogenous calmodulin gene locus. However, analyses of the LplA2-KO mutant
parasites was not straightforward. Southern blot analyses using a gene specific probe did
not produce a clear result (Panel C). Two bands at 5249 bp and 4199 bp were expected
in case of integration of the knock-out plasmid into the lplA2 gene locus. Only one band
of approximately 4 kb was detected, however, precise size determination of this band was
difficult due to the way the digested DNA ran through the gel.
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C Pf lplA2-probe D hDHFR-probe E Pf CAM5’-probe
Figure 4.5.: Knock-out studies of P. falciparum lplA2
(Panel A) The 792 bp lplA2 knock-out fragment was cloned into pHH1 (5760 bp) using the re-
striction enzymes BglII and XhoI. (Panel B) The lplA2 knock-out fragment lacks the ATG-start
codon and is truncated at the C-terminus, where in addition, an artificial stop-codon is introduced.
Knock-out is achieved by single cross-over of this plasmid with the gene locus, which should re-
sult in an interruption of the locus generating two non-functional copies of the gene. For Southern
blot analyses, the DNA was digested with the restriction enzyme NdeI. Panel C-E display South-
ern blots of parasite gDNA digested with NdeI and probed with P. falciparum lplA2, hDHFR and
P. falciparum CAM5’, respectively. In all blots, lane 1 contains D10 wild-type gDNA and lane 2
gDNA of parasites transfected with the knock-out construct taken through two cycles of WR99210
selection. Blots probed with hDHFR and PfCAM5’ show the expected integration band (4199 bp),
suggesting integration of the knock-out plasmid in the lplA2 locus. The blot probed with PflplA2
is ambiguous. Two bands are expected in the event of integration (5249 bp and 4199 bp). Only
one band is detected and size determination of this band is not clearly possible because the band
did not appear straight (although all three blots shown were separated on the same agarose gel).
To clarify the genotypical analyses of the parasites transfected with the lplA2 knock-out
plasmid, PCR was performed using the following primer pairs that were diagnostic for
wild-type, plasmid and integration (Figure 4.6, Panel A). The gene locus specific primers
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LplA2-fwd and LplA2-rev (black arrows) were used to amplify a lplA2 specific band of
1152 bp, the plasmid specific primers CAM5’-check-F and PbDT3’-check-R (red arrows)
were used to amplify a 1027 bp plasmid specific band and the integration specific bands
(5’ 1024 bp; 3’ 1155 bp) were amplified by combining the above described primers (see
2.1.7). Figure 4.6 (Panel B) shows the result of the PCRs performed using the parasite
population taken through two cycles of drug selection. A band of the correct size was
amplified for 3’ integration (lane 1) and wild-type lplA2 (lane 4). No specific bands
were amplified for either the 5’ integration (lane 2) or plasmid (lane 3). The amplified
3’ integration band was cloned into pCR 2.1-TOPO (see 2.5.2.1) and its sequence was
verified. The sequencing result showed that no integration into the lplA2 gene locus had
occurred, because the band amplified did not match the expected sequence for integration.
A B
Figure 4.6.: PCR analyses of P. falciparum lplA2 knock-out studies
Panel A is a schematic diagram of the integration of LplA2-KO-pHH1. Transfectants were anal-
ysed by PCR using gene locus specific primers (black arrows) and plasmid specific primers (red
arrows). Panel B displays the PCR analyses of parasites transfected with the LplA2-KO-pHH1
construct and taken through two cycles of WR99210 selection. Lane 1 shows the 3’ integration
specific PCR (1155 bp), lane 2 the 5’ integration specific PCR (1024 bp), lane 3 the plasmid spe-
cific PCR (1027 bp) and lane 4 the wild-type lplA2 specific PCR (1152 bp). PCR showed that
wild-type lplA2 was present (lane 4), but the PCR specific for plasmid did not amplify a band of
the correct size (lane 3). Nothing was amplified by the 5’ integration specific PCR (lane 2), but a
band of the expected size was amplified by the 3’ integration specific PCR. However, sequencing
of this PCR product revealed that no integration into the correct gene locus had occurred.
These results are somewhat puzzling because the lplA2 gene is still present although
Southern blot analyses using the hDHFR and CAM5’ probes suggest that integration into
the lplA2 gene locus had occurred. A possible explanation for this is that the transfected
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plasmid integrated non-specifically into the P. falciparum genome resulting in similar "in-
tegration" banding pattern when digested with NdeI. Although required, time constraints
have prevented further analyses of the genotype of the "LplA2-KO" mutants.
4.6. Knock-out studies in P. berghei
As explained for LplA1, knock-out studies in P. berghei were carried out in collabora-
tion with Prof Kai Matuschewski, University of Heidelberg, Germany using the plasmid
b3D.DT∧H.∧D (see Figure 2.2) (kindly provided by A. P. Waters, Leiden University, The
Netherlands). Knock-out studies were performed using single and double cross-over ap-
proaches.
4.6.1. Knock-out studies via single cross-over recombination
For single cross-over recombination, a knock-out fragment was generated which was trun-
cated at the N- and C-terminus, and contained an artificial stop codon at the C-terminus
to ensure the disruption of the gene locus after integration (Figure 4.7, Panel B). The
knock-out fragment was first generated in the plasmid pBluescript II SK (Stratagene).
Because linearised DNA is transfected in P. berghei, a NdeI site had to be introduced 331
bp into the knock-out fragment. This was achieved by amplifying two lplA2 fragments
and cloning them in pBluescript II SK. The primer pairs Pb-LplA2-int-fwd / Pb-LplA2-
NdeI-rev and Pb-LplA2-NdeI-fwd / Pb-LplA2-int1-rev (see 2.1.7) were used. The first
PCR product was cloned into pBluescript II SK using the restriction enzymes BamHI
and XbaI, and the second PCR product was then cloned 3’ using NdeI and SacII. Thus,
a 882 bp knock-out fragment was generated containing an internal NdeI site, which was
cloned directional into b3D.DT∧H.∧D using the restriction enzymes BamHI and SacII
(Figure 4.7, Panel A). NdeI linearised PbLplA2-KO-b3D was transfected twice according
to Janse et al. (2006), and independent parasite populations obtained after pyrimethamine
selection in mice were analysed by PCR using the gene specific primers Pb-LplA2-5’-fwd
and Pb-LplA2-3’-rev (black arrows) and the plasmid specific primers Tg-for and b3D-rev
(red arrows) (Figure 4.7, Panel B). gDNA of the parasite populations was made and was
analysed by diagnostic PCRs. The results shown in Figure 4.7 (Panel C) are exemplary for
both populations. Only recombined plasmid (1496 bp; lane 2) and lplA2 wild-type (2577
bp; lane 3) were amplified in both parasite populations, but no 3’ integration (2182 bp;
lane 1) was detected. This indicated that PbLplA2-KO-b3D had not integrated into the
lplA2 gene locus. There are several explanations as to why the construct did not integrate
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into the lplA2 gene locus. Either lplA2 is essential for P. berghei intraerythrocytic stages,
in which case knock-out is not possible, or the lplA2 locus is refractory to integration. A
third possibility is that technical problems are responsible for this result.
A B
C
Figure 4.7.: Knock-out studies of P. berghei lplA2 using the integration strategy
(Panel A) Two lplA2 fragments were amplified by PCR and fused together in pBluescript II
SK (Stratagene) to generate the 882 bp knock-out fragment which was cloned directionally into
b3D.DT∧H.∧D (7514 bp) with BamHI and SacII (lane 1). Before transfection, PbLplA2-KO-b3D
was linearised using NdeI resulting in a 8396 bp fragment (lane 2). Panel B is a schematic di-
agram of the integration of PbLplA2-KO-b3D. Transfectants were analysed by PCR using gene
locus specific primers (black arrows) and plasmid specific primers (red arrows). Panel C displays
the PCR analyses of transfected parasites. Lane 1 shows the 3’ integration specific PCR (2182 bp),
lane 2 the plasmid specific PCR (1496 bp) and lane 3 the wild-type specific PCR (2577 bp). The
knock-out plasmid did not integrate into the gene locus. The plasmid was present as an episome.
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4.6.2. Knock-out control studies via single cross-over recombination
To investigate whether the lplA2 gene locus can be targeted by single cross-over recom-
bination, a knock-out control construct was designed. As described for the knock-out
construct, the knock-out control fragment was first generated in the plasmid pBluescript
II SK (Stratagene) to introduce an internal NdeI site. The primers used were identical to
the ones described previously (see 4.6.1) except for the antisense primer Pb-LplA2-int1-
rev. Instead the primer Pb-LplA2-3’-rev was used (see 2.1.7), to include the endogenous
lplA2 stop codon and 3’ UTR. The 1645 bp control fragment was then cloned direction-
ally into b3D.DT∧H.∧D using the restriction enzymes BamHI and SacII, and prior to
transfection of PbLplA2-KOkon-b3D the plasmid was linearised using NdeI (Figure 4.8,
Panel A). The control plasmid was transfected twice (Janse et al., 2006), and the two
independent parasite populations obtained after pyrimethamine selection were analysed
by PCR using the gene specific primers Pb-LplA2-5’-fwd and Pb-LplA2-REP-rev (black
arrows), and the plasmid specific primers Tg-for and b3D-rev (red arrows) (Figure 4.8,
Panel B). PCR analyses of both parasite populations revealed that PbLplA2-KOkon-b3D
had integrated into the gene locus. Figure 4.8 (Panel C) shows the PCR results of one
parasite population exemplary for both. The 3’ (2289 bp; lane 1) and 5’ (2655 bp; lane
2) specific PCRs amplified bands of the expected size. Their sequence was verified by
sequencing confirming the integration into the lplA2 gene locus. This control experiment
shows that the lplA2 gene locus is not refractory to integration. It seems to be targeted very
efficiently by PbLplA2-KOkon-b3D since neither plasmid (2259 bp; lane 3) nor endoge-
nous lplA2 (2684 bp; lane 4) were detected by PCR. Therefore, it appears that lplA2 is
essential for intraerythrocytic stages as knock-out by single cross-over was not achieved.
However, technical problems cannot be ruled out because the knock-out construct was
only transfected twice.
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Figure 4.8.: Knock-out control studies of P. berghei lplA2 using the integration strategy
(Panel A) Two lplA2 fragments were amplified by PCR and fused together in pBluescript II SK
(Stratagene) to generate the 1645 bp knock-out control fragment which was cloned directionally
into b3D.DT∧H.∧D (7514 bp) with BamHI and SacII (lane 1). Before transfection, PbLplA2-
KOkon-b3D was linearised using NdeI resulting in a 9159 bp fragment (lane 2). Panel B is a
schematic diagram of the integration of PbLplA2-KOkon-b3D. Transfectants were analysed by
PCR using gene locus specific primers (black arrows) and plasmid specific primers (red arrows).
Panel C displays the PCR analyses of the transfectants. Lane 1 shows the 3’ integration specific
PCR (2289 bp), lane 2 the 5’ integration specific PCR (2655 bp), lane 3 the plasmid specific
PCR (2259 bp) and lane 4 the wild-type specific PCR (2684 bp). The knock-out control plasmid
did integrate into the gene locus. Even without cloning of the transfected parasite population, no
plasmid or wild-type was detected by PCR, suggesting that the gene locus was very efficiently
targeted.
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4.6.3. Knock-out studies via double cross-over recombination
To further analyse whether lplA2 is essential for P. berghei erythrocytic stages, knock-out
studies via double cross-over recombination were performed. Using this strategy lplA2 is
replaced with the T. gondii DHFR/TS, the selectable marker of b3D.DT∧H.∧D. To achieve
double cross-over recombination, the 5’ and 3’ UTR of P. berghei lplA2 were amplified
using Pb-LplA2-5’-fwd / Pb-LplA2-5’-rev and Pb-LplA2-3’-fwd / Pb-LplA2-3’-rev, re-
spectively (see 2.1.7). The amplified 5’ UTR (698 bp) was cloned directionally into the
first multiple cloning site of b3D.DT∧H.∧D using KpnI and HindIII whereas the 3’ UTR
(581 bp) was cloned into the second multiple cloning site using NotI and SacII, generating
the plasmid PbLplA2-REP-b3D (Figure 4.9, Panel A). Before transfection according to
Janse et al. (2006), the plasmid was digested using the restriction enzymes KpnI and SacII
resulting in two fragments, the first containing the lplA2 UTRs and the selectable marker
(5919 bp), and the second containing the plasmid backbone (2864 bp) (Figure 4.9, Panel
A). The digested plasmid was transfected twice, but only one transfection was successful
resulting in a pyrimethamine resistant parasite population. This population was analysed
by PCR using the gene specific primers LplA2-test-for and LplA2-test-rev (amplifying a
3008 bp band). For amplification of plasmid, the primers Tg-for and b3D-rev (red arrows)
were used (amplifying a 1215 bp band) (Figure 4.9, Panel B). 3’ integration specific PCRs
were performed using either Tg-for / Pb-LplA2-REP-rev (amplifying a 1252 bp band) or
Tg-for / LplA2-test-rev (amplifying a 1432 bp band), and 5’ integration specific PCR
was performed using LplA2-test-for / Tg-rev (amplifying a 1184 bp band). The PCR
results shown in Figure 4.9 (Panel C) suggest that PbLplA2-REP-b3D had replaced the
lplA2 gene locus. The 3’ specific (1252 bp; lane 1) and 5’ specific (1184 bp; lane 2)
replacement PCRs resulted in the amplification of bands of the expected size and replace-
ment was confirmed by sequencing of these PCR products. The parasite population also
contained recombined plasmid (1215 bp; lane 3) and wild-type lplA2 (3008 bp; lane 4),
indicating that it was a mixed parasite population. These results suggest that lplA2 is not
essential for P. berghei intraerythrocytic stages, and that the failure to knock-out lplA2 by
single cross-over recombination is possibly be due to technical problems, like transfection
of incompletely digested plasmid DNA.
To further analyse the potential effects of lplA2 replacement, the mixed population was
cloned as described in material and methods (see 2.3.9). After three cloning attempts, 12
independent clones were obtained of which the three clones shown in Figure 4.10 (clone
II-1, II-5 and III-5) were used for further analyses (see below).
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Figure 4.9.: Knock-out studies of P. berghei lplA2 using the replacement strategy
(Panel A) A 698 bp fragment was amplified as the P. berghei lplA2 5’ UTR and was cloned into
b3D.DT∧H.∧D (8020 bp) using the restriction enzymes KpnI and HindIII (lane 1). The 3’ UTR
PCR fragment (581 bp) was cloned into the plasmid using NotI and SacII (lane 2). Before trans-
fection, PbLplA2-REP-b3D was digested with KpnI and SacII resulting in a 5919 bp fragment
containing the two UTRs and the T. gondii DHFR/TS expression cassette, and a 2864 bp fragment
containing the plasmid backbone (lane 3). Panel B is a schematic diagram of the replacement of
P. berghei lplA2. Transfectants were analysed by PCR using gene locus specific primers (black ar-
rows) and plasmid specific primers (red arrows). Panel C displays the PCR analyses of transfected
parasites. Lane 1 shows the 3’ replacement specific PCR (1252 bp), lane 2 the 5’ replacement spe-
cific PCR (1184 bp), lane 3 the plasmid specific PCR (1215 bp) and lane 4 the wild-type specific
PCRs (3008 bp). The parasite population obtained after transfection was mixed, containing par-
asites that had the lplA2 gene locus replaced and others which carried the plasmid episomally.
4. LplA2 136
A Clone II-1 B Clone II-5 C Clone III-5
Figure 4.10.: PCR analyses of P. berghei lplA2 knock-out clones
The mixed parasite population was cloned and obtained clones were analysed by PCR (Panel A-
C). Lane 1 shows the 3’ replacement specific PCR (1432 bp), lane 2 the 5’ replacement specific
PCR (1184 bp), lane 3 the plasmid specific PCR (1215 bp) and lane 4 the wild-type specific PCRs
(3008 bp).
4.6.4. Knock-out control studies via double cross-over recombination
Knock-out control studies via double cross-over recombination were also carried out.
The control plasmid contained an expression cassette of P. falciparum LplA2 to com-
plement effects that the loss of P. berghei lplA2, after replacement, might induce. As
described for LplA1 (see 3.6.4), the P. falciparum LplA2 expression cassette consisted of
the P. falciparum CAM promotor (amplified using PfCAM5’-F2 and PfCAM5’-R1), P.
falciparum lplA2 (amplified using Pf-LplA2-ORF-fwd and Pf-LplA2-ORF-rev) and the
3’ UTR of P. falciparum histidine rich protein 2 (HRP2) (amplified using PfHRPII3’-F1
and PfHRPII3’-R1) (see 2.1.7). The expression cassette was first generated in the plasmid
pBluescript II SK (Stratagene) followed by sub-cloning into PbLplA2-REP-b3D using the
restriction sites BamHI and NotI (Figure 4.11, Panel A). The resulting plasmid was named
PbLplA2-comp-b3D which was digested with the restriction enzymes KpnI and SacII, be-
fore it was transfected four times into wild-type parasites (Janse et al., 2006). Three of the
four transfections were successful, resulting in parasite populations after pyrimethamine
selection in mice which were analysed by PCRs diagnostic for wild-type, plasmid and
integration. The gene specific primers Pb-LplA2-int-fwd and Pb-LplA2-REP-rev (ampli-
fying a 1744 bp band) (black arrows) were used to amplify endogenous lplA2, and the
primers Pb-LplA2-3’-fwd and b3D-rev were used to amplify recombined plasmid (am-
plifying a 652 bp band) (red arrows). The 3’ integration specific PCR was set up using
the primers PfHRPII3’-F1 and Pb-LplA2-REP-rev (amplifying a 1296 bp band) (Figure
4.11, Panel B). The results shown in Figure 4.11 (Panel C) are exemplary for the three
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parasite populations. PbLplA2-comp-b3D did not integrate into the lplA2 gene locus.
No 3’ replacement specific PCR band (1296 bp; lane 1) was amplified, but recombined
plasmid (651 bp; lane 2) and wild-type lplA2 (1744 bp; lane 3) were present. These data
suggest that the complementation construct had not replaced the endogenous gene locus,
which is surprising given that a knock-out of lplA2 by double cross-over recombination
was possible. These results could have several explanations. Firstly, the P. falciparum
gene is not driven by its endogenous or the P. berghei lplA2 promoter, but by the strong
P. falciparum calmodulin promoter, which might lead to untimely over-expression of the
protein. This may have a negative effect on parasite development, which possibly could
explain my findings. However, technical problems could also be the cause of these results.
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Figure 4.11.: Knock-out control studies of P. berghei lplA2 using the replacement strategy
(Panel A) For the control construct, a P. falciparum LplA2 expression cassette was cloned into
PbLplA2-REP-b3D. The expression cassette consisted of the P. falciparum CAM promoter, lplA2
gene and HRP2 3’ UTR. First, the expression cassette (2418 bp) was generated in the plasmid
pBluescript II SK (3000 bp; Stratagene) (lane 1). Using the restriction enzymes BamHI and
NotI the expression cassette was cloned into PbLplA2-REP-b3D (8783 bp) in front of the P.
berghei lplA2 3’ UTR, resulting in the plasmid PbLplA2-comp-b3D (lane 2). Before transfection,
PbLplA2-comp-b3D was digested with KpnI and SacII resulting in a 8325 bp fragment contain-
ing the 5’ and 3’ P. berghei lplA2 UTRs, the T. gondii DHFR/TS and the P. falciparum LplA2
expression cassettes, and a 2864 bp fragment containing the plasmid backbone (lane 3). Panel
B is a schematic diagram of the complementation of P. berghei lplA2 replacement. Transfec-
tants were analysed by PCR using gene locus specific primers (black arrows) and plasmid specific
primers (red arrows). Panel C displays the PCR analyses of transfected parasites. Lane 1 shows
the 3’ replacement specific PCR (1296 bp), lane 2 the plasmid specific PCR (651 bp) and lane 3
the wild-type specific PCR (1744 bp). PbLplA2-comp-b3D did not integrate into the lplA2 gene
locus, indicating that the complementation of lplA2 replacement was not successful.
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4.6.5. Phenotypical analyses of lplA2 replacement mutants
4.6.5.1. Analyses of P. berghei erythrocytic stages
To analyse potential effects of lplA2 knock-out, the intraerythrocytic stages of P. berghei
were analysed first. Initial western blot analyses were performed on parasite extract us-
ing an antibody against protein bound lipoic acid, to assess whether knock-out of lplA2
affects the lipoylation state of the KADH-E2 subunits and the H-protein (Figure 4.12,
Panel A). The expected size of P. berghei PDH-E2 is 69.1 kDa, of BCDH-E2 50 kDa, of
KGDH-E2 46.6 kDa and of H-protein 14 kDa. The anti-lipoic acid antibody detected two
bands in the NK65 wild-type extract (lane 1), probably corresponding to PDH-E2 and
BCDH-E2. KGDH-E2 and H-protein were not detected by the antibody. Western blot
analyses of the lplA2 mutant clones II-1 (lane 2) and III-5 (lane 4) showed in comparison
to wild-type parasites no major differences in the lipoylation pattern observed. No load-
ing control was used which makes it impossible to finally conclude whether lipoylation
intensities changed in the LplA2-KO parasite clones. However, Ponceau staining of the
membrane after transfer (see 2.6.5) did not show obvious differential loading of clones
II-1 and III-5 in comparison to wild-type (not shown). Western blot analysis of clone
II-5 (lane 3) suggested that the KADH-E2 subunits were less lipoylated than in wild-type
parasites. This, however, is more likely due to different loading, which I observed after
transfer with Ponceau staining of the membrane for this clone (not shown). Thus, initial
western blotting suggests that lplA2 knock-out does not reduce lipoylation of the enzyme
complexes in comparison to wild-type parasites. Rather, it seems that the complexes are
slightly stronger lipoylated which could be due to an up-regulation of the other ligases
present in Plasmodium. This, however, needs to be further investigated by western and
northern blotting of the LplA2-KO mutants.
Furthermore, it was analysed whether knock-out of lplA2 affected the growth of P. berghei
blood stages in vivo. Growth rate assays (see 2.3.10) were set up for the LplA2-KO mu-
tant clones II-1, II-5 and III-5 monitoring growth of each clone in five mice for eight
days. Growth rate assays for NK65 wild-type parasites were set up twice thus monitoring
growth of NK65 in ten mice (Figure 4.12, Panel B). The results show that clone II-1 and
clone II-5 had a slightly decreased growth phenotype with constantly lower parasitemia
each day. The differences in parasitemia were significant on day five and six. In contrast,
clone III-5 showed significantly higher parasitemia on day five and equal parasitemia on
day six in comparison to wild-type parasites, suggesting a moderately accelerated growth
phenotype of this clone. However, the last two days monitored (day seven and eight) the
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parasitemia of clone III-5 was lower in comparison to wild-type parasites. Overall, the
experiment suggests that LplA2-KO affects the blood stage parasite growth only mod-
estly, and the significant differences observed are likely to be due to the fact that this
experiment was performed in animals in vivo. This is supported by the standard errors
obtained and the general growth pattern observed, because once the parasitemia reaches a
certain level (>1%), the immune system of the animal kills parasites and generally keeps
the parasitemia ≤1%.
To further analyse a possible effect of the LplA2 mutant parasites in the blood stages,
a transfer assay (see 2.3.11) was set up using clone II-5 and NK65 wild-type parasites.
Two naive mice were infected with 1000 mutant and 1000 wild-type parasites each. The
obtained mixed parasite populations were transferred into new naive mice. This was re-
peated five times and the genotype of the first and the last obtained parasite populations
were analysed by PCR using the diagnostic primer sets described in Figure 4.9 (Panel B).
The PCR results of the transfer assay are shown in Figure 4.12 (Panel C). After infection
of the first animals with equal numbers of mutant and wild-type parasites, the 3’ (1252
bp; lanes 1) and 5’ (1184 bp; lanes 2) replacement specific bands were amplified. No
lplA2 wild-type specific PCR was amplified (3008 bp; lanes 3), which could be explained
by either technical PCR problems or that the number of wild-type parasites was too low
to be detected by PCR. However, after five transfers lplA2 wild-type is present in both an-
imals (lanes 3). On the contrary, the 3’ replacement specific band is not detected anymore
in either of the two animals (lanes 1). The 5’ replacement specific PCR still amplifies a
band of the expected size (1184 bp; lanes 2), but in addition a second band at 900 bp is
visible. These results suggest that wild-type parasites seem to grow better over longer pe-
riods, which is supported by the growth experiment described above (Figure 4.12, Panel
B). Here, the LplA2-KO clone II-5 grew slightly slower in comparison to wild-type para-
sites. Over the eight day period this had only a small effect but in direct competition with
wild-type parasites over a longer time period, the effects are likely to be more obvious.
However, this experiment was only performed once and should be repeated not only by
PCR, but by quantitative PCRs, Southern blotting and PFGE. Moreover, analyses of the
the parasite populations obtained after the four transfers in between would possibly clar-
ify after how many transfers the lplA2 mutant parasites were outcompeted by wild-type
parasites in vivo.
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A B
C
Figure 4.12.: Phenotypical analyses of P. berghei LplA2 mutant intraerythrocytic stages
(Panel A) Western blot analysis was performed on parasite extract using an anti-lipoic acid anti-
body. Lane 1 contains wild-type parasites, lane 2 clone II-1, lane 3 clone II-5 and lane 4 clone
III-5. Two bands were detected by the lipoic acid antibody likely corresponding to PDH-E2 (ex-
pected size 69.1 kDa) and BCDH-E2 (expected size 50 kDa). No major differences were observed
in the clonal lines, except for clone II-5 where lipoylation seems to be less in comparison to wild-
type. However, this is more likely due to different loading (not shown). The other two clones show
no reduction in lipoylation. On the contrary, lipoylation of the enzyme complexes seems slightly
stronger. Panel B displays growth of the LplA2-KO clones in comparison to wild-type (WT) par-
asites. Growth of NK65 wild-type in ten mice and in five mice for each clone was monitored for
eight days. Each bar represents the mean ± standard error. Levels of significance were calculated
by paired t-test using SigmaPlot 9.0 software (Systat). Differences were considered significant at
P<0.05. Significant differences (*) in parasitemia of the clones in comparison to wild-type were
observed on day five, six and seven. Panel C displays PCR results of animal 1 and 2 after the first
infection (0) and after five transfers (5). Lane 1 shows the 3’ replacement specific PCR (1184 bp),
lane 2 the 5’ replacement specific PCR (1184 bp) and lane 3 the wild-type specific PCR (3008 bp).
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4.6.5.2. Analyses of P. berghei sexual developmental stages
To investigate potential effects of lplA2 knock-out on the sexual development of P. berghei
in the insect vector, clone II-5 was used for further analyses. Mosquitoes were infected
via a blood-meal on infected mice, and 10-14 days after the blood-meal the presence of
oocysts in the mosquitoes midgut was analysed. Midguts were dissected and were anal-
ysed microscopically for the presence of oocysts. The results are summarised in Table
4.4.
Table 4.4.: In vitro oocyst development of clone II-5 in the mosquitoes midgut
Infected midguts Oocysts per Re-infection of mice
infected midgut
WT 8/10 62.25 Yes
clone II-5 (1st feeding) 0/12 - No
clone II-5 (2nd feeding) 0/10 - No
clone II-5 (2mM LA) 0/10 - No
clone II-5 + WT 3/10 7.67 Yes
In two independent experiments mosquitoes were infected with LplA2-KO clone II-5
and in both experiments no oocysts were detected in the midguts analysed. However, in
mosquitoes infected with NK65 wild-type parasites, oocysts were detected in almost all
midguts analysed. A third infection with clone II-5 was performed and mosquitoes were
supplied with 2 mM lipoic acid via their food, but no infected midguts were observed. In
another experiment, mosquitoes were infected with equal numbers of clone II-5 and wild-
type parasites by letting them feed on a mouse, which was infected with equal numbers of
knock-out clone and wild-type parasites. After 10-14 days, oocysts were detected in the
midguts of the mosquitoes. Comparison to mosquitoes infected with wild-type parasites,
however, revealed that less mosquitoes were infected, and that additionally the number
of oocysts per infected midgut was drastically reduced. The mosquitoes listed in Table
4.4 were also used to infect naive mice. As expected, only mosquitoes infected with wild-
type parasites, or mosquitoes infected with clone II-5 and wild-type, were able to re-infect
mice.
Further analyses of the sexual developmental stages was carried out. In Giemsa stained
blood smears of mice infected with LplA2-KO clone II-5, male as well as female ga-
metocytes were observed suggesting that gametocytogenesis is not, or only modestly,
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affected by lplA2 knock-out. Moreover, exflagellation of male gametes was assessed be-
fore mosquito feedings (see 2.3.12) and was comparable to exflagellation of wild-type
parasites, suggesting that knock-out of lplA2 has no effect on male gametes. Thus, in
vitro ookinete cultures were set up of NK65 wild-type parasites and clone II-5, to investi-
gate whether the development of ookinetes is affected. Ookinetes were purified and their
number was determined microscopically (see 2.3.13) (Table 4.5).
Table 4.5.: In vitro ookinete development of clone II-5
Ookinetes per ml blood
WT 7,500,000
clone II-5 409,091
The formation of ookinetes is drastically reduced in the LplA2-KO clone II-5. The LplA2
mutant developed about 18 times less ookinetes in comparison to wild-type parasites.
However, this experiment needs to be repeated since it was only performed once due to
time constraints.
Overall, these data strongly suggest that the sexual development is severely affected. Fu-
ture work will involve the analyses of gametocytogenesis and gametogenesis in more
detail, and it will be analysed whether knock-out of lplA2 causes a sex-specific defect.
4.7. Summary
• Plasmodium possess a second lipoic acid protein ligase like protein named LplA2. Or-
thologues were found in other apicomplexan parasites like Theileria, but probably not in
Toxoplasma. The Toxoplasma predicted protein sequence misses amino acids crucial for
functionality of LplA2, suggesting that the Toxoplasma LplA2 is not functional.
• P. falciparum LplA2 complements the growth defect of lipB deficient and lipB/lplA
deficient bacteria, showing that it is a functional lipoic acid protein ligase.
• Prediction of LplA2 localisation within Plasmodium spp. using several prediction pro-
grams is not clearly possible.
• Localisation studies of LplA2-GFP expressing parasites suggested dual localisation of
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LplA2 to mitochondrion and apicoplast. These data were experimentally supported by
immunofluorescence analyses performed on wild-type parasites using antibodies against
LplA2 and apicoplast localised lipoamide dehydrogenase (aE3).
• Knock-out studies of P. falciparum lplA2 were attempted by single cross-over recom-
bination and disruption of the gene locus using the plasmid pHH1. No disruption of the
endogenous lplA2 locus was obtained.
• Knock-out studies of P. berghei lplA2 by single cross-over recombination appeared
impossible. The 3’ replacement construct did, however, target the lplA2 gene locus.
• Knock-out studies of P. berghei lplA2 by double cross-over recombination resulted in
replacement of the lplA2 gene. However, the control complementation construct did not
replace the gene locus.
• Overall these studies show that (1) the lplA2 locus can be targeted by both methods
and (2) that it is difficult to conclude that a gene locus is essential simply because the
gene locus is not targeted.
• Phenotypical analyses of the lplA2 mutant parasites revealed that the erythrocytic stages
were only modestly affected by the knock-out of lplA2. However, lplA2 null mutants were
unable to progress through the sexual developmental cycle. The formation of ookinetes is
drastically reduced and consequently no oocysts are formed by the mutant parasites.
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5. Biochemical characterisation of LplA1 and LplA2
5.1. Introduction
Lipoic acid is an essential cofactor of the acyltransferase (E2) subunit of the KADHs and
the H-protein of the GCV (Perham, 2000, Douce et al., 2001). It is covalently attached to
a conserved lysine residue of the lipoyl-domain of the E2 subunits and to the H-protein,
which is structurally homologous to the lipoyl-domains (see Figure 1.6). Lipoate protein
ligases (LplA) catalyse the attachment of lipoic acid to the lipoyl-domain using ATP, re-
leasing AMP and inorganic pyrophosphate (PPi) as shown in the following equation:
Lipoyl-domain + lipoic acid + ATP → lipoylated-domain + AMP + PPi
During the reaction a lipoyl-AMP intermediate is formed which facilitates the transfer
of lipoic acid to the lysine residue of the lipoyl-domain. This means that the activity of
LplA can be assessed by determining the lipoylation state of the lipoyl-domain, which
can be achieved in a variety of ways. Assay systems include the analyses of lipoylation
of the KADH-E2 subunits and H-protein by native PAGE (Ali and Guest, 1990, Fuji-
wara et al., 1992). This allows distinction between lipoylated and non-lipoylated proteins
due to a shift in their mobility, induced by a charge difference between the modified and
non-modified proteins (Fujiwara et al., 1992). Other methods monitor the increase of en-
zymatic activity of H-protein (Walker and Oliver, 1986, Fujiwara et al., 1992), PDH or
KGDH (Jordan and Cronan, 1997) as a measure of lipoylation. The latter assay systems,
however, rely on the availability of a number of additional protein components, which are
usually not commercially available and therefore need to be generated in addition to LplA
and the apo-E2 domains that are required for the analyses of the transferase activity.
Therefore, in this study I attempted to establish and validate an enzyme assay for LplA
which detects the release of PPi, the product of the first part of the LplA reaction. This,
however, did not allow the analyses of the final product of the reaction - the lipoylated pro-
tein. Therefore, I also analysed the lipoylation state of H-protein and E2 lipoyl-domains
of the three KADH by western blotting with an antibody directed against protein-bound
lipoic acid.
This chapter thus describes the initial biochemical characterisation of P. falciparum LplA1
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and LplA2. As a positive control, E. coli LplA was used (Green et al., 1995, Fujiwara
et al., 2005) to establish and validate both assay systems used. The protein substrates that
were used for the characterisation of the LplAs were the P. falciparum H-protein and the
lipoyl-domains of the PDH, BCDH and KGDH, rather than the entire apo-E2-subunits
of the enzyme complexes. Previous studies have shown that the lipoyl-domains in isola-
tion can be recombinantly expressed and used for lipoylation experiments (Ali and Guest,
1990, Dardel et al., 1990, Quinn et al., 1993).
5.2. P. falciparum LplA1 - Recombinant protein expression and
purification
5.2.1. Cloning of P. falciparum LplA1 expression constructs
For the recombinant expression of LplA1, the coding region of the gene was cloned into
the two expression plasmids pJC40 (see Figure 2.10) and pASK-IBA3 (see Figure 2.11).
pJC40 attached a (His)10-tag at the N-terminus of the recombinant protein whereas pASK-
IBA3 attached a Strep-tag at the C-terminus. For cloning into pJC40, lplA1 was amplified
from P. falciparum 3D7 gDNA using AccuPrime Pfx Supermix (Invitrogen). The oligonu-
cleotide primers PfLplA-NdeI-S and PfLplA-BamHI-AS (see 2.1.7), used to amplify the
gene, introduced a NdeI and BamHI site at the 5’ and 3’ end of the PCR product, re-
spectively. The 1182 bp PCR fragment was equivalent to nucleotides 46-1227. The gene
was truncated at the 5’ end to remove the N-terminal mitochondrial targeting sequence
of the protein (Wrenger and Müller, 2004) (see 3.2), that potentially could interfere with
protein’s solubility in the prokaryotic expression system. The PCR product was initially
cloned into the TOPO-Blunt PCR cloning vector (Invitrogen) and its sequence was ver-
ified, before it was sub-cloned into the expression plasmid pJC40 using the NdeI and
BamHI restriction sites (Figure 5.1, Panel A). The second expression construct, LplA1
in pASK-IBA3, was available in the laboratory (Wrenger and Müller, 2004) (Figure 5.1,
Panel A). The two constructs were named LplA1-pJC40 and LplA1-pASK-IBA3.
5.2.2. Recombinant expression of P. falciparum LplA1
Test expressions of LplA1-pJC40 and LplA1-pASK-IBA3 were carried out to optimise
expression conditions for both constructs. Expression of LplA1-pJC40 was tested in E.
coli BLR(DE3) (Novagen) at three different temperatures (37◦C, 30◦C and 18◦C) and
for varying lengths of time after induction with 1 mM IPTG. Samples were taken before
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induction and hourly after induction. The bacteria were harvested at the respective time
points, and the pellets were lysed using the BugBuster protein extraction kit (Novagen).
Soluble and insoluble protein fractions were analysed for recombinant LplA1 expression
by western blotting using an anti-His-tag antibody (dilutions given in Table 2.1). Figure
5.1 (Panel B) shows the western blot analysis of the test expressions performed at 37◦C.
The expression pattern did not change at different temperatures. A band was detected on
the western blot of the expected size of (His)10-tagged LplA1 (48.3 kDa) and was ex-
pressed at similar levels throughout the experiment. For large-scale expressions it was
decided to express the protein for two to three hours at 37◦C to obtain a high bacteria
density.
Figure 5.1 (Panel C) shows the western blot analysis of Strep-tagged LplA1 test expres-
sions using an anti-Strep-tag antibody (dilutions given in Table 2.1). The construct was
transformed into E. coli BLR(DE3) (Novagen), Ker184 (Reed and Cronan, 1993) and
Tm134 (Morris et al., 1994), and recombinant expression was tested at 37◦C, 30◦C and
18◦C for varying lengths of expression after induction with 200 ng/ml AHT. Samples
were taken before induction, hourly after induction and after overnight expression. The
bacteria were harvested and lysed as described above, and the recombinant expression
of the 47.3 kDa protein was analysed by western blotting using an antibody against the
Strep-tag. Strep-tagged LplA1 was not expressed in detectable amounts in BLR(DE3)
and Ker184. In Tm134, the expression pattern observed was independent of temperature
and thus only the western blot of the test expression performed at 37◦C is shown (Figure
5.1, Panel C). The expression level of recombinant Strep-tagged LplA1 was similar in all
hourly samples analysed, and decreased overnight. Therefore, large-scale expressions for
purification were performed at 37◦C for two to three hours.
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A
B anti-His C anti-Strep
Figure 5.1.: Cloning of P. falciparum LplA1 expression constructs and western blot anal-
yses of test expressions of P. falciparum LplA1 constructs
LplA1 was cloned into the two expression plasmids pJC40 and pASK-IBA3. Panel A shows the
digests of the expression plasmids. LplA1 cloned into pJC40 (lane 1) was digested using the
restriction enzymes NdeI and BamHI, resulting in two bands corresponding to lplA1 (1187 bp)
and pJC40 (2381 bp). The pASK-IBA3 construct (lane 2) was linearised using the restriction
enzyme XbaI resulting in a 4334 bp band. Test expressions of both constructs were analysed
by western blotting (Panel B and C) using anti-His-tag and anti-Strep-tag antibodies, respectively
(for dilutions see Table 2.1). The blots show the protein in the supernatant fractions (SN) and pellet
fractions (P) before induction (0), 1 to 3 hours after induction (1-3) and after overnight expression
(ON). The expected size of the His-tagged LplA1 (Panel B) was 48.6 kDa and 47.3 kDa for the
Strep-tagged LplA1 (Panel C). The expression of both constructs shown here was performed at
37◦C, but was also tested at 30◦C and 18◦C. The expression pattern did not change at different
temperatures. The expression of LplA1-pJC40 was tested in E. coli BLR(DE3). The expression
of LplA1-pASK-IBA3 was tested in various E. coli cells. Expression in Tm134 is shown here.
5.2.3. Purification of P. falciparum LplA1
For purification of both recombinant LplA1 forms, large-scale expressions at 37◦C were
set up for each construct. The bacteria were harvested and the recombinant proteins were
purified by batch nickel affinity chromatography (see 2.6.9.1) of the (His)10-tagged LplA1
and Strep-Tactin column affinity chromatography (see 2.6.10) of the Strep-tagged LplA1.
Generally, 2L expression cultures resulted in ∼2 mg (His)10-tagged and ∼3 mg Strep-
tagged LplA1. Figure 5.2 shows the recombinant proteins after purification. 5 µg of
the elution fraction was separated by 12.5% SDS-PAGE, and was analysed by Coomassie
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staining (Panel A) and western blotting (Panel B) using anti-His-tag and anti-Strep-tag an-
tibodies, respectively. (His)10-tagged LplA1 appeared to be less stable than Strep-tagged
LplA1, as demonstrated by the presence of degradation products of the recombinant pro-
tein in the elution fraction. These were particulary obvious in the western blot (Figure
5.2, Panel B).
A B
Figure 5.2.: Purification of recombinant expressed P. falciparum LplA1s
Panel A displays 5 µg of recombinantly expressed LplA1 with an N-terminal (His)10-tag (48.6
kDa) (lane 2) and a C-terminal Strep-tag (47.3 kDa) (lane 3), separated on 12.5% SDS-PAGE
stained with Coomassie. Panel B shows the equivalent western blot of His-tagged LplA1 (lane 1)
using anti-His-tag antibody, and of Strep-tagged LplA1 (lane 2) using anti-Strep-tag antibody.
5.3. P. falciparum LplA2 - Recombinant protein expression and
purification
5.3.1. Cloning of P. falciparum LplA2 expression constructs
For the recombinant protein expression of P. falciparum LplA2, the plasmids pJC40 (see
Figure 2.10) and pASK-IBA3 (see Figure 2.11) were also used. Three expression con-
structs were generated and cloned into each plasmid. The sizes of the three constructs
are summarised in Table 5.1. The constructs varied in length at their N-termini because
of a possible, but not predictable, targeting sequence at the N-terminus of the predicted
protein (see Table 4.3).
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Table 5.1.: Sizes of P. falciparum LplA2 constructs
Construct Length in bp Length in aa
Pf LplA2-full length (fl) 1-1155 1-385
Pf LplA2-short 1 (S1) 79-1155 27-385
Pf LplA2-short 2 (S2) 235-1155 79-385
For cloning into pJC40, the antisense oligonucleotide primer PfLplA2-BamHI-AS was
used for all three constructs introducing a BamHI site. The full length construct was
amplified using the sense oligonucleotide PfLplA2-FL-NdeI-S, resulting in a 1155 bp
PCR fragment. PfLplA2-S1-NdeI-S was used to amplify the S1 construct (1077 bp) and
PfLplA2-S2-NdeI-S was used to amplify the S2 construct (921 bp). The sense primers
introduced a NdeI site which then allowed directional cloning into pJC40 (Figure 5.3,
Panel A) (for primer sequences see 2.1.7).
For cloning into pASK-IBA3, the antisense primer PfLplA2-IBA3-rev was used to am-
plify all three constructs. The primer had no stop codon so that the Strep-tag was at-
tached at the C-terminus of the recombinant protein. In combination with the sense primer
PfLplA2-IBA3-1-fwd, the full length fragment was amplified. The sense primer PfLplA2-
IBA3-2-fwd generated the S1 fragment from nucleotide 79-1152. The third fragment (S2)
was amplified using PfLplA2-IBA3-3-fwd corresponding to nucleotide 235-1152. All
primers contained a BsaI restriction site which allowed directional cloning into pASK-
IBA3 (Figure 5.3, Panel B) (for primer sequences see 2.1.7).
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A B
Figure 5.3.: Cloning of P. falciparum LplA2 expression constructs
For recombinant protein expression, the expression plasmids pJC40 and pASK-IBA3 were used.
Panel A displays the three LplA2 expression constructs in pJC40. They were digested using the
restriction enzymes NdeI and BamHI, resulting in a 2383 bp band corresponding to pJC40 (lane
1-3), a 1155 bp band corresponding to the LplA2-full length construct (lane 1), a 1077 bp band
corresponding to the LplA2-S1 construct (lane 2) and a 921 bp band corresponding to the LplA2-
S2 construct (lane 3). Panel B shows the LplA2 expression constructs in pASK-IBA3 linearised
using the restriction enzyme XbaI. The linearised full length construct (lane 1) resulted in a 4305
bp band, the S1 construct (lane 2) in a 4229 bp band and the S2 construct (lane 3) resulted in a
4073 bp band.
5.3.2. Recombinant expression of P. falciparum LplA2
To find optimal expression conditions for each of the constructs, small-scale test expres-
sions were set up. The three pJC40 constructs were transformed into E. coli BLR(DE3)
(Novagen), and expression of the recombinant protein was monitored at different temper-
atures (37◦C, 30◦C, 23◦C and 18◦C) for varying expression times after induction with 1
mM IPTG, similar to the test expressions described for LplA1 (see 5.2.2). Figure 5.4,
Panel A shows the western blots of the test expressions of the LplA2-fl construct (ex-
pected size 48.6 kDa) and Panel B displays the western blots of the test expressions of the
LplA2-S1 construct (expected size 45.7 kDa). Regardless of the temperature used after
induction of recombinant protein expression, both constructs were not solubly expressed.
The recombinant proteins were only detected in the pellet fractions. The LplA2-S2 con-
struct (expected size 39.6 kDa) was expressed in a small amount in the soluble fraction
(Figure 5.4, Panel C). The expression level of the recombinant protein was constant in
the first two hours after induction, but disappeared after overnight expression. Further,
degradation of the recombinant protein was detected and it was decided that expression at
30◦C, rather than 37◦C, for two hours were the best conditions for large-scale expressions
of the (His)10-tagged LplA2-S2 construct. Expression at 30◦C resulted in a high bacteria
density, but was more gentle in terms of protein degradation in comparison to expression
at 37◦C.
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A LplA2-fl-pJC40
I) 37◦C II) 30◦C
III) 23◦C IV) 18◦C
B LplA2-S1-pJC40
I) 37◦C II) 30◦C
III) 23◦C IV) 18◦C
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C LplA2-S2-pJC40
I) 37◦C II) 30◦C
III) 23◦C IV) 18◦C
Figure 5.4.: Western blot analyses of test expressions of P. falciparum LplA2-pJC40 con-
structs in E. coli BLR(DE3)
Test expressions of LplA2-pJC40 constructs were performed in E. coli BLR(DE3) at (I) 37◦C, (II)
30◦C, (III) 23◦C and (IV) 18◦C each and were analysed by western blotting using an anti-His-tag
antibody. Panel A displays test expressions of the full length construct (expected size 48.6 kDa),
Panel B of the S1 construct (expected size 45.7 kDa), and Panel C of the S2 construct (expected
size 39.6 kDa). The blots show the protein in the pellet fractions (P) and supernatant fractions (SN)
before induction (0), 1 to 3 hours after induction and after overnight expression (ON). The full
length and S1 construct were not expressed in soluble form and only a small amount of LplA2-S2
was expressed in the soluble fraction (arrow). However, degradation products of the recombinant
protein were also detected by the antibody. Degradation seemed to be worse if expression was
carried out at lower temperatures.
The pASK-IBA3 constructs were transformed into E. coli BLR(DE3) (Novagen), Ker184
(Reed and Cronan, 1993) and Tm134 (Morris et al., 1994), and recombinant expression
was tested at 37◦C, 30◦C, 23◦C and 18◦C for varying lengths of time after induction with
200 ng/ml AHT. As described above, samples were taken before induction, hourly after
induction and after overnight expression, and were analysed using the BugBuster protein
expression kit (Novagen) followed by western blotting with an anti-Strep-tag antibody.
All three constructs, LplA2-fl (expected size 47.3 kDa), LplA2-S1 (expected size 44.3
kDa) and LplA2-S2 (expected size 38.3 kDa) were not solubly expressed in any of the
bacteria tested (Figure 5.5). The western blots shown here display the recombinant protein
test expressions performed in Tm134.
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A LplA2-fl-pASK-IBA3
I) 37◦C II) 30◦C
III) 23◦C IV) 18◦C
B LplA2-S1-pASK-IBA3
I) 37◦C II) 30◦C
III) 23◦C IV) 18◦C
5. Biochemical characterisation of LplA1 and LplA2 155
C LplA2-S2-pASK-IBA3
I) 37◦C II) 30◦C
III) 23◦C IV) 18◦C
Figure 5.5.: Western blot analyses of test expressions of P. falciparum LplA2-pASK-IBA3
constructs in E. coli Tm134
Test expressions of LplA2-pASK-IBA3 constructs were performed in E. coli Tm134 at (I) 37◦C,
(II) 30◦C, (III) 23◦C and (IV) 18◦C each and were analysed by western blotting using an anti-
Strep-tag antibody. Panel A displays test expressions of the full length construct (expected size
47.3 kDa), Panel B of the S1 construct (expected size 44.3 kDa), and Panel C of the S2 construct
(expected size 38.3 kDa). The blots show the protein in the pellet fractions (P) and supernatant
fractions (SN) before induction (0), 1 to 3 hours after induction and after overnight expression
(ON). Regardless of the construct and of the temperature used after induction of recombinant
LplA2 expression, the protein was not expressed in soluble form. It was only detected in the pellet
fractions.
5.3.3. Purification of P. falciparum LplA2
Only the (His)10-tagged LplA2-S2 construct was expressed in soluble form and was there-
fore used for large-scale expressions and purification. The construct was expressed at
30◦C for two hours before the bacteria were harvested and the recombinant protein was
purified by batch nickel affinity chromatography (see 2.6.9.1). Figure 5.6 shows 5 µg of
the elution fraction after purification of LplA2-S2 separated by 12.5% SDS-PAGE and
stained with Coomassie (Panel A, lane 2), or analysed by western blotting (Panel B, lane
1) using an anti-His-tag antibody. The Coomassie stained gel showed the presence of sev-
eral protein bands, three of them between 50 and 75 kDa, a faint protein band at 36 kDa
and bands at 27 kDa and 22 kDa. Western blot analyses using the anti-His-tag antibody
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confirmed that LplA2-S2 corresponded to the 36 kDa band. The 27 kDa band was also
detected by the anti-His-tag antibody, possibly being a degradation product of the recom-
binant protein. This suggests that LplA2-S2 was co-purified with non-His-tagged pro-
teins present in the E. coli extract, leading to the conclusion that recombinantly expressed
LplA2-S2 may form complexes during expression with E. coli proteins which were not
broken up using this purification method. It is known that recombinantly expressed pro-
teins, if not folded properly, may form complexes with bacterial chaperones to enhance
their solubility (Goloubinoff et al., 1989, Georgiou and Valax, 1996, Keresztessy et al.,
1996). To analyse which proteins co-purified with LplA2-S2, the three proteins were
analysed by tandem mass spectrometry (LC-MS/MS). The analyses was performed by Dr
Richard Burchmore of the Sir Henry Wellcome Functional Genomics Facility based at
the University of Glasgow. The proteins were identified as GroEL (gi|18028158), chaper-
onin Cpn60 (gi|119366229) and a nucleoside-diphosphate-sugar epimerase (gi|75187041)
from E. coli. These data strongly suggest that LplA2-S2 indeed needs assistance during
recombinant protein expression in the E. coli system.
A B
Figure 5.6.: Purification of His10-tagged P. falciparum LplA2-S2
Panel A and B display LplA2-S2 purified by batch nickel affinity chromatography. 5 µg of the
elution fraction was separated by 12.5% SDS-PAGE followed by Coomassie staining (Panel A)
or western blot analyses (Panel B) using an anti-His-tag antibody. The expected protein size was
39.6 kDa. Several protein bands were detected in the elution fraction and western blot analysis
confirmed that LplA2-S2 corresponds to the faint protein band at 36 kDa. It also showed degra-
dation products of LplA2-S2 in the elution fraction. The three prominent bands between 50 and
75 kDa were analysed by tandem mass spectrometry and were identified as E. coli nucleoside-
diphosphate-sugar epimerase (74.2 kDa), chaperonin Cpn60 (57.4 kDa) and GroEL (52 kDa),
strongly suggesting that LplA2-S2 has folding problems during recombinant expression in E. coli.
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Furthermore, I tested whether purification by FPLC nickel affinity chromatography (see
2.6.9.2) was able to separate the E. coli proteins from the recombinant LplA2-S2. How-
ever, it was not possible to separate the E. coli proteins from the recombinant protein.
During FPLC, the recombinant LplA2-S2 and its degradation products eluted together
with the E. coli proteins in the same peak (data not shown).
Unfortunately, it was not possible for me to continue with the optimisation of expression
and purification of the LplA2 constructs due to time constraints. LplA2-S2 was also not
tested in any activity assay (described below) since the quality of the purified recombinant
protein was too poor. Only≤10% of the elution fraction corresponded to the recombinant
protein.
5.4. E. coli LplA - Recombinant protein expression and purification
The construct used for recombinant expression of E. coli LplA was kindly provided by
John E. Cronan, Jr., University of Illinois at Urbana-Champaign, USA. The construct con-
tained the full length E. coli lplA coding region cloned into the expression plasmid pQE-2,
which attaches a (His)6-tag to the N-terminus of the recombinant protein. Before testing
the construct, it was analysed by restriction digest using the restriction enzymes NdeI and
HindIII (Figure 5.7, Panel A).
To optimise the expression conditions of the E. coli LplA construct, a small-scale test
expression at 37◦C was set up. The construct was transformed into E. coli BLR(DE3)
(Novagen), and recombinant protein expression was induced using 1 mM IPTG. Samples
were analysed by using the BugBuster protein extraction kit (Novagen) followed by west-
ern blotting with an anti-His-tag antibody. Recombinant E. coli LplA (expected size 39.1
kDa) was highly expressed and it was decided that expression for three hours at 37◦C
is sufficient for further protein purification of large-scale expressions (Figure 5.7, Panel
B). Recombinant E. coli LplA was purified by batch nickel affinity chromatography (see
2.6.9.1). Figure 5.7 (Panel C) displays a Coomassie stained SDS-PAGE of samples taken
during the batch purification (lanes 2-8) and of the elution fraction (lane 9). 5 µg of the
elution fraction was loaded onto the gel showing purified E. coli LplA of the expected
size. Generally, a 100 ml culture used for recombinant protein expression resulted in ∼30
mg of recombinant E. coli LplA.
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Figure 5.7.: Cloning, expression and purification of E. coli LplA in pQE-2
E. coli LplA in pQE-2 was kindly provided by John E. Cronan, Jr., University of Illinois at Urbana-
Champaign, USA. Panel A shows a digest of the expression plasmid using the restriction enzymes
NdeI and HindIII, resulting in a 1183 bp band (E. coli lplA) and a 4704 bp band (pQE-2). The
optimal expression conditions were determined by western blot analysis of test expressions using
an anti-His-tag antibody (Panel B). The recombinant protein (39.1 kDa) was expressed in E. coli
BLR(DE3) cells at 37◦C. The blot shows the protein in the pellet fractions (P) and supernatant
fractions (SN) before induction (0), hours after induction (1-3) and after overnight expression
(ON). Panel C displays the purification of recombinant E. coli LplA by batch nickel affinity chro-
matography, run on a 12.5% SDS-PAGE and stained with Coomassie for analysis. The gel was
loaded with samples taken during the purification. Lane 2 shows the insoluble pellet fraction, lane
3 the supernatant fraction, lane 4 the flow through, lanes 5-8 the wash fractions and lane 9 the
elution fraction of which 5 µg was loaded.
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5.5. P. falciparum H-protein and lipoyl-domains - Recombinant
protein expression and purification
5.5.1. Cloning and recombinant expression of P. falciparum H-protein and
lipoyl-domains
The lipoyl-domains are part of the E2 subunits of the KADHs. Like the H-protein of
the GCV, these domains are recognised by LplA and lipoic acid is covalently attached
to them post-translationally. For in vitro LplA activity assays, expression constructs for
the lipoyl-domains of the P. falciparum KADH-E2 subunits and for the H-protein were
generated. The lipoyl-domains are located at the N-terminus of the E2 subunits (Reed and
Hackert, 1990) and for expression of the domains, the constructs were truncated at the N-
terminus to remove their subcellular targeting sequences (Foth et al., 2005, Günther et al.,
2005, McMillan et al., 2005, Salcedo et al., 2005). The Plasmodium PDH-E2 subunit
has two lipoyl-domains, whereas the BCDH-E2 and KGDH-E2 subunits have only one
lipoyl-domain (see Figure 1.6). The sizes of the domains and their position within the
E2 subunits, and the size and position of the H-protein used for cloning/expression are
summarised in Table 5.2.
Table 5.2.: Sizes of P. falciparum H-protein and lipoyl-domain constructs
Lipoyl domain (LD) Length in bp Length in aa
1. H-protein 103-603 35-201
2. PDH-E2-LD1 82-315 28-105
3. PDH-E2-LD2 466-873 156-291
4. BCDH-E2-LD 40-372 14-124
5. KGDH-E2-LD 52-390 18-130
The H-protein and the lipoyl-domains of BCDH-E2 and KGDH-E2 as well as both PDH-
E2 lipoyl-domains, were PCR amplified using the oligonucleotide primers specified in
2.1.7. The primers introduced NdeI and BamHI restriction sites at the 5’ and 3’ ends of
the PCR products for directional cloning into pJC40 (Figure 5.8).
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Figure 5.8.: Cloning of P. falciparum H-protein and lipoyl-domains in pJC40
For recombinant expression of the H-protein and the lipoyl-domains, the expression plasmid
pJC40 was used. The expression constructs were digested using the restriction enzymes NdeI
and BamHI resulting in a 2383 bp band corresponding to pJC40 (lanes 1-5), a 501 bp band corre-
sponding to the H-protein (lane 1), a 234 bp band corresponding to PDH-E2-LD1 (lane 2), a 407
bp band corresponding to PDH-E2-LD2 (lane 3), a 333 bp band corresponding to BCDH-E2-LD
(lane 4) and a 339 bp band corresponding to KGDH-E2-LD (lane 5).
The optimal expression conditions for each construct were determined by small-scale test
expressions as described above for the LplAs. Table 5.3 summarises the results of the test
expressions and shows the optimal expression conditions for each construct.
Table 5.3.: Optimal expression condition of P. falciparum H-protein and lipoyl-domains
expressed in E. coli BLR(DE3)
Construct Temperature Time
H-protein-pJC40 37◦C 2-3 hours
PDH-E2-LD1-pJC40 18◦C overnight
PDH-E2-LD2-pJC40 18◦C overnight
BCDH-E2-LD-pJC40 23◦C 2-3 hours
KGDH-E2-LD-pJC40 37◦C 2-3 hours
5.5.2. Purification of P. falciparum H-protein and lipoyl-domains
Large-scale expressions of recombinant H-protein and lipoyl-domains were set up for pu-
rification at the respective temperature and for the respective time. The bacteria were
harvested and the recombinant proteins were purified by batch nickel affinity chromatog-
raphy (see 2.6.9.1). Figure 5.9 shows 5 µg of each elution fraction loaded onto a 15%
SDS-PAGE and analysed by Coomassie staining. 5 µg of H-protein elution fraction (ex-
pected size of 21.1 kDa) was separated in lane 1, PDH-E2-LD1 (expected size of 11.3
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kDa) in lane 2, PDH-E2-LD2 (expected size of 18.9 kDa) in lane 3, BCDH-E2-LD (ex-
pected size of 15.4 kDa) in lane 4 and KGDH-E2-LD (expected size of 15.1 kDa) in
lane 5. The expected sizes were calculated using Vector NTI software (Invitrogen) and
were confirmed by MALDI-TOF mass spectrometry (performed by the Fingerprints pro-
teomics facility, University of Dundee), although in the SDS-PAGE most of the domains
had a higher apparent mass. It is not unusual that the apparent mass of a protein in
a SDS-PAGE varies slightly from its original mass and ∼5 kDa is within the tolerable
range. Post-translational modifications like glycosylation can, for example, affect the
electrophoretic mobility of a protein, but also hydrophobic areas within a protein itself
can affect the mobility (Banker and Cotman, 1972, Müller et al., 2007). Generally, 2L
cultures used for recombinant protein expression resulted in ∼3.8 mg H-protein, ∼7 mg
PDH-E2-LD1, ∼47 mg PDH-E2-LD2, ∼8 mg BCDH-E2-LD and ∼46 mg KGDH-E2-
LD.
Figure 5.9.: Purification of P. falciparum H-protein and lipoyl-domains
The recombinant H-protein and lipoyl-domains were purified by batch nickel affinity chromatog-
raphy. 5 µg of each elution fraction was separated on a 15% SDS-PAGE and was analysed by
Coomassie staining. Lane 1 corresponds to purified H-protein (expected size 21.7 kDa), lane 2
corresponds to PDH-E2-LD1 (expected size 11.3 kDa), lane 3 corresponds to PDH-E2-LD2 (ex-
pected size 18.9 kDa), lane 4 corresponds to BCDH-E2-LD (expected size 15.4 kDa) and lane
5 corresponds to KGDH-E2-LD (expected size 15.1 kDa). Lanes 1-4 contain additional proteins
which co-purified with the domains. It is hypothesised that these either correspond to multimers of
the domains, or that they maybe correspond to chaperones of E. coli, because the sizes are similar
to the proteins co-purified with LplA2-S2 (see 5.3.3).
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5.5.3. Circular dichroism (CD) analysis of recombinant H-protein and
lipoyl-domains
The CD spectra of recombinantly expressed H-protein and lipoyl-domains were analysed
at far UV (Figure 5.10, Panel A) and near UV/visible ranges (Figure 5.10, Panel B) in or-
der to investigate the secondary structures of the H-protein and lipoyl-domains. This was
examined to analyse whether all recombinant expressed domains were potential protein
substrates for LplA activity assays, or whether some were likely to be not accepted by
LplA due to improper folding after recombinant expression. The experiments were car-
ried out by Dr Sharon Kelly of the protein characterisation facility, Institute of Biomedical
and Life Sciences, University of Glasgow. The obtained data were analysed using the on-
line server DICHROWEB (Lobley et al., 2002, Whitmore and Wallace, 2004). Standard
algorithms and datasets for secondary structure comparison were used to analyse the CD
data and the "goodness of fit" parameter NRMSD was obtained for each recombinant
protein. The parameter measures how good the experimental data fit with the theoretical
CD spectrum back-calculated from the obtained secondary structure (Kelly et al., 2005).
NRMSD values range from 0 (perfect fit) to 1 (no fit). Data above 0.25 are not reliable
whereas data ≤0.05 are considered reliable. NRMSD obtained for the recombinant pro-
teins were as follows: 0.03 for fresh purified H-protein (shown in blue in the spectra),
0.055 for H-protein stored one month at 4◦C (shown in red in the spectra), 0.061 for
PDH-E2-LD1 (shown in green in the spectra), 0.021 for PDH-E2-LD2 (shown in black
in the spectra), 0.487 for BCDH-E2-LD (shown in pink in the spectra) and 0.042 for
KGDH-E2-LD (shown in purple in the spectra). The data suggested that the BCDH-E2-
LD and potentially the PDH-E2-LD1 were not folded properly after recombinant protein
expression.
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Figure 5.10.: Circular dichroism (CD) analysis of recombinant H-protein and lipoyl-
domains
The CD spectra of recombinantly expressed H-protein and lipoyl-domains were analysed at far
UV and near UV/visible wavelengths in order to investigate the secondary structure of the H-
protein and lipoyl-domains. The experiments were carried out by Dr Sharon Kelly of the protein
characterisation facility, Institute of Biomedical and Life Sciences, University of Glasgow. Data
were collected in a JASCO J-180 instrument with protein samples at 0.5 mg/ml. Panel A displays a
comparison of far UV CD spectra and Panel B of near UV CD spectra of fresh purified H-protein
(blue), H-protein stored one month at 4◦C (red), PDH-E2-LD1 (green), PDH-E2-LD2 (black),
BCDH-E2-LD (pink) and KGDH-E2-LD (purple). The upper graph in Panel A and B represents
the CD spectra and the lower graph the High Tension voltage traces.
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5.6. "Gel assays"
LplA activity can be determined by analysing the lipoylation state of the protein substrate
in the "gel assay" (Ali and Guest, 1990, Fujiwara et al., 1992). The attachment of lipoic
acid to a conserved lysine residue of the lipoyl-domains of the KADH-E2 subunits and of
the H-protein of the GCV results in the neutralization of a positive charge and enhances
therefore the mobility of the lipoylated protein in a native PAGE. Thus, the lipoylated
form of a protein migrates faster in native PAGE in comparison to the non-lipoylated
form of the protein, and results in a shift of the protein band (Fujiwara et al., 1992).
The lipoylation reaction catalysed by LplAs was set up in a general reaction buffer con-
taining 100 mM phosphate buffer (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid
and 1 mM DTT in a final volume of 30 µl. The concentration of the protein substrate
varied between 2-4.4 µM and of LplA between 0-3.5 µM in each assay.
The assay shown in Figure 5.11 was performed using 4.4 µM KGDH-E2-LD and an
increasing concentration of E. coli LplA (0-3.4 µM). The reaction mix was incubated at
37◦C for 30 min before half of it was separated on a 20% native PAGE. Panel A shows
the Coomassie stained native PAGE in which the band shift of KGDH-E2-LD is visible.
The protein migrated faster in the native PAGE the more lipoylated it had become during
the reaction. Panel B displays the native PAGE analysed by western blotting using an an-
tibody that detects lipoic acid bound to proteins (for dilutions see Table 2.1). It is obvious
that even the lowest concentration of E. coli LplA used in this assay (0.04 µM; lane 4)
lipoylated the KGDH-E2-LD, although only to a small degree. The lipoylation level was
so low that it was not detected in the Coomassie stained gel (Panel A, lane 4). Further,
it can be seen that under the conditions used this lipoylation reaction reached saturating
levels when 0.9 µM or more E. coli LplA were used (lanes 8-10), which is not surprising
because only 4.4 µM of the protein substrate were used.
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Figure 5.11.: Analyses of E. coli LplA lipoylation assay using native PAGE followed by
(A) Coomassie staining or (B) western blotting
The lipoylation reaction was carried out in a final volume of 30 µl containing 100 mM phosphate
buffer (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid, 1 mM DTT and 4.4 µM KGDH-
E2-LD. The reaction was started by addition of varying concentrations of E. coli LplA. Lane 1
and 2 were controls to determine the possible lipoylation state of E. coli LplA and KGDH-E2-LD
after purification and contained 3.4 µM E. coli LplA (lane 1) and 4.4 µM KGDH-E2-LD (lane
2) not incubated in the reaction mix. Lane 3 contained 0 µM, lane 4 contained 0.04 µM, lane 5
contained 0.09 µM, lane 6 contained 0.2 µM, lane 7 contained 0.4 µM, lane 8 contained 0.9 µM,
lane 9 contained 1.7 µM and lane 10 contained 3.4 µM E. coli LplA. The reaction was incubated
at 37◦C and after 30 min half of the reaction (15 µl) was loaded onto a 20% native PAGE and was
analysed by Coomassie staining (Panel A) and western blotting (Panel B) using an anti-lipoic
acid antibody that detects lipoic acid bound to proteins.
Using the anti-lipoic acid antibody had several advantages over the Coomassie staining
in analysing LplA activity. As can be seen in Figure 5.11, the sensitivity and clarity
in detecting lipoylated protein was markedly increased with the antibody. Further, the
shift observed in the Coomassie stained gel was not very clear and densitometric analy-
ses would be difficult and probably not very reliable using this method. In contrast, the
antibody gave a strong signal which would allow densitometric quantification. Moreover,
analysing the lipoylation reaction by western blotting using the anti-lipoic acid antibody
allowed the separation of the lipoylation reaction by SDS-PAGE, which was quicker and
easier to handle in comparison to a native PAGE. However, using the antibody for analy-
ses brought up different problems. The signal produced from the anti-lipoic acid antibody
differed in intensity when using different antibody batches. Therefore, the batches were
always mixed in order to achieve uniformity, but there were never more than two batches
available to be mixed at any one time. Thus, this method was not used for kinetic analyses
of LplAs and was only used to assess LplA activity qualitatively.
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5.6.1. E. coli LplA
Using E. coli LplA, I first analysed whether the enzyme distinguished between the re-
combinant P. falciparum H-protein and the different lipoyl-domains as substrates (Figure
5.12). The assays were set up in the general reaction buffer containing 3 µM H-protein
(Panel A), 4.4 µM PDH-E2-LD1 (Panel B), 2.7 µM PDH-E2-LD2 (Panel C), 3.3 µM
BCDH-E2-LD (Panel D) and 3.3 µM KGDH-E2-LD (Panel E). Three different concen-
trations of E. coli LplA were used in each assay (0 µM, 0.06 µM and 0.6 µM). The
reaction was incubated at 37◦C for 30 min and half of the reaction was analysed us-
ing a 15% SDS-PAGE followed by western blotting using anti-lipoic acid antibody. The
western blots in Figure 5.12 show that E. coli LplA indeed accepts the H-protein and
the lipoyl-domains as substrates but discriminates between them. It seems that H-protein
was the best substrate since 0.06 µM E. coli LplA were sufficient to lipoylate H-protein
(Panel A). A further increase of H-protein lipoylation was observed when the LplA con-
centration was elevated. The other lipoyl-domains were also accepted by E. coli LplA as
substrates especially PDH-E2-LD2 (Panel C) and KGDH-E2-LD (Panel E), which were
strongly lipoylated at higher concentrations of E. coli LplA, whereas at 0.06 µM LplA
no discernable difference compared to the ground-level lipoylation was observed (lane 1).
Ground-level lipoylation is the lipoylation of the domain after purification. Since the H-
protein and the domains were not expressed in lipoylation deficient bacteria, it is possible
that the domains are partly lipoylated by the E. coli lipoylation pathways during expres-
sion. To determine the ground-level lipoylation for each assay, a control assay was set up
in parallel which contained no LplA. PDH-E2-LD1 (Panel B) and BCDH-E2-LD (Panel
D) were only poorly lipoylated. Only a very slight increase in lipoylation was observed
at high concentrations of E. coli LplA. These results suggest that at low concentrations
of E. coli LplA, H-protein is the best substrate and that PDH-E2-LD2 and KGDH-E2-LD
require a higher enzyme concentration to become lipoylated. The reason for the virtual
lack of lipoylation of the BCDH-E2-LD and PDH-E2-LD1 might be explained by their
improper/poor folding as shown by the CD analyses (see 5.5.3). It could also be that E.
coli LplA possesses substrate specificity and is thus not able to use these two domains as
substrates. According to these data, only the H-protein, PDH-E2-LD2 and KGDH-E2-LD
were used as substrates in the following assays.
Additional bands at 75 kDa and 50 kDa were detected in the western blots by the anti-
lipoic acid antibody suggesting that these proteins also have lipoic acid bound to them.
One possible explanation is that these bands correspond to lipoylated multimers of the
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A H-protein B PDH-E2-LD1 C PDH-E2-LD2
D BCDH-E2-LD E KGDH-E2-LD
Figure 5.12.: Western blot analyses of E. coli LplA lipoylation assays using P. falciparum
H-protein and lipoyl-domains
The lipoylation reactions were carried out in a final volume of 30 µl containing 100 mM phosphate
buffer (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid, 1 mM DTT and 3 µM H-protein
(Panel A), 4.4 µM PDH-E2-LD1 (Panel B), 2.7 µM PDH-E2-LD2 (Panel C), 3.3 µM BCDH-
E2-LD (Panel D) and 3.3 µM KGDH-E2-LD (Panel E). The reaction was started by addition of
varying concentrations of E. coli LplA. Lane 1 contained 0 µM E. coli LplA, lane 2 contained
0.06 µM E. coli LplA and lane 3 contained 0.6 µM E. coli LplA. The reaction was incubated
at 37◦C and after 30 min half of the reaction (15 µl) was loaded onto a 15% SDS-PAGE, and
was analysed by western blotting using anti-lipoic acid antibody. It seemed that E. coli LplA
discriminated between the H-protein and lipoyl-domains as substrates. H-protein was the best
accepted substrate. Small concentrations of E. coli LplA were enough to lipoylate the protein
(Panel A). Also well accepted were PDH-E2-LD2 (Panel C) and KGDH-E2-LD (Panel E). Only
poorly lipoylated were the PDH-E2-LD1 (Panel B) and BCDH-E2-LD (Panel D), which could be
due to improper folding of these recombinant proteins.
H-protein and domains. It is known that the E2 subunits form large multimers (Reed and
Hackert, 1990). The H-protein is generally present in the monomeric form (Oliver et al.,
1990), however, recently it was shown that recombinantly expressed H-protein of the
cyanobacterium Synechocystis forms dimers (Hasse et al., 2007). Another band at ∼37
kDa appeared in Panel C and E which possibly corresponds to "lipoylated" E. coli LplA,
which contains the reaction intermediate lipoyl-AMP tightly (although non-covalently)
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bound to it (Kim et al., 2005, McManus et al., 2006). Further evidence for this specula-
tion will be provided below.
To optimise the reaction conditions of E. coli LplA, the lipoylation reaction was per-
formed at different temperatures and different incubation times. The assays were carried
out in the general reaction buffer containing 3 µM H-protein in the presence of 0.03 µM
E. coli LplA (Figure 5.13). The assays were incubated at 37◦C (Panel A) and 30◦C (Panel
B), for 30 min (lane 2) or 1 hour (lane 3). Lane 1 in both assays contained the reaction mix
without E. coli LplA to determine the ground-level lipoylation of the H-protein. Incuba-
tion at 37◦C resulted in higher lipoylation levels than incubation at 30◦C. The lipoylation
level increased only slightly after 1 hour incubation at 37◦C. At 30◦C the lipoylation level
of H-protein is markedly higher after 1 hour incubation, however, it is still less compared
to incubation at 37◦C.
A 37◦C B 30◦C
Figure 5.13.: Western blot analyses of E. coli LplA lipoylation assays to optimise reaction
conditions
The lipoylation assays were carried out in a final volume of 30 µl containing 100 mM phosphate
buffer (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid, 1 mM DTT and 3 µM H-protein.
The reactions were started by addition of 0.03 µM E. coli LplA. The assays were incubated at
37◦C (Panel A) and 30◦C (Panel B), for 30 min (lane 2) and 1 hour (lane 3). Lane 1 contained the
reaction mix without LplA, and was incubated for 1 hour to analyse the ground-level lipoylation
of the H-protein. After incubation, half of the reaction was analysed by SDS-PAGE, followed
by western blotting using anti-lipoic acid antibody. Incubation at 37◦C clearly resulted in higher
lipoylation levels of the protein substrate in comparison to incubation at 30◦C. The lipoylation
increase from 30 min to 1 hour incubation is only marginal at 37◦C, but clearly visible at 30◦C.
Furthermore, it was investigated whether E. coli LplA accepts GTP as well as ATP as
a substrate. It was shown that the mammalian lipoate activating enzyme accepts both,
ATP and GTP, for the activation of lipoic acid (Fujiwara et al., 2001) (Figure 5.14). The
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reaction was set up in the general reaction buffer but with either 5 mM ATP (Panel A)
or 5 mM GTP (Panel B) containing 2.7 µM PDH-E2-LD2 as protein substrate. Varying
concentrations of E. coli LplA (between 0 and 0.6 µM) were used to start the lipoy-
lation reaction, which was incubated at 37◦C for 30 min. Analysis revealed that both,
ATP (Panel A) and GTP (Panel B), were used by E. coli LplA resulting in lipoylation of
the PDH-E2-LD2, although lipoylation detected in the assay using ATP appeared to be
slightly stronger than in the assay using GTP.
A ATP B GTP
Figure 5.14.: Western blot analyses of E. coli LplA lipoylation assays using (A) ATP and
(B) GTP as substrates
The lipoylation reactions were carried out in a final volume of 30 µl containing 100 mM phosphate
buffer (pH 7.5), 2 mM MgCl2, 0.5 mM lipoic acid, 1 mM DTT, 2.7 µM PDH-E2-LD2 and 5 mM
ATP (Panel A) or 5 mM GTP (Panel B). The reactions were started by the addition of varying
concentrations of E. coli LplA. Lane 1 contained 0 µM E. coli LplA, lane 2 contained 0.06 µM
E. coli LplA and lane 3 contained 0.6 µM E. coli LplA. The reactions were incubated at 37◦C and
after 30 min half of the reaction was analysed by SDS-PAGE, followed by western blotting using
anti-lipoic acid antibody.
5.6.2. P. falciparum LplA1
The activity of the N-terminal and C-terminal tagged forms of P. falciparum LplA1 was
qualitatively analysed using the "gel assay" (Figure 5.15). The lipoylation activity was
tested using 3.1 µM H-protein as protein substrate in the general reaction buffer. The
reaction was started by addition of recombinant P. falciparum LplA1 with the N-terminal
(His)10-tag (Panel A) or the C-terminal Strep-tag (Panel B), with concentrations varying
between 0 and 3.5 µM. The reactions were carried out at 37◦C for 1 hour to initially
determine whether the recombinant proteins were active. The reactions were terminated
by addition of 6x loading buffer and boiling of the reaction mix. Half of the reaction was
analysed by SDS-PAGE, followed by western blotting using anti-lipoic acid antibody.
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Both recombinant P. falciparum LplA1s were able to lipoylate H-protein, but it appeared
that the Strep-tagged protein (Panel B) was more active than the (His)10-tagged protein
(Panel A). A possible explanation could be that the N-terminal (His)10-tag interfered with
the catalytic sites at the N-terminus of the protein that were shown to be important for
lipoic acid binding and activation (Fujiwara et al., 2005, Kim et al., 2005, McManus
et al., 2006). Comparison with E. coli LplA suggests that both P. falciparum recombinant
proteins are much less active than the bacterial recombinant protein. In the assay shown
in Figure 5.13 (Panel A), only 0.03 µM E. coli LplA was used with H-protein as the
protein substrate. The resulting lipoylation level of H-protein in this assay is comparable
to the lipoylation level of H-protein incubated with 3.5 µM (His)10-tagged P. falciparum
LplA1 (Panel A; lane 6) or 1.8 µM Strep-tagged P. falciparum LplA1 (Panel B; lane 5).
Differences in the intensities of the detected bands could also be due to different antibody
batches that were used in the E. coli and P. falciparum assays, which makes the direct
comparison difficult. However, also taking the E. coli assay displayed in Figure 5.12
(Panel A) into account, the data strongly suggests that the E. coli protein is more active.
A (His)10-tagged LplA1 B Strep-tagged LplA1
Figure 5.15.: Western blot analyses of lipoylation assays using recombinant P. falciparum
LplA1 with (A) a N-terminal (His)10-tag and (B) a C-terminal Strep-tag
The lipoylation reactions were carried out in a final volume of 30 µl containing 100 mM phosphate
buffer (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid, 1 mM DTT and 3.1 µM H-
protein. The reactions were started by addition of varying concentrations of P. falciparum LplA1
with a N-terminal (His)10-tag (Panel A) or a C-terminal Strep-tag (Panel B). Lane 1 contained
0 µM, lane 2 contained 0.07 µM, lane 3 contained 0.4 µM, lane 4 contained 0.7 µM, lane 5
contained 1.8 µM and lane 6 contained 3.5 µM of the respective recombinant LplA1. The reaction
was incubated at 37◦C for 1 hour. 15 µl of the reactions were separated on a 15% SDS-PAGE
and analysed by western blotting using anti-lipoic acid antibody. Direct comparison of the two
blots showed that P. falciparum LplA1 with the C-terminal Strep-tag was more active than the
N-terminal (His)10-tagged recombinant protein. Other protein bands beside the H-protein band
above 25 kDa appeared on the western blots. It is believed that one of these bands corresponds
to a dimer of H-protein (about 50 kDa) and another to a trimer of H-protein (about 75 kDa). A
third band appearing with increasing concentration of P. falciparum LplA1 might correspond to P.
falciparum LplA1 carrying activated lipoic acid.
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In both western blots displayed in Figure 5.15, other protein bands in addition to H-protein
were detected by the anti-lipoic acid antibody, suggesting these were also lipoylated. As
already hypothesised above for the E. coli assays, the additional bands at 50 kDa and
75 kDa may correspond to multimers of the H-protein (Hasse et al., 2007). A band at
48 kDa which is detected with increasing concentration of P. falciparum LplA1 might
correspond to LplA1 with lipoyl-AMP bound to it. To further test this hypothesis lipoyla-
tion assays were performed without any protein substrate (Figure 5.16). The assays were
carried out in general reaction buffer with varying concentrations of Strep-tagged P. fal-
ciparum LplA1 (between 0 and 3.5 µM), at 37◦C for 1 hour. Western blotting using the
anti-lipoic acid antibody indeed detected lipoic acid bearing proteins in the assays con-
taining the enzyme (lanes 2-4). The band at 48 kDa possibly corresponds to P. falciparum
LplA1 with lipoyl-AMP bound to it, suggesting that the reaction intermediate is tightly
bound and that SDS-PAGE is not able to break up this linkage. The nature of the 75 kDa
band is unknown and is somewhat puzzling because the elution fraction of recombinant
Strep-tagged P. falciparum LplA1 after purification is very pure and contains no other
contaminating proteins (see Figure 5.2). It also seems that P. falciparum LplA1 without
protein substrate is less "lipoylated" in comparison to the assay in Figure 5.15 (Panel B),
where H-protein as protein substrate was present.
Figure 5.16.: Western blot analysis of P. falciparum LplA1 lipoylation assay without
protein substrate
The lipoylation reactions were carried out in a final volume of 30 µl containing 100 mM phosphate
buffer (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid and 1 mM DTT. The reactions
were started by addition of varying concentrations of Strep-tagged P. falciparum LplA1. Lane
1 contained 0 µM P. falciparum LplA1, lane 2 contained 0.7 µM P. falciparum LplA1, lane 3
contained 1.8 µM P. falciparum LplA1 and lane 4 contained 3.5 µM P. falciparum LplA1. The
reaction was incubated at 37◦C for 1 hour. 15 µl of the reactions were separated on a 15% SDS-
PAGE and analysed by western blotting using anti-lipoic acid antibody. The 48 kDa band detected
likely corresponds to P. falciparum LplA1 with lipoyl-AMP bound to it. The nature of the 75 kDa
band is unknown.
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Because P. falciparum LplA1 with the C-terminal Strep-tag appeared to be more active
than the N-terminal (His)10-tagged recombinant protein, the following assays were per-
formed using only the Strep-tagged P. falciparum LplA1. The optimal reaction conditions
were qualitatively identified by incubating the lipoylation reaction catalysed by P. falci-
parum LplA1 at different temperatures and different incubation times. The assay was
carried out in the general reaction buffer using 3.1 µM H-protein as protein substrate and
3.5 µM Strep-tagged P. falciparum LplA1 (Figure 5.17). The assays were incubated at
37◦C (Panel A), 30◦C (Panel B) and 20◦C (Panel C), for 30 min (lane 2) and 1 hour (lane
3). Lane 1 in each assay contained the reaction mix with 0 µM P. falciparum LplA1
to investigate the possible ground-lipoylation level of H-protein after purification. The
assays were analysed by western blotting using anti-lipoic acid antibody. Highest lipoyla-
tion levels were obtained after 1 hour incubation at 37◦C (Panel A, lane 3). P. falciparum
LplA1 showed also activity at 30◦C (Panel B) which was after 30 min comparable to
incubation at 37◦C. However, after 1 hour incubation at 30◦C, the lipoylation level of H-
protein was noticeably less when compared to 1 hour incubation at 37◦C. The intensity of
the detected band after 1 hour incubation at 37◦C appears, however, less when compared
to Figure 5.15 (Panel B; lane 6). This is possibly due to different antibody batches used
for the two assays. At 20◦C (Panel C) LplA1 showed no activity at all.
A 37◦C B 30◦C C 20◦C
Figure 5.17.: Western blot analyses of P. falciparum LplA1 lipoylation assays to optimise
the reaction conditions
The lipoylation assays were carried out in a final volume of 30 µl containing 100 mM phosphate
buffer (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid, 1 mM DTT and 3.1 µM H-protein.
The reactions were started by addition of 3.5 µM Strep-tagged P. falciparum LplA1. The assays
were incubated at 37◦C (Panel A), 30◦C (Panel B) and 20◦C (Panel C), for 30 min (lane 2) and 1
hour (lane 3). Lane 1 contained the reaction mix without LplA1, and was incubated for 1 hour to
analyse the lipoylation state of H-protein alone. After incubation, half of the reaction was analysed
by SDS-PAGE followed by western blotting using anti-lipoic acid antibody. The best lipoylation
result was obtained after 1 hour incubation at 37◦C.
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To investigate whether P. falciparum LplA1 uses the other lipoyl-domains as protein sub-
strates in vitro, assays were performed containing the general reaction buffer, 3 µM of
each domain and varying concentrations of P. falciparum LplA1 (between 0 and 1.8 µM).
The reaction was incubated at 37◦C for 1 hour, and half of the reaction mix was analysed
by SDS-PAGE and western blotting using anti-lipoic acid antibody (Figure 5.18).
A PDH-E2-LD1 B PDH-E2-LD2
C BCDH-E2-LD D KGDH-E2-LD
Figure 5.18.: Western blot analyses of P. falciparum LplA1 lipoylation assays using P.
falciparum lipoyl-domains
The lipoylation reactions were carried out in a final volume of 30 µl containing 100 mM phosphate
buffer (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid, 1 mM DTT and 3 µM PDH-E2-
LD1 (Panel A), PDH-E2-LD2 (Panel B), BCDH-E2-LD (Panel C) and KGDH-E2-LD (Panel
D). The reaction was started by addition of varying concentrations of Strep-tagged P. falciparum
LplA1. Lane 1 contained 0 µM, lane 2 contained 0.4 µM, lane 3 contained 0.7 µM and lane 4
contained 1.8 µM P. falciparum LplA1. The reaction was incubated at 37◦C and after 1 hour, half
of the reaction (15 µl) was loaded onto a 15% SDS-PAGE and analysed by western blotting using
anti-lipoic acid antibody. Hardly any activity can be observed with either of these domains at the
used conditions.
No activity is observed with the PDH-E2-LD1 (Panel A) and KGDH-E2-LD (Panel D)
and only a marginal increase in lipoylation is detected using the PDH-E2-LD2 (Panel B)
and BCDH-E2 (Panel C). The assay was repeated to analyse whether technical problems
were the cause of these results. However, the second assays confirmed the data sug-
gesting that P. falciparum LplA1 does not, or only very poorly, accept the recombinant
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lipoyl-domains as protein substrates in vitro at the conditions used.
Further, the length of time that the Strep-tagged and (His)10-tagged recombinant P. fal-
ciparum LplA1 remained stable for after purification, was also tested. Their activity
was tested in lipoylation assays after storage at different temperatures for certain times.
Aliquots of the purified recombinant proteins were stored at 4◦C and -20◦C and the ac-
tivity was tested one week, two weeks and five weeks after purification (Figure 5.19). P.
falciparum LplA1 activity was qualitatively investigated by using 3.5 µM of the recombi-
nant LplA1 in the general reaction buffer, containing 3.1 µM H-protein. The assays were
incubated at 37◦C for 1 hour, and were analysed by western blotting using anti-lipoic acid
antibody. After one week both recombinant P. falciparum LplA1s showed activity (Panel
A). Strep-tagged LplA1 was more active when stored at 4◦C rather than -20◦C (lanes 1-
3), whereas no obvious difference in activity of the (His)10-tagged LplA1 stored at 4◦C or
-20◦C was observed (lanes 4-6). After two weeks storage at -20◦C and 4◦C, P. falciparum
LplA1 with the Strep-tag was able to lipoylate H-protein equally well (Panel B, lanes 1-3),
while LplA1 with the (His)10-tag showed reduced activity (Panel B, lanes 4-6). After five
weeks of storage, the Strep-tagged recombinant protein still showed minor lipoylation
activity (Panel C, lanes 1-3), but no activity was observed of the (His)10-tagged LplA1
(Panel C, lanes 4-6). The strong lipoylation signals obtained in the western blot after two
weeks of storage (Panel B) are the result of a different antibody batch which was used,
rather than the result of an increase of LplA1 activity during storage.
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A After one week B After two weeks
C After five weeks
Figure 5.19.: Western blot analyses of lipoylation assays to investigate the stability of P.
falciparum LplA1 recombinant proteins
The lipoylation assays were carried out in a final volume of 30 µl containing 100 mM phosphate
buffer (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid, 1 mM DTT and 3.1 µM H-protein.
The reactions were started by addition of 3.5 µM P. falciparum LplA1 with a C-terminal Strep-tag
(lanes 1-3) or a N-terminal (His)10-tag (lanes 4-6). The assays were incubated at 37◦C for 1 hour
before they were analysed by western blotting using anti-lipoic acid antibody. Panel A displays
assays carried out with recombinant P. falciparum LplA1 proteins stored for one week at -20◦C
(lanes 2 and 5) and at 4◦C (lanes 3 and 6). Panel B shows activity of recombinant P. falciparum
LplA1 proteins stored for two weeks at -20◦C (lanes 2 and 5) and at 4◦C (lanes 3 and 6) and Panel
C displays lipoylation assays performed with recombinant P. falciparum LplA1 proteins stored
for five weeks at -20◦C (lanes 2 and 5) and at 4◦C (lanes 3 and 6). Lanes 1 and 4 in each assay
contained no recombinant LplA1, to analyse the ground-level lipoylation of H-protein. After one
week, both recombinant proteins showed lipoylation activity. The Strep-tagged protein was more
active when stored at 4◦C in the first week. After two weeks, the recombinant LplA1 proteins were
still able to lipoylate H-protein although the (His)10-tagged LplA1 to a much lesser degree. After
five weeks, only the Strep-tagged LplA1 showed minor lipoylation activity. Different antibody
batches were used for the three blots resulting in the different relative signals.
5.7. Spectrophotometric assay
The "gel assays" described above were laborious and time consuming, and using differ-
ent antibody batches to detect lipoylation made it difficult to directly compare different
assays with each other. Therefore, a major aim was to establish a spectrophotometric
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assay to determine LplA activity. Instead of analysing the lipoylation state of the pro-
tein substrate, this assay assessed the release of pyrophosphate (PPi) during the catalytic
reaction as a measure of lipoylation. PPi is released during the LplA reaction through
activation of lipoic acid with ATP to form the reaction intermediate lipoyl-AMP. In the
assay, the released PPi was then converted to inorganic phosphate (2Pi2−) by an inorganic
pyrophosphatase in the presence of MgCl2. The Pi2− reacted with ammonium molyb-
date and formed a blue coloured complex which was detected spectrophotometrically
at 710 nm (see Figure 2.12). Addition of bismuth citrate and sodium citrate stabilised
the formed complex and prevented that more phosphate-molybdate were formed (Cariani
et al., 2004).
Data obtained by the spectrophotometric assay were analysed using a standard curve of
known Pi2− concentrations. Known amounts of Pi2− varying between 0 and 30 nmol
were used for the standard curve, and were set up in a final volume of 200 µ l containing
30 mM Tris/HCl (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid and 1 mM DTT.
The assay was carried out as described in material and methods (see 2.7.3), and the ab-
sorbance was determined at 710 nm (Figure 5.20).
Figure 5.20.: Standard curve of spectrophotometric assay
The standard curve was set up using known concentrations of Pi2−. 0-30 nmol of Pi2− were used in
the reaction buffer containing 30 mM Tris/HCl (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic
acid and 1 mM DTT in a final volume of 200 µl. After addition of solution 1 and 2 and incubation
at the respective temperatures (see materials and methods), the absorbance was measured at 710
nm. Each assay was performed in duplicate. Shown here are two independent assays and each
point represents the mean ± standard error.
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To establish and validate whether this assay system is suitable to determine kinetic param-
eters of LplAs, E. coli LplA was used initially, and the results obtained were compared to
published data that were obtained using a variety of other assay systems (summarised in
Table 5.4) (Green et al., 1995, Fujiwara et al., 2005).
5.7.1. E. coli LplA
At first, I investigated whether an increase of E. coli LplA led to an increase of released
PPi in the reaction in the new assay system. 5 µM of KGDH-E2-LD in a reaction mix
containing 30 mM Tris/HCl (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid and
2.5 U inorganic pyrophosphatase were used. The reaction was initiated with addition of
0-1 µM E. coli LplA and after 30 min incubation the absorbance at 710 nm was deter-
mined (Figure 5.21).
Figure 5.21.: Increase of E. coli LplA led to increase of PPi released and effect of DTT
to the reaction
The standard lipoylation reactions were carried out in 200 µl final volume containing 5 µM
KGDH-E2-LD, 30 mM Tris/HCl (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid and
2.5 U inorganic pyrophosphatase (black). The DTT assays contained in addition 1 mM DTT
(red). The assays were started by addition of E. coli LplA (0-1 µM) and were incubated at 37◦C
for 30 min. After addition of solution 1 and 2 and incubation at the respective temperatures (see
materials and methods), the absorbance was measured at 710 nm. DTT enhanced the activity of E.
coli LplA. The assays were performed in duplicate and each point represents the mean± standard
error.
Indeed, an increase of E. coli LplA led to an increase of PPi generated in the reaction
(labeled as "Standard"). Further, the effect of DTT to the reaction was investigated by
repeating the assay in the presence of 1 mM DTT (labeled as "+DTT"). It showed that
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the activity of E. coli LplA was enhanced in the presence of DTT. Indeed Green and col-
leagues found, that the E. coli enzyme becomes inactive during oxidation containing at
least one intramolecular disulphide bond, and that activity was restored upon incubation
with DTT or β -mercaptoethanol (Green et al., 1995).
According to these data, the general reaction buffer for the spectrophotometric assay con-
tained 30 mM Tris/HCl (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid, 1 mM
DTT and 2.5 U inorganic pyrophosphatase unless stated otherwise.
To analyse the dependence of the lipoylation reaction on the three substrates (lipoic acid,
ATP and protein substrate) a standard assay was set up in general reaction buffer contain-
ing 5 µM of KGDH-E2-LD and 0-1 µM E. coli LplA (Figure 5.22). Beside the standard
assay, five additional assays were carried out, the first without KGDH-E2-LD, the second
without ATP and KGDH-E2-LD, the third without lipoic acid and KGDH-E2-LD, the
fourth without lipoic acid and ATP and the last without all three substrates. In the second
assay (without KGDH-E2-LD), PPi was released, however, slightly less compared to the
standard reaction containing all assay components. The released PPi likely results from
the activation of lipoic acid with ATP to form lipoyl-AMP and PPi. It supports the the-
ory that the LplA reaction is a "two-step" reaction in which lipoic acid is first activated
and then ligated to the apo-protein (Fujiwara et al., 2005). This is similar to what can
be observed in biotin protein ligases (BPL) which first activate biotin with ATP to form
biotin-AMP and then transfer the reaction intermediate to the apo-protein in a "two-step"
reaction (Perham, 2000). The PPi released in the assay without KGDH-E2-LD was only
marginally increased when the domain was present, suggesting that the transfer of acti-
vated lipoic acid to the lipoyl-domain might be the rate limiting part of the LplA reaction.
However, it is not known whether PPi is firstly stoichiometrically released as lipoyl-AMP
is formed, and secondly, whether PPi needs to be released before the apo-protein can bind
to LplA. If the latter is the case, then it is possible that release of PPi is the rate limiting
step. However, this remains unclear. Small amounts of PPi were also produced during
the reaction without lipoic acid and KGDH-E2-LD. This was due to the ATP in the re-
action mix which also contains some free Pi2−. During the other three reactions, no PPi
was measured showing the total dependence of the lipoylation reaction on lipoic acid and
ATP.
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Figure 5.22.: Dependence of E. coli LplA lipoylation reaction on its substrates
The standard lipoylation reaction was carried out in 200 µl final volume containing 5 µM KGDH-
E2-LD, 30 mM Tris/HCl (pH 7.5), 2 mM MgCl2, 5 mM ATP, 0.5 mM lipoic acid, 2.5 U inorganic
pyrophosphatase and 0-1 µM E. coli LplA (black). In red was the standard assay without KGDH-
E2-LD, in blue without ATP and KGDH-E2-LD, in green without lipoic acid and KGDH-E2-LD,
in purple without lipoic acid and ATP and in orange without all three substrates. The lipoylation
reaction was incubated at 37◦C for 30 min. After addition of solution 1 and 2 and incubation at
the respective temperatures (see materials and methods), the absorbance was measured at 710 nm.
In the reaction without KGDH-E2-LD (red) PPi was produced due to the activation of lipoic acid
with ATP. This led to the conclusion that the reaction catalysed by LplA happened in two steps;
first, activation of lipoic acid and second, transfer of activated lipoic acid to the protein substrate.
These assays were performed only once with only one lipoyl-domain.
To analyse the time frame in which the E. coli LplA reaction was linear in the spectropho-
tometric assay, the lipoylation reaction was set up and was incubated for 5 to 60 min at
37◦C. The assays were carried out using 0.9 µM H-protein as protein substrate in the
general reaction buffer and 0.3 µM E. coli LplA to start the reaction (Figure 5.23). The
reaction was linear up to 40 min incubation at 37◦C before it slowly reached saturating
levels.
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Figure 5.23.: Time dependence of E. coli LplA lipoylation reaction at 37◦C in the spec-
trophotometric assay
The lipoylation reactions were carried out in 200 µl final volume containing 0.9 µM H-protein,
30 mM Tris/HCl (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid, 1 mM DTT, 2.5 U
inorganic pyrophosphatase and 0.3 µM E. coli LplA. The reactions were incubated 0 to 60 min
before the reaction was stopped by addition of solution 1 and 2 (see materials and methods), and
the absorbance was measured at 710 nm. The reaction was in the linear range for up to 40 min.
The assay was measured in duplicate and each point represents the mean ± standard error.
Finally, I determined the apparent kinetic parameters of E. coli LplA using the spec-
trophotometric assay and compared them to published kinetic data of E. coli LplA which
are summarised in Table 5.4 (Green et al., 1995, Fujiwara et al., 2005). Different assay
systems were used to determine E. coli LplA activity. The "gel assay" used by Green et al.
(1995) is similar to that described earlier using native PAGE. In this paper a radioactive
method to determine LplA activity was also used in which the attachment of [3H]-labelled
lipoic acid to recombinant E. coli PDH-E2 lipoyl-domains was assessed. No information
about the kinetic parameters of E. coli LplA for the E. coli PDH-E2 lipoyl-domains is
given in this paper. Fujiwara and colleagues utilised the glycine-14CO2 exchange reaction
as a measure for LplA activity (Fujiwara et al., 2005). Recombinant E. coli H-protein was
used as protein substrate in a lipoylation reaction. After incubation for a certain time, the
lipoylation reaction was terminated and used in the glycine-14CO2 exchange reaction (Fu-
jiwara et al., 1992). Only the lipoylated H-protein was used by this assay and the amount
of [14C]-glycine formed was determined by liquid scintillation spectrometry as a measure
of lipoylated H-protein.
Figure 5.24 displays the E. coli LplA apparent Km and Vmax determined using the spec-
trophotometric assay for lipoic acid in the absence of H-protein (Panel A) and in the
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presence of 1.2 µM (Panel B) or 10 µM H-protein (Panel C).
A 0 µM H-protein B 1.2 µM H-protein
C 10 µM H-protein
Figure 5.24.: Determining apparent kinetic parameters of E. coli LplA for lipoic acid
The apparent kinetic parameters of E. coli LplA for lipoic acid were determined at 37◦C in 30 mM
Tris/HCl (pH 7.5), 2 mM MgCl2, 2 mM ATP, 1 mM DTT and 2.5 U inorganic pyrophosphatase.
In addition, Panel A contained no H-protein, Panel B contained 1.2 µM H-protein and Panel C
contained 10 µM H-protein. The lipoylation reaction was carried out with 1.6 µM E. coli LplA
and varying concentrations of lipoic acid (0.5-50 µM). The production of PPi was measured after
30 min at 710 nm. Each point represents the mean± standard error for two independent measure-
ments, with apparent Km and Vmax determined using the Grafit 5.0 software (Erithacus software).
Shown are the Michaelis-Menten and Lineweaver-Burke (double reciprocal) plots (insets) of the
data obtained. The apparent Km and Vmax of E. coli LplA for lipoic acid without H-protein were
determined to be 1.7 ± 0.2 µM and 21.0 ± 0.8 nmol/min/mg, respectively. In the presence of
1.2 µM H-protein the apparent Km and Vmax were determined to be 1.0 ± 0.2 µM and 17.9 ± 0.8
nmol/min/mg, respectively. With 10 µM H-protein in the lipoylation reaction the apparent Km and
Vmax were determined to be 3.5 ± 0.7 µM and 15.7 ± 1.0 nmol/min/mg, respectively, indicating
that the P. falciparum H-protein concentration does not affect the apparent kinetic parameters of
E. coli LplA towards lipoic acid.
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The assays were carried out in general reaction buffer containing 1.6 µM E. coli LplA,
and different concentrations of lipoic acid varying between 0.5 and 50 µM. The produc-
tion of PPi was measured after 30 min at 710 nm. The apparent Km’s and Vmax’s obtained
from these assays are listed in Table 5.4. Surprisingly, the H-protein concentration in the
assays did not seem to affect the Km and Vmax of E. coli LplA for lipoic acid.
Similar results were obtained for the Km and Vmax determination of E. coli LplA for
ATP (Figure 5.25). The assays were set up as described above but contained saturating
levels of lipoic acid (0.5 mM) and variable concentrations of ATP (1-300 µM). The ap-
parent Km’s and Vmax’s determined are summarised in Table 5.4. As for lipoic acid, the
H-protein concentration in the assays did not affect the Km and Vmax of E. coli LplA for
ATP.
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A 0 µM H-protein B 1.2 µM H-protein
C 10 µM H-protein
Figure 5.25.: Determining apparent kinetic parameters of E. coli LplA for ATP
The apparent kinetic parameters of E. coli LplA for ATP were determined at 37◦C in 30 mM
Tris/HCl (pH 7.5), 2 mM MgCl2, 0.5 mM lipoic acid, 1 mM DTT and 2.5 U inorganic pyrophos-
phatase. In addition, Panel A contained no H-protein, Panel B contained 1.2 µM H-protein and
Panel C contained 10 µM H-protein. The lipoylation reaction was carried out with 1.6 µM E.
coli LplA and varying concentrations of ATP (1-300 µM). The production of PPi was measured
after 30 min at 710 nm. Each point represents the mean ± standard error for two independent
measurements, with apparent Km and Vmax determined using the Grafit 5.0 software (Erithacus
software). Shown are the Michaelis-Menten and Lineweaver-Burke (double reciprocal) plots (in-
sets) of the data obtained. The apparent Km and Vmax of E. coli LplA for ATP without H-protein
were determined to be 27.9 ± 5.3 µM and 12.7 ± 0.7 nmol/min/mg, respectively. In the presence
of 1.2 µM H-protein the apparent Km and Vmax were determined to be 24.6 ± 1.7 µM and 13.8
± 0.3 nmol/min/mg, respectively. With 10 µM H-protein in the lipoylation reaction the apparent
Km and Vmax were determined to be 26.4 ± 4.1 µM and 15.5 ± 0.7 nmol/min/mg, respectively,
indicating that the H-protein concentration does not affect the apparent kinetic parameters of E.
coli LplA towards ATP.
Determination of the kinetic parameters of E. coli LplA for P. falciparum H-protein as
the protein substrate was not possible (Figure 5.26). The assay was set up in general
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reaction buffer containing 0.1 µM E. coli LplA and varying concentrations of P. falci-
parum H-protein (0-40 µM). The lipoylation assays were incubated at 37◦C for 30 min
before the release of PPi was determined by measuring of the absorbance at 710 nm. The
obtained data showed that the reaction with 40 µM P. falciparum H-protein was still in
the linear range suggesting a very high Km for the P. falciparum H-protein in contrast to
the published data for E. coli H-protein. The published Km of E. coli LplA for E. coli
H-protein is 1.2 µM (Fujiwara et al., 2005). P. falciparum and E. coli H-protein share
only modest sequence similarities with 32.2%, which may account for some differences
in the Km. Further, the glycine-14CO2 exchange reaction was inhibited when more than 5
µM H-protein were used (Fujiwara et al., 2005), concluding that the lipoylation reaction
was not set up with saturating levels of H-protein as the protein substrate. This raises the
question of the accuracy of the Km determination of E. coli LplA for E. coli H-protein.
Using higher H-protein concentrations in the spectrophotometric assay was impossible
and resulted in precipitation of the proteins in the assay, pulling down the formed Pi2−-
molybdate complex. It was therefore impossible to determine the Km and Vmax of E. coli
LplA for P. falciparum H-protein. It also meant that all reactions performed using the
spectrophotometric assay were limited by the protein substrate, since the concentrations
used were below the Km.
Figure 5.26.: E. coli LplA lipoylation reaction is limited by the protein substrate
The lipoylation reactions were carried out in 200 µl final volume containing 0-40 µM H-protein,
30 mM Tris/HCl (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid, 1 mM DTT, 2.5 U
inorganic pyrophosphatase and 0.1 µM E. coli LplA. The reactions were incubated at 37◦C for
30 min before solution 1 and 2 (see materials and methods) were added. The absorbance was
measured at 710 nm. The reaction was still in the linear range at high H-protein concentrations,
suggesting that E. coli LplA has a high Km for P. falciparum H-protein. The assay was performed
in duplicate and each point represents the mean ± standard error.
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The apparent Km of E. coli LplA for lipoic acid and ATP obtained with the spectrophoto-
metric assay correspond very nicely to the published data (Table 5.4). Large differences
can be seen in the apparent Vmax which might be explained by the different methods used
to determine LplA activity.
Table 5.4.: Kinetic parameters of E. coli LplA
Km [µM] Vmax [nmol/min/mg]
Lipoic acid
Gel assaya 1.7 2
Radioactive assaya 1.7 0.038
Glycine-14CO2 exchange reactionb 4.5 219
Spectrophotometric assay
0 µM H-protein 1.7 ± 0.2 21.0 ± 0.8
1.2 µM H-protein 1.0 ± 0.2 17.9 ± 0.8
10 µM H-protein 3.5 ± 0.7 15.7 ± 1.0
ATP
Gel assaya 1.9 40
Radioactive assaya 3 0.007
Glycine-14CO2 exchange reactionb 15.8 133
Spectrophotometric assay
0 µM H-protein 27.9 ± 5.3 12.7 ± 0.7
1.2 µM H-protein 24.6 ± 1.7 13.8 ± 0.3
10 µM H-protein 26.4 ± 4.1 15.5 ± 0.7
H-protein
Gel assaya NDc NDc
Radioactive assaya NDc NDc
Glycine-14CO2 exchange reactionb 1.2 258
a Green et al. (1995)
b Fujiwara et al. (2005)
c Not determined
I also determined the apparent Km and Vmax of E. coli LplA for octanoic acid. The assays
were set up as before containing saturating levels of ATP (2 mM) but instead of lipoic acid,
varying concentrations of octanoic acid (1-100 µM). After 30 min at 37◦C, the PPi levels
were determined by measuring the absorbance at 710 nm (Figure 5.27). The apparent
Km and Vmax of E. coli LplA for octanoic acid were determined to be 75.1 ± 15.6 µM
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and 49.1 ± 5.5 nmol/min/mg, respectively. This indicates that octanoic acid is used by E.
coli LplA but only poorly, especially in comparison to lipoic acid, suggesting that under
physiological conditions, only lipoic acid is used. However, the assay was only performed
once in duplicate and therefore needs to be repeated to confirm the data obtained from the
first assay.
Figure 5.27.: Determining apparent kinetic parameters of E. coli LplA for octanoic acid
The apparent kinetic parameters of E. coli LplA for octanoic acid were determined at 37◦C in 30
mM Tris/HCl (pH 7.5), 2 mM MgCl2, 2 mM ATP, 1 mM DTT, 2.5 U inorganic pyrophosphatase
and 1.2 µM H-protein. The lipoylation reaction was carried out with 1.6 µM E. coli LplA and
varying concentrations of octanoic acid (1-100 µM). The production of PPi was measured after
30 min at 710 nm. Each point represents the mean ± standard error for two measurements, with
apparent Km and Vmax determined using the Grafit 5.0 software (Erithacus software). Shown
are the Michaelis-Menten and Lineweaver-Burke (double reciprocal) plots (insets) of the data
obtained. The apparent Km and Vmax of E. coli LplA for octanoic acid were determined to be 75.1
± 15.6 µM and 49.1 ± 5.5 nmol/min/mg, respectively.
5.7.2. P. falciparum LplA1
Initial assays for P. falciparum LplA1 were performed using the recombinant C-terminal
Strep-tagged form. First, the time dependence of the P. falciparum LplA1 lipoylation re-
action at 37◦C was analysed. The lipoylation reaction containing 1.2 µM H-protein and
0.2 µM P. falciparum LplA1 was set up in general reaction buffer, and was incubated at
37◦C for variable incubation times between 0 and 90 min (Figure 5.28). The reaction was
linear for up to 10 min before it reached saturating levels.
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Figure 5.28.: Time dependence of P. falciparum LplA1 lipoylation reaction at 37◦C in the
spectrophotometric assay
The lipoylation reactions were carried out in 200 µl final volume containing 1.2 µM H-protein, 30
mM Tris/HCl (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid, 1 mM DTT, 2.5 U inorganic
pyrophosphatase and 0.2 µM P. falciparum LplA1. The reactions were incubated 0 to 90 min at
37◦C before the reaction was stopped by adding solution 1 and 2 (see materials and methods), and
the absorbance was measured at 710 nm. The reaction was in the linear range for up to 10 min
before it reached saturation. The assay was measured in duplicate and each point represents the
mean ± standard error.
The dependence of the P. falciparum LplA1 reaction on the H-protein was also initially
analysed using the spectrophotometric assay. As for E. coli LplA, the determination of
kinetic parameters for H-protein was not possible. The assay was incubated at 37◦C and
contained 0.1 µM P. falciparum LplA1 in general reaction buffer with variable H-protein
concentrations between 0 and 20 µM. After 30 min incubation, the PPi level was analysed
by measuring the absorbance at 710 nm (Figure 5.29). This was an end point determina-
tion, however, no saturating levels were reached with the highest H-protein concentrations
used in the assay. The reaction was still in the linear range, indicating that the apparent
Km of P. falciparum LplA1 for H-protein is much higher than 20 µM.
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Figure 5.29.: P. falciparum LplA1 lipoylation reaction is limited by the protein substrate
The lipoylation reactions were carried out in 200 µl final volume containing 0-20 µM H-protein,
30 mM Tris/HCl (pH 7.5), 2 mM MgCl2, 2 mM ATP, 0.5 mM lipoic acid, 1 mM DTT, 2.5 U in-
organic pyrophosphatase and 0.1 µM P. falciparum LplA1. The reactions were incubated at 37◦C
for 30 min before solution 1 and 2 (see materials and methods) were added. The absorbance was
measured at 710 nm. The reaction was still in the linear range at high H-protein concentrations,
suggesting that P. falciparum LplA1 had a high Km for P. falciparum H-protein. The assay was
performed in duplicate and each point represents the mean ± standard error.
Both assays performed suggest that the P. falciparum protein behaves somewhat different
in comparison to the E. coli protein. The reaction of P. falciparum LplA1 reaches satu-
rating levels after 10 min incubation (see Figure 5.28), whereas the E. coli enzyme is in
the linear range for up to 40 min, although more LplA enzyme and less H-protein sub-
strate were used (see Figure 5.23). Further, using exactly the same reaction conditions, P.
falciparum LplA1 releases more PPi than E. coli LplA (compare Figure 5.26 and Figure
5.29). However, the cause of this finding is not known and requires further investigation.
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5.8. Summary
• Recombinant P. falciparum LplA1 was expressed and purified with either a N-terminal
(His)10-tag or a C-terminal Strep-tag.
• Of six P. falciparum LplA2 expression constructs generated, only LplA2-S2 with an
N-terminal (His)10-tag was expressed in soluble form. However, purification proved to
be difficult because the recombinant protein was unstable and degradation products were
present in the elution fraction. Further, the recombinant protein co-purified with E. coli
proteins, including chaperons indicating that LplA2-S2 required folding assistance during
recombinant protein expression. Because the LplA2-S2 elution fraction was contaminated
with other proteins and thus only ≤ 10% of the elution fraction actually corresponded to
recombinant LplA2-S2, it was not tested for activity in either the "gel assay" or spec-
trophotometric assay.
• The lipoyl-domains of P. falciparum KADH-E2 subunits and the H-protein of the GCV
were expressed and purified with N-terminal (His)10-tags. CD analysis suggested that
only three of the domains are adequately folded.
• Recombinant E. coli LplA was used in both the "gel assay" and spectrophotomet-
ric assay as a positive control for activity. The "gel assay" showed, that H-protein is
the preferred substrate followed by PDH-E2-LD2 and KGDH-E2-LD. PDH-E2-LD1 and
BCDH-E2-LD were not used as substrates by E. coli LplA likely because they were not
folded properly as shown by CD analysis.
• Analysing Strep-tagged and (His)10-tagged P. falciparum LplA1 showed that both en-
zymes were active although the C-terminally-tagged form had a higher enzymatic activity
than the N-terminally-tagged version. The optimal reaction conditions for Strep-tagged
LplA1 were at 37◦C for 1 hour incubation.
• The "gel assays" suggested that recombinant P. falciparum LplA1 is less active than
the recombinant E. coli LplA. Further it suggested, that P. falciparum LplA1 only uses H-
protein as a protein substrate in vitro. "Gel assays" using the other four domains resulted
in no lipoylation at the conditions used.
• A spectrophotometric assay system based on the detection of PPi release was estab-
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lished.
• Using the spectrophotometric assay I could show for E. coli LplA that DTT enhances
the activity of the enzyme. The spectrophotometric assay further supported that the LplA
reaction is a "two-step" reaction in which firstly lipoic acid is activated forming lipoyl-
AMP and secondly the activated lipoic acid is transferred to the apo-enzyme.
• Kinetic parameters for E. coli LplA were determined using the spectrophotometric as-
say, and the apparent Km’s and Vmax’s determined were compared to published data. The
apparent Km’s for lipoic acid and ATP were overall comparable to the published data,
however, the apparent Vmax’s were not. This is likely due to the different enzyme as-
says used, but could also be the result of the different protein substrates used. It was
surprising that the determined kinetic parameters were not affected by the presence or
absence of H-protein, suggesting that the release of PPi is only marginally affected by the
protein substrate. It was not possible to determine kinetic parameters for P. falciparum
H-protein. The data obtained by the spectrophotometric assay suggest that the Km of E.
coli LplA for P. falciparum H-protein is above 40 µM. Additionally, apparent Km and
Vmax of E. coli LplA for octanoic acid were determined to be 75.1 ± 15.6 µM and 49.1
± 5.5 nmol/min/mg, respectively.
• Initial tests were performed using Strep-tagged P. falciparum LplA1 in the spectropho-
tometric assay. Using this assay, the P. falciparum LplA1 reaction was in a linear range
for up to 10 min. As for E. coli LplA, it was not possible to determine kinetic parameters
for P. falciparum H-protein. The obtained data suggest that the apparent Km of P. falci-
parum LplA1 for P. falciparum H-protein is above 20 µM.
• The spectrophotometric assay showed differences in the kinetic behaviour of E. coli
LplA and the Plasmodium enzyme. However, this requires further investigation.
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6. Discussion
The apicomplexan parasites Plasmodium and Toxoplasma possess two lipoylation path-
ways to post-translationally modify their KADHs and GCV. Biosynthesis of lipoic acid
occurs in the apicoplast whereas scavenged lipoic acid is ligated to the enzyme complexes
in the mitochondrion (Thomsen-Zieger et al., 2003, Wrenger and Müller, 2004). The dis-
tribution of the lipoylation pathways is in accordance with the subcellular localisation of
the lipoic acid dependent enzyme complexes. The parasites possess a single PDH located
in the apicoplast, and BCDH and KGDH complexes located in the mitochondrion (Foth
et al., 2005, Günther et al., 2005, McMillan et al., 2005). The GCV is predicted to be
mitochondrial (Salcedo et al., 2005), and indeed I could experimentally confirm that the
H-protein, which is an integral part of the complex, is present in the mitochondrion of P.
falciparum (see Figure 3.4). Lipoylation of these complexes is likely to be essential in
most organisms and was also proposed to be crucial for P. falciparum and T. gondii via-
bility (Crawford et al., 2006, Mazumdar et al., 2006, Allary et al., 2007). Salvage of lipoic
acid in the mitochondrion of these parasites is achieved by LplA1, which attaches scav-
enged lipoic acid to the mitochondrial enzyme complexes (Wrenger and Müller, 2004,
Crawford et al., 2006, Allary et al., 2007). It was shown that P. falciparum and T. gondii
rely on the uptake of exogenous lipoic acid and it is believed that the scavenged lipoic acid
is exclusively used for lipoylation in the mitochondrion, but not in the apicoplast (Craw-
ford et al., 2006, Allary et al., 2007). Further, it is thought that biosynthesis of the cofactor
solely occurs in the apicoplast by the action of LipB and LipA (Thomsen-Zieger et al.,
2003, Wrenger and Müller, 2004). Octanoyl-ACP, the precursor which is attached to the
apo-PDH-E2 by LipB, is provided by fatty acid biosynthesis in this organelle. Indeed, it
appears that one of the main functions of fatty acid biosynthesis in the apicoplast is to
provide the precursor for lipoylation, as knock-down of ACP in T. gondii abolished PDH
lipoylation (Mazumdar et al., 2006). It seems that this finding also applies to mitochon-
dria in plants and mammals, where one of the main products of fatty acid biosynthesis
is octanoyl-ACP, believed to be used by the lipoylation machinery (Gueguen et al., 2000,
Witkowski et al., 2007). Thus, the evidence to date suggests that lipoic acid metabolism
in the apicomplexan parasites P. falciparum and T. gondii is carried out by two indepen-
dent organelle-specific lipoylation pathways. However, a second gene encoding a lipoic
acid protein ligase was identified during the course of this work, which was designated
lplA2 (Allary et al., 2007, Günther et al., 2007). The presence of a potential second LplA
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raised the following questions about lipoic acid metabolism in Plasmodium, which I tried
to address during my thesis:
1. Is LplA2 a functional ligase and when and where is it expressed?
2. Are the ligases essential for Plasmodium survival or are they redundant?
3. What are the biochemical properties of the two LplA proteins?
6.1. Identification of LplA2
LplA2 was identified by TBlastN searching the PlasmoDB database (Bahl et al., 2003)
using A. thaliana LplA. Despite modest sequence similarities to the A. thaliana protein,
bacterial LplAs and P. falciparum LplA1 (see Table 4.1), sequence analyses of the iden-
tified protein showed the presence of three highly conserved sequence motifs required
for LplA activity (Fujiwara et al., 2005, Kim et al., 2005, McManus et al., 2006). This
strongly suggests that LplA2 is a functional lipoic acid protein ligase and indeed com-
plementation assays experimentally confirmed that LplA2 is functional, as it was able to
replace LplA as well as LipB activity in deficient bacteria. The results of the function-
ality assays are in contrast to Allary et al. (2007), who suggested that LplA2 can only
compensate LplA, but not LipB activity. The conflicting findings in both studies might be
explained by the different expression constructs used to complement the growth defect of
the lipB/lplA deficient bacterial strain. LplA2 expression constructs used by Allary et al.
(2007) were truncated at the C-terminus, whereas I used constructs which were full length
at the C-terminus. This difference is likely to account for the different results obtained
and also implies that the C-terminal part missing in the LplA2 constructs used by Allary
and colleagues is somehow required by the enzyme to use the ACP thioester bound form
of octanoic acid as a substrate.
LplA2 is highly conserved in other Plasmodium spp. and also in Theileria. However,
a potential orthologue in T. gondii appears not to be a functional lipoic acid protein ligase,
because one highly conserved sequence motif (RRxxGGGxVxHD) required for lipoic
acid binding and activation is absent in the deduced protein sequence. Thus, it appears
that lipoic acid metabolism in the two apicomplexan parasites Plasmodium and Toxo-
plasma differs to some extent, although this hypothesis requires further investigation.
The discovery of the second LplA in Plasmodium spp. is particularly interesting with re-
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gard to potential redundancy between the three ligases LplA1, LplA2 and LipB. In E. coli
it is known that lipoic acid biosynthesis and salvage are redundant and can switch depend-
ing on the environmental situation (Cronan et al., 2005). This is in contrast to the bacterial
pathogen L. monocytogenes, which also possesses two LplA-like proteins, but is not able
to generate lipoic acid de novo and relies entirely on salvage of the cofactor (O’Riordan
et al., 2003). It appears that LplA1 is absolutely required for intracellular growth and
virulence of the pathogen despite the presence of LplA2. It was suggested that substrate
specificity of LplA1 and LplA2 are the reason for this, as only LplA1 seems to be able to
utilise degraded host cell lipoyl-protein as a source of lipoic acid (O’Riordan et al., 2003,
Keeney et al., 2007). Thus, it appears that the two LplA-like proteins in L. monocytogenes
are non-redundant because of their distinct substrate specificities. This is an interesting
point regarding lipoic acid metabolism in Plasmodium, because the parasites possess four
proteins that require the cofactor lipoic acid for their activity, and substrate specificities
of the Plasmodium ligases will be further discussed below. Nevertheless, in Plasmodium,
as opposed to Listeria, a crucial prerequisite for potential redundancy between the lig-
ases is their subcellular localisation, and therefore the localisation of LplA2 was further
investigated.
6.2. Localisation of LplA2
It was not possible to clearly predict the subcellular localisation of LplA2 and thus it was
investigated in vivo by expressing full length LplA2 in frame with GFP in P. falciparum.
Surprisingly, LplA2-GFP was targeted to two distinct, but closely associated organelles
in the parasites, suggesting dual localisation of LplA2. One organelle was identified as
the mitochondrion since LplA2-GFP fluorescence co-localised with Mitotracker-stained
mitochondria. Because of the structure and close association of the second organelle with
the mitochondrion, the apicoplast was suggestive (van Dooren et al., 2005). Immunofluo-
rescence analyses were performed to further analyse this hypothesis. Wild-type parasites
were analysed using antibodies against LplA2 and apicoplast localised dihydrolipoamide
dehydrogenase (aE3) supporting that LplA2 is dually targeted to two organelles, one be-
ing the apicoplast. Together these data strongly suggest that LplA2 is targeted to both the
mitochondrion and the apicoplast.
Recently, multiple protein targeting was observed in the two apicomplexan parasites P.
falciparum and T. gondii (Pino et al., 2007, Ponpuak et al., 2007). In P. falciparum,
the metalloprotease falcilysin was shown to be targeted to the food vacuole, apicoplast
6. Discussion 194
and possibly mitochondrion (Ponpuak et al., 2007), however, the mechanism responsi-
ble for multiple targeting of this protein is not known. Several possibilities including
post-translational modifications and alternative splicing were suggested (Ralph, 2007).
In plants, multiple protein targeting has emerged to be an important process, but how
it is regulated is poorly understood (Silva-Filho, 2003, Mackenzie, 2005, Millar et al.,
2006). Many different mechanisms were shown to influence the localisation of a pro-
tein including post-translational modification, alternative splicing, different translation
initiation sites or translation initiation from non-AUG codons, and thus it appears that
multiple protein targeting can be achieved in a variety of different ways (Silva-Filho,
2003, Mackenzie, 2005). Often dual targeting is observed between the plastid and mito-
chondrion, possibly because of similar mechanisms of post-translational protein import
into these organelles (Mackenzie, 2005), although some chloroplast proteins, like the α-
carbonic anhydrase, were shown to be transported to the chloroplast via the secretory
pathway (Villarejo et al., 2005). Furthermore, protein targeting to multiple destinations is
not necessarily based on similar protein import mechanisms of these organelles. Indeed,
dual targeting of plant proteins is also observed for destinations which either require entry
into the secretory pathway (e.g. ER, Golgi, plasma membrane) or which facilitate pro-
tein import independently from the secretory system (e.g. mitochondrion, peroxisome,
most chloroplast proteins) (Silva-Filho, 2003, Mackenzie, 2005). This is of particular
interest in the light of multiple protein targeting in Plasmodium and Toxoplasma, espe-
cially concerning dual protein targeting of LplA2 to the apicoplast and mitochondrion.
Mitochondrial protein import in these parasites occurs, like in plants and other organ-
isms, post-translationally (van Dooren et al., 2006), but apicoplast targeting is exclusively
via the ER from which apicoplast proteins are directly diverted to the apicoplast without
entering the Golgi (DeRocher et al., 2005, Tonkin et al., 2006b). Pino and colleagues
suggest that one of the main mechanisms for dual targeting to the apicoplast and mito-
chondrion in T. gondii is bimodal targeting by which an ambiguous targeting peptide is
recognised by both protein import machineries (Pino et al., 2007). A critical step for this
mechanism in apicoplast and mitochondrial targeting in these parasites is the entry into
the ER mediated by the signal peptide. It suggests that proteins dually targeted to both
organelles contain a week signal peptide which is only poorly recognised by the signal
recognition particle (SRP), resulting in a proportion of the protein being targeted via the
secretory system to the apicoplast, and another proportion being translated in the cytosol
and imported to the mitochondrion (Pino et al., 2007). Interestingly, for the microso-
mal cytochrome P4502E1 (CYP2E1) protein in mammals it has been shown that bimodal
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targeting to mitochondrion and ER (microsomes) is regulated by phosphorylation of an
internal serine residue (Robin et al., 2002). It was shown that phosphorylation markedly
increased binding of heat shock protein 70 (Hsp70) to CYP2E1. Subsequently, increased
mitochondrial protein import was observed, suggesting that phosphorylation of the pro-
tein activated mitochondrial protein import (Robin et al., 2002).
The mechanism(s) involved in dual targeting of LplA2 are not yet understood and re-
quire further investigations. Bimodal targeting of LplA2 via the ambiguous N-terminal
targeting peptide appears most likely. This is supported by the fact that the subcellular
localisation of Plasmodium LplA2s was not reliably predictable, suggesting both, poten-
tial mitochondrial and apicoplast localisation (see Table 4.3). However, a second in frame
methionine is found 78 amino acids downstream of the annotated start methionine (see
Figure 4.1) and thus the use of two different translation initiation sites could also be re-
sponsible for dual targeting of LplA2. The latter, however, appears unlikely because the
predicted subcellular localisation of the shorter LplA2 protein is neither mitochondrial nor
apicoplast. However, how dual targeting of LplA2 is precisely achieved and moreover,
how it is regulated remains elusive. If, for example, phosphorylation of LplA2 affects its
subcellular localisation requires further investigation.
Multiple protein targeting to various destinations is generally observed of proteins that
are required by the different organelles for their biological processes (Silva-Filho, 2003,
Millar et al., 2006). The multiple targeted metalloprotease falcilysin in P. falciparum is
known to participate in haemoglobin degradation in the food vacuole, and it has been sug-
gested that in the apicoplast as well as in the mitochondrion it might be involved in transit
peptide degradation (Ponpuak et al., 2007). The proteins shown to be dually targeted in
T. gondii are involved in antioxidant defense and metabolic processes in both mitochon-
drion and apicoplast (Pino et al., 2007). Thus, dual localisation of LplA2 to the apicoplast
and the mitochondrion suggests that the ligase participates in lipoic acid metabolism in
both organelles. Allary et al. (2007) suggested that LplA2 possesses substrate specificity
and showed that if expressed in lipoylation deficient E. coli, only the bacterial PDH-E2
is post-translationally modified by the Plasmodium enzyme. This further supports local-
isation of LplA2 to the apicoplast as PDH is only found in this organelle (Foth et al.,
2005, McMillan et al., 2005). E. coli possesses three lipoic acid dependent enzyme com-
plexes, namely the PDH, KGDH and the GCV (Cronan et al., 2005). Allary et al. (2007)
clearly showed that bacterial KGDH-E2 is not a substrate of LplA2, but they did not clar-
ify whether H-protein was lipoylated in the bacterial extract or not. Thus, H-protein and
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BCDH-E2, which is absent in E. coli, could be other potential substrates of LplA2 in the
mitochondrion of P. falciparum and this would support LplA2 localisation to the mito-
chondrion. The fact that LplA2 did not lipoylate E. coli KGDH-E2 points in the direction
of substrate specificity, but certainly requires further investigation.
Recently, we showed that knock-out of lipB, the octanoyl-ACP transferase present in the
apicoplast, is not lethal for the parasites (Günther et al., 2007). PDH lipoylation in these
parasites was drastically reduced but not completely abolished, suggesting that dual tar-
geted LplA2 can partially replace LipB. Reduced lipoylation of the PDH-E2 suggests that
either only low levels of free lipoic acid are available in the apicoplast, or that LplA2 uses
octanoyl-ACP, provided by fatty acid biosynthesis, for transfer. Bacterial LplA is able to
use octanoyl-ACP as a substrate, although less efficient then free lipoic acid (Jordan and
Cronan, 2002, Cronan et al., 2005). The fact that LplA2 complemented the growth defect
of lipB deficient and lipB/lplA deficient bacteria in the absence of lipoic acid shows that
LplA2 too can transfer octanoyl-ACP to the enzyme complexes, but like the bacterial en-
zyme less efficiently. Furthermore, previous studies in P. falciparum and T. gondii suggest
that scavenged lipoic acid is exclusively used by the mitochondrial lipoylation machinery
and not by the apicoplast (Crawford et al., 2006, Allary et al., 2007). The only source
for lipoylation in the apicoplast was suggested to be octanoyl-ACP (Mazumdar et al.,
2006). This would explain the reduction of PDH-E2 lipoylation in the P. falciparum lipB
knock-out mutants, as LplA2 can use octanoyl-ACP albeit only poorly.
6.3. LplA1 knock-out studies
Dual targeting of LplA2 potentially suggests that not only LipB but also LplA1 activ-
ity is redundant. This hypothesis was further investigated by knock-out studies of lplA1
in P. falciparum and P. berghei. Knock-out of lplA1 in P. falciparum by single cross-
over recombination was not achieved. It was further attempted to knock-out the gene by
providing the parasites with a copy of P. berghei lplA1. If the gene is essential for intraery-
throcytic stages, knock-out of the gene should theoretically be possible if a second copy is
provided and the protein it encodes is functionally expressed. This method was shown to
be successful for knock-out of P. falciparum thioredoxin reductase (Krnajski et al., 2002).
P. berghei lplA1 was chosen to prevent recombination with the P. falciparum gene locus.
But despite the presence of P. berghei LplA1, the P. falciparum lplA1 gene locus was not
targeted. Instead, non-specific integration of transfected plasmid into non-related gene
loci occurred. The same phenomenon was also observed for the 3’ replacement construct,
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which did not target the lplA1 gene locus, but seemed to integrate unspecifically into the
P. falciparum genome. Thus, from the knock-out and knock-in studies in P. falciparum,
it cannot be concluded whether lplA1 is essential for intraerythrocytic stages of P. falci-
parum or whether LplA1 and LplA2 are redundant because the lplA1 gene locus appeared
to be refractory to single cross-over recombination.
Knock-out studies were also performed in P. berghei, the rodent malaria parasite. Knock-
out of lplA1 by single cross-over recombination was not achieved in three independent
attempts, in contrast to the 3’ replacement construct, which targeted the gene locus after
only one transfection. This suggested that (1) lplA1 is essential for parasite survival as
knock-out appeared impossible and (2) the lplA1 gene locus in P. berghei is easily tar-
getable and not refractory as it appeared to be in P. falciparum. However, the P. berghei
lplA1 gene locus was also targeted by the replacement construct resulting in the replace-
ment of lplA1 with the T. gondii DHFR/TS, the selectable marker of the plasmid. But this
parasite population was quickly overgrown by parasites containing the endogenous lplA1
gene and carrying the selectable marker episomally, strongly suggesting that knock-out
of lplA1 has a severe effect on parasite viability. Complementation of P. berghei lplA1 re-
placement by over-expression of the P. falciparum gene also resulted in the replacement
of lplA1, but again the population was quickly overgrown by parasites with the endoge-
nous lplA1 gene and episomal selectable marker.
The results obtained by knock-out studies of lplA1 in P. falciparum and P. berghei suggest
that LplA1 is crucial for the intraerythrocytic stages, as knock-out of the gene appears im-
possible. This strongly suggests that LplA1 is required for parasite survival and further
implies that LplA1 function cannot be replaced by LplA2, leading to the conclusion that
LplA1 and LplA2 are not redundant. Substrate specificity of the two proteins could be a
potential explanation for this finding, as was already suggested by Allary et al. (2007) and
discussed above. Another potential explanation includes the stage specific expression of
LplA1 and LplA2 in Plasmodium parasites during their developmental cycle. Analysis of
the expression data available through the PlasmoDB database indeed implies that LplA1
is present throughout the intraerythrocytic development stages, whereas LplA2 is present
in late trophozoites and mainly in gametocytes (Figure 6.1). Thus, substrate specificity
and timing of protein expression may be the key components regulating the function of
the two proteins in Plasmodium parasites.
A surprising and somewhat conflicting finding of the knock-out studies in P. falciparum
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A LplA1
B LplA2
Figure 6.1.: Expression profile of (A) LplA1 and (B) LplA2
This figure displays the expression profile of P. falciparum LplA1 (Panel A) and P. falciparum
LplA2 (Panel B) taken from the PlasmoDB website (www.plasmodb.org). Shown is the per-
centiled expression level of the respective gene relative to all other genes. Data in green are of
parasites synchronised by sorbitol, in purple of parasites synchronised by temperature and in grey
is data below the confidence threshold. Data for gametocytes were obtained by sorbitol synchro-
nisation and sporozoite data represent an average of two replicates.
Abbreviations: S, sporozoite; ER, early ring; LR, late ring; ET, early trophozoite; LT, late tropho-
zoite; ES, early schizont; LS, late schizont; M, merozoite; G, gametocyte
and P. berghei was that the lplA1 gene locus in P. berghei was targeted by single and
double cross-over recombination, whereas the gene locus on P. falciparum appeared re-
fractory to integration. Given the high degree of synteny between the P. falciparum and
P. berghei lplA1 gene loci, it seemed highly unlikely that one locus can be targeted when
the other cannot be targeted at least by the knock-in construct. It rather appears that the
transfected plasmid in P. falciparum was rapidly lost after unspecific integration into the
parasites genome and thus the possibility to address the lplA1 gene locus never occurred.
Another unexpected result was that the complementation attempts in both, P. falciparum
and P. berghei knock-out studies were unsuccessful giving reason to speculate as to why
these attempts failed. A possible explanation is that P. falciparum LplA1 and P. berghei
LplA1 are unable to compensate the function of the other protein. This, however, seems
unlikely given the high degree of sequence similarity between the two proteins (78%
amino acid sequence similarity). Technical problems might also be the reason for this
outcome, because the constructs were only transfected once (in P. berghei) or twice (in P.
6. Discussion 199
falciparum). A third possibility is that the intracellular concentration of LplA1 is impor-
tant for the parasites. Over-expression of LplA1 might have a negative effect on parasite
viability and this possibility will be further discussed below. Moreover, in the comple-
mentation studies, the subcellular localisation of the over-expressed LplA1 was never
analysed in P. falciparum or in P. berghei. The localisation is, however, crucial for suc-
cessful complementation of the potential loss of the endogenous copy. If, for instance, the
over-expressed LplA1 copy has negative effects on parasite viability, it could, as a con-
sequence, be transported to the food vacuole for degradation and thus complementation
would not be possible. This, however, is only speculative and requires further analyses.
To investigate the effect of LplA1 over-expression further, mutant parasites were gen-
erated by transfecting wild-type P. falciparum with the P. berghei LplA1 over-expression
construct. In this construct, P. berghei lplA1 is not controlled by its endogenous or the
P. falciparum lplA1 promoter, but by the P. falciparum Hsp86 promoter, which is consti-
tutively active throughout the erythrocytic development stages (Wu et al., 1995, Militello
et al., 2004). The presence of P. berghei LplA1 was experimentally confirmed by western
blotting and was further supported given that these parasites contained slightly elevated
levels of protein bound lipoic acid in comparison to wild-type parasites. Interestingly,
the parasites displayed a slight growth phenotype, progressing modestly slower through
the intraerythrocytic development stages than wild-type parasites. These data suggest that
indeed the concentration of LplA1 is important for the parasites viability. The increased
levels of protein bound lipoic acid in these parasites could be due to an increased lipoy-
lation of the enzyme complexes, however, it could also be the result of sequestration of
lipoic acid to the ligases. In Chapter 5, I showed that lipoic acid is bound to the ligases
strongly enough that the linkage is not broken up during SDS-PAGE. It is conceivable
that strong sequestration of lipoic acid by the ligases results in inhibition of the enzymes,
but it may also imply that lipoic acid fulfils other functions in the parasites. Mammalian
cells contain very little free lipoic acid (Biewenga et al., 1997) and this is also found in P.
falciparum (Günther et al., 2007). However, by over-expressing LplA1, the small amount
of free lipoic acid that potentially is present in the parasites might be sequestered by the
ligases and thus depletes sources of free lipoic acid which might be involved in other pro-
cesses like for instance in antioxidant defense.
The lplA1 gene loci of P. falciparum and P. berghei share a high degree of synteny apart
from three small proteins in the P. berghei gene locus, that are not annotated in P. fal-
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ciparum. However, one of these small annotated proteins could be an additional up-
stream exon of P. berghei lplA1. Indeed closer analysis of the genomic sequence of the
P. berghei locus revealed potential splicing sites, and the predicted localisation of the re-
sulting LplA1 would be the apicoplast (Table 6.1). Moreover, searching the P. falciparum
lplA1 gene locus for a similar exon also revealed the presence of a potential upstream
exon. As for P. berghei, the potential localisation of the resulting protein was predicted
using the available prediction programs (Table 6.1). The results obtained are ambiguous
for the "long" P. falciparum LplA1, as it is predicted to be in the mitochondrion and api-
coplast, depending on the program used.
Table 6.1.: Predicted localisations of potential "long" LplA1s
MitoProt PlasMit Predotar PATS SignalP
P. falciparum 0.9916 non-mito 0.01 mito 0.95 0.005
CSa→74 99% 0.00 plastid
P. berghei 0.0193 non-mito 0.04 mito 0.92 0.091
99% 0.00 plastid
a predicted cleavage site
The presence of these potential transcripts in P. falciparum and P. berghei is currently
being investigated by reverse transcriptase PCR. If these transcripts are really present in
parasite RNA, it would suggest that LplA1, like LplA2, is potentially dually targeted to
apicoplast and mitochondrion. This possibility is also currently analysed by immunoflu-
orescence analyses in P. falciparum using anti-LplA1 antibodies and mitochondrial and
apicoplast markers, respectively. If dual targeting also applies for LplA1 it would be an-
other explanation why the complementation of lplA1 knock-out failed. The localisation
of the annotated LplA1 proteins in all Plasmodium spp. are predicted to be mitochondrial
and thus, the proteins used in the complementation studies possibly only compensate for
mitochondrial LplA1 loss and not that of the apicoplast. However, even if LplA1 was
dually targeted, it can only be speculated whether apicoplast targeting is of any relevance
as long as LipB is functional. The potential exons in P. falciparum and P. berghei lplA1
were only identified while writing this thesis. At the time when the constructs for the
knock-out studies in P. falciparum and P. berghei were designed, this information was not
available.
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6.4. LplA2 knock-out studies
To analyse the potential function of LplA2 in the parasites, knock-out studies in P. falci-
parum and P. berghei were performed. Knock-out of lplA2 in P. falciparum was attempted
by single cross-over recombination, but integration into the lplA2 gene locus was not
achieved. The results obtained by Southern blot analyses were ambiguous, possibly sug-
gesting unspecific integration of the knock-out construct into the P. falciparum genome,
but this speculation requires further investigation by PFGE.
As for lplA1, knock-out of lplA2 in P. berghei was attempted by single and double cross-
over approaches. Knock-out of lplA2 via integration was unsuccessful, although the 3’
replacement construct integrated very efficiently into the lplA2 gene locus. This demon-
strated that the gene locus is not refractory, but it appeared that knock-out of lplA2 by
single cross-over is not possible. However, replacement of the gene was accomplished
by double cross-over recombination and clonal lplA2 knock-out mutants were generated.
Surprisingly, the complementation construct by which P. berghei lplA2 is replaced with
P. falciparum lplA2 did not target the gene locus. In this construct, P. falciparum lplA2
is not under control of its endogenous or the P. berghei lplA2 promoter. It is likely to
be over-expressed as it is driven by the P. falciparum calmodulin promoter, which was
shown to be strongly active throughout the intraerythrocytic stages (Crabb and Cowman,
1996), and this could potentially have negative effects on parasites viability as discussed
above for LplA1. However, technical problems could also be the cause of this result. If,
for instance, incomplete digested plasmid DNA was transfected, it could easily re-ligate
and never target the gene locus.
The results obtained by the knock-out studies in P. berghei clearly show that LplA2 is
not essential for intraerythrocytic development stages, as replacement of the gene with
T. gondii DHFR/TS, the selectable marker, is possible. Phenotypical analyses of LplA2
mutant parasites revealed that asexual stages were only modestly affected by lplA2 knock-
out, growing slightly slower in comparison to wild-type parasites. In another experiment
where lplA2 mutants were mixed with wild-type parasites one to one, which were then
taken through five mice, the mutant parasites were outcompeted over time by wild-type
parasites, further supporting a mild growth defect in comparison to wild type parasites.
However, a drastic effect was observed during the sexual development of LplA2 null
mutants. The development of ookinetes was drastically reduced, suggesting a potential
effect of lplA2 knock-out in gametocytes, gametes and/or the zygote. Thin blood smears
of the lplA2 knock-out clones were analysed regularly to monitor parasitemia, and in
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these blood smears male as well as female gametocytes were observed, thus potentially
narrowing down the effect of lplA2 knock-out to gametes and/or the zygote. The effect of
lplA2 knock-out, however, can possibly be further confined. Before the knock-out popu-
lations were used to feed mosquitoes or to set up ookinete cultures, exflagellation of male
gametes was investigated. As exflagellation appeared to be comparable to wild-type para-
sites, it may allow potential exclusion of a direct effect of the knock-out on male gametes,
leaving female gametes and the zygote as the sexual stages which are most likely affected
in the LplA2 null mutants. However, this is speculative and definitively requires further
analyses of these developmental stages to identify when, where and why lplA2 knock-out
causes its drastic effect on sexual development of the parasites.
The knock-out studies of both lplA1 and lplA2 strongly suggest that the two ligases are
non-redundant. One major factor involved appears to be the stage specificity of both en-
zymes. As mentioned above, LplA1 is expressed throughout the asexual stages, whereas
LplA2 is mainly expressed in gametocytes (see Figure 6.1). Additionally, it appears that
the lipoic acid dependent enzyme complexes are up-regulated during gametocytogenesis
and gametogenesis (Hall et al., 2005, Salcedo et al., 2005, Young et al., 2005). Analyses
of the expression profile of the KADH complexes available through PlasmoDB implies
that particularly the PDH and KGDH are important during sexual developmental of the
parasites (Figure 6.2). In general, analyses of proteome and transcriptome of the ro-
dent malaria parasites P. chabaudi and P. berghei revealed that mitochondrial enzymes
involved in, for instance, the TCA cycle or oxidative phosphorylation were up-regulated
in gametocytes, and were present at even higher levels in ookinetes in comparison to the
asexual stages (Hall et al., 2005). In accordance, analysis of the P. falciparum transcrip-
tome of sexual stages showed down-regulation of enzymes involved in glycolysis and
up-regulation of enzymes which are part of the TCA cycle (Young et al., 2005), suggest-
ing a different role of the mitochondrion in energy metabolism in these developmental
stages. The fact that gametocytes contain multiple, cristate mitochondria in contrast to
the asexual stages, which contain a single acristate mitochondrion, further supports the
suggestion that the mitochondria in sexual stages fulfil a different role, as cristate mi-
tochondria are generally associated with "active" mitochondria (Rudzinska, 1969, van
Dooren et al., 2006). Further experiments on gametocyte mitochondria support the theory
that these are more active than their asexual counterparts, as activity of the mitochondrial
dihydroorotate dehydrogenase, cytochrome c reductase and cytochrome c oxidase appears
to be about 8-10 times higher in gametocytes (Learngaramkul et al., 1999). Interestingly,
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A H-protein
B PDH-E2
C BCDH-E2
D KGDH-E2
Figure 6.2.: Expression profile of lipoic acid dependent enzymes
This figure displays the expression profile of P. falciparum H-protein (Panel A), P. falciparum
PDH-E2 (Panel B), P. falciparum BCDH-E2 (Panel C) and P. falciparum KGDH-E2 (Panel D)
taken from the PlasmoDB website (www.plasmodb.org). Shown is the percentiled expression level
of the respective gene relative to all other genes. Data in green are of parasites synchronised by
sorbitol, in purple of parasites synchronised by temperature and in grey is data below the confi-
dence threshold. Data for gametocytes were obtained by sorbitol synchronisation and sporozoite
data represent an average of two replicates.
Abbreviations: S, sporozoite; ER, early ring; LR, late ring; ET, early trophozoite; LT, late tropho-
zoite; ES, early schizont; LS, late schizont; M, merozoite; G, gametocyte
an up-regulation in gametocytes was also observed for δ -aminolevulinate synthase, por-
phobilinogen deaminase and uroporphyrinogen decarboxylase, which are all part of the
haem biosynthesis pathway present in the mitochondrion, apicoplast and possibly cytosol
6. Discussion 204
(Young et al., 2005). Given this background, it appears that the lipoic acid dependent
enzyme complexes like KGDH, which produces succinyl-CoA required in the first step of
haem biosynthesis, fulfil crucial metabolic functions in the sexual developmental stages,
and potentially explains its strong expression in these stages. Indeed, PDH up-regulation
was also observed in gametocytes together with gametocyte specific expression of LipA,
the lipoic acid synthase (Young et al., 2005). These data strongly suggest that most of the
lipoic acid dependent enzyme complexes display increased activity in the sexual stages
and thus adequate lipoylation, possibly mediated by LplA2, is crucial in these stages. In-
terestingly, Khan et al. (2005) analysed for the first time the sex specific proteomes of P.
berghei male and female gametocytes. The studies described above were all performed
on mixed gametocytes populations, not allowing to distinguish between male and female
specific processes. However, Khan et al. (2005) showed that only 69 proteins are shared
by both male and female gametocytes. Intriguingly, mitochondrial proteins like BCDH-
E2 and KGDH-E2 were more abundant in female gametocytes together with proteins
involved in protein synthesis, whereas in the proteome of male gametocytes, proteins in-
volved in DNA replication and axoneme formation were mainly expressed (Khan et al.,
2005). This strongly suggests that the mitochondrion is particularly important in female
gametocytes, further supporting my speculations that lplA2 knock-out possibly affects fe-
male rather than male gamete development.
During the course of this thesis, knock-out studies were performed in the human and
rodent malaria parasites P. falciparum and P. berghei. For the studies in P. falciparum, the
plasmid pHH1 was used, targeting the gene of interest by single cross-over recombination
which should result in the disruption of the gene (Reed et al., 2000). A common problem,
not only observed during this study, but also during knock-out studies of several other
genes performed in the laboratory was that the plasmid integrated unspecifically into the
genome of P. falciparum. This is very unsatisfactory as it can hinder integration into the
correct gene locus if the episomal plasmid is lost after this unspecific integration event.
A better alternative to pHH1 are the transfection plasmids pHTK and pCC, which allow
replacement of the gene of interest by double cross-over recombination (Duraisingh et al.,
2002, Maier et al., 2006). The plasmids contain, in addition to the positive selection cas-
sette, a negative selectable marker, which is either the thymidine kinase or cytosine deam-
inase. The possibility to select for parasites that contain the positive selectable marker but
which have lost the negative selection cassette drastically decreases the time required to
select for parasites that have integrated the plasmid. The pCC plasmids are particularly
6. Discussion 205
useful as negative selection with the cytosine deaminase is more stringent and reliable in
comparison to the thymidine kinase (Maier et al., 2006).
In P. berghei two techniques were carried out, as it was attempted to knock-out the genes
of interest by single and double cross-over approaches. Generally, the P. berghei system
has several advantages over P. falciparum. First of all, the transfection efficiency is much
greater in P. berghei in comparison to P. falciparum, with 10−2-10−3 in P. berghei and
∼10−6 in P. falciparum (O’Donnell et al., 2002, Janse et al., 2006). This allows more
efficient transfection and thus allows the possibility of repeating transfections more often,
whereas in P. falciparum the selection of parasites after transfection is a very lengthy pro-
cess, particularly if the pHH1 plasmid is used, which restricts the amount of transfections
due to practicality. Another advantage of knock-out studies in P. berghei is the fact that
all life cycle stages can be investigated. Indeed, the whole Plasmodium life cycle can be
analysed in vivo. There only remains the question how diverged P. berghei and P. falci-
parum are, or wether P. berghei can actually be used as a model system for P. falciparum.
However, significant differences in the life cycle of both parasites can be observed. The
intraerythrocytic development in P. berghei takes only 24 hours, whereas P. falciparum
requires twice as long to complete this part of its development. Differences are even more
obvious during gametocytogenesis in both parasites. Mature gametocytes emerge after
only one day for P. berghei, whereas this process in P. falciparum takes∼11 days (Alano,
2007). Moreover, recent knock-out studies suggest that orthologue proteins may fulfil dif-
ferent roles in P. berghei and P. falciparum. Knock-out studies of the mitogen-activated
protein (MAP) kinase map-2 in P. berghei showed that the kinase is required for male
gamete formation, but no obvious effects in the intraerythrocytic stages were observed
(Khan et al., 2005, Rangarajan et al., 2005, Tewari et al., 2005). This is in contrast to P.
falciparum, where knock-out studies implied that Pfmap-2 already fulfils essential func-
tions in the asexual stages, as knock-out of the gene seemed impossible (Dorin-Semblat
et al., 2007), suggesting that indeed differences between P. falciparum and P. berghei ex-
ist on the protein level. Thus, it is questionable whether P. berghei is a suitable model
organism for P. falciparum, particularly in the quest of new potential drug targets. Rather,
it seems that analyses in both organisms would be ideal to potentially also identify more
exciting differences between these two parasites, which are reflected by differences in
their biology and physiology.
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6.5. Biochemical characterisation
6.5.1. Recombinant protein expression and purification
To analyse the biochemical properties of P. falciparum LplA1 and LplA2 in vitro, con-
structs for recombinant protein expression were designed. Both, LplA1 and LplA2, were
expressed with either a N-terminal (His)10-tag or a C-terminal Strep-tag. The LplA1
constructs were both truncated at the N-terminus and missed the first 15 amino acids,
which are predicted to constitute mitochondrial targeting of the annotated LplA1. They
were removed because the transit peptide, which is usually cleaved after import into the
mitochondrion, could interfere with protein expression and solubility in the prokaryotic
expression system. (His)10- and Strep-tagged LplA1 were both expressed and purified,
however, the Strep-tagged recombinant protein appeared more stable. Because a poten-
tial targeting peptide could not be predicted for LplA2, three different LplA2 constructs
were generated differing in length at their N-termini. The first construct was full length
at the N-terminus, whereas the second construct (S1) was truncated and missed the first
27 amino acids. The S1 construct thus starts where the bacterial LplAs align with the
P. falciparum LplA2 sequence (see Figure 4.1). Furthermore, this starting site is in the
same region of the predicted mitochondrial transit peptide cleavage sites of P. knowlesi
and P. vivax LplA2 (see Table 4.3). The third construct (S2) is further truncated at the
N-terminus and misses the first 79 amino acids. All three constructs complemented the
growth defect of lipB and lipB/lplA deficient bacteria, suggesting that all three constructs
produce functional enzymes. Thus, six LplA2 expression construct were generated, three
containing a N-terminal (His)10-tag and three a C-terminal Strep-tag. Of these only one,
the (His)10-tagged LplA2-S2 construct, was expressed in soluble form. The other con-
structs were not expressed solubly, despite different expression temperatures and bacterial
strains used. Purification of LplA2-S2 via batch and FPLC nickel affinity chromatogra-
phy proved difficult, as the recombinant protein was not very stable and degraded during
expression. Moreover, the recombinant protein co-purified with bacterial chaperones,
strongly suggesting that the protein had folding problems and required assistance during
expression (Goloubinoff et al., 1989, Georgiou and Valax, 1996, Keresztessy et al., 1996).
Interestingly, small scale test expression analyses of the other two (His)10-tagged LplA2
constructs also showed degradation of the proteins during expression, whereas this was
hardly observed for the Strep-tagged constructs. It appears that the N-terminal tag inter-
feres with protein stability as also the LplA1 construct with the N-terminal (His)10-tag was
partially degraded after purification, whereas this was not observed with the C-terminal
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Strep-tag. Interestingly, recombinant protein expression of P. falciparum Pfg27, a cyto-
plasmic protein crucial for gametocyte formation (Lobo et al., 1999), yielded a highly
stable protein when a C-terminal extension was attached to the recombinant protein (Sati
et al., 2002). Thus, it appears that the C-terminal Strep-tag may "protect" the recombinant
P. falciparum proteins from degradation of bacterial proteases. However, the N-terminal
(His)6-tagged E. coli LplA recombinant protein, which was used as a positive control for
LplA activity, was in contrast not degraded during expression. This could, however, sim-
ply be due to the fact that it is an E. coli protein, not alien to the bacteria expressing it,
whereas it is known that P. falciparum displays a different codon usage in comparison to
E. coli, which can be problematic for recombinant protein expression in the prokaryotic
expression system (Sayers et al., 1995).
In addition to the LplAs, the lipoyl-domains of the P. falciparum KADHs and the H-
protein of the P. falciparum GCV were recombinantly expressed and purified with N-
terminal (His)10-tags (see Figure 1.6 and Table 5.2). The four lipoyl-domains and the
H-protein share between 25%-42% amino acid sequence similarity and all possess the
highly conserved target lysine residue, which becomes post-translationally lipoylated, in
the conserved DKA/V motif generally found in lipoyl-domains (Wallis and Perham, 1994,
Reche and Perham, 1999). It was shown in previous studies that LplAs do not require the
full length apo-enzyme complex, but that the lipoyl-domain itself is sufficient for lipoyla-
tion (Ali and Guest, 1990, Dardel et al., 1990, Quinn et al., 1993), although correct folding
of these domains appears to be important (Reche and Perham, 1999). Therefore, the re-
combinantly expressed H-protein and lipoyl-domains were analysed by CD to investigate
their secondary structures (Kelly et al., 2005), and the analysis revealed that only three of
the five recombinant proteins are properly folded.
6.5.2. LplA enzyme assays
A variety of different enzyme assays can be employed to analyse LplA activity and to
determine the kinetic parameters of these enzymes. All of these assays are based on the
lipoylated protein substrate and thus determine LplA activity as a measure of lipoylation
of the apo-protein substrate. The most frequently used assay is the "gel assay" which
involves native PAGE (Ali and Guest, 1990, Fujiwara et al., 1992). In this assay, the
lipoylated form of a protein can be distinguished from the non-lipoylated form by a shift
of the protein band in the native gel. The attachment of lipoic acid to the ε-amino group
of the target lysine residue neutralises a positive charge in the protein, and thus changes its
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electrophoretic mobility in the native gel, causing it to run faster to the cathode (Fujiwara
et al., 1992). This assay can be used with all possible protein substrates (the H-protein
as well as the KADH-E2s) but its accuracy for determination of kinetic parameters is
questionable. Other enzyme assays to determine LplA activity are specific for the protein
substrate used and usually require other proteins which are part of the respective enzyme
complex to be present. For example, the activity of apo-PDH-E2 or apo-KGDH-E2 can
be determined after the lipoylation reaction as a measure of LplA activity, but require the
respective E1 and E3 subunits to be present (Jordan and Cronan, 1997). Another pos-
sibility is to use the H-protein as protein substrate in the LplA reaction, and then use
the lipoylated H-protein in the glycine-14CO2 exchange reaction by which [14C]glycine
is generated in the reverse reaction of the P- and H-protein (Walker and Oliver, 1986,
Fujiwara et al., 1992). Finally, Gueguen et al. (1999) developed the dihydrolipoamide
dehydrogenase / tris(2-carboxyethyl)phosphine (TCEP) assay to determine LplA activity.
In this assay, TCEP reduces protein bound lipoic acid to dihydrolipoamide, which in turn
is re-oxidised by LipDH with NAD+ as the final electron acceptor. Thus, LplA activity
can be determined spectrophotometrically by following the generation of NADH at 340
nm (Gueguen et al., 1999). A problem of these enzyme assays is that, as already men-
tioned above, other proteins, that are part of the respective enzyme complex, are required.
Usually, these proteins are not commercially available and therefore need to be gener-
ated in addition to the ligase and apo-protein substrate. Thus, I aimed to establish a new
spectrophotometric assay system, which, in contrast to the above described assays, is not
based on the lipoylated substrate but on the PPi, which is produced during the lipoylation
reaction. In this assay, the LplA reaction is coupled with an inorganic pyrophosphatase,
converting the released PPi to Pi. Pi then reacts with acidified ammonium molybdate and
forms a complex, which can be detected at 710 nm (Cariani et al., 2004). The colori-
metric determination of Pi with ammonium molybdate was first described by Fiske and
Subbarow (1925), and has been used since to determine activities of ATPases and phos-
phatases. It is a well established method, which is also very sensitive, detecting Pi in the
low nmol range (Chifflet et al., 1988, Cariani et al., 2004). Using this assay to charac-
terise P. falciparum LplAs has, in the long run, the advantage that the assay is suitable for
high-throughput screening of potential inhibitors, as the assay volume can be scaled down
to set it up in 96 well or even smaller plates. This is of particular interest as the knock-out
studies of lplA1 and lplA2 revealed that both proteins fulfil crucial functions at differ-
ent points in the parasites development. Inhibitors of LplA1 could potentially be used
in chemotherapy as knock-out studies suggest that LplA1 is crucial for intraerythrocytic
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development, whereas inhibitors against LplA2 may be used as transmission blockers as
knock-out studies imply that LplA2 is essential for sexual development in the mosquito.
However, a disadvantage of the spectrophotometric assay is that it is a coupled assay and
LplA activity can only be measured via the inorganic pyrophosphatase. Therefore, sub-
stances that inhibit this assay either inhibit LplA activity or the activity of the inorganic
pyrophosphatase.
The biochemical characteristics of recombinant P. falciparum LplA1 were investigated
using a gel based assay and the new spectrophotometric assay. Recombinant E. coli LplA
was used as a positive control. Unfortunately, activity of recombinantly expressed P. fal-
ciparum LplA2 was not tested due to the poor quality of the recombinant protein after
purification. Initially, the "gel assay" was carried out as described above, using native
PAGE. However, the protein shift caused by lipoylation was not very clear and also ap-
peared not very reliable, so an antibody that specifically detects protein bound lipoic acid
was used instead. Using the antibody also meant that normal SDS-PAGE could be per-
formed, which is faster and easier to handle in comparison to native PAGE. Allary et al.
(2007) also used this modified "gel assay" with the anti-lipoic acid antibody to show in
vitro activity of P. falciparum LplA1 with P. falciparum H-protein as protein substrate.
With this assay it was only possible to analyse the lipoylation reaction qualitatively, as
the use of different antibody batches varied immensely in the signal they produced. Thus
without standards, it is impossible to directly compare the assays or to quantify a reaction
densitometrically. Currently, standards for this assay, consisting of different concentra-
tions of fully lipoylated protein substrate, are being tested. This will allow the quantifica-
tion of the results obtained with this assay in the future.
ATP is used by E. coli LplA for the activation of lipoic acid by which the reaction interme-
diate lipoyl-AMP is formed (Green et al., 1995, Fujiwara et al., 2005). The mammalian
lipoic acid activating enzyme, however, appears to use GTP instead of ATP for the activa-
tion of lipoic acid, as the lipoyl-AMP reaction intermediate is not easily released from the
enzyme in contrast to lipoyl-GMP (Fujiwara et al., 2001). Therefore, it was tested whether
E. coli LplA specifically uses ATP or whether it could also use GTP instead. The "gel as-
say" showed that E. coli LplA is indeed able to use GTP for the activation and transfer
reaction of lipoic acid, almost as efficiently as ATP. Thus, both nucleotide triphosphates
may be used for the activation of lipoic acid in vivo, as ATP and GTP are both present in
E. coli in the mM range with∼3 mM and∼1.5 mM, respectively (Buckstein et al., 2007).
Whether E. coli LplA uses both ATP and GTP for lipoic acid activation, or whether one
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nucleotide triphosphate is preferred is not known and requires additional investigations.
Furthermore, the recombinantly expressed P. falciparum lipoyl-domains and H-protein
were tested as substrates for E. coli LplA. H-protein was best accepted as low concen-
trations of E. coli LplA (0.06 µM) lipoylated P. falciparum H-protein. PDH-E2-LD2
and KGDH-E2-LD were also accepted as protein substrate whereas PDH-E2-LD1 and
BCDH-E2-LD were hardly lipoylated by the enzyme. This supports the belief that a
properly folded domain is required for adequate lipoylation (Reche and Perham, 1999),
as the PDH-E2-LD1 and BCDH-E2-LD are the two domains suggested to be not prop-
erly folded by CD analyses. Interestingly, recombinant P. falciparum LplA1 also uses
H-protein as a protein substrate, but lipoylation of the other domains is hardly observed,
even at the highest LplA1 concentration used (1.8 µM). Generally, the activity of recom-
binant P. falciparum LplA1 appears to be lower in comparison to recombinant E. coli
LplA, as much higher enzyme concentrations of the recombinant Plasmodium enzyme
were required in the lipoylation assays. For instance, it seemed that 0.03 µM E. coli
LplA lipoylated H-protein as efficient as 1.8 µM of the recombinant Strep-tagged LplA1.
Thus, higher concentrations of the recombinant Plasmodium enzyme could be required
for lipoylation of the other domains in the in vitro assay, since lipoylation of PDH-E2-LD2
and KGDH-E2-LD in the E. coli LplA assay were only observed at the highest E. coli
LplA concentration (0.6 µM) used. However, this assay also potentially implies substrate
specificity of LplA1. Distinct substrate specificity of P. falciparum LplA1 and LplA2 was
previously suggested and shown to exist for LplA2, when expressed in lipoylation defi-
cient E. coli (Allary et al., 2007). P. falciparum LplA1, however, was able to lipoylate
bacterial PDH-E2 and KGDH-E2 when expressed in E. coli (Allary et al., 2007). There-
fore, further analyses is required to elucidate which apo-enzyme complexes are lipoylated
by P. falciparum LplA1 and LplA2 in vivo, keeping potential stage specificity and dual
targeting to the apicoplast and mitochondrion in mind.
As already mentioned, the Plasmodium enzyme seemed less active in comparison to the
E. coli protein. Moreover, the N-terminal (His)10-tagged LplA1 showed even poorer ac-
tivity and stability than the C-terminal Strep-tagged recombinant protein. It appears that
the N-terminal (His)10-tag does not only result in less stable recombinant protein, but it
also seems to interfere with LplA activity. Lipoic acid binding and activation occurs in
the N-terminal part of LplA proteins (Fujiwara et al., 2005, Kim et al., 2005, McManus
et al., 2006), and it is therefore conceivable that the N-terminal (His)10-tag interferes with
these sites reducing LplA activity. However, surprisingly, the N-terminal (His)6-tag of the
recombinant E. coli protein does not seem to interfere with enzyme activity, suggesting
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that maybe the ∼1 kDa difference between the (His)6- and (His)10-tag is responsible for
this difference.
Another curious phenomenon observed in the gel assay for both, P. falciparum LplA1 and
E. coli LplA, was that lipoic acid appeared to bind covalently to the enzyme. This was
surprising as the linkage is believed to be non-covalent (Fujiwara et al., 2005, Kim et al.,
2005, McManus et al., 2006). Recently, bovine lipoyltransferase was recombinantly ex-
pressed in the prokaryotic expression system for structural analyses, and purified enzyme
had lipoyl-AMP tightly, but non-covalently, bound to it (Fujiwara et al., 2007). A loop
in the lipoyltransferase structure was found to interact with lipoyl-AMP. This loop is also
present in E. coli LplA, but it does not appear to interact with lipoyl-AMP (Fujiwara et al.,
2007). However, other parts of the LplA protein may be involved in the strong interaction
with the lipoyl-AMP reaction intermediate.
The new spectrophotometric assay was set up using E. coli LplA. Kinetic parameters of
this protein were previously determined by two independent experiments using the "gel
assay" involving native PAGE and the glycine-14CO2 exchange reaction (Green et al.,
1995, Fujiwara et al., 2005). This allowed me to directly compare the apparent Km’s and
Vmax’s determined by the spectrophotometric assay with the published data. The appar-
ent Km’s for ATP and lipoic acid are in accordance with the published data, however, the
apparent Vmax’s are not. But the Vmax for ATP and lipoic acid vary not only between the
published data and the spectrophotometric assay data, but also among the published data
themselves. It is possible that the different assay systems used to determine the kinetic
parameters of LplA affect the specific activity in the different reactions. Furthermore,
different protein substrates were used in the different assays, which potentially affect the
specific activity of E. coli LplA. Indeed, Green et al. (1995) mentioned that the specific
activity of E. coli LplA for E. coli apo-PDH-lipoyl-domain is 11-fold higher compared to
human mitochondrial PDH apo-domain. Thus, it appears that the different domains, al-
though similarly folded, are differentially accepted by LplA, further supporting substrate
specificity of these enzymes. Surprisingly, changing the concentration of P. falciparum
H-protein in these assays did not influence the kinetic behaviour of E. coli LplA for ATP
or lipoic acid, suggesting that the transfer reaction does not, or only marginally, influence
the activation of lipoic acid. Trying to determine apparent Km and Vmax of E. coli LplA
for P. falciparum H-protein was impossible because the reaction was still in the linear
range at high H-protein concentrations (up to 40 µM), suggesting that the lipoylation re-
action is limited by the protein substrate. This is in contrast to Fujiwara et al. (2005),
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who determined the Km of E. coli LplA for E. coli H-protein to be 1.2 µM. However, this
determination was performed using the glycine-14CO2 exchange reaction, which is inhib-
ited if more than 5 µM H-protein is used (Fujiwara et al., 2005), and thus the accuracy of
their determined kinetic parameters for H-protein are questionable.
In an initial assay, it was also tested whether octanoic acid is used by E. coli LplA as a
substrate. The apparent Km and Vmax, but especially the Km, were much higher in com-
parison to lipoic acid, rendering it a "poor" substrate. In the physiological context, the
preferred substrate is lipoic acid and its low Km ensures that the low concentration of
lipoic acid in the cell is utilised efficiently by LplA. Interestingly, Crawford et al. (2006)
performed in vivo inhibition studies in T. gondii using octanoic acid. The parasites were
grown in lipoic acid depleted medium and were incubated with octanoic acid. Only at
500 µM octanoic acid, a toxic effect on parasites was observed which was reversed in
the presence of 1 µM lipoic acid, suggesting that indeed LplA has a very low affinity
for octanoic acid and that the toxic effect is possibly due to post-translational modifica-
tion of the enzyme complexes (Crawford et al., 2006). Additionally, in this study another
lipoate analogue, 8-bromooctanoic acid, was used which affected T. gondii viability at
much lower concentrations (10 µM). Again, the effect was reversed in the presence of 1
µM lipoic acid, suggesting a higher affinity of LplA for 8-bromooctanoic acid in compar-
ison to octanoic acid, but a lower affinity in comparison to lipoic acid. However, further
investigations using recombinant protein are required to clearly show that LplA and sub-
sequently the lipoic acid dependent enzyme complexes are affected by these substances
and are the cause for the results obtained by Crawford et al. (2006). Similar studies using
8-bromooctanoic acid were performed in P. falciparum, however, P. falciparum cannot be
cultured in the absence of lipoic acid, since the parasites require serum/Albumax in the
culture medium. Thus, in this study, high concentrations of 8-bromooctanoic acid were
used and caused a growth defect at 400 µM and parasite death at 1 mM (Allary et al.,
2007). However, how specific these effects can be ascribed to ligation of the substance to
the enzyme complexes and thus their inhibition, requires further analyses. In vitro assays
using recombinantly expressed enzyme should help to clarify these points.
Initial tests of P. falciparum LplA1, to determine the linearity of its reaction and its de-
pendence on the protein substrate, were also performed using the spectrophotometric as-
say. Surprisingly, it appears that the Plasmodium enzyme behaves enzymatically differ-
ent from the E. coli counterpart. In the same assay set up, P. falciparum LplA1 released
more PPi during the reaction in comparison to E. coli LplA. If this is, however, due to
a higher production of the reaction intermediate lipoyl-AMP with subsequent release of
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PPi, or whether PPi formed is released more quickly from the Plasmodium enzyme in
comparison to the E. coli protein is not known. Further analyses is required to identify
the potential differences between the two proteins.
6.6. Conclusions and future directions
Lipoic acid is an essential cofactor of enzyme complexes that are integral to energy
metabolism and amino acid degradation. In the malaria parasite Plasmodium falciparum,
the cofactor is synthesised in the apicoplast, employing lipoic acid synthase (LipA) and
octanoyl-ACP:protein N-octanoyl transferase (LipB), whereas the mitochondrion relies
on salvage of lipoic acid using lipoic acid protein ligase 1 (LplA1). Previous studies have
suggested that both pathways are strictly independent.
We showed that a recently identified second lipoic acid ligase (LplA2) compensates to
some extent for the loss of LipB function, because the protein is dually targeted to both
apicoplast and mitochondrion. This clearly suggests that salvage and biosynthesis are not
entirely independent and that there exists some redundancy between the ligases present in
both organelles. The situation could be even more flexible because scrutiny of the lplA1
gene locus also suggests the possibility of dual targeting as outlined in the discussion of
the thesis. However, the latter has to be verified experimentally and work towards this is
currently underway.
Despite the finding of redundancy between the ligases, they also appear to have distinct
functions during the parasites life cycle. Surprisingly, it was not possible to generate
lplA1 null mutants in P. falciparum and P. berghei, suggesting that LplA2 cannot replace
the function of the mitochondrial ligase during erythrocytic development. Similarly, it
was not possible for LplA1 to replace the functions of LplA2 during sexual development
- the lplA2 knock-out in P. berghei arrests parasite development before oocysts are gen-
erated. These results suggest that LplA1 and LplA2 firstly might have distinct substrate
specificities, which is currently being analysed using recombinantly expressed proteins.
In addition, these data support the hypothesis that the proteins might be differentially
expressed during progression of the parasites through their developmental cycle. This
suggestion is supported by data obtained from several transcriptome and proteome ex-
pression studies, and will be further analysed in the future.
Overall, my work suggests that LplA1 is essential for the survival of Plasmodium during
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erythrocytic development whereas LplA2 is of crucial importance during sexual develop-
ment in the insect host. The ligation of octanoyl-ACP in the apicoplast pathway appears to
be of utmost importance since this reaction is at least carried out by LipB and LplA2, and
potentially LplA1 to guarantee the functionality of the apicoplast-located pyruvate dehy-
drogenase complex. Figure 6.3 summarises these new findings and displays the resulting
complexity of lipoic acid metabolism in Plasmodium spp.
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Figure 6.3.: Lipoic acid metabolism in Plasmodium spp. - revisited
Lipoic acid dependent enzyme complexes are found in the parasites mitochondrion and apicoplast
and thus both organelles possess ways to post-translationally lipoylate these complexes. It ap-
pears that in the mitochondrion LplA1 as well was LplA2 are responsible for the attachment of
scavenged lipoic acid to the enzyme complexes. LplA1 is present throughout the intraerythrocytic
stages and it seems that LplA2 takes over in the sexual stages of the parasites life cycle. Lipoic
acid biosynthesis occurs in the apicoplast by the action of LipB and LipA. However, it is believed
that LipB function can be replaced by LplA2, which was shown to be dually targeted to mitochon-
drion and apicoplast. LplA1 might also be able to replace LipB function as it too is potentially
dually targeted to the mitochondrion and apicoplast, but further analyses is required to support this
hypothesis.
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A. Appendix
A.1. Amino acids
Table A.1.: Amino acid abbreviations
Amino acid Abbreviation Single letter code
Alanine Ala A
Arginine Arg R
Asparagine Asn N
Aspartate Asp D
Cysteine Cys C
Glutamate Glu E
Glutamine Gln Q
Glycine Gly G
Histidine His H
Isoleucine Ile I
Leucine Leu L
Lysine Lys K
Methionine Met M
Phenylalanine Phe F
Proline Pro P
Serine Ser S
Threonine Thr T
Tryptophan Trp W
Tyrosine Tyr Y
Valine Val V
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A.2. Vector map of pBluescript II SK
Figure A.1.: Vector map of pBluescript II SK
This figure displays the important features of the pBluescript II SK plasmid (Stratagene). The
plasmid contains the ampicillin resistance cassette (AmpR; 861 bp) for selection in E. coli, and a
multiple cloning site (NotI-KpnI). The primers M13F and M13R were used to verify the sequence
of the cloned inserts.
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A.3. Vector map of pQE-2
Figure A.2.: Vector map of pQE-2
This figure displays the important features of the pQE-2 (Quiagen) recombinant expression plas-
mid. These include the ampicillin resistance cassette (AmpR; 861 bp) and the multiple cloning site
(NdeI-HindIII). Recombinant expression using this plasmid is under control of the T5 promoter
and attaches a (His)6-tag at the N-terminus of the recombinant protein.
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A.4. Gene and/or protein IDs
The ID numbers of the genes and proteins described in this study are as follows:
P. falciparum (obtained from PlasmoDB)
ACP PFB0385w
BCDH-E2 PFC0170c
H-protein PF11_0339
KGDH-E2 PF13_0121
LipA MAL13P1.220
LipB MAL8P1.37
LipDH (apicoplast) PF08_0066
LplA1 PF13_0083
LplA2 PFI1160w
PDH-E2 PF10_0407
P. berghei (obtained from PlasmoDB)
BCDH-E2 PB001239.02.0
H-protein PB000228.00.0
KGDH-E2 PB000860.02.0
LipA PB300672.00.0
LipB PB001047.01.0
LipDH (apicoplast) PB001049.01.0
LplA1 PB000283.02.0
LplA2 PB001158.00.0
PDH-E2 PB000163.02.0
Other apicopmlexan LplA2s
P. chabaudi LplA2 PC000179.03.0 (obtained from PlasmoDB)
P. knowlesi LplA2 PKH_072080 (obtained from PlasmoDB)
P. vivax LplA2 Pv099590 (obtained from PlasmoDB)
P. yoelii LplA2 PY02395 (obtained from PlasmoDB)
T. gondii LplA2 83.m01296 (obtained from ToxoDB)
T. parva LplA2 XP_954802 (obtained from NCBI-DB)
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Bacterial genes/proteins (obtained from NCBI-DB)
E. coli H-protein CAA52145
E. coli KGDH-E2 NP_415255
E. coli LipA AAB40828
E. coli LipB NP_415163
E. coli LplA NP_418803
E. coli PDH-E2 NP_414657
L. monocytogenes LplA1 NP_464456
L. monocytogenes LplA2 NP_464291
T. acidophilum LplA CAC11654
Plant and mammalian genes/proteins (obtained from NCBI-DB)
Arabidopsis thaliana LplA BAA95754
Bos taurus lipoate-activating enzyme BAB40420
Bos taurus lipoyltransferase BAA24354
